UNAIDS report on the global AIDS epidemic 2010. by unknown
UNAIDS REPORT ON THE
GLOBAL AIDS EPIDEMIC | 2010
Copyright © 2010
Joint United Nations Programme on HIV/AIDS (UNAIDS)
All rights reserved
The designations employed and the presentation of the material in this publication do not imply the expression of any 
opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its 
authorities, or concerning the delimitation of its frontiers or boundaries. UNAIDS does not warrant that the information 
published in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
WHO Library Cataloguing-in-Publication Data
Global report: UNAIDS report on the global AIDS epidemic 2010.
“UNAIDS/10.11E | JC1958E”
1.Acquired immunodefi ciency syndrome − epidemiology. 2.Acquired immunodefi ciency syndrome − prevention and control. 
3.HIV infections − epidemiology. 4.HIV infections − prevention and control. I.UNAIDS.
ISBN 978-92-9173-871-7      (NLM classifi cation: WC 503.4)
GLOBAL REPORT
UNAIDS REPORT ON THE
GLOBAL AIDS EPIDEMIC | 2010
UNAIDS VISION
ZERO NEW HIV INFECTIONS. 
ZERO DISCRIMINATION. 
ZERO AIDS-RELATED DEATHS.
 04 FOREWORD 
 06  CHAPTER 1 
  INTRODUCTION 
 16 CHAPTER 2 
  EPIDEMIC UPDATE 
 62 CHAPTER 3 
  HIV PREVENTION 
 94 CHAPTER 4 
  HIV TREATMENT 
 120 CHAPTER 5
  HUMAN RIGHTS AND GENDER 
144  CHAPTER 6
  HIV INVESTMENTS 
 164 REFERENCES
 178 ANNEX 1
  HIV AND AIDS ESTIMATES AND DATA, 
  2009 AND 2001
 208 ANNEX 2
  COUNTRY PROGRESS INDICATORS 
  AND DATA, 2004 TO 2010 
TABLE OF CONTENTS
FOREWORD
Ebube Sylvia Taylor at the 2010 United Nations 
Millennium Development Goals Summit 
“No child should be born with HIV; no child should be an orphan because of HIV; 
no child should die due to lack of access to treatment,” urged Ebube Sylvia Taylor, 
an eleven year old born free of HIV, to world leaders gathered in New York to share 
progress made towards achieving the Millennium Development Goals by 2015. 
We have halted and begun to reverse the epidemic. Fewer people are becoming 
infected with HIV and fewer people are dying from AIDS. 
We must be proud of these successes and the potential of our shared future—
breakthroughs in a prevention revolution are at hand with a new microbicide gel 
holding promise for a generation of women who will be able to initiate usage and 
take control of their ability to stop HIV. Political breakthroughs will be achieved 
as more countries abolish discriminatory practices led by voices of a new law 
commission, and Treatment 2.0—a breakthrough that could save an additional 
10 million lives. 
However we are not yet in a position to say “mission accomplished”. 
Growth in investment for the AIDS response has fl attened for the fi rst time in 2009. 
Demand is outstripping supply. Stigma, discrimination, and bad laws continue to 
place roadblocks for people living with HIV and people on the margins. 
To fulfi ll Ebube’s hope, we must break the trajectory of the AIDS epidemic by 
redoubling our eff orts to ensure countries meet their goals towards universal access 
to HIV prevention, treatment, care and support. We must leverage the growing 
integration of AIDS with maternal and child health and all of our Millennium 
Development Goals. 
We know that there are solutions. We know that there is political and societal will 
to bring change. Th e real challenge is following through. Th is new fourth decade 
of the epidemic should be one of moving towards effi  cient, focused and scaled-up 
programmes to accelerate progress for Results. Results. Results. 
 
Michel Sidibé
UNAIDS Executive Director 
Under Secretary-General of the United Nations
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On the cusp of the fourth decade of the AIDS epidemic, the world has turned 
the corner—it has halted and begun to reverse the spread of HIV (Millennium 
Development Goal 6.A). The question remains how quickly the response can 
chart a new course towards UNAIDS’ vision of zero discrimination, zero new 
HIV infections, and zero AIDS-related deaths through universal access to 
effective HIV prevention, treatment, care and support.
Since 1999, the year in which it is thought that the epidemic peaked, globally, 
the number of new infections has fallen by 19%. Of the estimated 15 million 
people living with HIV in low- and middle-income countries who need 
treatment today, 5.2 million have access—translating into fewer AIDS-related 
deaths. For the estimated 33.3 million people living with HIV after nearly 
30 years into a very complex epidemic, the gains are real but still fragile. 
Future progress will depend heavily on the joint efforts of everyone involved in 
the HIV response.
At a time of fi nancial constraint, good investments are more important than 
ever. The evidence supporting increased investment in the HIV response has 
never been clearer or more compelling. New data from 182 countries, along 
with extensive input from civil society and other sources, clearly show that steady 
progress is being made towards achieving universal access to HIV prevention, 
treatment, care and support. HIV prevention is working. Treatment is working.
Increasing evidence defi nitively demonstrates that investments in the HIV 
response can lead to clear reductions in discrimination and stigma, help 
people in accessing information and services to reduce their risk of HIV 
infection, and deliver the treatment, care, and support that will extend and 
improve the lives of people living with HIV.
INTRODUCTION 
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More than 5 million people are now receiving HIV treatment 
In 2009 alone, 1.2 million people received HIV antiretroviral therapy for the 
fi rst time—an increase in the number of people receiving treatment of 30% 
in a single year. Overall, the number of people receiving therapy has grown 
13-fold, more than fi ve million people in low- and middle-income countries, 
since 2004. Expanding access to treatment has contributed to a 19% decline in 
deaths among people living with HIV between 2004 and 2009. Th is is just the 
beginning: 10 million people living with HIV who are eligible for treatment 
under the new WHO guidelines are still in need.
Eff orts are now underway for Treatment 2.0, a new approach to simplify the 
way HIV treatment is currently provided and to scale up access to life-saving 
medicines. Using a combination of eff orts, this new approach could bring down 
treatment costs, make treatment regimens simpler and smarter, reduce the bur-
den on health systems, and improve the quality of life for people living with HIV 
and their families. Modelling suggests that, compared with current treatment 
approaches, Treatment 2.0 could avert an additional 10 million deaths by 2025.
In addition, the new platform could reduce the number of people newly infect-
ed with HIV by up to one million annually if countries provide antiretroviral 
therapy to all people in need, following revised WHO treatment guidelines.
HIV prevention works—new HIV infections are declining in many 
countries most aff ected by the epidemic
In 33 countries, HIV incidence has fallen by more than 25% between 2001 
and 2009. Of these countries 22 are in sub-Saharan Africa. Th e biggest epi-
demics in sub-Saharan Africa—Ethiopia, Nigeria, South Africa, Zambia, and 
Zimbabwe—have either stabilized or are showing signs of decline.
Howevever, several regions and countries do not fi t the overall trend. In seven 
countries, fi ve of them in Eastern Europe and Central Asia, HIV incidence 
increased by more than 25% between 2001 and 2009.
Th ese fi gures demonstrate that positive behaviour change can alter the 
course of the epidemic—while stigma and discrimination, lack of access to 
services and bad laws can make epidemics worse. In both cases, the eff ects are 
oft en profound.
CHAPTER 1 | INTRODUCTION
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Figure 1.1
The virtual elimination of mother-to-child 
transmission of HIV is possible 
Estimated New HIV infections among children 0-14: 
Different scenarios for 25 countries
Source: Mahy M, Stover J, Kiragu K, et al. What will it take to achieve virtual elimina-
tion of mother-to-child transmission of HIV? An assessment of current progress and 
future needs. Sex Trans Infect (Suppl) 2010.
Among young people in 15 of the most severely aff ected countries, HIV 
prevalence has fallen by more than 25% as these young people have adopted 
safer sexual practices. Similar to treatment access, the room for continued 
improvement on this success is great. Young people’s knowledge about HIV is 
increasing but needs to grow further.
Virtual elimination of mother-to-child transmission of HIV is possible
In 2009, an estimated 370 000 children [220 000–520 000] contracted HIV 
during the perinatal and breastfeeding period, down from 500 000 [320 000–
670 000] in 2001. 
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Although this is a signifi cant reduction, HIV continues to weigh heavily on 
maternal and child mortality in some countries. But in South Africa, which 
achieved almost 90% coverage of treatment to prevent mother-to-child 
transmission of HIV, transmission to infants has been drastically reduced. In 
many communities, countries and regions of the world, however, access to 
services to halt mother-to-child transmission needs to be scaled up.
In 2009, UNAIDS called for the virtual elimination of mother-to-child trans-
mission of HIV by 2015 (Figure 1.1). In the 10 most severely aff ected countries, 
this is a realistic aim and can be achieved with signifi cantly increased action to 
implement proven strategies to eliminate HIV transmission to young people.
Women and girls need support
Slightly more than half of all people living with HIV are women and girls. In sub-
Saharan Africa, more women than men are living with HIV, and young women 
aged 15–24 years are as much as eight times more likely than men to be HIV 
positive. Protecting women and girls from HIV means protecting against gender-
based violence and promoting economic independence from older men.
Human rights are increasingly a part of national strategies
Human rights are no longer considered peripheral to the AIDS response. 
Today, the vast majority of countries (89%) explicitly acknowledge or address 
human rights in their national AIDS strategies, with 92% of countries 
reporting that they have programmes in place to reduce HIV-related stigma 
and discrimination.
At the same time, however, criminalization of people living with HIV still 
presents signifi cant challenges to the AIDS response. More than 80 countries 
across the world have laws against same-sex behaviour, and the free travel of 
people living with HIV is restricted in 51 countries, territories and areas. Such 
laws are not only discriminatory and unjust—they also drive HIV underground 
and inhibit eff orts to expand access to life-saving HIV prevention, treatment, 
care and support.
Financing the response is a shared responsibility
Increasingly, countries with heavy HIV burdens are assuming their 
responsibilities to resource the response to the degree that their means permit. 
Domestic expenditure is the largest source of HIV fi nancing globally today, 
accounting for 52% of resources for the HIV response in low- and middle-
income countries. Improving fi nancing for the global response will require 
ongoing eff orts to mobilize domestic resources among countries that appear to 
be under-investing in the HIV response, increasing the effi  cient use of funds 
for HIV and other related health and development programmes, and increasing 
external aid in a global environment of constrained resources.
A fragile progress
Despite extensive progress against a number of indicators on the global scale, 
many countries will fail to achieve Millennium Development Goal 6: halting 
and reversing the spread of HIV (Figure 1.2 and Figure 1.3).
10m
Treatment 2.0 could 
avert an additional 10 million 
deaths by 2025.
>50%
Slightly more than half 
of all people living with HIV 
are women and girls.
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1Figure 1.2 
Millennium Development Goal 6 indicators
Population-adjusted averages for indicators for Millennium 
Development Goal target 6.A (halt and begin to reverse the 
spread of HIV/AIDS), 1999–2003 and 2004–2009.
Source: DHS and UN Population Statistics.
Figure 1.3
Young people and sexual risk 
People aged 15–25 years who had sex before age 
15 years and who had multiple partners in the past 
12 months.
Source: DHS and UN Population Statistics.
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Having more than 5 million people receiving treatment is a major public 
health achievement—but still represents only 35% of the people who need HIV 
therapy now, according to WHO guidelines issued in early 2010. Reaching 
the two thirds of people who need treatment, but are not yet receiving it, and 
fi nancing this expansion in access to HIV therapy will require a continued and 
expanded global commitment to providing high quality HIV care for all.
Knowledge of the epidemic and how to prevent HIV infection has increased 
among young people aged 15–24 years—people frequently at the highest risk 
for infection. Six countries have achieved greater than 80% condom use at last 
higher-risk sex among males, and two countries have achieved this high level of 
condom use among females (see the HIV prevention scorecard).
Young people still lack knowledge and, importantly, oft en lack the tools they 
need to practice HIV risk-reduction strategies, however. Many people still lack 
ready access to condoms and lubrication, and people who inject drugs also lack 
suffi  cient access to sterile needles.
A new vision
Fulfi lling the UNAIDS vision of zero new infections will require a hard look at 
the societal structures, beliefs and value systems that present obstacles to eff ec-
tive HIV prevention eff orts. Poverty, gender inequity, inequity in health and 
the education system, discrimination against marginalized people, and unequal 
resource pathways all aff ect—and oft en slow—the HIV response.
In a world that has had to learn to live with an evolving and seemingly unstop-
pable epidemic over the course of three decades, UNAIDS’ vision of zero 
discrimination, zero new infections and zero AIDS-related deaths poses a 
challenge. But it is not a hopeless challenge. Th e vision of eliminating the toll 
that HIV imposes on human life can be made real using the knowledge and 
resources available today. Planners, programme administrators and imple-
menters must make a sustained and dedicated eff ort to use the best social and 
scientifi c knowledge available. Strengthened programming using the latest 
knowledge and best practices to deliver eff ective prevention, treatment and care 
services to people in need, or at risk, is highly eff ective. 
Building social coalitions to reduce vulnerability to HIV infection supports 
individuals and strengthens communities. Safeguarding the health of mothers 
and infants and optimizing infant feeding provides a strong basis for the growth 
of new generations. Investing in health care and social support systems, work-
ing to eliminate violence against women and girls and promote gender equality 
and working to end stigma and discrimination against people living with HIV 
and members of other marginalized groups help to provide social environ-
ments that are eff ective against the spread of HIV and promote more general 
mental and physical well-being. And in providing HIV-specifi c services with 
an awareness of other health and social issues and forging appropriate linkages, 
the response to HIV can make an important contribution to global health.
“MANY PEOPLE STILL LACK 
READY ACCESS TO CONDOMS 
AND LUBRICATION, AND 
PEOPLE WHO INJECT DRUGS 
ALSO LACK SUFFICIENT 
ACCESS TO STERILE NEEDLES.”
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Figure 1.4
Treatment coverage in low- and middle-income 
countries 
Population-adjusted averages for treatment coverage in low- and 
middle-income countries by geographical region in 2009 based on 
2010 WHO guidelines: Millennium Development Goal target 6.B 
(achieve, by 2010, universal access to treatment for HIV/AIDS for 
all those who need it). The regional fi gure for North America is not 
shown because of lack of data.
Source: WHO Towards Universal Access 2010.
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Th e Millennium Development Goals are intertwined. Without achieving sub-
stantive progress towards the HIV-specifi c Goal 6, few other Goals are likely to 
be reached; likewise, without integration and signifi cant progress towards most 
other Goals being made, Goal 6 will probably not be achieved.
Stopping infections, saving lives and improving the quality of life of people 
living with HIV have always been at the heart of the global AIDS response. Th e 
successes and continuing challenges described in this report should serve as 
catalysts for continued action. ■
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AIDS SCORECARDS
For the fi rst time, UNAIDS is publishing scorecards to provide a quick overview 
of the progress made by United Nations Member States in the global AIDS 
response. Five scorecards for (1) HIV incidence (2) prevention, (3) treatment, care, 
and support, (4) human rights and gender equality, and (5) investment, show the 
top national values for key indicators at the end of each chapter. They provide a 
snapshot of achievements, failures and obstacles in achieving universal access to 
HIV prevention, treatment, care and support. Readers seeking more detailed data 
can fi nd a comprehensive tabulation of all available data on each of the indicators 
used for the international monitoring of national responses to HIV in the annexes.
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THE OVERALL GROWTH OF THE GLOBAL AIDS EPIDEMIC APPEARS TO 
HAVE STABILIZED. THE ANNUAL NUMBER OF NEW HIV INFECTIONS 
HAS BEEN STEADILY DECLINING SINCE THE LATE 1990S AND THERE ARE 
FEWER AIDS-RELATED DEATHS DUE TO THE SIGNIFICANT SCALE UP OF 
ANTIRETROVIRAL THERAPY OVER THE PAST FEW YEARS. ALTHOUGH 
THE NUMBER OF NEW INFECTIONS HAS BEEN FALLING, LEVELS OF 
NEW INFECTIONS OVERALL ARE STILL HIGH, AND WITH SIGNIFICANT 
REDUCTIONS IN MORTALITY THE NUMBER OF PEOPLE LIVING WITH HIV 
WORLDWIDE HAS INCREASED. 
New HIV infections are declining
In 2009, there were an estimated 2.6 million [2.3 million–2.8 million] people 
who became newly infected with HIV. Th is is nearly one fi ft h (19%) fewer than 
the 3.1 million [2.9 million–3.4 million] people newly infected in 1999, and 
more than one fi ft h (21%) fewer than the estimated 3.2 million [3.0 million–3.5 
million] in 1997, the year in which annual new infections peaked (Figure 2.1).
In 33 countries, the HIV incidence has fallen by more than 25% between 2001 
and 2009 (Figure. 2.2); 22 of these countries are in sub-Saharan Africa. In sub-
Saharan Africa, where the majority of new HIV infections continue to occur, 
an estimated 1.8 million [1.6 million–2.0 million] people became infected in 
2009; considerably lower than the estimated 2.2 million [1.9 million–2.4 mil-
lion] people in sub-Saharan Africa newly infected with HIV in 2001. Th is 
trend refl ects a combination of factors, including the impact of HIV prevention 
eff orts and the natural course of HIV epidemics.
CHAPTER 2 | EPIDEMIC UPDATE
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Figure 2.1 
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Figure 2.2
Changes in the incidence rate of HIV infection, 2001 to 2009, selected countries 
Source: UNAIDS.
In the absence of a reliable diagnostic test that can directly measure the level of new HIV infections in a population, estimates of HIV 
incidence have been produced through modeling The map includes 60 countries for which reliable estimates of new HIV infections 
over time were available from the 2010 round of country-specific estimation using the EPP/Spectrum tools, and 3 countries for which 
peer-reviewed publications with incidence trends were available. The EPP/Spectrum methods estimate HIV incidence trends from HIV 
prevalence over time combined with the changing level of antiretroviral therapy. The criteria for including countries in this analysis were as 
follows. EPP files were available and trends in EPP were not derived from workbook prevalence estimates; prevalence data were available 
up to at least 2007; there were at least four time points between 2001 and 2009 for which prevalence data were available for concentrated 
epidemics and at least three data points in the same period for generalized epidemics; for the majority of epidemic curves for a given 
country, EPP did not produce an artificial increase in HIV prevalence in recent years due to scarcity of prevalence data points; data were 
representative of the country; the EPP/Spectrum–derived incidence trend was not in conflict with the trend in case reports of new HIV 
diagnoses; and the EPP/Spectrum–derived incidence trend was not in conflict with modelled incidence trends derived from age-specific 
prevalence in national survey results. For some countries with complex epidemics including multiple populations groups with different 
risk behaviours as well as major geographic differences, such as Brazil, China and the Russian Federation, this type of assessment is highly 
complex and it could not be concluded in the 2010 estimation round. UNAIDS will continue to work with countries and partners to improve 
the quality of available information and modeling methodologies to include HIV incidence data for additional countries in future reports.
Several regions and countries do not fi t the overall trend. In seven countries, 
the HIV incidence increased by more than 25% between 2001 and 2009. In 
Western, Central, and Eastern Europe, Central Asia, and North America, the 
rates of annual new HIV infections have been stable for at least the past fi ve 
years. However, evidence is increasing of a resurgence of HIV in several high-
income countries among men who have sex with men. In Eastern Europe and 
Central Asia, high rates of HIV transmission continue to occur in networks of 
people who inject drugs and their sexual partners.
Young people leading a revolution in HIV prevention
A recent analysis among young people provides further evidence of decreasing 
incidence and safer sexual behaviour (Table 2.1). Seven countries showed a sta-
tistically signifi cant decline of 25% or more in HIV prevalence (the percentage 
of people living with HIV) by 2008 among young pregnant women attending 
antenatal clinics.
Increasing >25%
Stable
Decreasing >25%
Not included in analysis
Note about Figures:
Dotted lines in fi gures represent ranges, 
solid lines represent the best estimate.
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Table 2.1 
HIV prevalence and behaviour
Trends in HIV prevalence and behaviour among young 
people in countries most severely affected by HIV
Source: UNAIDS.
Angola
Bahamas
Belize
Botswana
Burundi
Cameroon
Central African Republic
Chad
Congo
Côte d’Ivoire
Djibouti
Ethiopia
Gabon
Guyana 
Haiti
Kenya
Lesotho
Malawi
Mozambique
Namibia
Nigeria
Rwanda
South Africa 
Suriname
Swaziland
Togo
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
Trend in HIV 
prevalence 
from national 
surveys
Prevalence 
trend among 
antenatal care 
attendees
National HIV 
prevalence 
surveys 
conducted
Prevalence 
data were 
available from 
antenatal care 
surveillance
Percentage 
who have 
had sex by 
age 15
Percentage 
who have 
had sex with 
more than 
one partner 
in past year
Proportion 
who have had 
more than one 
partner not 
using condoms 
during last sex
URBAN RURAL F M F M F M F M
2004–2007
2000–2008
NA
2001–2006
2000–2007
NA
ID
ID
NA
2000–2008
ID
2001–2005
ID
NA
2000–2007
2000–2005
2003–2007
1999–2007
2001–2007
2002–2008
2003–2008
2002–2007
2000–2007
NA
2002–2008
2004–2007
2003–2008
2002–2006
2002–2006
2000–2006
2004, 2008
2002, 2007
2003, 2007
2002, 2007
2002, 2006
2002,2005,
2007
2003,2004,
2007
PERIOD YEARS
NOTES: NA=Not Available ID=Insuffi cient Data M=Male F=Female
Declining trend is statistically signifi cantIncreasing Trends Decreasing Trends No Evidence of Change
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Five countries—Botswana, South Africa, United Republic of Tanzania, Zambia, 
and Zimbabwe—showed a signifi cant decline in HIV prevalence among young 
women or men in national surveys. Sexual behaviour changed in most coun-
tries. In eight countries with signifi cant declines in HIV prevalence, the sexual 
behaviour of either men or women also changed signifi cantly.
New infections among children decreasing
As access to services for preventing the mother-to-child transmission of HIV 
has increased, the total number of children being born with HIV has decreased. 
An estimated 370 000 [230 000–510 000] children were newly infected with 
HIV in 2009 (a drop of 24% from fi ve years earlier).
AIDS-related deaths are decreasing
Th e number of annual AIDS-related deaths worldwide is steadily decreasing 
from the peak of 2.1 million [1.9 million–2.3 million] in 2004 to an estimated 
1.8 million [1.6 million–2.1 million] in 2009 (Figure 2.3). Th e decline refl ects 
the increased availability of antiretroviral therapy, as well as care and support, 
to people living with HIV, particularly in middle- and low-income countries; it 
is also a result of decreasing incidence starting in the late 1990s.
Th e eff ects of antiretroviral therapy are especially evident in sub-Saharan 
Africa, where an estimated 320 000 (or 20%) fewer people died of AIDS-related 
causes in 2009 than in 2004, when antiretroviral therapy began to be dramatically 
expanded (Figure 2.5).
AIDS-related mortality began to decline in sub-Saharan Africa and the 
Caribbean in 2005. Diff erent patterns have emerged in other regions. In North 
America and Western and Central Europe, deaths due to AIDS began to decline 
soon aft er antiretroviral therapy was introduced in 1996. In Asia and Central 
and South America, the number of deaths has stabilized, but there is no indica-
tion yet of decline. Deaths continue to increase in Eastern Europe.
Globally, deaths among children younger than 15 years of age are also declining. 
Th e estimated 260 000 [150 000–360 000] children who died from AIDS-related 
illnesses in 2009 were 19% fewer than the estimated 320 000 [210 000–430 000] 
who died in 2004. Th is trend refl ects the steady expansion of services to prevent 
transmission of HIV to infants and an increase (albeit slow) in access to treat-
ment for children.
19%
Estimated decrease in 
AIDS-related deaths globally 
among children from 2004 
to 2009.
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Table 2.2 
Regional HIV and AIDS statistics, 2001 and 2009
Regional fi gures on adults and children newly infected and 
living with HIV and AIDS-related deaths
Source: UNAIDS.
Adults and children 
living with HIV
SUB-SAHARAN 
AFRICA
2009
2001
22.5 million
[20.9–24.2 million]
1.8 million
[1.6–2.0 million]
5.0
[4.7–5.2]
1.3 million
[1.1–1.5 million]
20.3 million
[18.9–21.7 million]
2.2 million
[1.9–2.4 million]
5.9
[5.6–6.1]
1.4 million
[1.2–1.6 million]
MIDDLE EAST AND
NORTH AFRICA
2009
2001
460 000
[400 000–530 000]
75 000
[61 000–92 000]
0.2
[0.2–0.3]
24 000
[20 000–27 000]
180 000
[150 000–210 000]
36 000
[32 000–42 000]
0.1
[0.1–0.1]
8300
[6300–11 000]
SOUTH AND 
SOUTH-EAST ASIA
2009
2001
4.1 million
[3.7–4.6 million]
270 000
[240 000–320 000]
0.3
[0.3–0.3]
260 000
[230 000–300 000]
3.8 million
[3.5–4.2 million]
380 000
[350 000–430 000]
0.4
[0.3–0.4]
230 000
[210 000–280 000]
EAST ASIA 2009
2001
770 000
[560 000–1.0 million]
82 000
[48 000–140 000]
0.1
[0.1–0.1]
36 000
[25 000–50 000]
350 000
[250 000–480 000]
64 000
[47 000–88 000]
<0.1
[<0.1–<0.1]
15 000
[9400–28 000]
OCEANIA 2009
2001
57 000
[50 000–64 000]
4500
[3400–6000]
0.3
[0.2–0.3]
1400
[<1000–2400]
29 000
[23 000–35 000]
4700
[3800–5600]
0.2
[0.1–0.2]
<1000
[<500–1100]
CENTRAL AND 
SOUTH AMERICA
2009
2001
1.4 million
[1.2–1.6 million]
92 000
[70 000–120 000]
0.5
[0.4–0.6]
58 000
[43 000–70 000]
1.1 million
[1.0–1.3 million]
99 000
[85 000–120 000]
0.5
[0.4–0.5]
53 000
[44 000–65 000]
Adults and children 
newly infected 
with HIV
% Adult prevalence 
(15–49 years)
AIDS-related deaths 
among adults and 
children
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Adults and children 
living with HIV
CARIBBEAN 2009
2001
240 000
[220 000–270 000]
17 000
[13 000–21 000]
1.0
[0.9–1.1]
12 000
[8500–15 000]
240 000
[210 000–270 000]
20 000
[17 000–23 000]
1.1
[1.0–1.2]
19 000
[16 000–23 000]
EASTERN EUROPE 
AND CENTRAL 
ASIA
2009
2001
1.4 million
[1.3–1.6 million]
130 000
[110 000–160 000]
0.8
[0.7–0.9]
76 000
[60 000–95 000]
760 000
[670 000–890 000]
240 000
[210 000–300 000]
0.4
[0.4–0.5]
18 000
[14 000–23 000]
WESTERN AND 
CENTRAL EUROPE
2009
2001
820 000
[720 000–910 000]
31 000
[23 000– 40 000]
0.2
[0.2–0.2]
8500
[6800–19 000]
630 000
[570 000–700 000]
31 000
[27 000–35 000]
0.2
[0.2–0.2]
7300
[5700–11 000]
NORTH AMERICA 2009
2001
1.5 million
[1.2–2.0 million]
70 000
[44 000–130 000]
0.5
[0.4–0.7]
26 000
[22 000–44 000]
1.2 million
[960 000–1.4 million]
66 000
[54 000–81 000]
0.4
[0.4–0.5]
30 000
[26 000–35 000]
Adults and children 
newly infected 
with HIV
% Adult prevalence 
(15–49 years)
TOTAL 2009
2001
33.3 million
[31.4–35.3 million]
2.6 million
[2.3–2.8 million]
0.8
[0.7–0.8]
1.8 million
[1.6–2.1 million]
28.6 million
[27.1–30.3 million]
3.1 million
[2.9–3.4 million]
0.8
[0.7–0.8]
1.8 million
[1.6–2.0 million]
AIDS-related deaths 
among adults and 
children
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Figure 2.3 
Annual AIDS-related deaths by region, 1990-2009
Source: UNAIDS.
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Trends in the number of people living with HIV
UNAIDS estimates that there were 33.3 million [31.4 million–35.3 million] 
people living with HIV at the end of 2009 compared with 26.2 million [24.6 mil-
lion–27.8 million] in 1999—a 27% increase (Figure 2.4 and Figure 2.5).  Although 
the annual number of new HIV infections has been steadily declining since the late 
1990s, this decrease is off set by the reduction in AIDS-related deaths due to the 
signifi cant scale up of antiretroviral therapy over the past few years (Table 2.2).
Th is report revises the estimate of the number of people living with HIV in 2008 
of 33.4 million [31.1 million–35.8 million] published in AIDS epidemic update: 
November 2009, to 32.8 million [30.9 million–34.7 million], which is within the 
uncertainty range of the previous estimate. Th is revision is based on additional 
data becoming available for many countries, including data from population-based 
surveys such as in Mozambique. AIDS epidemic update: November 2009 included 
Mexico in Latin America. Th is report includes Mexico in North America and 
categorizes the rest of Latin America as Central and South America. Th is report 
presents trend analysis based on the new defi nition of these regions.
Th e estimated number of children living with HIV increased to 2.5 million 
[1.7 million–3.4 million] in 2009 (Figure 2.3). Th e proportion of women living with 
HIV has remained stable, at slightly less than 52% of the global total (Figure 2.6).
Figure 2.4
Global prevalence of HIV, 2009
Source: UNAIDS. 
No data <.1% .1% – <.5% .5% – <1% 1% – <5% 5% – <15% >15% – 28%
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Figure 2.5 
Global HIV trends, 1990 to 2009
Source: UNAIDS.
‘90
M
IL
L
IO
N
S
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
40
35
30
25
20
15
10
5
0
Number of people living with HIV
‘90
M
IL
L
IO
N
S
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Number of children living with HIV
‘90
M
IL
L
IO
N
S
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
2.5
2.0
1.5
1.0
0.5
0.0
Adult and child deaths due to AIDS
Number of orphans due to AIDS
‘90
M
IL
L
IO
N
S
20
16
12
8
4
0
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
25Chapter 2: Epidemic update | 2010 GLOBAL REPORT
2
Sub-Saharan Africa still bears an inordinate share of the global HIV burden. 
Although the rate of new HIV infections has decreased, the total number of 
people living with HIV continues to rise. In 2009, that number reached 
22.5 million [20.9 million–24.2 million], 68% of the global total. Sub-Saharan 
Africa has more women than men living with HIV. 
Th e largest epidemics in sub-Saharan Africa—Ethiopia, Nigeria, South Africa, 
Zambia, and Zimbabwe—have either stabilized or are showing signs of decline. 
Th e estimated 1.3 million [1.1 million–1.5 million] people who died of HIV-
related illnesses in sub-Saharan Africa in 2009 comprised 72% of the global total 
of 1.8 million [1.6 million–2.0 million] deaths attributable to the epidemic. 
Figure 2.6
Trends in women living with HIV 
Proportion of people 15 years and older living 
with HIV who are women, 1990–2009.
Source: UNAIDS.
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Table 2.3 
AIDS statistics for sub-Saharan Africa, 2001 and 2009
Source: UNAIDS.
Figure 2.7 
HIV prevalence in sub-Saharan Africa
HIV prevalence among adults aged 15–49 years old in sub-Saharan Africa, 1990 to 2009.
Source: UNAIDS.
SUB-SAHARAN AFRICA
No data <1% 1% – <5% 5% – <10% 10% – <20% 20% – 28%
SUB-SAHARAN 
AFRICA
2009
2001
People living 
with HIV
22.5 million
[20.9–24.2 million]
20.3 million
[18.9–21.7 million]
People newly 
infected with HIV
1.8 million
[1.6–2.0 million]
2.2 million
[1.9–2.4 million]
Children living 
with HIV
2.3 million
[1.4–3.1 million]
1.8 million
[1.1–2.5 million]
AIDS-related 
deaths
1.3 million
[1.1–1.5 million]
1.4 million
[1.2–1.6 million]
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Figure 2.8 
HIV trends in sub-Saharan Africa
Source: UNAIDS.
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Sub-Saharan Africa still bears an inordinate share of the global HIV burden
Th e epidemics in sub-Saharan Africa vary considerably, with southern 
Africa1 still the most severely aff ected (Table 2.2 and Figure 2.8). An esti-
mated 11.3 million [10.6 million–11.9 million] people were living with HIV 
in southern Africa in 2009, nearly one third (31%) more than the 8.6 million 
[8.2 million– 9.1 million] people living with HIV in the region a decade earlier.
Globally, 34% of people living with HIV in 2009 resided in the 10 countries in 
southern Africa; 31% of new HIV infections in the same year occurred in these 
10 countries, as did 34% of all AIDS-related deaths. About 40% of all adult 
women with HIV live in southern Africa.
HIV incidence falling in 22 countries in sub-Saharan Africa
Th e HIV incidence (number of people newly infected with HIV) appears to 
have peaked in the mid-1990s, and there is evidence of declines in incidence in 
several countries in sub-Saharan Africa. Between 2001 and 2009, the incidence 
of HIV infection declined by more than 25% in an estimated 22 countries.
In Zimbabwe, the main behavioural change appears to have been a reduction 
in the proportion of men with casual partners, while condom use with non-
regular partners has remained high since the late 1990s (1,2).
With an estimated 5.6 million [5.4 million–5.8 million] people living with HIV 
in 2009, South Africa’s epidemic remains the largest in the world. New indi-
cations show a slowing of HIV incidence amid some signs of a shift  towards 
safer sex among young people (3). Th e annual HIV incidence among 18-year-
olds declined sharply from 1.8% in 2005 to 0.8% in 2008, and among women 
15–24 years old it dropped from 5.5% in 2003–2005 to 2.2% in 2005–2008 (4).
Other epidemics in southern Africa have also levelled off  at very high levels. 
At an estimated 25.9% [24.9%–27.0%] in 2009, Swaziland has the highest adult 
HIV prevalence in the world.
Th e epidemics in East Africa have declined since 2000 but are stabilizing in 
many countries. Th e HIV incidence slowed in the United Republic of Tanzania 
to about 3.4 per 1000 person-years between 2004 and 2008 (5). Th e national 
HIV prevalence in Kenya fell from about 14% in the mid-1990s to 5% in 2006 
(6). Th e HIV prevalence in Uganda has stabilized at between 6.5% and 7.0% 
since 2001. Th e HIV prevalence in Rwanda has been about 3.0% since 2005.
Th e HIV prevalence in West and Central Africa remains comparatively low, 
with the adult HIV prevalence estimated at 2% or under in 12 countries in 
2009 (Benin, Burkina Faso, Democratic Republic of the Congo, Gambia, 
Ghana, Guinea, Liberia, Mali, Mauritania, Niger, Senegal, and Sierra Leone). 
Th e prevalence of HIV is highest in Cameroon at 5.3% [4.9%–5.8%], Central 
African Republic 4.7% [4.2%–5.2%], Côte d’Ivoire 3.4% [3.1%–3.9%], Gabon 
5.2% [4.2%–6.2%], and Nigeria 3.6% [3.3%–4.0%].
1 Angola, Botswana, Lesotho, Malawi, 
Mozambique, Namibia, South Africa, 
Swaziland, Zambia, and Zimbabwe.
SUB-SAHARAN AFRICA
5.6m
With an estimated 5.6 million 
people living with HIV in 2009, 
South Africa’s epidemic remains the 
largest in the world.
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Slight declines in prevalence have been detected in household surveys in Mali 
and Niger and among antenatal clinic attendees in Benin, Burkina Faso, Côte 
d’Ivoire, and Togo (7).
Reducing new HIV infections among children
Th ere has been pronounced progress in reducing the incidence and impact of 
HIV among children younger than 15 years in southern Africa. Th ere were 
32% fewer children newly infected—an estimated 130 000 [90 000–160 000] 
versus 190 000 [140 000–230 000]—and 26% fewer AIDS-related deaths among 
children—90 000 [61 000–110 000] versus 120 000 [88 000–150 000]—in 2009 
compared with 2004. About 890 children became newly infected with HIV in 
Botswana in 2007, down from 4600 in 1999 (information from NACA).
South Africa is one of the few countries in the world where child and maternal 
mortality has risen since the 1990s (8). AIDS is the largest cause of maternal 
mortality in South Africa and also accounts for 35% of deaths in children 
younger than fi ve years (3).
AIDS-related mortality decreasing
Th e scaling up of treatment is profoundly aff ecting sub-Saharan Africa. At the 
end of 2009, 37% of adults and children eligible for antiretroviral therapy were 
receiving it in the region overall (41% in Eastern and Southern Africa and 25% 
in Western and Central Africa), compared with only 2% seven years earlier (9).
AIDS-related deaths decreased by 18% in southern Africa—an estimated 
610 000 [530 000–700 000] people died from AIDS-related illnesses in southern 
Africa in 2009, compared with 740 000 [670 000–820 000] fi ve years earlier.
In Botswana, where antiretroviral therapy coverage exceeds 90%, the estimated 
annual number of AIDS-related deaths declined by half (from 18 000 [15 000–
22 000] in 2002 to 9100 [2400–19 000] in 2009), while the estimated number of 
children newly orphaned by AIDS fell by 40% (10). Th e extensive provision of 
antiretroviral therapy has averted an estimated 50 000 adult deaths and, if this 
is sustained, Botswana could avert a further estimated 130 000 deaths through 
2016 (11).
AIDS-related deaths in Kenya fell by 29% between 2002 and 2007 (6). In rural 
Malawi, provision of antiretroviral therapy was linked to a 10% drop in the 
adult death rate between 2004 and 2008 (12). Antiretroviral therapy and other 
types of treatment have expanded since the early 2000s, but the number of 
AIDS-related deaths remains high.
Most people receiving antiretroviral therapy in sub-Saharan Africa start treat-
ment late (13), which limits the overall impact of HIV treatment programmes. 
Th e infrastructure, systems, and staff  required to properly monitor treatment 
retention and loss are becoming increasingly inadequate as programmes are 
scaled up. As HIV testing expands, systems are strengthened to monitor the 
health status of people living with HIV, and access to treatment is provided at 
the appropriate time, AIDS-related mortality is likely to further reduce.
25.9%
At an estimated 25.9% in 2009, 
Swaziland has the highest adult HIV 
prevalence in the world.
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Addressing sexual behaviour to prevent the sexual transmission of HIV
Th e vast majority of people newly infected with HIV in sub-Saharan Africa 
are infected during unprotected heterosexual intercourse (including paid sex) 
and onward transmission of HIV to newborns and breastfed babies. Having 
unprotected sex with multiple partners remains the greatest risk factor for HIV 
in this region. Large proportions of people living with HIV are in long-term 
relationships—62% in Kenya and 78% in Malawi, for example (14).
As mainly heterosexual epidemics evolve, the numbers of discordant couples 
(only one person is infected with HIV) increase and HIV transmission within 
long-term relationships increases (15). Research in 12 countries in eastern and 
southern Africa shows that prevalence of discordant couples is high, ranging 
between 36% and 85% (16).
Urban data in Zambia suggest that 60% of the people newly infected through 
heterosexual transmission are infected within marriage or cohabitation (17), 
compared with more than half (50%–65%) in Swaziland (18), 35%–62% in 
Lesotho (19) and an estimated 44% in Kenya (20).
Prevention strategies, however, oft en do not adequately address the patterns of 
HIV transmission. Couples testing and other prevention services for serodis-
cordant couples receive inadequate support (20).
Increasing evidence indicates that unprotected paid sex, sex between men, and 
the use of contaminated drug-injecting equipment by two or more people on 
the same occasion are signifi cant factors in the HIV epidemics of several coun-
tries with generalized epidemics. Together, those modes of transmission are 
believed to account for about 33% of new HIV infections in Kenya and almost 
40% in Ghana, for example. However, comparatively little funding is chan-
nelled into prevention services for populations at higher risk (20).
Paid sex remains an important factor in many of the HIV epidemics in 
Western, Central and Eastern Africa. It is estimated that almost one third 
(32%) of new HIV infections in Ghana, 14% in Kenya and 10% in Uganda are 
linked to sex work (HIV infection among sex workers, their clients, or their 
other sex partners) (20, 21).
Results from recent studies in sub-Saharan Africa indicate the existence of 
groups of men who have sex with men and high levels of HIV infection among 
them (Figure 2.9) (22). Up to 20% of new HIV infections in Senegal (23) and 
15% of those in Kenya (20) and Rwanda (24) could be linked to unprotected 
sex between men. Available evidence suggests that in sub-Saharan Africa, as 
elsewhere in the world, the majority of men who have sex with men also have 
sex with women. In Senegal, four fi ft hs (82%) of the surveyed men who have 
sex with men said that they also have sex with women (25). In Malawi, one 
third of men who have sex with men were married or cohabiting with a woman 
(26), as were two thirds of those surveyed in the Nigerian state of Enugu (27).
SUB-SAHARAN AFRICA
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Figure 2.9 
HIV among men who have sex with men in sub-Saharan Africa
HIV prevalence (%) among male adults 15–49 years old who have sex with men 
in seven countries in sub-Saharan Africa, 2009 or latest available year.
Source: Baral et al. (28); Nigeria Federal Ministry of Health (29); Lane et al. (30); Parry et al. (31); 
Sander et al. (32); Sander et al. (33); and Wade et al. (34).
Injecting drug use appearing in sub-Saharan Africa
Injecting drug use is a relatively recent phenomenon in sub-Saharan Africa 
that features in some of the region’s epidemics, including in Kenya, Mauritius, 
South Africa, and the United Republic of Tanzania. Uniquely in sub-Saharan 
Africa, injecting drug use is the main driver of the comparatively small HIV 
epidemic in Mauritius (35). Available research shows high HIV prevalence 
among people who inject drugs: 36% among those tested in Nairobi (Kenya) 
(36), 26% in Zanzibar (37), and an estimated 12% in South Africa (38). In 2007, 
10% of people who inject drugs surveyed in the Kano region of Nigeria tested 
HIV-positive (29). Overall, however, injecting drug use remains a minor factor 
in most of the epidemics in the region. In Kenya, for example, it accounted for 
an estimated 3.8% of people newly infected with HIV in 2006 (20). ■
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Table 2.4 
AIDS statistics for Asia, 2001 and 2009
Source: UNAIDS.
Figure 2.10 
HIV prevalence in Asia
HIV prevalence among adults aged 15–49 years old in Asia, 1990 to 2009.
Source: UNAIDS.
ASIA
ASIA 2009
2001
People living 
with HIV
4.9 million
[4.5–5.5 million]
4.2 million
[3.8–4.6 million]
People newly 
infected with HIV
360 000
[300 000–430 000]
450 000
[410 000–500 000]
Children living 
with HIV
160 000
[110 000–210 000]
100 000
[69 000–140 000]
AIDS-related 
deaths
300 000
[260 000–340 000]
250 000
[220 000–300 000]
No data <.1% .1% – <.5% .5% – <1% 1% – <1.5% 1.5% – 2.5%
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Figure 2.11 
HIV trends in Asia
Source: UNAIDS.
‘90
M
IL
L
IO
N
S
6
5
4
3
2
1
0
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
Number of people living with HIV
‘90
T
H
O
U
S
A
N
D
S
250
200
150
100
50
0
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
Number of children living with HIV
‘90
T
H
O
U
S
A
N
D
S
400
300
200
100
0
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
Adult and child deaths due to AIDS
‘90
T
H
O
U
S
A
N
D
S
700
600
500
400
300
200
100
0
‘98‘91 ‘99‘92 ‘00‘93 ‘01 ‘06‘94 ‘02 ‘07‘95 ‘03 ‘08‘96 ‘04 ‘09  ‘97 ‘05
Number of people newly infected with HIV
34 Chapter 2: Epidemic update | 2010 GLOBAL REPORT
Asian epidemic largely stable
In Asia, an estimated 4.9 million [4.5 million–5.5 million] people were living 
with HIV in 2009, about the same as fi ve years earlier (Table 2.4 and Figure 
2.11). Most national HIV epidemics appear to have stabilized. No country in 
the region has a generalized epidemic. Th ailand is the only country in this 
region in which the prevalence is close to 1%, and its epidemic appears to be 
stable overall. A resurgent epidemic in the late 1990s (when up to 60 000 people 
were becoming newly infected annually) has since receded. Th e adult HIV 
prevalence was 1.3% [0.8%–1.4%] in 2009, and the HIV incidence had slowed 
to 0.1% (39). In Cambodia, the adult HIV prevalence declined to 0.5% [0.4%–
0.8%] in 2009, down from 1.2% [0.8%–1.6%] in 2001. But the HIV prevalence 
is increasing in such low-prevalence countries as Bangladesh, Pakistan (where 
drug injecting is the main mode of HIV transmission), and the Philippines.
New HIV infections—mixed progress
Th ere were 360 000 [300 000–430 000] people newly infected with HIV in 2009, 
20% lower than the 450 000 [410 000–500 000] in 2001. Incidence fell by more 
than 25% in India, Nepal, and Th ailand between 2001 and 2009. Th e epidemic 
remained stable in Malaysia and Sri Lanka during this time period.
Incidence increased by 25% in Bangladesh and Philippines between 2001 and 
2009 even as the countries continue to have relatively low epidemic levels.
Epidemic patterns vary—between and within countries
Th e overall trends in this region hide important variation in the epidemics, 
both between and within countries. In most of them, the epidemics appear sta-
ble. In many countries in the region, national epidemics are concentrated in a 
relatively small number of provinces. In China, fi ve provinces account for just 
over half (53%) of the people living with HIV (40), and HIV infection levels in 
Indonesia’s Papua province are 15 times higher than the national average (41).
Asia’s epidemics remain concentrated largely among people who inject drugs, 
sex workers and their clients, and men who have sex with men. Incidence pat-
terns can vary considerably in large countries such as India. About 90% of 
people newly infected with HIV in India are believed to have acquired it during 
unprotected sex, but the common use of contaminated injecting equipment by 
two or more people on the same occasion is the main mode of HIV transmission 
in the country’s north-eastern states (42).
Sex work—central to the region’s epidemics
Paid sex features centrally in the region’s HIV epidemics. In some countries such 
as Viet Nam, condom use during commercial sex is infrequent. Further, the peo-
ple who inject drugs in some countries are also buying or selling sex. Almost one 
in fi ve (18%) surveyed female sex workers in Myanmar tested HIV-positive in the 
mid-2000s. In southern India, up to 15% of female sex workers were living with 
HIV (43). Th e Indian state of Karnataka has shown evidence that intensive HIV 
prevention eff orts among female sex workers can be highly eff ective. A four-year 
prevention programme in 18 of the state’s 27 districts almost halved HIV preva-
lence among young antenatal clinic attendees (from 1.4% to 0.8%) (44).
ASIA
“HIV PREVALENCE IS 
INCREASING IN LOW-
PREVALENCE COUNTRIES SUCH 
AS PAKISTAN, WHERE DRUG 
INJECTING IS THE MAIN MODE 
OF HIV TRANSMISSION.”
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Injecting drug use—fuelling new epidemics
It is estimated that as many as 4.5 million people in Asia inject drugs, more than 
half of whom live in China (38). India, Pakistan, and Viet Nam also have large 
numbers of people who inject drugs. In Asia, on average, an estimated 16% of 
the people who inject drugs are living with HIV, although the prevalence is 
considerably higher in some countries. In studies in Myanmar, up to 38% of the 
people who inject drugs have tested HIV-positive; this is estimated to be 30%–
50% in Th ailand and more than half in parts of Indonesia (41,45,46). In Viet 
Nam, between 32% and 58% of people who inject drugs are living with HIV in 
various provinces (47–49). In China, an estimated 7%–13% of the people who 
inject drugs are living with HIV (40).
Men who have sex with men—marginalized but not marginal to the 
growth of the epidemic
High HIV prevalence among men who have sex with men has been reported in 
several countries: 29% in Myanmar (50), 5% nationally in Indonesia (41), 6% in 
the Laotian capital of Vientiane (51), between 7% and 18% in parts of southern 
India (52), and 9% in rural parts of Tamil Nadu state in India (53). Th e epidemic 
among men who have sex with men in Th ailand had been largely ignored until a 
study uncovered 17% prevalence in Bangkok in 2005. Subsequent studies in 2005 
and 2007 found that the infection levels had risen to 28% and 31% (54), and an 
annual HIV incidence of 5.5% was recorded in 2008 (55).
Surveys have also found rising HIV prevalence in China among men who have 
sex with men, including in Shandong (56) and Jiangsu provinces (57) and in the 
city of Beijing (58). Although studies in Asia suggest that a signifi cant proportion 
of men who have sex with men also have sex with women (51), the risk of living 
with HIV appears to be much higher for men who only have sex with men (56,59).
As the epidemics mature in Asia, HIV is spreading more widely, especially to the 
female partners of people who inject drugs and the clients of sex workers and 
their other sex partners. In Asia overall, women account for a growing propor-
tion of HIV infections: from 21% in 1990 to 35% in 2009.
New HIV infections among children
Th e estimated number of children younger than 15 years living with HIV has 
increased marginally, from 140 000 [92 000–190 000] in 2005 to 160 000 [110 000 
–210 000] in 2009. But decreasing HIV incidence and slowly widening access to 
services that prevent mother-to-child transmission of HIV have led to a steep 
drop in the number of children becoming newly infected. An estimated 22 000 
[15 000–31 000] children aged 0–14 years became infected in 2009—a 15% 
decrease on the 1999 estimate of 26 000 [18 000–38 000]. AIDS-related deaths in 
this age group have declined by 15% since 2004, from 18 000 [11 000–25 000] to 
15 000 [9000–22 000].
AIDS-related mortality stable
Th e number of deaths has stabilized in Asia, but there are no indications of a 
decline. Th ere were an estimated 300 000 [260 000–340 000] AIDS-related deaths 
in 2009 compared with 250 000 [220 000–300 000] in 2001. ■
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Table 2.5 
AIDS statistics for Eastern Europe and Central Asia, 2001 and 2009
Source: UNAIDS.
Figure 2.12 
HIV prevalence in Eastern Europe and Central Asia 
HIV prevalence among adults aged 15–49 years old in Eastern Europe and Central Asia, 1990 to 2009.
Source: UNAIDS.
EASTERN EUROPE AND CENTRAL ASIA
EASTERN EUROPE 
+ CENTRAL ASIA
2009
2001
People living 
with HIV
1.4 million
[1.3–1.6 million]
760 000
[670 000–890 000]
People newly 
infected with HIV
130 000
[110 000–160 000]
240 000
[210 000–300 000]
Children living 
with HIV
18 000
[8600–29 000]
4000
[2000–6100]
AIDS-related 
deaths
76 000
[60 000–95 000]
18 000
[14 000–23 000]
No data <.1% .1% – <.5% .5% – <1% 1% – <2% 2% – 5%
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Figure 2.13 
HIV trends in Eastern Europe and Central Asia  
Source: UNAIDS.
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Th e largest regional increase in HIV prevalence
In Eastern Europe and Central Asia, the number of people living with HIV 
has almost tripled since 2000 and reached an estimated total of 1.4 million 
[1.3 million–1.6 million] in 2009 compared with 760 000 [670 000–890 000] in 
2001 (Table 2.5 and Figure 2.13). A rapid rise in HIV infections among people 
who inject drugs at the turn of the century caused the epidemic in this region 
to surge.
Overall, the HIV prevalence is 1% or higher in two countries in this region, 
the Russian Federation and Ukraine, which together account for almost 90% of 
newly reported HIV diagnoses.
At 1.1% [1.0%–1.3%], the adult HIV prevalence in Ukraine is higher than in 
any other country in all of Europe and Central Asia (60). Annual HIV diagnoses 
in Ukraine have more than doubled since 2001.
Th e HIV epidemic in the Russian Federation also continues to grow, but at a 
slower pace than in the late 1990s. Newly reported HIV cases have increased 
in several of the countries in Central Asia, including Uzbekistan, which has the 
largest epidemic in Central Asia (61).
Concentrated epidemics—sex work, drug use and sex between men linked
Th e HIV epidemics in Eastern Europe and Central Asia are concentrated mainly 
among people who inject drugs, sex workers, their sexual partners and, to a 
much lesser extent, men who have sex with men. An estimated one quarter of 
the 3.7 million people (most of whom are men) who inject drugs in the region 
are living with HIV (38). In the Russian Federation, more than one third (37%) 
of the country’s estimated 1.8 million people who inject drugs are believed to 
be living with HIV (38), compared with between 39% and 50% in Ukraine (60). 
Surveys among people who inject drugs in 2007 found HIV prevalence as high 
as 88% (in the city of Kryvyi Rih) (62).
High HIV prevalence has also been found in prison populations, especially 
among incarcerated people who inject drugs (63). An estimated 10 000 prison-
ers are living with HIV in Ukraine (60).
Th e interplay between sex work and injecting drug use is accelerating the 
spread of HIV in the region. At least 30% of sex workers in the Russian 
Federation, for example, have injected drugs (64), and the high HIV infection 
levels found among sex workers in Ukraine (14% to 31% in various studies) 
(60) are almost certainly due to the overlap of paid sex with injecting drug use.
Because most people who inject drugs are sexually active, sexual transmission 
of HIV has increased in older epidemics such as that in Ukraine, making these 
more challenging to manage (65). As the epidemic spreads from (predomi-
nantly male) people who inject drugs to their sexual partners, the proportion 
of women living with HIV is also growing. By 2009, an estimated 45% of the 
people living with HIV in Ukraine were women, compared with 41% in 2004 
EASTERN EUROPE AND 
CENTRAL ASIA
200%
The number of people living 
with HIV in Eastern Europe 
and Central Asia has almost 
tripled since 2000.
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and 37% in 1999. Diff erent people using the same contaminated injecting 
equipment within a short time frame remains a core driver of these epidemics. 
An estimated 35% of women living with HIV probably acquired HIV through 
injecting drug use, while an additional 50% were probably infected by partners 
who inject drugs (61,66).
Unprotected sex between men is responsible for a small share of new infections 
in the region—less than 1% of people newly diagnosed with HIV infection for 
whom the route of transmission was identifi ed (67). Nevertheless, offi  cial data 
may underplay the actual extent of infection in this highly stigmatized popula-
tion (68). In small surveys, the HIV prevalence among men who have sex with 
men has ranged from zero in Belarus, Lithuania and parts of Central Asia to 5% 
in Georgia (69), 6% in the Russian Federation (70) and between 4% (in Kyiv) 
and 23% (in Odessa) in Ukraine (60).
AIDS-related mortality
AIDS-related deaths continue to rise in the region. Th ere were an estimated 
76 000 [60 000–95 000] AIDS-related deaths in 2009 compared with 18 000 
[14 000–23 000] in 2001, a four-fold increase during this period. ■
“AS THE EPIDEMIC 
SPREADS FROM 
PREDOMINANTLY MALE 
POPULATIONS WHO 
INJECT DRUGS TO THEIR 
SEXUAL PARTNERS, 
THE PROPORTION OF 
WOMEN LIVING WITH 
HIV IS ALSO GROWING.”
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Table 2.6 
AIDS statistics for the Caribbean, 2001 and 2009
Source: UNAIDS.
Figure 2.14 
HIV prevalence in the Caribbean 
HIV prevalence among adults aged 15–49 years old in the Caribbean, 1990 to 2009.
Source: UNAIDS.
CARIBBEAN
CARIBBEAN 2009
2001
People living 
with HIV
240 000
[220 000–270 000]
240 000
[210 000–270 000]
People newly 
infected with HIV
17 000
[13 000–21 000]
20 000
[17 000–23 000]
Children living 
with HIV
17 000
[8500–26 000]
18 000
[9100–27 000]
AIDS-related 
deaths
12 000
[8500–15 000]
19 000
[16 000–23 000]
No data <.1% .1% – <.5% .5% – <1% 1% – <2% 2% – 5%
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Figure 2.15 
HIV trends in the Caribbean  
Source: UNAIDS.
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High HIV prevalence but fewer people living with HIV
Th e HIV prevalence among adults in the Caribbean is about 1.0% [0.9%–1.1%], 
which is higher than in other all regions outside sub-Saharan Africa (Table 
2.5 and Figure 2.13). However, the number of people living with HIV in the 
Caribbean is relatively small—240 000 [220 000–270 000] in 2009—and has 
varied little since the late 1990s.
Th e burden of HIV varies considerably between and within countries. Th e 
exceptionally low HIV prevalence in Cuba (0.1% [0.08%–0.13%]) contrasts, for 
example, with a 3.1% [1.2%–5.4%] adult HIV prevalence in the Bahamas (64). 
Meanwhile, 12% of pregnant women using antenatal facilities in one of Haiti’s 
cities have tested HIV-positive, compared with less than 1% in the west of the 
country (71). In the neighbouring Dominican Republic, HIV infection levels 
also vary considerably, with HIV prevalence among communities near sugar 
plantations (the bateyes) about four times higher than the national average (72).
New HIV infections slightly declining
New infections have slightly declined between 2001 and 2009. An estimated 
17 000 [13 000–21 000] people became newly infected with HIV in 2009, about 
3000 less than the 20 000 [17 000–23 000] in 2001.
Unprotected sex between men and women—especially paid sex—is believed to 
be the main mode of HIV transmission in this region (73,74). Th e Caribbean 
remains the only region, besides sub-Saharan Africa, where women and girls 
outnumber men and boys among people living with HIV. In 2009, an estimated 
53% of people with HIV were female.
High infection levels have been found among female sex workers, including 4% 
in the Dominican Republic (72,76), 9% in Jamaica (77), and 27% in Guyana 
(78). Most countries in the region have focused their HIV prevention eff orts on 
paid sex.
CARIBBEAN
0.1%
Estimated HIV prevalence
 in Cuba, which 
is exceptionally low.
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Unsafe sex between men is a signifi cant but largely hidden facet of the 
epidemics in this region, where several countries still criminalize sexual 
relations between men (79). One in fi ve men who have sex with men surveyed 
in Trinidad and Tobago were living with HIV, for example, and one in four said 
they regularly also had sex with women (69). In Jamaica, a study found an HIV 
prevalence of 32% among men who have sex with men (73). Evidence indicates 
increasing HIV infections among men who have sex with men in Cuba (80) 
and the Dominican Republic (81).
In Bermuda and Puerto Rico, unsafe injecting drug use contributes signifi -
cantly to the spread of HIV. In Puerto Rico, contaminated injecting equipment 
accounted for about 40% of males becoming newly infected in 2006 and for 
27% among females (82).
AIDS-related mortality declining
AIDS-related deaths are falling in the Caribbean. An estimated 12 000 
[8500–15 000] people lost their lives due to AIDS in 2009 compared with 
19 000 [16 000–23 000] deaths in 2001. ■
“THE CARIBBEAN 
REMAINS THE ONLY 
REGION, BESIDES 
SUB-SAHARAN AFRICA, 
WHERE WOMEN AND 
GIRLS OUTNUMBER MEN 
AND BOYS AMONG 
PEOPLE LIVING WITH HIV.”
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Table 2.7 
AIDS statistics for Central and South America, 2001 and 2009
Source: UNAIDS.
Figure 2.16 
HIV prevalence in Central and South America  
HIV prevalence among adults aged 15–49 years old in Central and South America, 1990 to 2009.
Source: UNAIDS.
CENTRAL AND SOUTH AMERICA
CENTRAL AND 
SOUTH AMERICA
2009
2001
People living 
with HIV
1.4 million
[1.2–1.6 million]
1.1 million
[1.0–1.3 million]
People newly 
infected with HIV
92 000
[70 000–120 000]
99 000
[85 000–120 000]
Children living 
with HIV
36 000
[25 000–50 000]
30 000
[20 000–42 000]
AIDS-related 
deaths
58 000
[43 000–70 000]
53 000
[44 000–65 000]
No data <.1% .1% – <.5% .5% – <1% 1% – <2% 2% – 5%
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Figure 2.17 
HIV trends in Central and South America  
Source: UNAIDS.
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Stable epidemic—but HIV prevalence rises with 
high access to antiretroviral therapy
Th e HIV epidemics in South and Central America have changed little in recent 
years (Table 2.6 and Figure 2.14). Th e total number of people living with HIV 
continues to grow to an estimated 1.4 million [1.2 million–1.6 million] in 
2009 from 1.1 million [1.0 million–1.3 million] in 2001) due largely to the 
availability of antiretroviral therapy.
About one third of all people living with HIV in Central and South America 
live in populous Brazil, where early and ongoing HIV prevention and treatment 
eff orts have contained the epidemic. Th e adult HIV prevalence in Brazil has 
remained well under 1% for at least the past decade.
Concentrated epidemics—primarily among men who have sex with men
Most of the HIV epidemics in this region are concentrated in and around net-
works of men who have sex with men. Surveys conducted in groups of urban 
men who have sex with men have found HIV prevalence of at least 10% in 12 
of 14 countries (69), including in Costa Rica (83). High rates of HIV infection 
have been found in networks of men who have sex with men. In fi ve Central 
American countries, the annual HIV incidence was 5.1% (84) among men who 
have sex with men, while an incidence of 3.5% has been found among men who 
have sex with men who attended public health clinics in Lima, Peru. Th ese rates 
were higher than those observed among the men who have sex with men in 
Europe and North America (85).
Social stigma, however, has kept many of these epidemics among men who 
have sex with men hidden and unacknowledged. Several countries, especially 
in Central America and in the Andes, continue to have fewer programmes that 
address the key role of unsafe sex between men in their HIV epidemics (64).
Fear of being stigmatized can compel many men who have sex with men to 
also have sexual relationships with women. In Central America, for example, 
more than one in fi ve men who said that they had sex with other men reported 
having had sex with at least one woman in the previous six months (84).
Stopping HIV among sex workers—investments are reaping dividends
Most countries have focused attention on preventing HIV transmission during 
paid sex, and there are indications that these eff orts are paying off . High 
condom use rates and low HIV prevalence have been reported among female 
sex workers in Santiago, Chile (86), El Salvador (87) and Guatemala (88).
Injecting drug use has been the other main route of HIV transmission in this 
region, especially in the southern cone of South America. It has been estimated 
that as many as 2 million people in Central and South America inject drugs and 
that more than one quarter of these might be living with HIV (38).
CENTRAL AND 
SOUTH AMERICA
1/3
Proportion of the population 
living with HIV in Central 
and South America that live 
in Brazil.
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As in other regions with many people who inject drugs, prisoners and detainees 
also have a high HIV prevalence. Close to 6% of male inmates tested at a São 
Paulo (Brazil) penitentiary, for example, were living with HIV (89). Such 
evidence has prompted some countries to move towards introducing HIV 
prevention services in prisons.
Meanwhile, heterosexual HIV transmission is increasing in the older epidemics 
in South America. When injecting drug use receded as a mode of transmis-
sion in Argentina’s HIV epidemic, for example, an estimated four of fi ve new 
HIV diagnoses in the mid-2000s were attributed to unprotected sexual inter-
course, mainly between men and women (90). Almost half (43%) of the new 
HIV infections in Peru are now attributed to heterosexual transmission (91), 
although most of those infections are believed to occur during paid and other 
forms of higher-risk sex.
HIV among children
Th e number of children (younger than 15 years of age) living with HIV, how-
ever, remains small in Central and South America (around 4000 children newly 
infected in 2009) and appears to be declining. Th is trend is occurring despite 
the comparatively low coverage of services for preventing the transmission of 
HIV to infants. At the end of 2009, 54% [39%–83%] of the pregnant women 
living with HIV in the region were receiving antiretroviral drugs to prevent 
transmission to their newborns, only slightly higher than the global coverage of 
53% [40%–79%] in low- and middle-income countries (9). ■
“THE NUMBER OF 
CHILDREN LIVING WITH 
HIV REMAINS SMALL IN 
CENTRAL AND SOUTH 
AMERICA AND APPEARS 
TO BE DECLINING.”
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Table 2.8 
AIDS statistics for North America and Western and Central Europe, 2001 and 2009
Source: UNAIDS.
Figure 2.18 
HIV prevalence in North America and Western and Central Europe   
HIV prevalence among adults aged 15-49 years old in North America and Western and Central 
Europe, 1990 to 2009.
Source: UNAIDS.
NORTH AMERICA AND WESTERN AND CENTRAL EUROPE
NORTH AMERICA 
AND WESTERN AND 
CENTRAL EUROPE
2009
2001
People living 
with HIV
2.3 million
[2.0–2.7 million]
1.8 million
[1.6–2.0 million]
People newly 
infected with HIV
100 000
[73 000–150 000]
97 000
[82 000–110 000]
Children living 
with HIV
6000
[3500– 8000]
7400
[4500–10 000]
AIDS-related 
deaths
35 000
[29 000–56 000]
37 000
[32 000–44 000]
No data <.1% .1% – <.5% .5% – 1% 1% – 1.5% 1.5% – 2%
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Figure 2.19 
HIV trends in North America and Western and Central Europe  
Source: UNAIDS.
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AIDS is not over in the higher-income countries
Th e total number of people living with HIV in North America and Western 
and Central Europe continues to grow and reached an estimated 2.3 million 
[2.0 million–2.7 million] in 2009—30% more than in 2001 (Table 2.8, 
Figure 2.18).
Unprotected sex between men continues to dominate patterns of HIV 
transmission in North America and Western and Central Europe, although 
injecting drug use and unprotected paid sex also feature (especially in Mexico 
and parts of southern Europe).
In France, for example, men who have sex with men account for more than 
half the men newly diagnosed with HIV, yet they represent only 1.6% of 
the country’s population (92,93). Th is epidemic pattern means that men 
outnumber women among people living with HIV. In 2009, women comprised 
about 26% of the people living with HIV in North America and 29% of those in 
Western and Central Europe.
Resurging epidemics among men who have sex with men
Th ere is strong evidence of resurgent HIV epidemics among men who have 
sex with men in North America and in Western Europe (94). Data from 
23 European countries show that the annual number of HIV diagnoses among 
men who have sex with men rose by 86% between 2000 and 2006 (95).
Th e 3160 new HIV diagnoses among men who have sex with men in 2007 
in the United Kingdom were the most ever reported up to that point (96). 
National surveillance data also show signifi cant increases in new HIV 
diagnoses between 2000 and 2005 among men who have sex with men in 
Canada, Germany, the Netherlands, Spain, and the United States of America 
(97). In the United States of America, new HIV infections attributed to 
unprotected sex between men increased by more than 50% from 1991–1993 
to 2003–2006 (98). Similar trends have been reported in Canada (99).
Increases in higher-risk sexual behaviour are associated with this trend. 
Researchers in Catalonia (Spain), for example, have reported that one third 
(32%) of men who have sex with men had recently had unprotected anal sex 
with a casual partner (100), and surveys in Denmark and Amsterdam (the 
Netherlands) have reported similar fi ndings (101,102).
Th e HIV epidemics are disproportionately concentrated in racial and ethnic 
minorities in some countries. In the United States of America, for example, 
African-Americans constitute 12% of the population but accounted for 45% of 
the people newly infected with HIV in 2006 (98). African-American males are 
6.5 times and African-American females 19 times more likely to acquire HIV 
compared with their Caucasian counterparts (103).
NORTH AMERICA AND 
WESTERN AND CENTRAL 
EUROPE
3160
Number of new HIV diagnoses 
among men who have sex with 
men in 2007 in the UK, the most 
ever reported up to that point.
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In Canada in the mid-2000s, aboriginal people comprised 3.8% of the popula-
tion but accounted for 8% of the cumulative people living with HIV and 13% 
of the people newly infected annually. Two thirds (66%) of the people newly 
infected inject drugs (99).
Rates of new infections among people who inject drugs have been falling 
overall—largely due to harm-reduction services. In the Netherlands (67) and 
Switzerland (98), for example, HIV infections due to ‘social’ drug using—
several people using the same contaminated injecting equipment—have almost 
been eliminated: at most 5% of new infections (in 2008 and 2007, respectively) 
were attributable to injecting drug use.
Th e epidemic is also declining among people who inject drugs in North 
America. Fewer than 10 000 people who inject drugs contracted HIV in 
2006 in the United States of America, for example, one third as many as 
in 1984–1986.
Multiple use by diff erent people of contaminated drug-injecting equipment can 
still dramatically accelerate an HIV epidemic, as Estonia has discovered. Hardly 
any people newly infected with HIV were detected there a decade ago; within a 
few years, a majority of the surveyed people who inject drugs (72% in one survey) 
were living with HIV (38).
Th ere are also fl ashpoints along the border between Mexico and the United 
States of America where intersecting networks of drug use and paid sex appear 
to be driving the spread of HIV. Studies have found an HIV prevalence of 12% 
among female sex workers who inject drugs in Ciudad Juarez and Tijuana (104) 
and 3% among other people who inject drugs (105) in Tijuana. Th ese localized 
epidemics have considerable potential for growth. In a large study among preg-
nant women in Tijuana, for example, the HIV prevalence was 1%, and among 
those who used drugs it was 6% (106).
Immigrants living with HIV have become a growing feature of the epidemics in 
several countries in Europe. Heterosexual transmission accounts for about half 
of the people newly infected with HIV in Central Europe (67), but many of 
these people were infected abroad (mostly in sub-Saharan Africa, the Caribbean, 
and Asia).
In the United Kingdom, about 44% of the people newly infected with HIV in 
2007 had acquired HIV abroad, mainly in sub-Saharan Africa (96). Overall in 
Europe, almost one in fi ve (17%) people newly diagnosed with HIV in 2007 
were from countries with generalized epidemics (107). ■
19x
Increase in likelihood that 
African-American females 
will aquire HIV,  compared to 
their Caucasian counterparts, 
in the United States.
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Table 2.9 
AIDS statistics for the Middle East and North Africa, 2001 and 2009
Source: UNAIDS.
Figure 2.20
HIV prevalence in Middle East and North Africa   
HIV prevalence among adults aged 15–49 years old in Middle East and North Africa, 1990 to 2009.
Source: UNAIDS.
MIDDLE EAST AND NORTH AFRICA
MIDDLE EAST AND 
NORTH AFRICA
2009
2001
People living 
with HIV
460 000
[400 000–530 000]
180 000
[150 000–200 000]
People newly 
infected with HIV
75 000
[61 000–92 000]
36 000
[32 000– 42 000]
Children living 
with HIV
21 000
[13 000–28 000]
7100
[3800–13 000]
AIDS-related 
deaths
23 000
[20 000–27 000]
8300
[6300–11 000]
No data <.1% .1% – <.5% .5% – <1% 1% – <1.5% 1.5% – 3%
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Figure 2.21 
HIV trends in the Middle East and North Africa  
Source: UNAIDS.
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Increasing HIV prevalence, new HIV infections and AIDS-related deaths
An estimated 460 000 [400 000–530 000] people were living with HIV 
in the Middle East and North Africa at the end of 2009, up from 180 000 
[150 000–200 000] in 2001 (Table 2.9 and Figure 2.20). Th e number of people 
newly infected has also increased over the last decade. Th ere were 75 000 
[61 000–92 000] people newly infected in 2009, more than twice the number 
(36 000 [32 000–42 000]) in 2001. AIDS-related deaths have nearly tripled: 
from 8300 [6300–11 000] in 2001 to 23 000 [20 000–27 000] at the end of 2009.
Reliable data on the epidemics in the Middle East and North Africa remain in 
short supply, creating diffi  culty in tracking recent trends with confi dence. Th e 
available evidence points to increases in HIV prevalence, new HIV infections, 
and AIDS-related deaths.
Th e HIV prevalence is low—with the exceptions of Djibouti and southern 
Sudan, where HIV is spreading in the general population, and pregnant women 
using antenatal services have a HIV prevalence of more than 1%.
Th e Islamic Republic of Iran is believed to have the largest number of people 
who inject drugs in the region, and its HIV epidemic is centred mainly within 
this population group. An estimated 14% of people who inject drugs country-
wide were living with HIV in 2007 (108).
Th e extremely high prevalence of hepatitis C virus (80%) found among detained 
people who inject drugs in Tehran (109) indicates considerable potential for 
the spread of HIV among and beyond people who inject drugs. It has been esti-
mated that close to half (45%) of the Iranian prison population is incarcerated 
for drug-related off ences (110,111). Exposure to contaminated drug-injecting 
equipment features in the epidemics of Algeria, Egypt, Lebanon, the Libyan 
Arab Jamahiriya, Morocco, Oman, the Syrian Arab Republic, and Tunisia.
MIDDLE EAST AND 
NORTH AFRICA
80%
Prevalence of hepatitis C 
virus among detained people 
who inject drugs in Tehran.
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Men who have sex with men disproportionately aff ected
Sex between men is heavily stigmatized in this region and is a punishable 
off ence in many countries. HIV services for men who have sex with men tend 
to be limited (112). Evidence indicates that men who have sex with men bear a 
disproportionate share of the HIV burden in at least some countries.
In surveys in Sudan, 8%–9% of men who have sex with men were living with 
HIV (70), compared with 6% in Egypt (113). As in other regions, many men 
who have sex with men also have sex with women (114).
Sex work networks exist but have low HIV prevalence
Th e available evidence suggests that HIV transmission is still limited in paid 
sex networks. When surveyed in 2006, about 1% of female sex workers in Egypt 
were living with HIV (113), compared with an estimated 2%–4% in Algeria, 
Morocco and Yemen (112). Th ere are not enough data to determine the extent 
to which HIV is being transmitted to sex workers’ male clients and other sex 
partners and to their respective partners. ■
“SEX BETWEEN MEN IS 
HEAVILY STIGMATIZED IN 
THE MIDDLE EAST AND 
NORTH AFRICA AND IS A 
PUNISHABLE OFFENCE IN 
MANY COUNTRIES.”
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Table 2.10 
AIDS statistics for Oceania, 2001 and 2009
Source: UNAIDS.
Figure 2.22
HIV prevalence in Oceania   
HIV prevalence among adults aged 15–49 years old in Oceania, 1990 to 2009.
Source: UNAIDS.
OCEANIA
OCEANIA 2009
2001
People living 
with HIV
57 000
[50 000–64 000]
28 000
[23 000–35 000]
People newly 
infected with HIV
4500
[3400–6000]
4700
[3800–5600]
Children living 
with HIV
3100
[1500– 4800]
<1000
[<500–1600]
AIDS-related 
deaths
1400
[900–2400]
<1000
[<500–1000]
No data <.1% .1% – .5% .5% – <1% 1% – <1.5% 1.5% – 2%
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Figure 2.23 
HIV trends in Oceania  
Source: UNAIDS.
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HIV epidemic begins to stabilize
Th e HIV epidemic in Oceania is small, but the number of people living with 
HIV in this region nearly doubled between 2001 and 2009—from 28 000 
[23 000–35 000] to 57 000 [50 000–64 000] (Table 2.10 and Figure 2.22). 
However, the number of people newly infected with HIV has begun to decline 
from 4700 [3800–5600] in 2001 to 4500 [3400–6000] in 2009.
Th e HIV epidemic in Papua New Guinea is the largest and the only generalized 
one in this region. Recent analysis of available data across the country shows 
that the epidemic is starting to level off . Th e national adult HIV prevalence in 
2009 was estimated at 0.9% [0.8%–1.0%], with about 34 000 [30 000–39 000] 
people living with HIV. Th e estimates were calculated using data from antenatal 
clinics in all parts of Papua New Guinea that off er HIV testing to pregnant 
women as part of routine care. Programmes that aim to prevent mother-to-
child transmission of HIV substantially increased the number of sites providing 
testing services to women during recent years, from 17 in 2005 to 178 in 2009, 
also resulting in more information available for the estimation process.
Sexual transmission promotes HIV epidemics
Th e HIV epidemics in Oceania are mainly driven by sexual transmission. 
Unprotected heterosexual intercourse is the main mode of transmission in 
Papua New Guinea, whereas unprotected sex between men predominates in the 
epidemics of the smaller Pacifi c countries and in those of Australia and New 
Zealand (115).
As in many other high-income countries with older HIV epidemics, new HIV 
diagnoses have increased among men who have sex with men in Australia and 
New Zealand in the past decade. Th e trend may point to increased higher-risk 
sexual behaviour in this population group (116,117).
A lack of survey data creates diffi  culty in determining the role of commercial 
sex work in Papua New Guinea’s epidemic, but paid sex appears to be com-
monplace among mobile populations, including migrant workers, transport 
workers, and military personnel (118).
OCEANIA
“THE HIV EPIDEMIC IN 
PAPUA NEW GUINEA IS 
THE LARGEST AND THE 
ONLY GENERALIZED ONE 
IN OCEANIA.”
161
From 2005 to 2009, increase 
in number of testing sites 
with programmes that aim 
to prevent mother-to-child 
transmission of HIV.
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Injecting drug use—a small but signifi cant factor
Injecting drug use is a minor factor in the epidemics in this region. But in parts 
of Australia, it features prominently in the HIV epidemic among aboriginal 
people. HIV infection among Aboriginal and Torres Strait Islander people was 
attributed to injecting drug use in 22% of cases over the past fi ve years (117). 
However, in French Polynesia and Melanesia (excluding Papua New Guinea), 
people who inject drugs comprise 12% and 6%, respectively, of cumulative HIV 
case reports (115).
Children newly infected—Papua New Guinea has most of the burden
Mother-to-child transmission of HIV is a signifi cant factor only in Papua New 
Guinea’s epidemic, where nearly 10% of all people newly diagnosed with HIV 
to date acquired it during perinatal exposure (115). ■
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SCORECARD: INCIDENCE
Changes in the incidence rate of HIV infection, 2001 to 2009, selected countries
Increasing >25%
Stable
Decreasing >25%
Not included in analysis
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Increasing >25%
Armenia
Bangladesh
Georgia
Kazakhstan
Kyrgyzstan
Philippines
Tajikistan
Stable
Angola
Argentina
Belarus
Benin
Cameroon
Democratic Republic 
  of the Congo
Djibouti 
France
Germany
Ghana
Haiti
Kenya
Lesotho
Lithuania
Malaysia
Niger
Nigeria
Panama
Republic of Moldova
Senegal
Sri Lanka
Uganda
United States of America
Decreasing >25%
Belize
Botswana
Burkina Faso
Cambodia
Central African Republic
Congo
Côte d’Ivoire
Dominican Republic
Eritrea
Ethiopia
Gabon
Guinea
Guinea-Bissau
India
Jamaica
Latvia
Malawi
Mali
Mozambique
Myanmar
Namibia
Nepal
Papua New Guinea
Rwanda
Sierra Leone
South Africa
Suriname
Swaziland
Thailand
Togo
United Republic of Tanzania
Zambia
Zimbabwe
In the absence of a reliable diagnostic test that can directly measure the level of new HIV infections in a population, estimates of HIV incidence have 
been produced through modeling The map includes 60 countries for which reliable estimates of new HIV infections over time were available from 
the 2010 round of country-specifi c estimation using the EPP/Spectrum tools, and 3 countries for which peer-reviewed publications with incidence 
trends were available. The EPP/Spectrum methods estimate HIV incidence trends from HIV prevalence over time combined with the changing 
level of antiretroviral therapy. The criteria for including countries in this analysis were as follows. EPP fi les were available and trends in EPP were not 
derived from workbook prevalence estimates; prevalence data were available up to at least 2007; there were at least four time points between 2001 
and 2009 for which prevalence data were available for concentrated epidemics and at least three data points in the same period for generalized 
epidemics; for the majority of epidemic curves for a given country, EPP did not produce an artifi cial increase in HIV prevalence in recent years due 
to scarcity of prevalence data points; data were representative of the country; the EPP/Spectrum–derived incidence trend was not in confl ict with 
the trend in case reports of new HIV diagnoses; and the EPP/Spectrum–derived incidence trend was not in confl ict with modelled incidence trends 
derived from age-specifi c prevalence in national survey results. For some countries with complex epidemics including multiple populations groups 
with different risk behaviours as well as major geographic differences, such as Brazil, China and the Russian Federation, this type of assessment is 
highly complex and it could not be concluded in the 2010 estimation round. UNAIDS will continue to work with countries and partners to improve 
the quality of available information and modeling methodologies to include HIV incidence data for additional countries in future reports.
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KEY FINDINGS
■  The global incidence of HIV infection declined by 19% between 1999 (the 
year of peak incidence) and 2009; the decline exceeded 25% in 33 countries, 
including 22 countries in sub-Saharan Africa.
■  In 2009, 370 000 [230 000–510 000] children were infected with HIV through 
mother-to-child transmission. This is a drop of 24% from fi ve years earlier. 
However, rapid expansion of delivery of effective advances in preventing 
mother-to-child transmission is being held back by inadequate access to 
antenatal and postnatal services.
■  HIV prevention investments are about 22% of all spending in 106 low- and 
middle-income countries.
■  Globally, comprehensive and correct knowledge about HIV among both 
young men and young women has increased slightly since 2008—but at only 
34%, the number of young people with this comprehensive knowledge is 
barely one third of the UNGASS target of 95%.
■  Trend analysis shows a general decline in the percentage of people who have 
had more than one sexual partner in the past year in sub-Saharan Africa.
■  Condom availability in places of need is increasing signifi cantly, with 
25.8 million female condoms provided through international and 
nongovernmental funding sources in 2009. Condom distribution increased 
by 10 million between 2008 and 2009.
■  Recent promising results of a tenofovir-based gel have raised hopes that 
an additional effective female-initiated prevention option may soon 
become viable.
HIV PREVENTION 
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New HIV infections are declining globally
Dedicated eff orts to promote and support combination HIV prevention 
are producing clear and impressive results. Th e incidence of HIV infection 
declined by 19% between 1999 and 2009 globally; the decline exceeded 25% in 
33 countries, including 22 countries in sub-Saharan Africa. But while parts of 
the world experienced signifi cant and encouraging decreases in HIV incidence 
between 2001 and 2009, during the same period the incidence increased 
by more than 25% in seven countries, including fi ve in Eastern Europe and 
Central Asia. And HIV incidence remained stable in 23 countries between 
2001 and 2009. Behaviour change is the most important factor accounting for 
these encouraging declines in new HIV infections in many countries. Among 
young people, noteworthy drops in HIV incidence have been associated with 
a signifi cant positive trend (for either or both sexes) in important behaviour 
indicators, including increased condom use, delayed sexual debut, and 
reductions in multiple partnerships (1).
Correct and consistent condom use has been found to be greater than 90% 
eff ective in preventing transmission of HIV and other sexually transmitted 
infections. Eleven countries reported levels of 75% or greater among either 
men or women for condom use at last higher-risk sex. Major successes in 
HIV prevention have been achieved in concentrated epidemic countries that 
have devoted substantial programming eff orts and funds to prevention among 
people at higher risk of exposure to HIV. Too oft en, however, prevention 
responses still do not focus on these key populations.
In 2009, 370 000 [230 000–510 000] children were infected with HIV through 
mother-to-child transmission (down from 500 000 [320 000–680 000] in 2001). 
Although this is an important achievement for the health of both mothers and 
infants, further rapid expansion in delivering advances in preventing mother-
to-child transmission is being held back by inadequate access to antenatal and 
postnatal services.
Focusing HIV-prevention investments appropriately
HIV prevention investments are about 22% of all spending in 106 low- and 
middle-income countries. Even with existing resources, one notable challenge 
to strengthening the eff ects of the response to the epidemic has been the reluc-
tance of planners and implementers to focus prevention eff orts where they 
produce maximum impact. HIV prevention investments do not always follow 
epidemic patterns. In Eastern Europe and Central Asia, areas experiencing 
CHAPTER 3 | HIV PREVENTION
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primarily concentrated epidemics, 89% of HIV-prevention investments in these 
regions are not focused on people at higher risk, such as people who inject 
drugs, sex workers and their clients, and men who have sex with men. A nota-
ble proportion of new infections are found among these population groups, 
even in countries with generalized epidemics, yet prevention spending oft en 
ignores this reality. For example, the proportion of HIV prevention expenditure 
devoted to programmes for sex workers and their clients, men who have sex 
with men and people who inject drugs is only 1.7% in Burkina Faso, 0.4% in 
Côte d’Ivoire and 0.24% in Ghana, yet the percentage of new infections in these 
population groups is 30%, 28% and 43%, respectively (2).
In both Kenya and Mozambique, between one quarter and one third of new 
HIV infections occur among people who inject drugs, men who have sex with 
men, and sex workers and their clients (3). Th e proportions of Kenya’s and 
Mozambique’s total AIDS spending directed to HIV prevention among these 
key populations are 0.35% and 0.25% respectively, and almost all is from inter-
national sources. Spending directed specifi cally to support these populations 
in their response to HIV is only one hundredth of their respective share of the 
national epidemic (4).
Similarly, investment focused on young people oft en does not achieve an 
appropriate balance between the need for continued investment in HIV 
prevention among all young people and the need to pay particular attention 
to the special needs of young people at higher risk from drug use, sex work, 
or unprotected sex between men. For example in Asia, 90% of resources for 
young people are spent on low-risk youth, who represent just 5% of the people 
becoming infected with HIV (5).
Combination HIV prevention eff orts are bearing results
Where key behavioural indicators related to the risk of HIV infection—condom 
use, sex before age 15 years (early sexual debut) and multiple partnerships—all 
have positive trends, the incidence of HIV infection is markedly reduced (1).
Evidence that combination HIV prevention eff orts that address the most press-
ing HIV risks have decisively changed the course of the epidemic continues to 
accumulate. In Namibia, improvements across key knowledge and behaviour 
indicators—including comprehensive knowledge, age of sexual debut, engage-
ment in higher-risk sex, and condom use among both males and females aged 
15–24 years—were associated with declines in HIV prevalence among young 
people, from slightly more than 10% in 2007 to about 5% in 2009. 
370K
In 2009, an estimated 370 000 
children were infected with HIV 
through mother-to-child transmission 
(down from 500 000 in 2001).
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Figure 3.1
HIV prevention in Zambia, 2000-2009   
Source: Zambia Sexual Behavior Survey.
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Between 2001 and 2009, overall HIV incidence in Namibia decreased by 
more than 25%. Similar trends were also recorded in Zimbabwe. But when 
diff erent types of behaviour change vary—for example, when condom use 
increases and multiple partnerships do also, or vice versa—the eff ects of 
changes in reducing incidence are less easy to identify clearly.
In Zambia, HIV incidence declined by more than 25% between 2001 and 
2009. Th e country has successfully increased both the age of sexual debut and 
abstinence among young people (6). Th e number of both young and older 
adults who have multiple partners has also declined. However, the proportion 
of men and women 15–24 years old with more than one partner in the past 
year who used a condom at last sex has also markedly declined.
Although fewer young men and women in Zambia are sexually active and 
fewer have had more than one partner in the past 12 months, condom use 
within this population has decreased rather than increased. For maximum 
eff ect, all routes to reducing the risk of sexual exposure to HIV must be 
pursued simultaneously (Figure 3.1).
Behaviour change and increased comprehensive correct knowledge 
reduces HIV incidence and prevalence in most countries with high 
HIV prevalence
Globally, comprehensive and correct knowledge about HIV among both 
young men and young women has increased slightly since 2003—but at only 
34%, the number of young people with this comprehensive knowledge is only 
slightly greater than one third of the UNGASS target of 95%.1 Ten countries 
have achieved comprehensive correct knowledge levels above 60% for either 
men or women 15–24 years old (Figure 3.2).
Opportunities to improve HIV prevention knowledge and behaviour still 
abound. Less than half of young people living in 15 of the 25 countries with 
the highest HIV prevalence can correctly answer fi ve basic questions about 
HIV and its transmission (these include Botswana, Burundi, Cameroon, 
Central African Republic, Chad, Congo, Cote d’Ivoire, Guinea-Bissau, Kenya, 
Malawi, Nigeria, South Africa, Togo, United Republic of Tanzania and 
Zambia). Young people ages 15–24 years old showed gradually improving 
knowledge about HIV in these 25 countries but still fall short of the global 
targets for comprehensive knowledge set in 2001.
Complex, changing, and multiple relationships
Understanding the varieties and patterns of sexual relationships is a necessary 
element in implementing eff ective prevention programmes. In most 
countries, a minority of males and females report having had sex with more 
than one partner in the last year. Trend analysis shows a general decline in 
the percentage of people who had more than one partner in the past year in 
sub-Saharan Africa, with some exceptions, such as Botswana, Congo, South 
Africa and Uganda. In Uganda, men older than 25 years are increasingly 
1 Limited data (nine of 41 countries) are 
available from Western and Central Europe, 
and to a lesser extent, the Middle East and 
North Africa (eight of 20 countries). Sub-
Saharan Africa is the region with the most 
complete data on comprehensive knowledge 
of HIV, largely due to the Demographic and 
Health Surveys that have been undertaken 
in 85 countries, with major support from the 
United States Government together with 
participating countries and other funders.
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Males Females
Figure 3.2
Young people’s knowledge of HIV
Countries with comprehensive correct knowledge of HIV 
exceeding 60% among people 15–24 years old.
Source: Country Progress Reports 2010. 
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Figure 3.3
Multiple sexual partners in the past year, Uganda 
Percentage of the population (ages 15–49 years old) that have had 
multiple sex partners in the past year in Uganda, by sex and age 
group, 1989–2006.
Source: Demographic and Health Surveys and other population-based 
behavioural survey data.
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reporting multiple partners, while the number of women reporting sex with 
more than one partner has remained fairly stable (Figure 3.3).
In 59 of the 93 countries reporting these data—including 18 of the 25 coun-
tries with the highest prevalence of HIV—less than 25% of men reported sex 
with more than one partner in the last 12 months. A substantially larger num-
ber—84 countries—reported that less than 25% of women had sex with more 
than one partner in the past 12 months. On average, the proportion of men 
who reported having had sex with more than one partner in the past year was 
16 percentage points higher than among women. Ten countries reported that 
26% to 50% of men had more than one partner in the past year; two countries 
reported that 26% to 50% of women did so.
Condom availability and condom uptake is improving
Eleven countries reported levels of 75% or greater among either men or women 
for condom use at last higher-risk sex—these countries include Botswana, India 
and South Africa. Country progress reports show that the median percentage 
of condom use at last sex for males with more than one partner in the past 
12 months is 48% versus 38% for women. Of the 83 countries for which data 
are available, 32 reported 60% or greater condom use at last sex among the men 
who have had sex with more than one partner in the past 12 months versus 20 
of 80 reporting countries among women.
Trend data from Demographic and Health Surveys show that condom use 
is increasing in sub-Saharan Africa. Botswana reported that at least 80% of 
men used a condom at last higher-risk sex; no countries reported this level of 
condom use for women. In contrast, 14 countries report condom use rates of 
20% or less at last sex for those with more than one partner in the past year 
among either males or females, including the high-prevalence countries of the 
Democratic Republic of the Congo, Ethiopia, Malawi, Rwanda, Uganda and the 
United Republic of Tanzania.
In Asia, women in Cambodia, Myanmar and Th ailand and men in Timor-Leste 
reported lower than 25% condom use at last higher-risk sex. Th e other coun-
tries in Asia showed higher rates of condom use at last higher-risk sex or did 
not report on this indicator. Of the countries reporting this indicator in Eastern 
Europe and Central Asia, most reported between 51% and 80% using a condom 
at last higher-risk sex.
Reports of condom use by sex workers at last sex with a client are encouraging. 
Of 86 countries providing data, 26 reported that 90% or more of sex workers 
report having used a condom with their last client, with another 13 countries 
reporting condom use levels from 80% to 90%. At the same time, 47 countries—
more than half of those reporting—report rates of condom use by sex workers 
with their last client below 80%, including less than 60% in 17 countries. Greater 
condom promotion eff orts are needed to increase the levels of usage of this tech-
nology for protection against HIV by sex workers and their clients.
Th e availability of female condoms in places of need is signifi cantly increasing, 
75%
Level of condom use 
in risky sex by men and 
women reported 
by 11 countries
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Figure 3.4
Harm reduction programmes and HIV prevalence in Ukraine  
Association between harm reduction programmes and 
HIV prevalence in Ukraine, 2004–2009.
Sources: M Mahy, C Chhea, T Saliuk, O Varetska, R Lyerla (2010). A proxy measure for 
HIV incidence among populations at increased risk to HIV Vol 2(1):8, Journal of HIV/AIDS 
Surveillance and Epidemiology. UNGASS Country Progress Reports 2010.
Recent Initiators
Young IDUs (15-24)
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Ukraine—significant strides in protecting people who 
use drugs from HIV infection
For many years, Ukraine has had the most severe HIV epidemic among people who inject drugs 
in Eastern Europe and Central Asia. However, four years of comprehensive, sustained funding for 
and implementation of evidence-based harm reduction programming have helped reduce the HIV 
incidence among people who inject drugs in Ukraine. Data from multiple sources, from behavioural 
surveillance, sentinel surveys and programmes serving people who inject drugs all indicate that HIV 
transmission among people who inject drugs in Ukraine appears to be signifi cantly decreasing. HIV 
infections among people who started injecting drugs in only the past two years (and are thus more 
likely to represent incident infections rather than ones acquired much earlier) decreased from a 
peak of 30% in 2004 to 11% in 2008 (14).
Behavioural surveillance in Ukraine shows that people who inject drugs are increasingly adapting 
key HIV risk-reduction measures. The percentage of people who inject drugs who report using 
sterile injecting equipment at last injection rose from 80% in 2006 to 86% in 2008. In 2009, about 
4600 people who inject drugs were accessing opioid substitution therapy at any time (15). Although 
the HIV epidemic among people who inject drugs in Ukraine has stabilized, they remain at high risk 
of acquiring HIV, whether by sharing contaminated equipment or through the sexual transmission of 
HIV from people who inject drugs to their partners (Figure 3.4).
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Figure 3.5
Availability of sterile injecting equipment, 2010  
Global estimates of the availability of sterile injecting equipment per 
person who uses drugs per year, 2010.
Source: Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV 
prevention, treatment and care for people who inject drugs: A systematic review of global, 
regional and national coverage. The Lancet 2010;375:1014-28.
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NSP absent
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No data available
with 25.8 million condoms provided through international and nongovern-
mental funding sources in 2009, as opposed to 10.7 million condoms fi nanced 
through these sources in 2006. Between 2008 and 2009 alone, condom distribu-
tion increased by 10 million. Global distribution of female condoms, however, 
still lags far behind that of male condoms. 
HIV prevention eff orts focused on people who inject drugs
An estimated 15.9 million [11.0 million–21.2 million] people inject drugs 
worldwide; of these, nearly 20%, an estimated 3 million [500 000–5.5 million] 
are living with HIV (12)(Table 3.1). Access to HIV prevention services, 
including harm-reduction programmes assisting people who use drugs, has 
increased, but not at the required scale. Globally, the median coverage of HIV 
prevention services was 32%. Although both men and women who inject 
drugs experience a signifi cant burden of HIV disease, infection with other 
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Table 3.1
Countries in which HIV 
infections among people who 
inject drugs represent 20% or 
more of the total number of 
people living with HIV
Source: Mathers et al. (12).
Azerbaijan 
Canada 
China
Estonia 
Georgia
Indonesia
Iran (Islamic Republic of)
Italy
Kazakhstan
Kyrgyzstan
Malaysia
New Zealand 
Pakistan
Russian Federation
Spain
Tajikistan
Ukraine
United States of America
Uzbekistan
bloodborne viruses and also potentially life-threatening conditions such as 
tuberculosis, women who inject drugs face even greater risks. Studies indicate 
that women who inject drugs are more likely to face violence and greater levels 
of stigma and are more likely to die earlier (13).
Making injecting safer for people who use drugs by providing sterile equipment 
is relatively easy and inexpensive and can signifi cantly reduce levels of HIV 
transmission. Half of the 50 countries that report data about the use of safe injec-
tion equipment estimate that 80% or more of the people who inject drugs used 
a sterile needle at last injection. In Eastern Europe and Central Asia, where the 
HIV epidemics are primarily driven by injecting drug use, fi ve of nine coun-
tries (Belarus, the Republic of Moldova, the Russian Federation, Ukraine and 
Uzbekistan) reported in 2009 that more than 80% of people who inject drugs 
used sterile injecting equipment at last injection. Eight of 12 countries reporting 
in South and South-East Asia report rates of sterile needle usage at last injection 
exceeding 80%. In Central and South America, Argentina reports more than 80% 
using a sterile needle at last injection (most other countries do not report on this 
indicator). In Oceania, Australia reports more than 80% using a sterile needle at 
last injection (other countries not reporting).
In North America and Europe, 10 countries report exceeding 80% usage of 
sterile equipment and nine below. In the Middle East and North Africa, all 
three reporting countries had levels below 80%. In the other regions, a large 
majority of countries did not report on this indicator.
According to WHO, UNODC and UNAIDS target-setting guidelines (16), the 
availability of fewer than 100 syringes per person who injects drugs per year is 
considered low, 100–200 medium, and more than 200 high. In addition to the 
survey data on the extent to which sterile needles were used at the most recent 
injection, Figure 3.5 illustrates that the number of sterile needles made available 
per estimated person who injects drugs is very low.
Men who have sex with men—a key population still needing support
Access to HIV prevention programmes and services for men who have sex with 
men has increased somewhat in the past two years but remains inadequate 
overall (Figure 3.6). Safer sex behaviour, especially not having unprotected 
penetrative sex, is eff ective in protecting individuals and the larger communi-
ties of men who have sex with men from HIV and other sexually transmitted 
infections. Data from 78 countries show that condom use by men who have sex 
with men was less than 50% in 24 countries, between 50% to 60% in 16 coun-
tries, 60% to 80% in 28 countries and more than 80% in only seven countries: 
Andorra, Cambodia, Guyana, Myanmar, Panama, Suriname, and Uzbekistan. 
Figure 3.7 gives the median and range of the proportion of reported condom 
use at last sex by men who have sex with men by geographical region.
Among countries reporting to UNGASS in 2010, a global median of 42% of 
men who have sex with men reported receiving an HIV test and the result in 
the past 12 months. A man knowing his HIV-positive status can protect his 
health by receiving appropriate treatment early and also be encouraged through 
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counselling and support to lessen the risk of transmitting the virus to his future 
partners. A man who tests HIV-negative can be supported to continue to 
avoid being infected. Some regions report testing rates considerably above the 
median, such as in Central and South America, where Argentina, El Salvador, 
Guyana, and Paraguay reported that more than 80% of men who have sex with 
men have had an HIV test and know the results in the past 12 months.
A recent survey by the Global Forum on MSM and HIV assessed the 
availability of and access to testing and prevention services for sexually 
transmitted infections and HIV among men who have sex with men in eight 
regions (18). Of the 17 services assessed (including sexually transmitted 
infection and HIV testing and counselling, HIV treatment, free condoms, 
mental health services, circumcision, and mass-media campaigns to reduce 
HIV and to reduce homophobia), only in two areas (sexually transmitted 
infection testing and circumcision) did a majority of respondents (only 51% 
in both cases) report that the services were easily accessible. Respondents also 
noted the many barriers to their access to services, including homophobia, 
stigma, criminalization of same-sex acts, policy barriers, and insensitivity or 
lack of awareness among health care providers.
Commercial and transactional sex
HIV prevention programmes among sex workers have achieved major progress 
both in increasing condom use in sex work and in reducing associated HIV 
infections. Considerable room remains, however, to improve the availability 
and use of condoms among sex workers and their clients. In 27 of 87 countries, 
data indicate that 90% or more of sex workers report condom use with their last 
client. A further 17 countries report condom use by sex workers at 80% to 90%. 
In contrast, 17 countries report rates of less than 60%.
In countries with concentrated epidemics, HIV prevalence trends among recent 
initiates into sex work provide insight into the trajectory of the HIV epidemic 
and are a proxy measure of HIV incidence. Figure 3.8 illustrates the case of 
sex workers in Cambodia: HIV prevalence among those engaged in sex work 
for less than one year declined steadily from 2002 to 2006, tracking a decline 
in estimated incidence. HIV prevalence also declined among sex workers who 
have been working for more than two years, but prevalence remains consider-
ably higher than for those more recently engaged in sex work.
In India, the Avahan programme, underway since 2003, has demonstrated 
signifi cant results among sex workers (19). Th e combined prevention approach 
of Avahan (community outreach, empowerment, condom programming and 
sexually transmitted infection and HIV testing services) explicitly addresses 
individuals with great vulnerability to HIV infection in six high-prevalence states: 
sex workers, men who have sex with men, people who inject drugs, and men at 
higher risk along key trucking routes. Recent results from an Avahan study of sex 
workers in Karnataka, in south India, showed that, from the time the programme 
was fi rst implemented, the HIV prevalence in this population declined from 20% 
to 16% and condom use at last client sex increased from 66% to 84% (20).
80%
Argentina, El Salvador, Guyana, and 
Paraguay reported that more than 
80% of men who have sex with men 
have had an HIV test and know the 
results in the past 12 months.
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Figure 3.6
HIV prevention programmes for selected populations
Median coverage of HIV prevention programmes for selected 
population groups, 2008 and 2010.
Source: Country Progress Reports 2010.
2008
Median
Medians were not calculated where 
number of countries was 5 or less
2010
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Figure 3.7
Condom use by men who have sex with men
Percentage (median and range) of men who have sex with men 
who used a condom at last sex by geographical region, 2010. 
Source: Country Progress Reports 2010
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Structural approaches to HIV prevention
Tackling the social and economic drivers of HIV risk and vulnerability can signifi cantly infl uence the epidemic if these 
approaches are implemented systematically.
One example of social change that could directly reduce the number of new HIV infections is reducing the violence faced 
by people who inject drugs. Moving beyond the availability of sterile needles and syringes and treatment programmes 
to reduce HIV for people who inject drugs—changes in the social, economic and policy environment can also have a 
marked effect. For example, an association has been observed between police violence against people who inject drugs 
and specifi c types of higher-risk behaviour such as using preloaded syringes. Building on this association, recent model-
ling has estimated the number of HIV infections that could be averted if police violence against people who inject drugs 
was eliminated (Figure 3.9).
Another approach is the IMAGE Programme in South Africa, which combines microfi nance for women with gender 
training and community mobilization. The programme was evaluated as a randomized trial and found positive effects on 
household economic well-being and women’s empowerment, a 50% reduction in intimate partner violence, and reduced 
HIV risk behaviour among young women participants. The programme has scaled up to reach more than 12 000 women 
in South Africa.
Schooling for girls has the potential to reduce HIV risk. The positive effects of both school participation and HIV pro-
grammes in schools on HIV-related risks have been well established (22). Age-disparate partnerships, in which young 
women are in relationships with men at least fi ve years older, are also associated with elevated risk of HIV infection (23). 
Cash transfers are emerging as a potential intervention to mitigate certain social or economic drivers of HIV vulnerability.
Several recent studies provide evidence of the effectiveness of cash transfers in educational retention and HIV prevention. 
In Zomba, Malawi, for example, both conditional and unconditional cash transfers for adolescent girls resulted in increased 
school attendance among benefi ciaries (24). Early marriage, pregnancy, and self-reported sexual activity declined notably 
among benefi ciaries of both types of cash transfers. According to the evidence, observed changes in self-reported sexual 
`account for less than half of the programme’s effects on HIV, with the rest due to a change in the risk profi le of the girls’ 
sexual partners (25). These results suggest that structural interventions such as cash transfers might be a promising tactic for 
overcoming age-disparate sex, a key driver of the epidemic in several countries.
In addition, structural approaches that strengthen solidarity and collective action `can play a critical role in enhancing resil-
ience to HIV among marginalized groups, including sex workers. Avahan, the India AIDS Initiative funded by the Bill & 
Melinda Gates Foundation (19), has found that structural activities can be feasible and cost-effective, and can contribute to 
more sustainable HIV prevention when integrated into a package of prevention activities. Pathfi nder International, a key part-
ner of Avahan, and its local implementing nongovernmental organization partner in Kolhapur are implementing a structural 
intervention that provides supported peer-led outreach, crisis response services and community mobilization to street-based 
sex workers, whose visibility makes them vulnerable to arrest and to violence from police, clients, and gangs (26).
Food insecurity is widespread globally (more than 1 billion people are undernourished) and forces people to use various 
types of coping behaviour, some of which increase the likelihood of engaging in unprotected sex, particularly sexual 
risk-taking among women, as they may engage in transactional sex to procure food for themselves and their children. 
A study, conducted in Botswana and Swaziland, showed that food insecurity was associated with inconsistent condom 
use with a “non-primary” partner: women reporting food insuffi ciency in the previous 12 months had 80% increased 
odds of selling sex for money or resources, 70% increased odds of engaging in unprotected sex and reporting lack of 
sexual control and 50% increased odds of intergenerational sex (27). Similarly, a study in Uganda that investigated the 
relationship between food insecurity and transactional sex showed the negative effects of food insecurity on control over 
condom use and the risk of staying in abusive relationships (28). Gender inequality, often reinforced by intergenerational 
sex, further weakens women’s negotiating power. A study from Nigeria reported that 35% of female sex workers said 
that poverty and lack of means to obtain food caused them to join the sex trade, and to engage in unprotected sex with 
clients (29). These associations remained even when controlling for other markers of socioeconomic status. 
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Figure 3.8
Condom use and HIV prevalence among sex workers in Cambodia
Percentage of sex workers using condoms and HIV prevalence among broth-
el-based sex workers in Cambodia by length of time involved in sex work, 
1998–2007.
Source: M Mahy, C Chhea, T Saliuk, O Varetska, R Lyerla (2010). A proxy measure for HIV inci-
dence among populations at increased risk to HIV Vol 2(1):8, Journal of HIV/AIDS Surveillance 
and Epidemiology.
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Figure 3.9
Averting HIV infection by eliminating police 
beatings of people who inject drugs, Ukraine
HIV infections that could be averted by eliminating police 
beatings of people who inject drugs in three cities in Ukraine 
Source: Strathdee et al 2010
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Signifi cant strides in preventing mother-to-child transmission
Preventing mother-to-child transmission of HIV has been a fundamental 
advance in the AIDS response for the past decade. Infection rates among 
children born to mothers living with HIV have dropped signifi cantly in recent 
years, from 500 000 [320 000–680 000] in 2001 to 370 000 [230 000–510 000] 
children infected with HIV in 2009.
Several countries have advanced eff orts to prevent the mother-to-child 
transmission of HIV. Botswana, Namibia, South Africa and Swaziland have 
achieved more than 80% coverage of antiretroviral prophylaxis to prevent 
mother-to-child transmission. Seven other countries in sub-Saharan Africa 
have coverage levels of 50% to 80%. Sub-Saharan Africa as a whole achieved 
54% [40%–84%] coverage. In East and Southern Africa, 68% [53%–95%] of 
pregnant women living with HIV received antiretroviral medication to prevent 
mother-to-child transmission in 2009 (up substantially from 15% in 2005). In 
West and Central Africa, however, coverage lags at 23% [16%–44%] (30).
Worldwide, 53% [40%–79%] of women in low- and middle-income countries 
received antiretroviral medication to prevent the mother-to-child transmission 
of HIV in 2009, versus 45% [37%–57%] in 2008 and 15% in 2005 (31). Th e gap 
in reaching the target of 80% coverage of antiretroviral prophylaxis for prevent-
ing mother-to-child transmission is becoming more concentrated in a handful 
of countries, with 14 countries comprising more than 80% of the global gap. 
Nigeria alone now contributes to 32% of the gap, with the Democratic Republic 
of the Congo next, contributing 7% of the gap (Figure 3.10, Figure 3.11).
Th e proportion of pregnant women in low- and middle-income countries 
who received an HIV test reached 26%, up from 21% in 2008 and 7% in 2005 
(31)—progress, but still a low fi gure, on the path towards the UNAIDS goal of 
virtually eliminating the mother-to-child transmission of HIV by 2015. In the 
25 countries with the greatest number of pregnant women living with HIV,2 the 
percentage receiving HIV testing and counselling varied greatly—from more 
than 95% in South Africa and Zambia to 9% in the Democratic Republic of the 
Congo and 6% in Chad (31).
Coverage for services for preventing mother-to-child transmission has lagged 
behind antenatal care access (Figure 3.12). In addition, women living with HIV 
continue to have a high unmet need for family planning: in some countries, more 
than one quarter of women living with HIV do not desire their current pregnan-
cy or would like to delay their next pregnancy by two years. Strengthening family 
planning services and the delivery of maternal, newborn and child health care 
would produce better outcomes for babies and their mothers.
Th e effi  cacy of antiretroviral drugs in preventing mother-to-child transmission 
of HIV varies with the type of regimen used and the duration over which it is 
given. Combination regimens which include diff erent types of antiretroviral 
drugs are more effi  cacious than monotherapies. Monotherapies are also 
prone to building antiretroviral resistance in the virus, which may limit future 
therapeutic options when treatment is needed. According to the 2010 WHO 
2 Countries with the largest number of 
pregnant women living with HIV in 2009: 
Angola, Botswana, Burkina Faso, Burundi, 
Cameroon, Chad, Cote d’Ivoire, Democratic 
Republic of the Congo, Ethiopia, Ghana, 
India, Kenya, Lesotho, Malawi, Mozambique, 
Namibia, Nigeria, Rwanda, South Africa, 
Sudan, Swaziland, Uganda, United Republic 
of Tanzania, Zambia, Zimbabwe.
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Figure 3.10
Gaps in antiretroviral therapy to prevent 
mother-to-child transmission 
Global gap in providing antiretroviral therapy to 80% of 
mothers to prevent mother-to-child transmission in low- 
and middle-income countries.
Source: WHO Towards Universal Access 2010.
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treatment guidelines it is recommended that pregnant women living with HIV and 
their exposed infants receive combination therapy rather than single-dose Nevirapine. 
Antiretroviral prophylaxis is also recommended during breastfeeding in settings where 
breastfeeding is judged to be the safest infant feeding option. In addition, all women 
eligible for treatment under WHO guidelines should receive an appropriate combination 
therapy for their own health.    
In the 59 low- and middle-income countries that provided disaggregated data for their 
prevention of mother-to-child regimens around 30% of pregnant women received single-
dose Nevirapine, while 54% received a combination regimen to avoid mother-to-child 
transmission of HIV. About 15% of all mothers received ongoing antiretroviral therapy 
based on eligibility criteria for treatment. Figure 3.11 shows the distribution of regimens 
given for the prevention of mother-to-child transmission in 2009 for the 25 countries with 
the greatest number of HIV positive pregnant women. Of those countries 10 have moved 
from using single-dose Nevirapine to providing more effi  cacious combination regimens. 
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However, in India, Ethiopia, the Democratic Republic of Congo, Zimbabwe and 
Malawi over two thirds of women who were provided with antiretrovial drugs 
for the prevention of mother-to-child transmission were still off ered single dose 
Nevirapine. In these countries there is an urgent need to update the regimens in 
line with the global standards. 
New tools to expanding eff ective HIV prevention
Th e goals and targets set at the United Nations General Assembly Special Session 
on HIV/AIDS (UNGASS) in 2001, which emphasize increasing knowledge 
and behaviour change, continue to be the mainstay of HIV prevention eff orts. 
Since 2001, major advances in HIV prevention tools and methods have been 
integrated progressively into increasingly eff ective HIV prevention programmes. 
Figure 3.11
Distribution of prophylactic regimens 
for the prevention of mother-to-child transmission
Source: Country Progress Reports 2010
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Figure 3.12
Preventing mother-to-child transmission  
Coverage of antenatal care services and services for 
preventing mother-to-child transmission among women 
living with HIV in high-prevalence countries, 2010 
Source: WHO and UN Statistics Division
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Among these are eff orts to prevent mother-to-child transmission and to promote male 
circumcision. On the horizon is the potential of expanded eff orts to reap the prevention 
benefi ts of access to antiretroviral therapy, topical uses of antiretroviral drugs in 
microbicides, and the potential expansion of the prophylactic use of antiretroviral drugs 
before exposure to HIV.
Male circumcision
Th ree clinical trials have demonstrated that adult male circumcision signifi cantly 
reduces the likelihood of uninfected men acquiring HIV from an HIV-infected female 
sex partner. UNAIDS and WHO have recommended that male circumcision be scaled 
up in areas of high HIV prevalence and low rates of male circumcision. A review of nine 
country experiences of scaling up adult male circumcision in Southern and Eastern 
Africa shows signifi cant roll-out in the Nyanza province of Kenya and considerable 
experience gained in other areas (Table 3.2).
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BOTSWANA
KENYA
NAMIBIA
RWANDA
SWAZILAND
UGANDA
UNITED REPUBLIC OF TANZANIA
ZAMBIA
ZIMBABWE
Number circumcised
 6 180 April 2009 – March 2010 35
 91 300 2009 – June 2010 
 (90 000 in Nyanza alone) 
 350 September 2009 – June 2010 3
 542 October 2009 – April 2010 9
 10 000 2008 – June 2010   
 5 340 October 2008 – March 2010   
 4 700 September 2009 – May 2010 3
 9 906 January – June 2010 56
 10 000 2009 
 9 179 2007 – 2008 
 6 070 May 2009 – April 2010 5
Time period Number of sites 
established
Table 3.2
Scaling up male circumcision
Recent roll-out of the scaling up of adult male circumcision in nine countries. 
Source: Meeting reports and presentations. Durham, NC, Clearinghouse on 
Male Circumcision for HIV Prevention, 2010.
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THE HIV TREATMENT AND PREVENTION CONTINUUM
When the United Nations General Assembly Special Session on HIV/AIDS was held in 2001, access 
to antiretroviral therapy in low- and middle-income countries was in its infancy. By 2006, Member 
States unanimously supported goals towards universal access to HIV prevention, treatment, care 
and support. This commitment was underpinned by successful country experiences in accelerating 
access to HIV treatment.
Antiretroviral therapy is now better seen as having several crucial roles in the AIDS response. This 
is especially true when prevention and treatment interact in synergy, for example in the prevention 
of mother-to-child transmission, in post-exposure prophylaxis, and in the benefi cial results from 
reduced viral load at both the individual and population levels in reducing the onward transmission 
of HIV. Trials are also underway to examine their role in pre-exposure prophylaxis.
A concerted focus on bridging the gap between HIV treatment need and HIV treatment access will 
maximize the potential of antiretroviral therapy to contribute to secondary individual, family and 
population-level HIV prevention benefi ts. These secondary benefi ts will be realized where antiret-
roviral therapy reaches everyone in need of treatment and where people living with HIV are able to 
shape HIV prevention programming in a framework of “positive health, dignity and prevention”.
Treatment is not a “magic bullet” to bring HIV epidemics to a halt (35), but antiretroviral therapy 
as an element of combination HIV prevention programmes seems likely to have potentially signifi -
cant secondary benefi ts beyond prevention programmes that do not include increased treatment 
access. The action agenda to build stronger prevention and treatment responses in tandem 
requires:
■ non-stigmatizing health services;
■  effective referral systems across HIV, tuberculosis, and sexually transmitted infection behaviour 
and social support services;
■  increased investment in the capacities of people living with HIV and key affected communities to 
organize and empower themselves; and
■ social and behavioural change communication around risk and treatment.
Microbicides
Recent promising results of a tenofovir-based gel have raised hopes that an additional 
female-initiated prevention option may soon become viable. Th is landmark proof-
of-concept study by the Centre for the AIDS Programme of Research in South Africa 
(CAPRISA) (34) found that the microbicide gel studied reduced HIV infection by 
39% and herpes simplex virus-2 infection by 51% and that the gel was both safe and 
acceptable when used once in the 12 hours before sex and once in the 12 hours aft er sex 
by women aged 18–40 years.
Moving forward, based on these data, and making a safe and eff ective tenofovir gel 
available to women who want it will require: rapidly moving to additional trials to 
confi rm results; determining the requirements for the approval by national drug 
regulatory authorities of this new indication for tenofovir; conducting the operations 
research needed to determine how to deliver and sustain product supplies within 
combination prevention programmes; determining the frequency of HIV testing 
needed to ensure the safe use of the microbicide gel; and accelerating studies to expand 
knowledge of whether the product is safe and eff ective for women younger than 18 years 
of age and pregnant women. ■
“RECENT PROMISING 
RESULTS OF A 
TENOFOVIR-BASED GEL 
HAVE RAISED HOPES THAT 
AN ADDITIONAL FEMALE-
INITIATED PREVENTION 
OPTION MAY SOON 
BECOME VIABLE.”
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ACTION ITEMS
■  HIV prevention programmes must be scaled up rapidly to defl ect the upward 
trajectory of the epidemic.
■  Investments in HIV prevention programmes are insuffi cient and should 
increase. National programmes should ensure that investments are given pri-
ority according to epidemic patterns to reach the populations most in need.
■  HIV prevention programmes must include a combination of behavioural, 
biomedical, and structural responses, and these activities should operate in 
synergy.
■  HIV prevention programmes should reach men who have sex with men, sex 
workers and their clients, transgender people, and people who inject drugs. 
Behaviour change and condom promotion efforts must work in tandem.
■  The virtual elimination of mother-to-child transmission of HIV is possible. 
Current advances in stopping new infections among children must be accel-
erated by integrating services in antenatal care settings.
■  New HIV prevention methods such as male circumcision must be scaled up 
in countries with generalized epidemics.
■  The results from the CAPRISA microbicide gel trial hold promise for a woman-
initiated and controlled HIV prevention option. The international community 
must fully support the next steps to confi rm the trial results at the earliest.
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Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Côte d’Ivoire
Democratic Republic of Congo
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
SCORECARD: HIV PREVENTION
SUB-SAHARAN 
AFRICA
Knowledge Higher risk sex Condom use Condom use by sex workers
Male
Female
No Data Available
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Nigeria
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
China
Democratic People’s Republic of Korea
Japan
Mongolia
Republic of Korea
Australia
Fiji
Kiribati
Marshall Islands
Micronesia, Federated States Of
Nauru
New Zealand
Palau
Papua New Guinea
Samoa
Solomon Islands
Tonga
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
SUB-SAHARAN 
AFRICA 
Continued
EAST ASIA
OCEANIA
Knowledge Higher risk sex Condom use Condom use by sex workers
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Tuvalu
Vanuatu 
Afghanistan
Bangladesh
Bhutan
Brunei Darussalam
Cambodia
India
Indonesia
Lao People’s Democratic Republic
Malaysia
Maldives
Myanmar
Nepal
Pakistan
Philippines
Singapore
Sri Lanka
Thailand
Timor-Leste
Viet Nam
Armenia
Azerbaijan
Belarus
Georgia
Kazakhstan
Kyrgyzstan
Moldova
Russian Federation
Tajikistan
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
OCEANIA
Continued
SOUTH AND
SOUTH-EAST 
ASIA
EASTERN 
EUROPE AND 
CENTRAL ASIA
Knowledge Higher risk sex Condom use Condom use by sex workers
SCORECARD: HIV PREVENTION
Male
Female
No Data Available
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Turkmenistan
Ukraine
Uzbekistan
Albania
Andorra
Austria
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
EASTERN 
EUROPE AND 
CENTRAL ASIA 
Continued
WESTERN 
AND CENTRAL 
EUROPE
Knowledge Higher risk sex Condom use Condom use by sex workers
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Norway
Poland
Portugal
Romania
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
The Former Yugoslav Republic of Macedonia
Turkey
United Kingdom of Great Britain 
and Northern Ireland
Canada
Mexico
United States of America
Algeria
Bahrain
Djibouti
Egypt
Iran, Islamic Republic Of
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab Jamahiriya
Morocco
Oman
Qatar
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
WESTERN AND 
CENTRAL EUROPE 
Continued
NORTH 
AMERICA
MIDDLE EAST 
AND NORTH 
AFRICA
Knowledge Higher risk sex Condom use Condom use by sex workers
SCORECARD: HIV PREVENTION
Male
Female
No Data Available
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Saudi Arabia
Somalia
Sudan
Syrian Arab Republic
Tunisia
United Arab Emirates
Yemen 
Antigua and Barbuda
Bahamas
Barbados
Cuba
Dominica
Dominican Republic
Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Trinidad and Tobago
Argentina
Belize
Bolivia
Brazil
Chile
Colombia
Costa Rica
Ecuador
El Salvador
Guatemala
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
MIDDLE EAST 
AND NORTH 
AFRICA 
Continued
CARIBBEAN
CENTRAL 
AND SOUTH 
AMERICA
Knowledge Higher risk sex Condom use Condom use by sex workers
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Guyana
Honduras
Nicaragua
Panama
Paraguay
Peru
Suriname
Uruguay
Venezuela
2
5
2
5
2
5
2
5
5
0
5
0
5
0
5
0
7
5
7
5
7
5
7
5% % % %
CENTRAL AND 
SOUTH AMERICA 
Continued
Knowledge Higher risk sex Condom use Condom use by sex workers
SCORECARD: HIV PREVENTION
Male
Female
No Data Available
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KEY FINDINGS
■  An additional 1.2 million people received antiretroviral therapy in 2009, 
bringing the total number of people receiving treatment in low- and middle-
income countries to 5.2 million, a 30% increase over 2008.
■  At the end of 2009, 36% (about 5.2 million) of the 15 million people in need 
in low- and middle-income countries were receiving antiretroviral therapy.
■  Fewer people are dying from AIDS-related causes. About 14.4 million life-
years have been gained by providing antiretroviral therapy since 1996.
■  About 50% of pregnant women testing HIV positive were assessed for their 
eligibility to receive antiretroviral therapy for their own health.
■  Children and marginalized populations (such as people who inject drugs) are 
less likely to receive antiretroviral therapy than the population at large.
■  While steady progress is being made in scaling up access to HIV services 
for people with tuberculosis (TB), the percentage of people with TB who 
received an HIV test in 2009 remained low, at 26%. Progress in scaling up TB 
services for people living with HIV is also very slow.
■  Children orphaned by AIDS were nearly as likely to attend school as other 
children.
■  The availability of palliative and home-based care services for people living 
with HIV remains uneven.
HIV TREATMENT 
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More people received antiretroviral therapy in all regions in 2009
Advances toward universal access to treatment, care and support services were 
a signifi cant achievement in 2009, especially given the considerable challenges 
that accompanied the fl attening of global funding for HIV programmes in low- 
and middle-income countries. More people are receiving antiretroviral therapy 
in all regions of the world than at any previous time in the epidemic. However, 
progress toward universal access goals remained mixed, with substantially 
greater gains in some settings and on certain aspects of treatment, care, and 
support than in others.
As of December 2009, an estimated 5.2 million people in low- and middle-
income countries were receiving antiretroviral therapy (1). Th is represented an 
increase of 1.2 million people, or 30%, over the number receiving such treat-
ment 12 months earlier.
In sub-Saharan Africa, nearly 37% [34%–40%] of people eligible for treatment 
were able to access life-saving medicines in 2009. Similarly 42% [35%–47%] 
in Central and South America, 51% [40%–60%] in Oceania, 48% [42%–55%] 
in the Caribbean, and 19% [15%-21%] in Eastern Europe and Central Asia 
were accessing such treatment. Th e increase in the number of people receiv-
ing antiretroviral therapy in 2009 was virtually even across Eastern Europe 
(34%), sub-Saharan Africa (33%), Asia (29%) and the Caribbean (30%). Only 
in Central and South America (6%), where antiretroviral therapy coverage was 
already high, was the rate of increase in access in 2009 signifi cantly lower.
Antiretroviral therapy coverage for children is lower than that for adults; a low 
percentage of pregnant women were assessed for their eligibility and received 
antiretroviral therapy for their own health; limited data show low coverage for 
key populations at higher risk. Coverage needs to be more equitable.
Th e number of health facilities delivering antiretroviral therapy increased by 
36% in 2009, and the average number of people receiving antiretroviral therapy 
per health facility rose from 260 in 2008 to 274 in 2009, according to data sub-
mitted by 99 countries.
In 2010, WHO issued revised treatment guidelines (2) recommending earlier 
initiation of antiretroviral therapy, at a CD4 count of <350 cells/mm3. Th ese 
new criteria increased the total number of people medically eligible for antiret-
roviral therapy by roughly 50%—from 10 million to 15 million in 2009.
CHAPTER 4 | HIV TREATMENT
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Half or more of all adults eligible for treatment (CD4 <350 cells/mm3) were 
receiving antiretroviral therapy in 29 of the 109 low- and middle-income 
countries for which data are available by December 2009. Eight countries—
Botswana, Cambodia, Croatia, Cuba, Guyana, Namibia, Romania and Rwanda 
—achieved antiretroviral therapy coverage of 80% or more.
Of the 19 of the 25 low- and middle-income countries with the largest 
number of people living with HIV, Rwanda achieved 88% coverage among 
adults, Botswana 83%, and Namibia 76%. Eleven countries (Cameroon, Côte 
d’Ivoire, Ghana, India, Indonesia, Mozambique, South Africa, Ukraine, United 
Republic of Tanzania, Viet Nam and Zimbabwe) had coverage of less than 40%. 
Indonesia and Ukraine reported less than 20% of eligible adults were receiving 
antiretroviral therapy (Table 4.1).
Antiretroviral therapy coverage for children is lower than that for adults
Th e number of children younger than 15 years receiving antiretroviral therapy 
increased by about 80 000 (or 29%) in 2009, from 275 000 to 354 000. However, 
37%
People in sub-Saharan Africa 
eligible for treatment who 
were able to access life-saving 
medicines in 2009.
KEY ELEMENTS OF WHO’S 2010 REVISION OF ANTIRETROVIRAL 
TREATMENT THERAPY GUIDELINES
Start antiretroviral therapy earlier: Begin antiretroviral therapy when the CD4 
cell count is less than 350 cells/mm3.
Use less toxic and more patient-friendly options: Reduce the risk of adverse 
events and improve adherence by using less toxic drugs and fi xed-dose 
antiretroviral therapy combinations.
Improve management of coinfections between HIV and TB or hepatitis B: 
Start antiretroviral therapy in all people living with HIV who have active TB and 
chronic active hepatitis B disease irrespective of CD4 cell count.
Promote strategic use of laboratory monitoring: Use laboratory monitoring 
such as CD4 and viral load counts to improve the effi ciency and quality of HIV 
treatment and care.
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Point Estimate a Point Estimate Point Estimate
Table 4.1
Treatment coverage for adults and children, 
2009 (2006 and 2010 WHO guidelines)
Coverage of antiretroviral therapy among adults and 
children in 25 countries with the most people living with 
HIV, 2009 based on 2006 and 2010 WHO guidelines.
Source: Country Progress Reports 2010 and UNAIDS estimates.
Botswana
Brazil b
Cameroon b
China b
Côte d’Ivoire b
Democratic Republic of the Congo
Ethiopia b
Ghana
India b
Indonesia
Kenya
Lesotho
Malawi
Mozambique
Nigeria
Russian Federation b
South Africa
Sudan b,e
Thailand
Uganda
Ukraine
United Republic of Tanzania
Viet Nam
Zambia
Zimbabwe
Low Low LowHigh High High
90%
11%
15%
12%
32%
23%
29%
14%
10%
54%
2%
18%
17%
36%
30%
83%
30%
29%
25%
21%
50%
50%
48%
32%
23%
36%
61%
43%
9%
32%
33%
68%
34%
>95%
46%
44%
40%
34%
72%
75%
72%
51%
35%
56%
75%
62%
15%
49%
44%
>95%
52%
76%
65%
8%
21%
10%
9%
14%
8%
24%
14%
22%
17%
21%
10%
7%
17%
41%
1%
73%
12%
69%
11%
54%
26%
23%
77%
50%
27%
19%
26%
15%
52%
23%
23%
14%
46%
45%
44%
29%
21%
16%
35%
49%
38%
8%
29%
25%
62%
32%
>95%
65%
40%
31%
38%
22%
72%
34%
37%
24%
64%
65%
62%
43%
30%
27%
49%
61%
54%
13%
43%
35%
84%
47%
>95%
>95%
20%
74%
30%
23%
38%
24%
59%
48%
59%
39%
51%
26%
19%
60%
94%
4%
>95%
33%
>95%
34%
>95%
65%
50%
>95%
89%
34%
38%
32%
20%
65%
29%
27%
30%
55%
54%
54%
35%
25%
23%
37%
77%
48%
10%
35%
44%
76%
37%
>95%
>95%
54%
67%
49%
32%
94%
46%
45%
58%
81%
86%
81%
59%
41%
42%
63%
95%
72%
17%
55%
55%
>95%
57%
Children d Adult Coverage 2010 
Guidelines (CD4 350) C
Adult Coverage 2006 
Guidelines (CD4 200) C
a Point estimates published for countries with generalized epidemics only.
b Estimates of the number of people needing antiretroviral therapy are currently being reviewed and will be
 adjusted, as appropriate, based on ongoing data collection and analysis.
c The coverage estimates are based on the estimated unrounded numbers of adults receiving antiretroviral
 therapy and the estimated unrounded need for antiretroviral therapy (based on UNAIDS/WHO methods).
 The ranges in coverage estimates are based on plausibility bounds in the denominator: that is, low and 
 high estimates of need. The estimates are standardized for comparability according to UNAIDS/WHO methods.
d The coverage estimates are based on the estimated unrounded numbers of children receiving antiretroviral 
 therapy and the estimated unrounded need for antiretroviral therapy (based on UNAIDS/WHO methods). 
 The ranges in coverage estimates are based on plausibility bounds in the denominator: that is, low and 
 high estimates of need. 
e Data for antiretroviral therapy coverage for adults in Sudan are not available for 2009.
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children continued to have less access to antiretroviral therapy than adults (28% 
coverage of children, compared with 37% coverage of adults).
An estimated 90% of the world’s children living with HIV reside in sub-Saharan 
Africa. Antiretroviral therapy coverage of children in the region is slightly 
below the global average, at just 26%. Among the 25 countries with the great-
est number of people living with HIV, only Botswana reported antiretroviral 
therapy coverage of children of greater than 80% (Table 4.1).
A number of countries report sharply lower antiretroviral therapy coverage 
for children than for adults. Adult coverage is higher in 12 of the 14 high-
burden countries for which coverage estimates for both adults and children 
are available. In six countries, antiretroviral therapy coverage of children is less 
than half that of adults, with particularly large diff erences in countries such 
as Cameroon (30% adults versus 11% children), Mozambique (32% versus 
12%) and Uganda (43% versus 18%). By contrast, two of the 12 countries 
(South Africa and Botswana) report greater antiretroviral therapy coverage for 
children than for adults.
Very few pregnant women living with HIV receive antiretroviral 
therapy for their own health
Access to services for preventing mother-child-transmission of HIV increased 
between 2008 and 2009, but still few pregnant women living with HIV are 
screened for their own health. Th e proportion of pregnant women who tested 
positive for HIV and were assessed for their eligibility to receive antiretroviral 
therapy for their own health increased from 34% to 51%. Only 15% of pregnant 
women living with HIV whose HIV status is detected while accessing maternal 
and child health services were also provided antiretroviral therapy for their 
own health at the same time.
In the 12 high-prevalence countries that reported on antiretroviral therapy 
access for pregnant women in both 2007 and 2009, the total number of women 
enrolled in treatment roughly doubled, from more than 18 000 to more 
than 37 000. In Swaziland, a major eff ort to provide antiretroviral therapy in 
maternal and child health settings increased the number of women beginning 
therapy from 259 in 2007 to 1844 in 2009.
Access to antiretroviral therapy eludes marginalized populations
Few data are available about access to antiretroviral therapy by sex workers, 
men who have sex with men and people who inject drugs. Most countries do 
not collect such data. For example, in Eastern Europe and Central Asia, only 
four of the 12 countries collect such data. Many countries in Asia, Central and 
South America and other regions report that negative attitudes on the part of 
health care workers oft en deter people at high risk of HIV infection from seek-
ing treatment services (4). Further obstacles to antiretroviral therapy access 
include laws in a number of countries with sizeable populations of people born 
outside national borders that limit antiretroviral therapy access to citizens (5). 
Many prison systems limit access to antiretroviral therapy, according to country 
reports to UNAIDS (6).
15%
15% of pregnant women living with 
HIV whose HIV status is detected 
while accessing maternal and child 
health services were also provided 
antiretroviral therapy for their own 
health at the same time.
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Of the 21 countries that have data on antiretroviral therapy coverage for people 
living with HIV who inject drugs, 14 countries treat 5% or fewer of all such 
individuals (7). In only nine countries does treatment reach more than 10% of 
people living with HIV who inject drugs.
Treatment retention is possible and can be achieved
New data provide strong evidence that high antiretroviral therapy retention 
rates are achievable. Of the countries for which data are available, 26 report that 
at least 95% of people are still receiving treatment one year aft er initiating anti-
retroviral therapy. Of the 25 countries with the highest number of people living 
with HIV, Botswana, Brazil and Cameroon report that 90% or more remain on 
treatment 12 months aft er initiation. Ghana, India, Kenya, Lesotho, Th ailand, 
Uganda, Ukraine, and Viet Nam all report retaining at least 80% of people in 
treatment for at least one year. Sudan reports a 12-month retention rate of 56% 
and Chad only 47%.
One likely reason for lower treatment retention rates is initiating treatment 
at a late stage of HIV illness and the premature death of the treatment recipi-
ent. Evidence shows that retention rates need to be improved, at least in part, 
through ongoing eff orts to initiate HIV treatment earlier. Long-term retention 
in treatment is critical for health outcomes, but many people are lost to follow-
up during the fi rst year. Loss to follow-up in antiretroviral therapy programmes 
tends to increase over time.
In Malawi, which has rapidly scaled up antiretroviral therapy in recent years, 
data suggest that 70% of the people initiating treatment are still recorded as “in 
treatment” aft er 24 months, dropping to about 55% aft er 48 months (Figure 
4.1). In Burundi and the Central African Republic, the 48-month retention 
rate is between 60% and 70%, whereas in Botswana it exceeds 80%. Retention 
rates may not always be directly comparable, however, as some countries may 
report data from tertiary hospitals only, report survival rather than retention, 
or erroneously record transfers to diff erent treatment sites as loss to follow-up.
Better understanding of the factors that depress longer-term retention is need-
ed, and new strategies are needed to increase retention in antiretroviral therapy 
programmes. Possible factors limiting treatment retention include constraints 
within health and community systems such as overly centralized treatment 
programmes that limit geographical accessibility; health worker shortages; drug 
stock-outs; and weak community treatment literacy.
Health systems challenged by and benefi t from HIV treatment, 
care and support
In many countries, overburdened health systems are struggling valiantly to 
address the challenges posed by HIV, including health worker shortages, cen-
tralized programmes, fragmented rather than integrated and holistic services 
delivery, and weak procurement and supply systems. Th is is especially true 
for health systems in sub-Saharan Africa, which must care for two of three 
people living with HIV but have only 3% of the world’s health care provid-
ers (8). Challenges associated with health-system capacity are not limited to 
“NEW DATA PROVIDE 
STRONG EVIDENCE THAT 
HIGH ANTIRETROVIRAL 
THERAPY RETENTION RATES 
ARE ACHIEVABLE. OF THE 
COUNTRIES FOR WHICH 
DATA ARE AVAILABLE, 26 
REPORT THAT AT LEAST 
95% OF PEOPLE ARE STILL 
RECEIVING TREATMENT ONE 
YEAR AFTER INITIATING 
ANTIRETROVIRAL THERAPY.”
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Figure 4.1
Adult retention in antiretroviral therapy in 
selected countries, 0–48 months, 2009 
Source: WHO Towards Universal Access 2010.
sub-Saharan Africa, however. Countries in Asia, the Middle East and North 
Africa report that an inadequate supply of health care workers skilled in deliv-
ering antiretroviral therapy impedes treatment scale-up.
In response, many countries have implemented innovative strategies to expand 
the capacity of health systems to address HIV and other challenges. Th ese 
include increasing the use of civil society partners to manage health care facili-
ties, other forms of task-shift ing in clinical settings, and institutional twinning 
arrangements between local clinics and institutions in high-income countries. 
Shortages of human resources for health have severely hampered the rolling 
out of antiretroviral therapy in sub-Saharan Africa. Current roll-out models 
are hospital- and physician-intensive. A recent review (9) has shown that task-
shift ing, or delegating tasks performed by physicians to staff  with lower-level 
qualifi cations, including lay and community workers, is an eff ective strategy for 
addressing shortages of human resources for health in HIV treatment and care.
South Africa is using a nurse-driven model to decentralize antiretroviral 
therapy provision and expedite treatment scale-up. A randomized controlled 
trial that has assessed the eff ectiveness of task-shift ing for antiretroviral 
therapy delivery in urban clinics of Johannesburg and Cape Town found that 
nurse-managed antiretroviral therapy was not inferior to doctor-managed 
antiretroviral therapy: both treatment arms had similar outcomes of viral 
suppression, adherence, toxicity, and death (10). Similarly, in Rwanda, nurses 
accurately determined eligibility for antiretroviral therapy for more than 
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INNOVATION AND FLEXIBILITY FOR INCREASING 
ACCESS TO ANTIRETROVIRAL MEDICINES
THE MEDICINES PATENT POOL
The Medicines Patent Pool was set up in July 2008 by the global health fi nancing mecha-
nism UNITAID, to increase access to newer antiretroviral medicines by creating a pool of 
patents and intelligence on antiretroviral drug production.
The Medicines Patent Pool aims to increase access to treatment by promoting price 
reductions of existing antiretroviral drugs, stimulating the production of newer fi rst- and 
second-line drugs and increasing the number of generic producers of these medicines.
The United States National Institutes of Health recently announced that they will be shar-
ing patents with the Medicines Patent Pool. This is the fi rst time that a patent holder 
has shared intellectual property on antiretroviral medicines with the newly established 
Medicines Patent Pool.
MAKING THE MOST OF THE TRIPS AGREEMENT
The World Trade Organization Declaration on the TRIPS Agreement and Public Health 
(the Doha Declaration) emphasizes that the TRIPS Agreement does not and should not 
prevent states from taking measures to protect public health and reaffi rms their right 
to use, to the full, the provisions of the TRIPS Agreement that provide fl exibility for 
public health purposes, in particular to promote access to medicines for all. The Doha 
Declaration also clarifi es some of the fl exibility contained in the TRIPS Agreement, includ-
ing that national authorities are free to determine the grounds on which compulsory 
licences are granted to allow the purchase and use of otherwise protected products, 
correcting the misconception that some form of emergency is required for issuing a com-
pulsory licence.
Although a number of middle- and low-income countries such as Brazil, Thailand and, 
more recently, Ecuador have used the fl exibility available to them under the TRIPS 
Agreement and Doha Declaration to make HIV medicines more affordable, in recent 
years fewer countries have taken advantage of such opportunities.
However, some middle- and low-income countries are entering bilateral and regional 
trade agreements with high-income countries that impose intellectual property protection 
that is stricter than necessary under the TRIPS Agreement and that may limit their rights 
to promote access to affordable HIV medicines and other pharmaceutical products in 
their countries.
99% of the people examined (11). In Mozambique, people seen by mid-level 
health workers (with 2.5 years of training) were almost 30% more likely to 
have CD4 counts done six months aft er antiretroviral therapy was initiated 
than those seen by doctors and were 44% less likely to be lost to follow-up. 
Th ere were no signifi cant diff erences in mortality, CD4 counts done at 12 
months, or adherence rates (12). A study from Malawi found that the training 
of lay workers as pharmacy assistants reduced prescribing errors by 25% by 
unburdening the system (13). In the Democratic Republic of the Congo, a study 
(14) examined concordance between the decisions of doctors and nurses to 
initiate antiretroviral therapy and found 95% agreement on initiating therapy.
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Task-shift ing off ers high-quality, cost-eff ective care to more people than a 
physician-centred model. Th e main challenges to implementation include 
adequate and sustainable training, support and pay for staff  in new roles, 
integrating new members into health care teams, and compliance with 
regulations. Task-shift ing should be considered for careful implementation 
where shortages of human resources for health threaten roll-out programmes.
Systemic defi ciencies in commodity procurement and supply management 
undermine treatment eff orts in many countries. Of 94 countries, 38% respond-
ing to surveys report at least one drug stock-out in 2009 (1). Th e Islamic 
Republic of Iran, Tunisia, Yemen and several countries in Central and South 
America cite drug supply interruptions as notable barriers to access to anti-
retroviral therapy (6). In an eff ort to avoid stock-outs, Rwanda has moved to 
convene a Coordinated Procurement and Distribution System, which unites the 
national government, donors, international organizations, and other country-
level partners in a common eff ort to ensure an uninterrupted supply of HIV 
drugs and other commodities (1).
Across health systems, scaling up antiretroviral therapy provision presents not 
only challenges but also opportunities and benefi ts that extend well beyond 
HIV. In hyper-endemic settings in which people living with HIV have account-
ed for the bulk of hospital patients in recent years, the scaling up of therapy 
is freeing up health system capacity to address other health priorities and is 
reducing absenteeism and deaths among health care workers living with HIV. 
In addition, infrastructure improvements fi nanced by HIV funding—including 
refurbished clinics, improved laboratory capacity and strengthened systems for 
commodity procurement and supply management—are enhancing the avail-
ability and quality of care services for everyone, regardless of HIV serostatus.
Reducing the burden of HIV among people with tuberculosis 
Tuberculosis (TB) is a leading cause of death among people living with HIV. 
In 2009, there were an estimated 380 000 deaths from TB among people living 
with HIV. In sub-Saharan Africa, which accounts for 78% of people with HIV-
related TB (1), the HIV prevalence among people with TB is as high as 80% in 
some countries. However, only 79 000 (0.2%) people living with HIV received 
isoniazid preventive therapy, a treatment that can greatly reduce a person’s risk 
of developing TB disease.
Under newly released WHO guidelines, everyone with TB who is living with 
HIV should receive antiretroviral therapy, regardless of their CD4 count. In 
2009, 1.6 million people with TB (26% of the total) were tested for HIV, up 
from 22% in 2008 and 4% in 2003. Of the people tested, 450 000 were found to 
be HIV positive; 75% of those who were positive received co-trimoxazole and 
37% received antiretroviral therapy. Two of the 21 countries with the highest 
burden of HIV-related TB provide treatment for both diseases for over half the 
people who need it (Figure 4.2 and Figure 4.3).
Widening the provision of antiretroviral therapy reduces the incidence of TB 
and AIDS mortality. Multiple research studies show that antiretroviral therapy 
“TUBERCULOSIS (TB) IS A 
LEADING CAUSE OF DEATH 
AMONG PEOPLE LIVING 
WITH HIV. IN 2009, THERE 
WERE AN ESTIMATED 380 000 
DEATHS FROM TB AMONG 
PEOPLE LIVING WITH HIV.”
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Figure 4.2
Coverage of TB services among people living 
with HIV, 2009
Coverage services aimed to reduce the burden of TB per 
1000 people living with HIV globally. 
Source: UNAIDS estimates, WHO Towards Universal Access 2010 and WHO 
Global TB Control Report 2010. 
Outer square equals 1000 HIV 
incident cases
Eligible for ART (441)
Know HIV status (333)
On ART (158)
Incident TB in people living 
with HIV (33)
Screened for TB (50) 
TB ART (5) 
IPT (2)
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Figure 4.3
Coverage of HIV services among people 
with TB, 2009
Coverage of services aimed to reduce the burden of 
HIV per 1000 people with TB globally, 2009.
Source: WHO Global TB Control Report 2010. 
Outer square equals 1000 TB 
incident cases
Diagnosed and registered to 
TB programme (656)
Offered HIV test (174)
HIV-positive incident TB 
cases (117)
HIV positive TB patients on 
ART (15)
HIV positive TB patients on 
co-trimoxazole (20)
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TREATMENT 2.0
Treatment 2.0 is a new approach to simplifying the way HIV treatment is currently pro-
vided and to scale up access to life-saving medicines. Using a combination of efforts, it 
could reduce treatment costs, make treatment regimens simpler and smarter, reduce the 
burden on health systems and improve the quality of life for people living with HIV and 
their families. Modelling suggests that, compared with current treatment approaches, 
Treatment 2.0 could avert an additional 10 million deaths by 2025. (Figure 4.4) 
In addition, the new approach could also reduce the number of people newly infected 
with HIV by up to 1 million annually if countries provide antiretroviral therapy to everyone 
who needs it, following the 2010 WHO treatment guidelines. Today, 5 million of the 15 
million people in need are accessing these life-saving medicines.
Achieving the full benefi ts of Treatment 2.0 requires progress across fi ve areas.
1.  Optimize drug regimes: UNAIDS calls for the development of new pharmaceutical 
compounds that will lead to a “smarter, better pill” that will be less toxic, longer-acting 
and easier to use. Combined with dose optimization and improved sequencing of fi rst 
and second line regimens this will simplify treatment protocols and improve effi cacy. 
Optimizing HIV treatment will also result in other health benefi ts, including much lower 
rates of TB and malaria among people living with HIV.
2.  Provide access to point of care diagnostics: Monitoring treatment requires complex 
equipment and specialized laboratory technicians. Simplifying diagnostic tools in order 
to provide viral load and CD4 cell counts at the point of care could help to reduce the 
burden on health systems. Such a simplifi ed treatment platform will defray costs and 
increase people’s access to treatment.
3.  Reduce costs: Despite drastic reductions in drug pricing over the past decade, the 
costs of antiretroviral therapy programmes continue to rise. While drugs must continue 
to be made more affordable- including fi rst and second line regimens – potential gains 
are highest in reducing the non-drug-related costs of providing treatment, such as 
hospitalization, monitoring treatment, and out-of-pocket expenses. These costs are 
currently twice the cost of the drugs themselves.
4.  Adapt delivery systems: Simpler diagnostics and treatment regimes will also allow 
for further decentralizing and integrating service delivery systems, thereby reducing 
redundancy and complexity, and facilitating a more effective continuum of care. Task-
shifting and strengthening procurement and supply systems will be important elements 
of this change.
5.  Mobilize communities: Treatment access and adherence can be improved by 
involving the community in managing treatment programmes. Strengthening the 
demand and uptake for testing and treatment will both improve treatment coverage 
and help to reduce costs for extensive outreach. Greater involvement of community 
based organizations in treatment maintenance, adherence support and monitoring will 
reduce the burden on health systems.
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Figure 4.4
Five pillars of Treatment 2.0
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can reduce the incidence of TB among people living with HIV. Data from 
Botswana (Figure 4.5) indicate a decline in the number of TB cases reported 
nationwide that has coincided with rapid antiretroviral therapy roll-out since 
2002–2003. Improvements in Botswana’s national TB programme over this 
same period, including case detection and reporting, mean that this decline 
probably refl ects a true reduction in TB infections due to antiretroviral therapy.
Eff ect of antiretroviral therapy on mortality
Th e expansion of antiretroviral therapy has yielded remarkable health 
dividends in countries in which an HIV diagnosis was regarded as a death 
sentence only a decade ago. Emerging evidence shows associations between 
rolling out treatment and reduced population mortality in high-prevalence 
settings. In South Africa’s North West Province, the roll-out of antiretroviral 
therapy, one of the earliest and most aggressive eff orts to improve access, 
coincides and appears to be associated with a decline in mortality in most 
aff ected age groups (Figure 4.6). Th e data also suggest initial mortality declines 
by 2007 in the Western Cape and KwaZulu-Natal. Th e preliminary fi ndings of 
a study on death registration undertaken by the Medical Research Council of 
South Africa provide supporting evidence of continued declines in mortality.
Estimates suggest that, worldwide, about 14.4 million life-years have been gained 
due to the provision of antiretroviral therapy (Table 4.2). More than 1.2 million 
life-years are estimated to have been gained in Brazil between 1996 and 2009, 
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Antiretroviral therapy and TB incidence 
in Botswana 
Reported incidence of TB and number of people 
receiving antiretroviral therapy in Botswana, 
1990–2007.
Source: Ministry of Health, Botswana. 
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Figure 4.6
Antiretroviral therapy and mortality, 
Northwest Province, South Africa 
Number of people ever receiving antiretroviral 
therapy and annual number of deaths by age group, 
Northwest Province, South Africa, 1997–2007.
Source: Ministry of Health, South Africa.
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which has had a long-standing policy of universal therapy 
coverage. In South Africa, more than 970 000 people are 
now enrolled in antiretroviral therapy and more than 700 
000 life-years have already been gained. Kenya and Nigeria 
have both enrolled more than 300 000 in treatment, lead-
ing to about 320 000 life-years gained in each country. Later 
roll-out of antiretroviral therapy and/or low coverage mean 
that signifi cant gains in life-years have yet to be documented 
in some of the concentrated epidemic countries such as 
Indonesia, Ukraine and Viet Nam.
Th e availability of palliative and home-based care 
services remains uneven
People living with HIV, including people enrolled and peo-
ple waiting for treatment, have a range of care and support 
needs in addition to antiretroviral therapy. Th ese include 
the need for psychosocial, physical, socioeconomic, and 
legal care and support. Home-based care, which includes 
the care of people who are home-bound or bedridden, 
distribution of basic supplies, palliative care, and providing 
care and support to children orphaned because of AIDS, 
are essential elements of care and support programmes.
Most countries (162 of 171) report they have “a policy or 
strategy to promote comprehensive HIV treatment, care 
and support”. Access to these comprehensive services is far 
from complete, however. Because of a lack of clarity about 
what comprises comprehensive care and support, current 
national HIV policies or strategies may not address many 
central aspects of care and support.
Only 44% of governments (and 35% of civil society 
responses) report that most people in need have access to 
home-based care services (Figure 4.7). As Uganda notes in 
its 2010 country report (6), inadequate political will and 
insuffi  cient resourcing are signifi cant challenges in increas-
ing access to high-quality care and support services.
While 73% of governments responding agree with the 
statement that the majority of people in need have access 
to palliative care and treatment of common HIV-related 
infections, only 57% of civil society respondents agree that 
that statement is true (Figure 4.8).
More oft en than not, volunteers rather than governments 
provide the bulk of needed psychosocial, physical, socio-
economic, and legal care services and support. Families 
and communities—particularly women, whose contribu-
tion to the HIV response oft en goes unrecognized and 
unsupported—meet most care and support responsibili-
ties. At the same time, these families and communities 
COMMUNITIES LEAD IN EXPANDING HIV 
TREATMENT
Community leadership helps drive the expansion of 
antiretroviral therapy worldwide. For example, the Lao 
People’s Democratic Republic has made concerted efforts 
to mobilize people living with HIV to support antiretrovi-
ral therapy initiatives, resulting in earlier diagnosis of HIV 
infection and increased survival rates (4). Through support 
provided by the HIV Collaborative Fund, about 30 com-
munity-based organizations headed by people living with 
HIV provide treatment literacy and adherence support 
services, home-based care, and HIV prevention education. 
In China, ongoing monitoring of more than 14 000 people 
by AIDS Care China indicates that individuals receiving 
such community-based services are more likely to adhere 
to treatment regimens and are better equipped to man-
age drug toxicity.
In Kenya, the AIDS Law Project and the East African 
Treatment Access Movement fi led a legal challenge in 
2008 requesting suspension of a national law prohibit-
ing the importation or manufacture of affordable generic 
antiretroviral drugs. In April 2010, the court hearing the 
lawsuit stayed enforcement of the legislation, fi nding that 
people living with HIV would suffer irreparable damage as 
a result of the law.
Also in Kenya, in the Lurambi area in the west of the 
country, a mass campaign to mobilize the population for 
HIV testing and referral led to the testing of more than 
47 000 residents in seven days, including 87% of the tar-
get age group 15–49 years. The 4% who tested positive 
were given a three-month supply of co-trimoxazole and 
were referred to treatment (18).
Community groups mostly undertake these efforts with 
little fi nancial or technical support. At present, relatively 
few funding channels exist to build the capacity of grass-
roots community groups, and many antiretroviral therapy 
programmes have yet to integrate community workers into 
their operations. In May 2010, the Global Fund to Fight 
AIDS, Tuberculosis and Malaria issued its fi rst guide on 
strengthening community systems in the context of Global 
Fund programming. The guide aims to encourage new 
funding channels to increase the capacity of communities 
to participate in designing, delivering, monitoring, and 
evaluating initiatives to improve health outcomes.
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Table 4.2
Adult life-years gained by antiretroviral therapy
Adult life years gained due to antiretroviral therapy in 25 
countries with the highest number of persons living with HIV.
Source: UNAIDS estimates, WHO Towards Universal Access Report 2010 
and WHO Global TB Control Report 2010. 
Point Estimate
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Côte d’Ivoire
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Ghana
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Kenya
Lesotho
Malawi
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Low High
83%
30%
29%
25%
21%
50%
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23%
145 190
76 228
12 762
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34 967
176 632
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25%
77%
89%
27%
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coverage (2010 WHO 
guidelines)
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Point Estimate Low High
980 000
[840 000 - 1 200 000]
5 600 000
[5 400 000 - 5 900 000]
260 000
[210 000 - 330 000]
530 000
[420 000 - 660 000]
1 200 000
[1 100 000 - 1 300 000]
350 000
[300 000 - 410 000]
1 400 000
[1 300 000 - 1 500 000]
280 000
[220 000 - 350 000]
980 000
[890 000 - 1 100 000]
1 200 000
[1 100 000 - 1 300 000]
65 000
707 000
3 000
389 000
293 000
16 000
150 000
27 000
270 000
172 000
36%
61%
43%
9%
32%
33%
68%
34%
23%
37%
0%
77%
48%
10%
35%
44%
76%
37%
16%
35%
0%
49%
38%
8%
29%
25%
62%
32%
Number of people living with 
HIV, 2009
Life years among adults 
gained due to ART between 
1996 and 2009
Number of people receiving 
antiretroviral therapy in 
December 2009
Antiretroviral therapy 
coverage (2010 WHO 
guidelines)
Russian Federation
South Africa
Sudan
Thailand
Uganda
Ukraine
United Republic of Tanzania
Viet Nam
Zambia
Zimbabwe
75 900
971 556
3 825
216 118
200 413
15 871
199 413
37 995
283 863
218 589
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oft en struggle to access adequate resources, training and support to provide 
these critical responses (Figure 4.9).
No decline in the number of children orphaned by AIDS
Despite the modest decline in HIV adult prevalence worldwide and increasing 
access to treatment, the total number of children aged 0–17 years who have lost 
their parents due to HIV has not yet declined. Indeed, it has further increased 
from 14.6 million [12.4 million–17.1 million] in 2005 to 16.6 million [14.4 mil-
lion–18.8 million] in 2009. Almost 90% live in sub-Saharan Africa. Th e number 
of orphans due to AIDS living in six countries—Kenya, Nigeria, South Africa, 
Uganda, United Republic of Tanzania, and Zimbabwe—is more than 9 mil-
lion, with Nigeria alone counting 2.5 million orphans due to HIV. More than 
10% of all children aged 0–17 years have lost one or two parents due to HIV in 
Zimbabwe (16%), Lesotho (13%), and Botswana and Swaziland (12%).
Among the most remarkable contributions to the global response to HIV 
are the systems and networks, both formal and informal, that have been 
established to support children orphaned by the epidemic (Figure 4.10). Th e 
narrowing of the diff erence in school attendance between orphans and non-
orphans is one main achievement of this response. Most households caring for 
children aff ected by HIV, however, are still not accessing any external care and 
support. ■
Figure 4.7
Access to home-based care 
Assessment by governments as to whether most 
people in need have access to home-based care. 
Source: Country Progress Reports 2010. 
Figure 4.8
Availability of palliative care 
Assessment by governments as to whether most 
people in need have access to palliative care. 
Source: Country Progress Reports 2010. 
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Figure 4.9
Types of care and support work performed by volunteers
Types of care and support work for people living with HIV performed by 1366 
volunteer caregivers interviewed in Cameroon, Kenya, Malawi, Nigeria, South 
Africa and Uganda.
Source: Compensation for Contributions: report on interviews with volunteer caregivers in six 
countries. Hairu Commission and Community Agency for Social Enquiry, Sept 2009.
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Figure 4.10
Trends in support for orphans and vulnerable children, 2005 to 2010
Changes in the coverage of support services for orphans and vulnerable children 
in three countries with high HIV prevalence, 2005 to 2010.
Source: World Vision. 
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ACTION ITEMS
■ HIV treatment must be scaled up to keep pace with increasing demand.
■  HIV testing and counselling must be expanded, as most people get to know 
their status very late and access treatment later, which reduces the effective-
ness of treatment programmes.
■  An integrated HIV and TB programme is essential to meet the challenges 
posed by the dual epidemics.
■  Maternal and child health services must be strengthened so that all pregnant 
women living with HIV can access comprehensive services for preventing 
maternal and child mortality and infants from becoming newly infected and 
for providing antiretroviral therapy for mothers.
■  Children’s access to antiretroviral therapy must improve. This will require 
maternal and child health and antiretroviral therapy centres to work closely. 
In addition, better diagnostic tools and antiretroviral therapy formulations for 
children continue to be needed.
■  Current approaches to treatment have not been optimal for the 15 million 
people in need. Treatment 2.0—a radically simplifi ed treatment platform—
holds promise to simplify treatment and provide all people needing it with a 
better pill less likely to lead to resistance, simpler diagnostics and monitor-
ing, easier HIV testing, and more community empowerment. All stakeholders 
should unite to make this a reality.
■  Social support for orphans must continue, and recent success in rolling out 
programmes of support such as cash transfers, food support, and education 
bursaries must be expanded and sustained.
■  Investments in treatment have brought results for AIDS-related mortality and 
reducing the number of people newly infected with HIV. These investments 
must be continued and sustained over the long term.
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KEY FINDINGS
HUMAN RIGHTS
■  Failing to address the human rights of key populations at higher risk of 
exposure to HIV facilitates the growth of the epidemic and enhances its 
socially damaging effects.
■  Punitive laws that affect people living with HIV, or other people at higher risk 
of exposure, remain widespread. Laws protecting such people exist in many 
countries, but there are not enough data to show whether they are actively 
or widely enforced.
■  Stigma, discrimination, and violence against transgender people, and men 
who have sex with men, increase their risk of HIV infection and also for their 
male and female partners.
GENDER EQUALITY
■  The vulnerability of women and girls to HIV remains particularly high in sub-
Saharan Africa; 80% of all women in the world living with HIV live in this 
region.
■  Efforts to promote universal access to HIV prevention, treatment, care and 
support services require a sharper focus on women and girls. Fewer than 
half of countries report having a specifi c budget for HIV-related programmes 
addressing women and girls.
■  Despite evidence that benefi cial behaviour change can be achieved, few HIV 
programmes engage men and boys.
HUMAN RIGHTS
AND GENDER EQUALITY 
122 Chapter 5: Human rights and gender equality | 2010 GLOBAL REPORT
Human rights and gender equality are critical 
to eff ective responses to HIV
In the context of HIV, protections comprise legal approaches that implement 
international human rights commitments as well as eff orts to address harm-
ful social and gender norms that put women, men, and children at increased 
risk of HIV infection and increase its impact. A rights-based approach to HIV 
requires: realization and protection of the rights people need to avoid exposure 
to HIV; enabling and protecting people living with HIV so that they can live 
and thrive with dignity; attention to the most marginalized within societies; 
and empowerment of key populations through encouraging social participa-
tion, promoting inclusion and raising rights-awareness. Signifi cant advances 
have been made in expanding HIV prevention, treatment, care, and support 
services in recent years but some key populations at higher risk such as sex 
workers, people who inject drugs, and men who have sex with men, remain 
oft en underserved. Resources directed towards the needs of these populations, 
including support for them to claim and exercise their rights, are oft en not pro-
portional to the degree to which they are aff ected by the epidemic.
Stigma and discrimination
In 2010, 91% of governments reported that they address stigma and 
discrimination as cross cutting issues in their national strategies. Further, from 
nongovernmental sources that have consistently reported on the National 
Composite Policy Index (NCPI) since 2006, reports of programmes to address 
stigma and discrimination have doubled in less than fi ve years (92% in 2010 
against 46% in 2006). Th is improvement indicates increased acknowledgement 
of the importance of working to eliminate stigmatization of, and discrimination 
against, people living with HIV.
However, these reports refer only to the existence of such programmes. Th ey do 
not confi rm whether eff orts are implemented at suffi  cient scale and of a quality 
to make real and sustained improvements to the lives of people living with HIV 
and other members of key populations at higher risk of exposure.
In 2008–2009, the UNAIDS Secretariat commissioned the International 
HIV/AIDS Alliance to review the national AIDS planning documents of 
56 countries to ascertain whether they included programmes to increase access 
to justice and reduce stigma and discrimination (e.g. law reform; know your 
rights/legal literacy; and human rights training for service providers, provision 
of legal services, and programmes supporting the human rights of women and 
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Figure 5.1
Countries with laws or regulations that create obstacles
Percentage of countries in which nongovernmental sources report laws or 
regulations that create obstacles to effective HIV prevention, treatment, 
care, and support for population groups at higher risk and other 
vulnerable population groups.
Source: Country Progress Reports 2006, 2008, 2010.
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girls). Th is study (to be published in 2010) found that, although about 90% 
of country activity plans included stigma and discrimination reduction pro-
grammes, fewer than 50% of countries costed or budgeted such programmes. 
Further, the review indicated that countries rarely included a comprehensive 
package of programmes to reduce stigma and discrimination in their national 
strategies (1).
Th e United Nations Development Programme, UNAIDS, and the Global Fund 
to Fight AIDS, Tuberculosis and Malaria examined whether human rights 
programmes were included in the Global Fund’s HIV portfolio for Rounds 
6 and 7. Th is 2009-2010 study found that one third of the key human-rights 
programmes identifi ed by Country Coordinating Mechanisms as being 
necessary for an eff ective HIV response were not implemented. Th e same study 
also found that less than one quarter of planned programmes explicitly engaged 
men who have sex with men, transgender people, people who use drugs, sex 
workers, and prisoners (2).
Results from the People Living with HIV Stigma Index illustrate the need to 
increase eff orts to reduce stigma and discrimination as part of national HIV 
responses. Th e Index, currently being rolled out in more than 70 countries and 
with preliminary results from 10 now available (Bangladesh, China, Dominican 
Republic, Fiji, Myanmar, Paraguay, Rwanda, United Kingdom—including a 
separate component for Scotland—and Zambia), provides rich evidence of the 
multi-layered ways in which stigma and discrimination manifest in the lives of 
people living with HIV.
In China, for example, more than 30% of people living with HIV said they had 
been subject to verbal abuse, 9% had been physically harassed, 14% refused 
employment, and 12% denied health care (2). In Paraguay, 12% were excluded 
from social gatherings, 11% were physically harassed and 9% physically 
assaulted (3). In Rwanda, more than 50% were verbally insulted, 36% physically 
harassed and 20% physically assaulted, 65% experienced loss of job or income 
and 88% were denied access to family planning services due to their HIV status 
(4). In the United Kingdom, 17% reported having been denied health care (5).
High percentages of respondents in all countries reported internalized 
stigma: feeling ashamed, guilty, suicidal, and blameworthy.
An extensive survey by the nongovernmental organization representatives of 
the UNAIDS Programme Coordinating Board in 2010 showed that people 
living with HIV and key populations at higher risk continue to experience 
high levels of HIV-related stigma and discrimination. Slightly less than half of 
respondents experienced negative attitudes or exclusion from family members. 
Other experiences in at least one third of the sample included loss of employ-
ment, refusal of care by health care workers, social or vocational exclusion, and/
or involuntary disclosure (6). Several examples from the UNGASS narrative 
reports (7) also show that stigma and discrimination continue to hinder eff ec-
tive HIV responses. Narrative reports from Cambodia, Malaysia, Nepal, and 
Pakistan include stigma and discrimination as barriers to providing prevention, 
treatment, and care services to key population groups and to providing treat-
ment and care for people living with HIV (8).
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SOURCES TO ASSESS STIGMA AND DISCRIMINATION
UNGASS country report narratives
Country progress reports submitted by governments (7) include a narrative on progress 
made in the AIDS response. Often these include narratives that provide a rich context on 
the impact of stigma and discrimination. In some instances nongovernmental organiza-
tions also submit shadow reports, which provide a point of view different from the offi cial 
version. Together, they may provide a realistic picture of national and community efforts 
to eliminate stigma and discrimination.
National Composite Policy Index
The National Composite Policy Index (NCPI) is an integral part of the core UNGASS 
indicators, which comprises a series of questions on each country’s legal and policy 
landscape in relation to HIV. The NCPI is divided into two parts: (a) the government’s 
responses to the questions and (b) the responses of civil society organizations, the United 
Nations and bilateral agencies (nongovernmental sources). Most questions are answered 
yes/no. The answers are not independently verifi ed but provide a snapshot of how differ-
ent organizations view the various national AIDS policies and their implementation.
People Living with HIV Stigma Index
The People Living with HIV Stigma Index is an innovative way to measure HIV-related 
stigma and discrimination experienced by people living with HIV. National networks of 
people living with HIV lead the implementation of the Index. The Index is supported 
jointly by the Global Network of People Living with HIV, International Community of 
Women Living with HIV, International Planned Parenthood Federation and UNAIDS.
Several countries reported that stigma and discrimination in health care 
facilities adversely aff ect access to and the provision of services. For example, 
in Central and South America, several reports note that some health care 
personnel are likely to discriminate against people living with HIV and deny 
services to population groups at higher risk such as sex workers and men who 
have sex with men; in Mexico, service providers may treat people who inject 
drugs as “delinquents” (8). Country progress reports for 2010 from Lesotho, 
Mozambique and Senegal (7) mentioned stigma and discrimination towards 
sex workers and sexual minorities as barriers to their accessing health services, 
HIV testing, and HIV treatment.
Th ere continue to be reports from many parts of the world of violence against 
and murder of individuals based on their perceived or actual sexual orientation 
(9–11). For example, the shadow report submitted under UNGASS reporting 
on Honduras described several murders and a climate of impunity for perpetra-
tors of violations of human rights that seriously undermines the HIV response 
(12). Such grave situations call for concerted action and advocacy by both 
human rights and HIV stakeholders.
Meaningfully involving people living with and vulnerable to HIV in national 
HIV responses is a part of realizing human rights. 
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Th e Greater Involvement of People Living with HIV (GIPA) has been a key 
human rights principle within the HIV response since the Paris Declaration 
of 1994. In 2010, governments in 96% of countries reported that their national 
HIV strategy explicitly addressed the involvement of people living with HIV, 
up from 75% in 2006. Civil society has been leading eff orts to assess the nature 
and quality of this participation. Th e Global Network of People Living with 
HIV has implemented the GIPA Report Card in six countries and is currently 
implementing assessments in four others. In Kenya, 33% of respondents indi-
cated that they either “somewhat agreed” or “strongly agreed” that people living 
with HIV were meaningfully involved in developing the country’s national 
AIDS plan; in Nigeria, the fi gure was 60%; and in Zambia, 66%. Fear of stigma 
was cited as one of the most signifi cant barriers to greater involvement in the 
national response in all three countries (13).
Laws, policies, and regulations that create obstacles to eff ective HIV 
responses are increasingly acknowledged but too oft en remain
Countries increasingly acknowledge the demonstrated and potential negative 
eff ects of punitive legislation, policies, and regulations on access to, and uptake 
of, HIV prevention, treatment, care, and support services and on the rights 
and dignity of people living with or vulnerable to HIV (14). In 2006, nongov-
ernmental sources in 41% of countries reported that the countries had laws, 
policies, or regulations that posed obstacles to eff ective HIV service provision 
for key populations at higher risk. In 2010, sources in 67% of the same coun-
tries reported the existence of such obstacles. In Asia and the Pacifi c, nearly 
90% of nongovernmental sources reported the existence of laws that pose 
obstacles to eff ective HIV responses for key populations at higher risk.  In the 
Middle East and North Africa 56% of countries, and 55% in sub-Saharan Africa 
reported similar laws. 
Government and civil society responses to the National Composite Policy 
Index (NCPI) in this area diff er notably. In 2010, the governments of 78 coun-
tries (46% of those reporting) acknowledged the existence of laws, regulations, 
and policies that obstructed access to prevention, treatment, care, and support 
services for populations at higher risk; in contrast, civil society from 106 coun-
tries (62%) reported the same (Figure 5.1).
Th ese reports do not capture the full reality of laws that can act as obstacles to 
the HIV response. For instance, 79 countries and territories criminalize same-
sex sexual relations between consenting adults, with six countries retaining 
the possibility of applying the death penalty for such acts (15). More than 100 
countries criminalize some aspect of sex work (16,17). Fift y-one countries, 
territories, and entities are reported to impose some form of restriction on the 
entry, stay, and residence of people living with HIV (Figure 5.2) (18,19).
In their narrative UNGASS reports (7), several countries recognized that crimi-
nalization of same-sex practices, sex work, and/or provision of sterile needles 
and syringes, and of punitive law enforcement are barriers to fully eff ective 
HIV responses. Bangladesh, for example, reports that existing laws are oft en 
used to harass vulnerable people, leading to the weakening of programme 
REMOVING PUNITIVE AND 
DISCRIMINATORY LAWS: HIV-
RELATED RESTRICTIONS ON 
ENTRY, STAY, AND RESIDENCE
In 2010, a number of countries lifted 
their HIV-related restrictions on entry, 
stay, and residence: the United States 
of America (January); China (April); 
and Namibia (July). However, such 
restrictions continue in 51 countries—
an indicator of the discrimination still 
faced by people living with HIV in 
today’s highly mobile world..
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Figure 5.3
Legal protections against discrimination for people living with HIV
Percentage of countries with legal protections against discrimination 
for people living with HIV and mechanisms for redress, as reported by 
nongovernmental sources. 
Source: Country Progress Reports 2010.
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Percentage of countries reporting non-discrimination laws for 
people living with HIV
Percentage of countries reporting a mechanism to record, 
document, and address cases of discrimination experienced by 
people living with HIV and/or most-at-risk populations
Figure 5.2
HIV-related restrictions on entry, stay, or residence
A total of 51 countries, territories, and areas impose some form of restriction on the 
entry, stay, or residence of people living with HIV based on their HIV status.
Source: Mapping of Restrictions on the entry, stay and residence of people living with HIV (UNAIDS, 
May 2009), and latest developments as of July 2010.
No
Yes
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implementation supporting people at higher risk of exposure to HIV. Malaysia’s 
report recognized the challenges posed by contradictory harm reduction and 
drug control policies. Reports from Botswana, Ghana, Malawi, Mozambique, 
and Zambia acknowledge that criminalizing homosexuality makes providing 
services to men who have sex with men more diffi  cult. Reports from Lebanon, 
Saudi Arabia, and the Syrian Arab Republic also note that laws that prohibit 
adultery, homosexuality, and sex work may hinder HIV prevention eff orts (7).
Studies confi rm that punitive laws have negative eff ects on access to HIV 
services and on the claiming and exercise of human rights by men who have 
sex with men (20), sex workers (21,22), and people who use drugs (14,23,24). 
Among those working in the response to HIV another concern is the apparent 
increased trend of passing laws that criminalize HIV transmission and/or the 
failure to disclose one’s HIV status. Such laws contradict the commitment made 
by governments in the Political Declaration on HIV/AIDS in 2006 “to promote 
a social and legal environment that is supportive of and safe for voluntary dis-
closure of HIV status” (25). Countries in North America and Western Europe 
have long criminalized HIV transmission, and about 20 countries in sub-Saha-
ran Africa have also chosen to do so in the past six years (26).
Parallel to increased acknowledgement of laws that pose obstacles to HIV 
responses, more countries report the existence of laws and regulations that pro-
tect people living with or vulnerable to HIV from discrimination but data are 
insuffi  cient to indicate whether they are adequately enforced. In 2010, nongov-
ernmental sources in 71% of countries reported the existence of laws protecting 
people living with HIV from discrimination versus 67% in 2008 and 56% in 2006 
(of the same 85 countries reporting in all three years). Most worrying, however, 
is that the 2010 data indicate that almost one third of countries still do not have 
such protective legislation. In addition, only 56% of countries report having a 
mechanism to record, document, and address cases of discrimination experi-
enced by people living with HIV or other people vulnerable to HIV (Figure 5.3).
In 2010, governments in 106 countries (62%) reported having laws or regula-
tions that specify protections for key populations at higher risk such as women, 
young people, men who have sex with men, people who inject drugs, sex work-
ers, prisoners and migrants. Nongovernmental sources in 112 countries (65%) 
reported the same. In 2004, when the fi rst UNGASS reports were submitted, 
nongovernmental sources in only 32% of countries reported the same (of the 
88 countries reporting that year). Th is suggests increased understanding among 
policy makers that protective laws are important in eff ectively responding to 
HIV (Figure 5.4).
Despite reporting of an increase in protective laws, there is little evidence whether 
these laws are eff ectively enforced or whether people living with HIV and other 
people key in the response have access to justice or can seek redress for wrongs 
experienced. For instance, while nongovernmental sources in 61% of countries 
in North Africa and the Middle East report the existence of non-discrimination 
laws, only 17% report having mechanisms to record, document, and address 
cases of discrimination experienced by people living with or vulnerable to HIV.
56%
Percentage of countries reporting 
having a mechanism to record and 
address cases of discrimination.
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Figure 5.4
Non-discrimination laws protecting key populations at higher risk
Countries in which nongovernmental sources report non-discrimination laws 
protecting key populations at higher risk.
Source: Country Progress Reports 2010.
Figure 5.5
Legal aid for HIV casework
Countries in which nongovernmental sources report legal aid systems for 
HIV casework, 2010.
Source: Country Progress Reports 2010.
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No
Missing data
Yes
No
Missing data
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Access to HIV-related legal services is one eff ective means to protect the human 
rights of people living with HIV and other key populations as are eff orts to 
sensitize offi  cials engaged in the administration of justice. However, nongov-
ernmental sources in only 51% of countries report having legal aid systems for 
HIV casework. Although this represents an increase from 2006, when 33% of 
countries reported having such systems, the fi gure has remained the same since 
2008. Legal aid systems appear to be more common in high-income countries, 
with 75% of countries reporting such systems (NCPI), whereas only 48% of 
low-income countries and 40% of lower-middle-income countries report hav-
ing them (Figure 5.5).
Gender equality
Although gender relationships, practices and HIV epidemics diff er around the 
world, power imbalances, harmful social gender norms, gender-based violence 
and marginalization clearly increase the vulnerability of both women and men 
to HIV infection. Th e consequences of gender inequalities in terms of low 
socioeconomic and political status, unequal access to education, and fear of 
violence, add to the greater biological vulnerability of women and girls being 
infected with HIV. Too oft en they have little capacity to negotiate safer sex, 
access the services they need, and utilize opportunities for empowerment (27). 
In nearly all countries in sub-Saharan Africa and certain Caribbean countries, 
the majority of people living with HIV are women, especially girls and women 
aged 15–24 years (28,29).
In sub-Saharan Africa, women are more likely to become infected with HIV 
than are men (Figure 5.6). Th e most recent prevalence data show that in sub-
Saharan Africa, 13 women become infected for every 10 men infected. One 
half of people living with HIV globally are women and 76% of all HIV-positive 
women live in sub-Saharan Africa.
Conversely, traditional roles and societal values related to masculinity might 
encourage boys and men to adopt risky behaviours, including excessive alcohol 
use and concurrent sexual relationships, so increasing their risk of acquiring 
and transmitting HIV. Many harmful norms related to masculinity and femi-
ninity also stigmatize transgender people, men who have sex with men, and 
other sexual minorities.
Levels of new HIV infections in sub-Saharan Africa continue to remain higher 
among women, a pattern that applies to every subregion in sub-Saharan Africa. 
Female-to-male ratios of new HIV infections range from 1.22:1 in West and 
East Africa to 1.33:1 in southern Africa, despite the diff erent types of epidemics 
and predominant modes of transmission in these subregions.
In other regions, men are more likely to be infected with HIV than women, 
oft en in concentrated epidemics involving men who have sex with men or 
people who inject drugs. Men who have sex with men continue to bear a high 
burden of HIV infection even in regions with generalized epidemics. In sub-
Saharan Africa, HIV programming has largely neglected same-sex behaviour 
because of homophobia and the widespread criminalization of homosexuality.
THE GLOBAL COMMISSION 
ON HIV AND THE LAW
On 24 June 2010, UNDP and UNAIDS 
launched the Global Commission 
on HIV and the Law composed of 
renowned and independent global 
leaders in the areas of law, public 
health policy and governance. The 
establishment of the Commission is 
an essential milestone in supporting 
countries to remove punitive laws, 
policies, practices, stigma and 
discrimination that block effective 
responses to HIV. The Commission 
is supported by a Technical Advisory 
Group of law, human rights and 
public health experts.
As an outcome of its fi rst meeting 
in October 2010, the Commission 
will focus on the following issues: 
criminalization of sex workers, drug 
users, people living with HIV, men 
who have sex with men, gender 
inequality and violence against 
women, and legal barriers to 
treatment. Through its work, the 
Commission will marshal the evidence 
on the impact of the law on the 
HIV response, and make actionable 
recommendations on how to create 
effective, protective and enabling 
legal responses to HIV.
In the course of 2011, the 
Commission will hold a number of 
regional policy dialogues that will 
allow submissions from regional 
and national stakeholders, including 
governments, civil society, people 
living with HIV and representatives of 
key populations. These submissions 
will shape the fi nal report and 
recommendations of the Commission, 
expected in December 2011. 
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Figure 5.6
People newly infected with HIV, 2009
Number of people newly infected with HIV annually by sex and 
geographical region, 2009.
Source: UNAIDS 2010.
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Figure 5.7
HIV prevalence among young people in 
sub-Saharan Africa
HIV prevalence among people 15–24 years old by 
sex in selected countries in sub-Saharan Africa.
Source: UNAIDS 2010.
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Research has found signifi cantly higher levels of infection among men who 
have sex with men than among men in general, and has also confi rmed 
that many men who have sex with men also have sex with women (30). 
Understanding the complexities of relationships engaged in by some married 
and long-term partners is important in focusing the HIV response. A recent 
study conducted in Botswana, Malawi, and Namibia found that 34% of men 
who have sex with men were married to women, and a total of 54% reported 
sex with both men and women in the previous six months (31). Marriage thus 
serves as a way to protect against possible prosecution and stigma against 
men who have sex with men (32,33). In Asia, data obtained through the Asia 
Intimate Partner Transmission Study (34) indicate that women are predomi-
nantly infected by their husband or intimate partner. For example, recent data 
on HIV infection patterns in India reveal that 90% of women in India were 
infected within long-term relationships.
Sociocultural practices signifi cantly contribute to the risk of HIV infection, 
especially among young women
Th e eff ects of gender constructs are refl ected in HIV infection rates among 
young women in Africa. Demographic and health surveys in selected countries 
in Africa show that young women are at particularly high risk of HIV infec-
tion, with rates substantially increasing among women 20–24 years old versus 
15–19 years old (Figure 5.7). Th is is probably because young women, who are 
biologically more susceptible to HIV than men, also oft en have older male 
sexual partners, who are more likely than younger men to be infected with HIV. 
As a result, while levels of HIV infection among men rise slowly and peak at a 
lower level than female infection rates when men are in their mid- to late thir-
ties, prevalence among women rises rapidly at a young age, with higher peaks 
when women are in their late twenties (35).
Data from sub-Saharan Africa indicate that women also engage in multiple 
concurrent partnerships (36). A recent ethnographic study conducted in the 
United Republic of Tanzania showed that both parents and daughters widely 
accepted transactional sex, including sex for power, pleasure, and material 
gain. Th e authors conclude that programmes that encourage young women to 
incorporate demands for safer sex into negotiations for gift s and money may 
ultimately be more eff ective than those that seek only to restrict transactional 
sex or highlight its health risks (37). Another study found that more affl  uent 
women are at greater risk of contracting HIV, as they are more mobile, more 
likely to live in an urban area, and more able to aff ord a lifestyle that includes 
having a higher number of sexual partners (38).
A 2009 study in Brazil (39) shows men who have sex with men have much higher 
levels of HIV infection than men in general (10.5% versus 0.8%). Th e study 
found that although men who have sex with men report more casual sexual part-
ners than men in general, condom use among was only at about 50%, despite a 
comprehensive programme to increase condom use among men who have sex 
with men. Furthermore, young men who have sex with men used condoms with 
slightly less frequency than men in general (54% versus 57%) (39).
“THE NUMBER OF 
COUNTRIES WITH A 
SPECIFIC BUDGET FOR HIV 
ACTIVITIES RELATED TO 
WOMEN IS LOW: 46% OF 
REPORTING COUNTRIES.”
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Figure 5.8
Multisectoral HIV strategies specifically including 
and budgeting for women
Percentage of countries in which governments report that 
multisectoral HIV strategies specifi cally include and budget 
for women.
Source: Country Progress Reports 2010.
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Women are included in HIV strategies but budgetary allocations are 
insuffi  cient
Governments in 80% of countries (137 of 171) reported that they include women 
as a specifi c component of a multisectoral HIV strategy, but the rate of inclusion 
of women diff ers by geographical regions (Figure 5.8). Th e number of countries 
with a specifi c budget for HIV activities related to women is considerably lower: 
46% (79 of the 171) reporting countries. Among countries in sub-Saharan Africa, 
nearly all strategic plans include interventions benefi ting women, and three quar-
ters of countries allocate budget accordingly, indicating a greater awareness of the 
need for and benefi ts of women-centred AIDS responses.
Th e HIV epidemic is intertwined with sexual and reproductive health
Data on unmet sexual and reproductive health needs, especially among young 
women a population highly aff ected by HIV and violence, underline the urgen-
cy to address Millennium Development Goals 3, 4, 5 and 6 simultaneously. A 
WHO report on women and health (40) highlights the critical role of gender 
inequality in increasing vulnerability to HIV infection and other conditions 
and limiting access to health care services and information. A review of mater-
nal mortality data revealed that HIV-related causes contributed to at least 20% 
of maternal deaths (41).
Countries with high HIV prevalence rates among young women are equally 
challenged by high teenage pregnancy rates, and the consequences of unintend-
ed pregnancies in terms of unsafe abortion.
According to WHO, each year about 16 million women 15–19 years old around 
the world give birth, with most living in sub-Saharan Africa. In addition, at 
least 2.5 million adolescents have unsafe abortions every year (42). Further, 
anecdotal reports indicate that women living with HIV are pressured, and even 
forced, to undergo sterilization or to have an abortion.
Recent research carried out by civil society on sexual and reproductive health 
policies, undertaken in 12 countries in sub-Saharan Africa, Central and South 
America, the Caribbean, South-East Asia, and Eastern Europe by GESTOS, 
Brazil (43) confi rms that countries have reproductive and sexual health policies 
oriented towards women in place but generally fail to translate these into com-
prehensive services, leaving many sexual and reproductive health needs unmet.
Violence and HIV infections are oft en associated and require integrated 
responses
Violence and the threat of violence can hamper women’s ability to adequately 
protect themselves from HIV infection and/or assert healthy sexual decision-
making. In addition, women living with HIV are more likely to experience 
violence due to their HIV status (44).
Th e WHO study also found that many women have a traumatic experience 
when engaging in sexual intercourse for the fi rst time, with the prevalence of 
forced fi rst sex among adolescent girls younger than 15 years ranging between 
11% and 45% globally. In addition, younger women, especially those 15–19 
“VIOLENCE AND THE 
THREAT OF VIOLENCE 
CAN HAMPER WOMEN’S 
ABILITY TO ADEQUATELY 
PROTECT THEMSELVES FROM 
HIV INFECTION AND/OR 
ASSERT HEALTHY SEXUAL 
DECISION-MAKING.”
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Figure 5.9
Violence against women
Proportion of ever-married women 15–49 years old who ever experienced physi-
cal or sexual violence from their most recent spouse or co-resident partner, by 
country, 2008 or most recent survey. 
Source: Demographic Health Surveys, 2002-2008, excepting Bangladesh, Ethiopia, Japan, Kenya, 
Samoa, Serbia, Tanzania and Thailand (WHO Multi-Country Study on Women’s health and 
Domestic Violence, 2004).
Figure 5.10
Governments involving men in reproductive health programmes 
Percentage of countries in which governments report involving men in reproductive 
health programmes through information, education and communication, 2010.
Source: Country Progress Reports 2010.
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years old, were generally at higher risk of physical and/or sexual violence by a 
partner. In Swaziland, which has one of the highest levels of HIV prevalence, a 
2007 study (45) showed that 33% of females 13–24 years old reported experi-
encing some form of sexual violence before reaching 18 years of age.
A 2010 study in South Africa (46) confi rmed the association between violence 
and HIV infection. Power inequity in relationships and intimate partner 
violence increased the incident risk of HIV infection among young South 
African women. Prevalence of the population-attributable risk was 14% for 
power inequity in relationships and 12% for intimate partner violence. Th e 
GESTOS research (43) found that few countries have undertaken focused 
actions to prevent violence or to empower women survivors of violence. Th is 
fi nding is confi rmed by the recent WHO/UNAIDS publication (44), indicating 
that eff ective programmatic models such as Stepping Stones, IMAGES, 
and Sasa! have so far only been incorporated to a limited extent in the HIV 
response. It is notable that countries might have laws in place to punish rapists, 
but few have legislation that penalizes domestic violence (43).
Figure 5.9 shows that the prevalence of violence against women can be as high 
as 50% in some countries. Th e limited availability of epidemiological data on 
violence underlines the urgent need for additional evidence to guide policy and 
programmatic action to address it.
UNGASS reports for several countries in sub-Saharan Africa (7) outline the 
increased HIV vulnerability of women due to violence and sexual coercion and 
highlight the link with armed confl ict, including sexual violence against women 
in refugee camps. Other countries underline that violence against sex workers 
aff ects their capacity to insist on the use of condoms. Reporting on gender-
based violence is not even. Outside sub-Saharan Africa, UNGASS reports are 
silent on violence against women and girls. In sub-Saharan Africa, countries 
have not reported on violence against men who have non-heterosexual 
identities or practices and transgender people.
Men who have sex with men and transgender people also face increased 
vulnerability to HIV infection due to violence and stigma. Historically, 
community-based organizations, rather than nationally funded HIV 
programmes, have led in attempting to increase access for men who have sex 
with men and transgender people. Such “self-help” eff orts are hampered where 
homosexuality is criminalized, as in sub-Saharan Africa, where men who have 
sex with men experience violence, live under the threat of anti-sodomy laws, 
and are oft en excluded from HIV responses (47).
Engaging men is crucial in eff ectively responding to HIV
Despite evidence of positive changes in men’s and boys’ behaviour and atti-
tudes when they participate in programmes that address HIV, sexual and 
reproductive health, and gender-based violence (48), few such programmes 
are in operation (49). UNGASS reporting also confi rms that governments in 
only 60% of countries report having promoted greater involvement of men 
“MEN WHO HAVE 
SEX WITH MEN AND 
TRANSGENDER PEOPLE 
ALSO FACE INCREASED 
VULNERABILITY TO HIV 
INFECTION DUE TO 
VIOLENCE AND STIGMA.”
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in reproductive health programmes in information, education, and commu-
nication on reproductive health (Figure 5.10). Th e failure to engage men also 
directly aff ects their health. For example, fewer men than women access HIV-
related treatment. ■
ACTION ITEMS
HUMAN RIGHTS
■  Laws, policies, and regulations that create obstacles to effective HIV 
responses are increasingly acknowledged by key actors in the response. 
Countries should now take action to decriminalize sex workers, people who 
use drugs, men who have sex with men and transgender people, and reform 
other laws that block effective responses to HIV.
■  Despite increased reporting on protective laws, countries and other stake-
holders should establish effective enforcement mechanisms and provide 
people living with HIV and other key populations with access to justice and 
redress through HIV-related legal services and legal literacy programmes.
■  Although progress has been noted, HIV-related stigma and discrimina-
tion are still highly prevalent globally and are not yet being suffi ciently 
addressed. Countries and other stakeholders should urgently scale up 
comprehensive programmes that build capacities of HIV-related service 
providers, address stigma and discrimination in laws, institutions and com-
munities, and empower those affected by HIV.
■  To help to realize human rights in the context of HIV, there must be more 
meaningful involvement of people living with and those vulnerable to HIV in 
national HIV responses, as well as meaningful coverage of all affected popu-
lations. The GIPA principles must be fully implemented.
GENDER EQUALITY
■  To achieve universal access goals towards HIV prevention, treatment, care 
and support, the AIDS response needs to be women and girls centred and 
include a dedicated budget to address their needs.
■  Given that violence is widespread and that there is a clear association 
between violence against women and the spread of HIV, national HIV 
responses must include specifi c interventions to address violence.
■  All countries need to ensure that women have access to integrated quality 
HIV and sexual and reproductive health services that enable women to exer-
cise their rights.
■  Men and boys need to be engaged in innovative approaches to change 
harmful social and cultural practices and norms, as part of HIV prevention.
■  Countries need to address the needs of men who have sex with men through 
prevention interventions that go beyond health service provision.
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Botswana
Burkina Faso
Burundi
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Cape Verde
Central African Republic
Chad
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Congo
Côte d’Ivoire
Democratic Republic of Congo
Equatorial Guinea
Eritrea
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Gabon
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Ghana
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Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
SUB-SAHARAN 
AFRICA
SCORECARD: HUMAN RIGHTS AND GENDER EQUALITY
A  NCPI Part A (government response)
B  NCPI Part B (civil society response)
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South Africa
Swaziland
Togo
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
China
Democratic People’s Republic of Korea
Japan
Mongolia
Republic of Korea 
Australia
Fiji
Kiribati
Marshall Islands
Micronesia, Federated States of
Nauru
New Zealand
Palau
Papua New Guinea
Samoa
Solomon Islands
Tonga
Tuvalu
Vanuatu
Afghanistan
Bangladesh
Bhutan
Brunei Darussalam
Cambodia
India
Indonesia
Lao People’s Democratic Republic
Malaysia
SUB-SAHARAN 
AFRICA 
Continued
EAST ASIA
OCEANIA
SOUTH AND 
SOUTH-EAST ASIA
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Maldives
Myanmar
Nepal
Pakistan
Philippines
Singapore
Sri Lanka
Thailand
Timor-Leste
Viet Nam
Armenia
Azerbaijan
Belarus
Georgia
Kazakhstan
Kyrgyzstan
Moldova, Republic of
Russian Federation
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Albania
Andorra
Austria
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
SOUTH AND 
SOUTH-EAST ASIA 
Continued
EASTERN EUROPE 
AND CENTRAL ASIA
WESTERN AND 
CENTRAL EUROPE
Yes/Agree
No/Disagree
Data not available
No NCPI report
No UNGASS report
A  NCPI Part A (government response)
B  NCPI Part B (civil society response)
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Greece
Hungary
Iceland
Ireland
Israel
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Romania
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Macedonia, The Former Yugoslav Republic of
Turkey
United Kingdom of Great Britain 
& Northern Ireland
Canada
Mexico
United States of America
Algeria
Bahrain
Djibouti
WESTERN AND 
CENTRAL EUROPE 
Continued
NORTH AMERICA
MIDDLE EAST 
AND NORTH 
AFRICA
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Egypt
Iran, Islamic Republic of
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab Jamahiriya
Morocco
Oman
Qatar
Saudi Arabia
Somalia
Sudan
Syrian Arab Republic
Tunisia
United Arab Emirates
Yemen 
Antigua & Barbuda
Bahamas
Barbados
Cuba
Dominica
Dominican Republic
Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Trinidad and Tobago
Argentina
Belize
Bolivia
Brazil
Chile
Colombia
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MIDDLE EAST 
AND NORTH 
AFRICA 
Continued
CARIBBEAN
CENTRAL AND 
SOUTH AMERICA
Yes/Agree
No/Disagree
Data not available
No NCPI report
No UNGASS report
A  NCPI Part A (government response)
B  NCPI Part B (civil society response)
SCORECARD: HUMAN RIGHTS AND GENDER EQUALITY
143Chapter 5: Human rights and gender equality | 2010 GLOBAL REPORT
5
W
o
m
en
 c
o
m
p
o
ne
nt
 o
f t
he
 n
at
io
na
l 
st
ra
te
g
ic
 p
la
n 
b
ud
g
et
ed
La
w
s,
 re
g
ul
at
io
ns
, p
o
lic
ie
s 
p
ro
te
ct
in
g
 
sp
ec
ifi 
c 
su
b
-p
o
p
ul
at
io
ns
La
w
s,
 re
g
ul
at
io
ns
, p
o
lic
ie
s 
o
b
st
ru
ct
in
g
 
ac
ce
ss
 t
o
 p
re
ve
nt
io
n,
 t
re
at
m
en
t,
 c
ar
e 
an
d
 
su
p
p
o
rt
 fo
r 
vu
ln
er
ab
le
 s
ub
p
o
p
ul
at
io
ns
M
ec
ha
ni
sm
 t
o
 re
co
rd
, d
o
cu
m
en
t 
an
d
 a
d
d
re
ss
 
ca
se
s 
o
f d
is
cr
im
in
at
io
n 
ex
p
er
ie
nc
ed
 b
y 
p
eo
p
le
 
liv
in
g
 w
ith
 H
IV
, v
ul
ne
ra
b
le
 s
ub
p
o
p
ul
at
io
ns
W
o
m
en
 a
s 
a 
sp
ec
ifi 
c 
co
m
p
o
ne
nt
 o
f 
th
e 
na
tio
na
l s
tr
at
eg
ic
 p
la
n
IE
C
 a
ct
iv
iti
es
 o
n 
fi g
ht
in
g
 V
io
le
nc
e 
A
g
ai
ns
t 
W
o
m
en
La
w
s 
&
 re
g
ul
at
io
ns
 p
ro
te
ct
in
g
 p
eo
p
le
 
liv
in
g
 w
ith
 H
IV
 a
g
ai
ns
t 
d
is
cr
im
in
at
io
n
B A A A B A    BA    B
Costa Rica
Ecuador
El Salvador
Guatemala
Guyana
Honduras
Nicaragua
Panama
Paraguay
Peru
Suriname
Uruguay
Venezuela
CENTRAL AND 
SOUTH AMERICA
Continued
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KEY FINDINGS
■  A total of US$ 15.9 billion was available for the AIDS response in 2009, 
US$ 10 billion short of what is needed in 2010.
■  In low- and middle-income countries, domestic resources account for over 
half of all AIDS-related investments. In low-income countries, however, 88% 
of spending on AIDS comes from international funding.
■  The majority of international funding for AIDS comes from bilateral donors. 
The United States of America is the largest international donor.
■  Investment in treatment and care is increasing—but many countries depend 
on international assistance for their treatment and care programmes.
■ HIV prevention programmes largely rely on international funds.
■  One third of countries make the AIDS response a high budgetary priority, 
based on disease burden and national income.
HIV INVESTMENTS
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CHAPTER 6 | HIV INVESTMENTS
Investing for AIDS is a shared responsibility
Investing for AIDS is a shared global responsibility that is paying clear dividends 
—it saves lives now, improves the quality of life of people living with HIV, and 
will lessen future burdens of cost and disease. In 2009, international donors and 
governments together provided US$ 15.9 billion for the global AIDS response, 
more than half of which came from domestic sources in low- and middle-
income countries.
As a result of this unprecedented health investment, HIV prevalence is falling 
due to programmes that reduce risk behaviour, more than 5 million people are 
receiving life-saving antiretroviral therapy, millions of orphans have received 
basic education and health care, and more tolerant and enabling social environ-
ments have been established in many countries through campaigns to reduce 
HIV-related stigma and discrimination. None of this would have been possible 
without the strong mobilization of the global community and the unprecedent-
ed levels of funding provided collectively by donors, governments, the private 
sector, philanthropic organizations and individuals to address HIV.
However, the gap between investment needs and resource availability is widen-
ing at a time of fi scal constraints. In 2009, there was a US$ 10 billion gap as, for 
the fi rst time, international assistance did not increase from 2008 levels.
In most countries, the AIDS response is funded by a complex interplay of 
domestic public spending, multilateral and bilateral aid, private-sector and 
philanthropic support and individual out-of-pocket spending. In many low- 
and middle-income countries, the largest source of HIV funding—52%—is 
domestic expenditure. Government donors provide an additional 42% and the 
international philanthropic sector 5% (1).
International investment levels have largely refl ected the epidemic distribution. 
Donors’ HIV-related spending is higher in countries with high HIV prevalence.
Th e sharing of the responsibility has largely matched the fi nancial capabilities 
of individual countries and the magnitude of national epidemics.
Middle-income countries contributed a far greater proportion of the resources 
to their national AIDS response. Low-income countries’ share of investment for 
the national AIDS response was much smaller.
»
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DOMESTIC INVESTMENT PRIORITY INDEX (DIPI)
A new UNAIDS Domestic Investment Priority Index attempts to measure 
the extent of investment priority given by governments to support their 
national AIDS response. The Index is calculated by dividing the percentage 
of government revenue each country directs to the AIDS response by the 
population HIV prevalence. A high value usually indicates a high level of priority.
Domestic 
investment priority 
index
= x
Public expenditure
on AIDS response
Government revenue
National population
People living with HIV
On average, the percentage of government revenue allocated to the AIDS 
response was one fi ft h of the population HIV prevalence. Fift y-fi ve countries 
allocated more than 0.5% of total government revenue. Data from 121 coun-
tries show that one third of all countries make investments at a level that is 
commensurate with their national income levels and share of the global epi-
demic burden. Among the 104 countries reporting, the median level of priority 
is 0.35. Th e Priority Index of a large majority of countries (70%), however, falls 
below this average—suggesting that many countries need to invest more in 
their AIDS responses.
Eight of 14 countries in West and Central Africa and six of 16 countries in east 
and southern Africa appear to be spending less on the AIDS response than 
might be expected given their disease burden and government resources. Th e 
Russian Federation and Ukraine, the two countries in Eastern Europe and 
Central Asia with the highest HIV prevalence, are spending at relatively low 
levels given their disease burden and ability to pay. Th e Domestic Investment 
Priority Index implies that both countries could contribute more domestic 
resources to the AIDS response (Figure 6.1). Figure 6.2 shows the distribution 
of funds to diff erent elements of the epidemic response.
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Figure 6.1
Domestic Investment Priority 
Index for countries with the 
highest HIV prevalence 
DIPIYear Median 
spending
Above median Below median
DIPI=Domestic Investment Priority Index
Botswana 2008 0.31 
Brazil 2008 0.80 
Cameroon 2008 0.06 
China 2009 0.69 
Colombia 2009 0.52 
Congo 2009 0.68 
Côte d’Ivoire 2008 0.05 
Democratic Republic of the Congo 2008 0.28 
Ghana 2008 0.10 
India 2009 0.07 
Indonesia 2008 0.29 
Kenya 2009 0.33 
Lesotho 2008 0.33 
Malawi 2009 0.03 
Mozambique 2008 0.03 
Nigeria 2008 0.13 
Russian Federation 2008 0.19 
South Africa 2009 0.18 
Thailand 2009 0.37 
Uganda 2008 0.72 
Ukraine 2008 0.09 
Viet Nam 2009 0.05 
Zimbabwe 2009 0.04
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Figure 6.2
HIV spending in low- and middle-income countries 
HIV spending in current US dollars by programmatic area in 
43 low- and middle-income countries, 2006–2008.
Source: Country Progress Reports 2010.
2006
US$ 2.6 billion
2007
US$ 3.3 billion
2008
US$ 4.1 billion
Treatment and care 
Prevention
Programme management and administration strengthening
Orphans and vulnerable children
Incentives for human resources
Social protection and social services
Enabling environment
Research
Overall size of square is proportional to the total amount 
spent each year.
International investments are not increasing; 
donor fair share is not being met
Donor governments’ actual disbursements for the AIDS response in 2009 
stood at US$ 7.6 billion in 2009, a slight decrease from the US$ 7.7 billion 
made available in 2008. Th ese disbursements include both bilateral aid 
(funds disbursed directly from a donor country to a recipient country) and 
contributions to multilateral organizations (Figure 6.3). Th e majority of these 
resources went to the countries most aff ected by the epidemic. Th e top 20 
recipients of aid account for 71% of the people living with HIV globally. Low-
income countries received 78% of international funds, with another 14% going 
to lower-middle-income countries.
International assistance is crucial to sustaining the AIDS response. Of the 132 
countries reporting HIV spending by funding source, 70 countries (53%) rely 
on international funds to fi nance 50% or more of HIV spending. And for the 
majority of the low- and middle-income countries, increasing domestic invest-
ment priority to the optimum levels is not suffi  cient to meet the needs of the 
AIDS response. Th e United States of America was the largest international 
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Canada 
US$ 129.9 million
Figure 6.3
Channels used by major donor countries for 
disbursing international AIDS funding in 2009 
Source: Kates et al. 2010.
Denmark
US$ 193.3 million
Ireland
US$ 81.2 million
Australia
US$ 99.9 million
Netherlands
US$ 381.9 million
United Kingdom
US$ 779 million
Sweden
US$ 171.8 million
Norway
US$ 130.2 million
Other Governments
US$ 73.3 million
France
US$ 338.4 million
European Union
US$ 118.1 million
Germany
US$ 397.9 million
Japan
US$ 141.8 million
Spain
US$ 163.6 million
% of aid disbursed to 
Global Fund/UNITAID
% of aid disbursed bilaterally
Size of the circle is proportional to 
total disbursements.
Italy 
US$ 9.5 million
Bilateral funding includes HIV-earmarked multilateral funding; multilateral funding 
includes Global Fund contributions adjusted to represent the estimated HIV share based 
on Global Fund grant distribution by disease to date (61% for HIV) and UNITAID contri-
butions adjusted to represent the estimated HIV share based on distribution by disease 
to date (49% for HIV).
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23
77
12
88
Total
US$ 7.6 billion
United States
US$ 4.4 billion
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donor, accounting for 58% of all donor-government disbursements for AIDS 
and for 27% of the funding available for AIDS from all sources (donor govern-
ments, multilateral institutions, domestic government spending, and private 
and individual out-of-pocket spending). Th e United Kingdom accounted for 
10% of total donor government disbursements for AIDS, and Germany and the 
Netherlands accounted for 5% each.
International investment funding channels
Bilateral funding remains the principal source of international AIDS funds for 
low- and middle-income countries. Of the US$ 7.6 billion donor governments 
made available for AIDS in 2009, US$ 5.9 billion (77%) was provided as bilater-
al aid. Th e United States of America, the largest donor, provides a vast majority 
(88%) of its resources directly to countries.
However, a sizeable proportion (23%) of all international assistance is avail-
able through multilateral institutions such as the Global Fund to fi ght AIDS, 
Tuberculosis and Malaria and UNITAID. Canada, the European Union, France, 
Japan and Spain each provided more than two thirds of their HIV-related inter-
national assistance through the Global Fund and UNITAID in 2009. Th e Global 
Fund, which accounts for 72% of disbursements from multilateral sources, was 
the main source of AIDS funding in 52 of its 92 recipient countries.
Donor fair share of international investments for AIDS response 
is not being met
Comparing donor country funding for AIDS with their national gross domestic 
product (GDP) is one way of determining whether the contribution represents 
a fair share to the HIV response (Figure 6.4). Some donors give less in absolute 
terms than others but dedicate a greater share of their GDP to international 
assistance on AIDS. Most donor countries have the potential to provide sub-
stantially more resources than they are currently providing.
 
Improving cost-eff ectiveness can help bridge the resource gap
Th e resource availability for the AIDS response has always fallen short of what 
is needed. National programmes have had to ensure that programme choices 
are eff ective and effi  cient to have the maximum impact in averting new HIV 
infections and AIDS-related deaths. Countries have seen best results when 
resources are tailored to epidemic patterns and have followed evidence: for 
example, treatment programmes that use the most eff ective combination 
of drugs and male circumcision as a priority component of prevention in 
generalized epidemics. In many countries, programmes promoting abstinence 
received far more resources than eff orts to increase condom use or reduce 
multiple partners. Evidence from Zambia shows that, without the right mix of 
behavioural interventions, gains are minimal.
Th e use of antiretroviral drugs for preventing mother-to-child HIV transmis-
sion has been reported with costs of US$ 34 per disability-adjusted life-year 
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Share of World GDP
Share of All Resources for AIDS
% 105 15 20 25 30
United States
Japan
Germany
France
United Kingdom
Italy
Spain
Canada
Australia
Netherlands
Sweden
Norway
Denmark
Ireland
Figure 6.4
Donor share of the world GDP and all resources 
available for AIDS, 2009 
Source: Kates J et al. 2010.
GDP = gross domestic product. Bilateral funding includes HIV-earmarked multilateral funding. Bilateral funding includes multi-
lateral funding earmarked for HIV but does not include the Global Fund or UNITAID. Global Fund contributions are adjusted to 
represent the estimated HIV share based on Global Fund grant distribution by disease to date (61% for HIV). UNITAID contribu-
tions are adjusted to represent the estimated HIV share based on distributions by disease to date (49% for HIV). The resources 
available are estimated and represent disbursements from all sources.
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Figure 6.5
Price trends for commonly used antiretroviral therapy regimens
Price trends for some of the most commonly used antiretroviral therapy 
regimens for adult patients in low-income countries, 2008-2010.
Source: World Health Organization. Transaction prices for Antiretroviral Medicines and HIV 
Diagnostics from 2008 to March 2010. A summary report from the Global Price Reporting. 
Mechanism. Geneva May, 2010.
Figure 6.6
Domestic and international HIV spending per person 
Domestic and international HIV spending in international US dollars (purchasing 
power parity) per person by country, 2009 or last available year.
Source: Country Progress Reports 2010.
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saved; however, providing full treatment to the pregnant woman saves the life 
of the mother and protects an infant from HIV infection and orphanhood.
Th ere is also scope for innovation in promoting cost–eff ectiveness. Malawi 
is considering providing all pregnant women living with HIV with full anti-
retroviral therapy (for their own health and for stopping the mother-to-child 
transmission of HIV). Although this is potentially expensive at the beginning, 
the cumulative benefi ts over the long term are better mother-to-child out-
comes, reduced maternal mortality, reduced orphanhood, and increased school 
retention rates.
Reducing the unit cost of procurement as well as delivery of services is one way 
to improve value for money. Antiretroviral therapy costs today are in many cases 
a fraction of what they used to be, due in large part to effi  ciency gained in service 
delivery and reduction in commodities prices (Figure 6.5). Th e median price 
of the most commonly prescribed regimen for adults has dropped to around 
US$ 0.17 per day. Prevention costs have also declined. Stopping a single case 
of infection among infants now costs a mere US$ 5 compared with thousands 
of dollars a few years ago. Th e cost of condoms has also declined to as low as 
US$ 0.04 per unit.
Investment for  the AIDS response must be predictable and sustainable
As resource availability for HIV increased over the last decade, spending 
on HIV prevention, treatment, care and support have increased. Overall 
investments for the AIDS response grew by 82% between 2006 and 2008. 
Treatment and care programmes received 56% and HIV prevention 
programmes received 20% of the total resources available. Nearly 71 countries 
depend on international sources for funding more than 50% of their prevention 
activities. In contrast, the cost of treatment and care programmes on average 
appears to be shared equally between domestic sources and international 
sources. However, 26 countries reported that nearly 77% or more of their 
treatment and care expenditure relies on external sources (Figure 6.6, 
Figure 6.7 and Figure 6.8).
At a time when demand for universal access for prevention and treatment is 
growing, lack of additional resources is slowing down the pace of achieving 
results for people. As countries strive to increase their investments for the 
AIDS response, attention is needed to make long-term resource availability 
predictable. ■
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Figure 6.7
Annual HIV domestic and international spending  
Annual HIV domestic public and international spending 
in current US dollars, total and per person living with HIV, 
among the 15 low- and middle-income countries with the 
highest spending, 2009 or last available year, international 
dollars (purchasing power parity).
Source: Country Progress Reports 2010
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Figure 6.8
Regional HIV spending in low- and middle-income countries 
HIV spending in current US dollars by region and programmatic area in 
106 low- and middle-income countries, 2009 or last available year.
Source: Country Progress Reports 2010.
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ACTION ITEMS
■  The AIDS response must be fully funded. This is a shared responsibility 
between governments, donor countries, civil society and the private sector.
■  Donor countries must continue to increase their allocations to the AIDS 
response.
■  Countries that have the potential to increase domestic investments must 
do so to accelerate progress towards universal access to HIV prevention, 
treatment, care, and support.
■  Resources for AIDS programmes must be predictable. National strategic 
plans must be realistic.
■  Each national programme should set priorities to ensure that available 
resources are invested appropriately in cost-effective programmes.
■ Donor investments must match country priorities.
■  Investments must be evidence informed and reach populations most in need 
fi rst so that the returns are maximized and meet human rights standards.
■  HIV treatment programmes should be expanded urgently and utilize optimal 
combinations of high-quality and less-toxic drugs that reduce mortality over 
the long term.
■  HIV prevention investments are cost-effective when they include combina-
tion approaches that maximize synergies rather than isolated interventions.
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SCORECARD: HIV INVESTMENTS
 Angola 2009 0.29
 Benin 2009 1.42
 Botswana 2008 0.31
 Burkina Faso 2008 1.25
 Burundi 2008 3.11
 Cameroon 2008 0.06
 Cape Verde 2009 -
 Central African Republic 2008 0.12
 Chad 2008 0.34
 Comoros - -
 Congo, Republic of the 2009 0.68
 Côte d’Ivoire 2008 0.05
 Democratic Republic of Congo 2008 0.28
 Equatorial Guinea 2009 0.19
 Eritrea 2009 -
 Ethiopia - -
 Gabon 2009 0.18
 Gambia 2008 0.23
 Ghana 2008 0.10
 Guinea 2009 0.24
 Guinea-Bissau 2009 0.46
 Kenya 2009 0.33
 Lesotho 2008 0.33
 Liberia - -
 Madagascar 2008 7.03
 Malawi 2009 0.03
 Mali 2008 0.38
 Mauritania - -
 Mauritius - -
 Mozambique 2008 0.03
 Namibia - -
 Niger 2008 0.21
 Nigeria 2008 0.13
 Rwanda 2008 0.61
 Sao Tome and Principe 2009 -
 Senegal 2008 0.38
 Seychelles 2009 -
 Sierra Leone 2007 0.11
 South Africa 2009 0.18
 Swaziland 2007 0.11
 Togo 2008 0.11
 Uganda 2008 0.72
 United Republic of Tanzania - -
 Zambia - -
 Zimbabwe 2009 0.04
 China 2009 0.69
 Democratic People’s Republic of Korea - -
 Japan 2009 0.67
 Mongolia 2009 1.05
 Republic of Korea - -
SUB-SAHARAN 
AFRICA
EAST ASIA
Year Domestic 
priority 
to HIV
2
5
5
0
7
5%
Total prevention
2
5
5
0
7
5%
Total care and treatment
2
5
5
0
7
5%
Total HIV spending
% of HIV spending from public and international sources
Public
International
Data not available
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 Australia - -
 Fiji 2009 0.55
 Kiribati - -
 Marshall Islands 2009 -
 Micronesia, Federated States of 2009 -
 Nauru 2009 -
 New Zealand - -
 Palau 2009 -
 Papua New Guinea - -
 Samoa 2009 -
 Solomon Islands 2009 -
 Tonga 2009 -
 Tuvalu 2009 -
 Vanuatu 2009 -
 Afghanistan 2009 -
 Bangladesh 2009 0.00
 Bhutan - -
 Brunei Darussalam - -
 Cambodia 2008 1.35
 India 2009 0.07
 Indonesia 2008 0.29
 Lao People’s Democratic Republic 2009 0.18
 Malaysia 2009 0.27
 Maldives - -
 Myanmar 2008 -
 Nepal 2007 0.19
 Pakistan 2009 1.21
 Philippines 2009 0.69
 Singapore 2009 0.43
 Sri Lanka 2009 0.32
 Thailand 2009 0.37
 Timor-Leste 2009 -
 Viet Nam 2009 0.05
 Armenia 2009 0.30
 Azerbaijan 2009 0.37
 Belarus 2009 0.35
 Georgia 2009 1.06
 Kazakhstan 2009 1.18
 Kyrgyzstan 2009 2.06
 Moldova 2009 1.16
 Russian Federation 2008 0.19
 Tajikistan 2009 0.88
 Turkmenistan - -
 Ukraine 2008 0.09
 Uzbekistan 2009 2.49
OCEANIA
SOUTH AND
SOUTH-EAST 
ASIA
EASTERN 
EUROPE AND 
CENTRAL ASIA
Year Domestic 
priority 
to HIV
2
5
5
0
7
5%
Total prevention
2
5
5
0
7
5%
Total care and treatment
2
5
5
0
7
5%
Total HIV spending
% of HIV spending from public and international sources
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SCORECARD: HIV INVESTMENTS
 Albania - - 
 Andorra - -
 Austria - -
 Belgium 2008 0.37
 Bosnia & Herzegovina 2009 0.38
 Bulgaria 2009 -
 Croatia 2009 1.90
 Cyprus - -
 Czech Republic 2009 6.68
 Denmark - -
 Estonia 2008 0.33
 Finland - -
 France - -
 Germany - -
 Greece 2008 0.65
 Hungary 2009 0.16
 Iceland - -
 Ireland - -
 Israel - -
 Italy  - -
 Latvia 2009 0.05
 Liechtenstein - -
 Lithuania - -
 Luxembourg 2009 0.00
 Malta - -
 Monaco - -
 Montenegro 2009 -
 Netherlands - -
 Norway - -
 Poland 2009 0.63
 Portugal - -
 Romania 2009 2.02
 San Marino - -
 Serbia - -
 Slovakia - -
 Slovenia - -
 Spain 2009 0.82
 Sweden 2009 0.00
 Switzerland 2009 0.05
 The Former Yugoslav Republic of Macedonia 2008 2.70
 Turkey - -
 United Kingdom of Great Britain 2009  0.06
 & Northern Ireland
 Canada - -
 Mexico 2009 1.09
 United States of America - -
 
 Algeria 2009 0.05
 Bahrain - -
 Djibouti 2009 0.00
MIDDLE EAST 
AND NORTH 
AFRICA
WESTERN 
AND CENTRAL 
EUROPE
NORTH 
AMERICA
2
5
5
0
7
5%
Total prevention
2
5
5
0
7
5%
Total care and treatment
2
5
5
0
7
5%
Total HIV spendingYear Domestic 
priority 
to HIV
% of HIV spending from public and international sources
Public
International
Data not available
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 Egypt 2008 0.74
 Iran, Islamic Republic of 2008 -
 Iraq - -
 Jordan 2009 1.14
 Kuwait 2009 0.23
 Lebanon - -
 Libyan Arab Jamahiriya - -
 Morocco 2008 0.26
 Oman 2009 -
 Qatar - -
 Saudi Arabia 2009 -
 Somalia 2009 -
 Sudan - -
 Syrian Arab Republic 2009 -
 Tunisia - -
 United Arab Emirates 2009 -
 Yemen  2009 -
 Antigua & Barbuda 2009 -
 Bahamas 2009 -
 Barbados 2009 0.61
 Cuba 2009 -
 Dominica 2009 -
 Dominican Republic 2008 0.21
 Grenada 2009 -
 Haiti - -
 Jamaica - -
 Saint Kitts & Nevis 2009 -
 Saint Lucia - -
 Saint Vincent & the Grenadines 2009 -
 Trinidad & Tobago 2009 0.20
 
 Argentina 2008 1.06
 Belize 2009 0.19
 Bolivia 2009 0.31
 Brazil 2008 0.80
 Chile 2008 1.07
 Colombia 2009 0.52
 Costa Rica 2008 1.16
 Ecuador 2009 0.00
 El Salvador 2008 1.22
 Guatemala 2008 0.00
 Guyana - -
 Honduras 2008 0.84
 Nicaragua 2008 3.96
 Panama 2008 0.83
 Paraguay 2009 0.68
 Peru 2009 0.35
 Suriname - -
 Uruguay 2007 0.36
 Venezuela 2009 0.21
MIDDLE EAST 
AND NORTH 
AFRICA 
Continued
CARIBBEAN
CENTRAL 
AND SOUTH 
AMERICA
2
5
5
0
7
5%
Total prevention
2
5
5
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7
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Total care and treatment
2
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Total HIV spendingYear Domestic 
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to HIV
% of HIV spending from public and international sources
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and improved coordination with countries have resulted 
in improved estimates of HIV and AIDS for 2009. To 
allow readers to assess recent trends in the epidemic, we 
also present 2001 estimates developed using the same 
methodology and data as for the 2009 estimates. 
Th e new estimates in this report are presented together 
with ranges, called ‘plausible bounds’. Th ese bounds 
refl ect the certainty associated with each of the estimates. 
Th e wider the bounds are, the greater the uncertainty 
surrounding an estimate. Th e extent of uncertainty 
depends mainly on the type of epidemic, the quality, 
coverage and consistency of a country’s surveillance 
system and, in generalized epidemics, whether or not a 
population-based survey with HIV testing was conducted. 
Adults in this report are defi ned as men and women aged 
15+ years, per the recommendations of the UNAIDS 
Reference Group on Estimates, Modelling and Projections. 
Th e group also recognizes the burden of infection and 
disease beyond the age of 49. However, the HIV prevalence 
percent (%) continues to be for adults aged 15–49 years to 
allow comparisons across countries.
Notes on specifi c indicators are listed in the following tables
1. ESTIMATED NUMBER OF PEOPLE LIVING WITH 
HIV, 2009 AND 2001 
Th ese estimates include all people with HIV infection, 
whether or not they have developed symptoms of AIDS, in 
2009 and 2001. 
ADULTS AND CHILDREN 
Estimated number of adults and children living with HIV 
in 2009 and 2001.
Adults are 15 years and over. Children are defi ned as those 
aged 0–14 years.
ADULTS (15+ YEARS) 
Estimated number of adults living with HIV, 2009 and 2001.
Epidemiology data tables
Th e estimates and data provided in these tables relate to 
2009 and 2001, unless stated otherwise. Th ese estimates 
have been produced and compiled by UNAIDS/WHO. 
Th ey have been shared with national AIDS programmes 
for review and comments but are not necessarily the 
offi  cial estimates used by national governments. For 
countries where no recent data were available or where 
the analysis could not be completed, country-specifi c 
estimates have not been listed in the table. In order to 
calculate regional totals, older data were used to produce 
estimates for these countries. 
Th e estimates are given in rounded numbers. However, 
unrounded numbers were used in the calculation of rates 
and regional totals, so there may be minor discrepancies 
between the regional and global totals and the sum of the 
country fi gures. 
Th e general methodology and tools used to produce the 
country-specifi c estimates in the table have been described 
in a series of papers in Sexually Transmitted Infections 
2010: “Methods and tools for the 2009 HIV and AIDS 
estimates and projections, and related analyses 86 (Suppl 2)”. 
Th e estimates produced by UNAIDS/WHO are based on 
methods and parameters that are informed by the UNAIDS 
Reference Group on HIV/AIDS Estimates, Modelling and 
Projections, described in reports available at www.epidem.
org/. Th is group is made up of leading researchers in HIV 
and AIDS, epidemiology, demography and related areas. 
Th e Reference Group assesses the most recent published and 
unpublished work drawn from research studies in diff erent 
countries. It also reviews advances in the understanding of 
HIV epidemics and suggests methods to improve the quality 
and accuracy of the estimates. 
According to suggestions from the Reference Group, 
soft ware has been developed to model the course of HIV 
epidemics and their impact. Country analysts were trained 
in the use of these tools during a series of workshops 
in 2009. Th ese changes in procedures and assumptions 
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ADULT (15–49 YEARS) PREVALENCE (%) 
To calculate adult HIV prevalence the estimated number 
of adults (15–49 years) living with HIV in 2009 was 
divided by the 2009 adult population (15–49 years) and 
similarly for 2001.
WOMEN (15+ YEARS) 
Estimated number of women (15+ years) living with HIV 
in 2009 and 2001.
CHILDREN (0–14 YEARS) 
Estimated number of children under age 15 living with 
HIV in 2009 and 2001.
YOUNG WOMEN (15–24 YEARS) PREVALENCE (%) 2009
Estimated percent of young women aged 15–24 who are 
living with HIV in 2009.
YOUNG MEN (15–24 YEARS) PREVALENCE (%) 2009
Estimated percent of young men (15–24 years) who are 
living with HIV in 2009.
2. NEW HIV INFECTIONS
ADULT (15–49 YEARS) INCIDENCE 
To calculate the adult HIV incidence, the estimated number 
of adults (15–49 years) newly infected with HIV in 2009 
was divided by the 2009 adult population (15–49 years) not 
infected at the start of 2009 and similarly for 2001.
ADULTS AND CHILDREN NEWLY INFECTED 2009
Estimated number of people newly infected with HIV 
in 2009.
ADULTS NEWLY INFECTED 2009
Estimated number of adults (15+ years) newly infected 
with HIV in 2009.
3. HIV-RELATED DEATHS: ADULTS AND CHILDREN 
Estimated number of adults and children who died of 
HIV-related causes during 2009 and 2001.
4. ORPHANS DUE TO AIDS 
ORPHANS (0–17 YEARS) CURRENTLY LIVING.
Estimated number of children (0–17 years) in 2009 and 
2001 who have lost one or both parents to AIDS.
5. TRENDS OF HIV PREVALENCE IN KEY 
POPULATIONS AT HIGHER RISK OF HIV
Th ese indicators are recommended for reporting against 
the goals of the 2001 United Nations General Assembly 
Special Session on HIV/AIDS in countries with low-level 
epidemics or concentrated HIV epidemics. In theory, 
assessing progress in reducing the occurrence of new 
infections is best done through monitoring changes in 
incidence over time. However, in practice, prevalence data, 
rather than incidence data, are what are actually available. 
In analysing prevalence data of key populations at higher 
risk of HIV, it is desirable to report on those persons who 
are newly initiated to behaviours that put them at risk for 
infection. In this round of UNGASS reporting, guidance 
was provided to encourage this type of reporting, though 
whether or not this restricted analysis was used for 
reporting is not represented in this table. 
Th e specifi c populations at higher risk of HIV in the tables 
include: 
• injecting drug users 
• female sex workers 
• men who have sex with men 
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults (15+)Adults + ChildrenAdults + Children
200920012009
 GLOBAL 33 300 000 [31 400 000 – 35 300 000] 28 600 000 [27 100 000 – 30 300 000] 30 800 000 [29 200 000 – 32 600 000]
 SUB-SAHARAN AFRICA 22 500 000 [20 900 000 – 24 200 000] 20 300 000 [18 900 000 – 21 700 000] 20 300 000 [19 000 000 – 21 600 000]
 Angola 200 000 [160 000 – 250 000] 140 000 [110 000 – 190 000] 180 000 [140 000 – 220 000]
 Benin 60 000 [52 000 – 69 000] 50 000 [42 000 – 62 000] 55 000 [48 000 – 63 000]
 Botswana 320 000 [300 000 – 350 000] 270 000 [250 000 – 290 000] 300 000 [280 000 – 330 000]
 Burkina Faso 110 000 [91 000 – 140 000] 140 000 [120 000 – 180 000] 93 000 [77 000 – 120 000]
 Burundi 180 000 [160 000 – 190 000] 170 000 [160 000 – 190 000] 150 000 [130 000 – 160 000]
 Cameroon 610 000 [540 000 – 670 000] 480 000 [430 000 – 530 000] 550 000 [500 000 – 610 000]
 Central African Republic 130 000 [110 000 – 140 000] 180 000 [160 000 – 220 000] 110 000 [98 000 – 120 000]
 Chad 210 000 [170 000 – 300 000] 140 000 [99 000 – 180 000] 180 000 [150 000 – 280 000]
 Comoros <500 [<200 – <500] <100 [<100 – <200] <500 [<200 – <500]
 Congo 77 000 [68 000 – 87 000] 69 000 [61 000 – 80 000] 69 000 [61 000 – 78 000]
 Côte d’Ivoire 450 000 [390 000 – 510 000] 630 000 [560 000 – 710 000] 380 000 [340 000 – 440 000]
 Democratic Republic of the Congo … [430 000 – 560 000] … [310 000 – 420 000] … [380 000 – 490 000]
 Equatorial Guinea 20 000 [14 000 – 26 000] 5700 [3900 – 9100] 18 000 [13 000 – 23 000]
 Eritrea 25 000 [18 000 – 33 000] 26 000 [19 000 – 34 000] 22 000 [16 000 – 29 000]
 Ethiopia … … … … … …
 Gabon 46 000 [37 000 – 55 000] 36 000 [29 000 – 46 000] 43 000 [35 000 – 51 000]
 Gambia 18 000 [12 000 – 26 000] 4300 [2400 – 8400] 17 000 [11 000 – 24 000]
 Ghana 260 000 [230 000 – 300 000] 250 000 [220 000 – 280 000] 240 000 [210 000 – 260 000]
 Guinea 79 000 [65 000 – 95 000] 78 000 [57 000 – 120 000] 70 000 [58 000 – 84 000]
 Guinea-Bissau 22 000 [18 000 – 26 000] 14 000 [12 000 – 17 000] 20 000 [16 000 – 24 000]
 Kenya 1 500 000 [1 300 000 – 1 600 000] 1 500 000 [1 400 000 – 1 600 000] 1 300 000 [1 200 000 – 1 400 000]
 Lesotho 290 000 [260 000 – 310 000] 240 000 [220 000 – 270 000] 260 000 [240 000 – 280 000]
 Liberia 37 000 [32 000 – 43 000] 51 000 [36 000 – 70 000] 31 000 [27 000 – 37 000]
 Madagascar 24 000 [19 000 – 30 000] 18 000 [15 000 – 22 000] 23 000 [18 000 – 28 000]
 Malawi 920 000 [830 000 – 1 000 000] 860 000 [770 000 – 960 000] 800 000 [730 000 – 890 000]
 Mali 76 000 [61 000 – 96 000] 89 000 [72 000 – 110 000] 66 000 [52 000 – 84 000]
 Mauritania 14 000 [11 000 – 17 000] 8900 [7300 – 11 000] 13 000 [11 000 – 16 000]
 Mauritius 8800 [6400 – 12 000] 3100 [2 100 – 4 200] 8700 [6300 – 12 000]
 Mozambique 1 400 000 [1 200 000 – 1 500 000] 850 000 [760 000 – 940 000] 1 200 000 [1 100 000 – 1 400 000]
 Namibia 180 000 [150 000 – 210 000] 160 000 [140 000 – 200 000] 160 000 [140 000 – 190 000]
 Niger 61 000 [50 000 – 77 000] 53 000 [43 000 – 67 000] 53 000 [43 000 – 67 000]
 Nigeria 3 300 000 [2 900 000 – 3 600 000] 2 700 000 [2 300 000 – 3 100 000] 2 900 000 [2 600 000 – 3 200 000]
 Rwanda 170 000 [140 000 – 190 000] 170 000 [150 000 – 210 000] 140 000 [120 000 – 160 000]
 Senegal 59 000 [50 000 – 69 000] 33 000 [29 000 – 38 000] 54 000 [46 000 – 63 000]
 Sierra Leone 49 000 [40 000 – 63 000] 25 000 [13 000 – 39 000] 46 000 [38 000 – 59 000]
 South Africa 5 600 000 [5 400 000 – 5 900 000] 4 600 000 [4 500 000 – 4 700 000] 5 300 000 [5 100 000 – 5 500 000]
 Swaziland 180 000 [170 000 – 200 000] 130 000 [120 000 – 150 000] 170 000 [160 000 – 180 000]
 Togo 120 000 [99 000 – 150 000] 100 000 [82 000 – 130 000] 110 000 [91 000 – 140 000]
 Uganda 1 200 000 [1 100 000 – 1 300 000] 980 000 [870 000 – 1 100 000] 1 000 000 [940 000 – 1 100 000]
 United Republic of Tanzania 1 400 000 [1 300 000 – 1 500 000] 1 400 000 [1 200 000 – 1 500 000] 1 200 000 [1 100 000 – 1 400 000]
 Zambia 980 000 [890 000 – 1 100 000] 830 000 [750 000 – 900 000] 860 000 [800 000 – 940 000]
 Zimbabwe 1 200 000 [1 100 000 – 1 300 000] 1 700 000 [1 600 000 – 1 800 000] 1 000 000 [950 000 – 1 200 000]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adult (15–49) prevalence percentAdult (15–49) prevalence percentAdults (15+)
200120092001
 26 700 000 [25 400 000 – 28 000 000] 0.8   [0.7 – 0.8] 0.8  [0.7 – 0.8]
 18 500 000 [17 500 000 – 19 700 000] 5.0  [4.7 – 5.2] 5.9  [5.6 – 6.1]
 130 000 [100 000 – 170 000] 2.0  [1.6 – 2.4] 1.9  [1.4 – 2.4]
 47 000 [40 000 – 56 000] 1.2  [1.0 – 1.3] 1.4  [1.2 – 1.7]
 260 000 [240 000 – 280 000] 24.8  [23.8 – 25.8] 26.3  [25.5 – 27.4]
 120 000 [99 000 – 150 000] 1.2  [1.0 – 1.5] 2.1  [1.7 – 2.5]
 150 000 [140 000 – 160 000] 3.3  [2.9 – 3.5] 5.0  [4.8 – 5.1]
 440 000 [400 000 – 490 000] 5.3  [4.9 – 5.8] 5.5  [5.1 – 6.0]
 170 000 [150 000 – 200 000] 4.7  [4.2 – 5.2] 8.9  [8.1 – 10.6]
 130 000 [91 000 – 170 000] 3.4  [2.8 – 5.1] 3.2  [2.3 – 4.0]
 <100 [<100 – <100] 0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 61 000 [54 000 – 71 000] 3.4  [3.1 – 3.8] 3.8  [3.4 – 4.4]
 570 000 [510 000 – 640 000] 3.4  [3.1 – 3.9] 6.5  [5.9 – 7.1]
 … [270 000 – 360 000] …  [1.2 – 1.6] …  [1.1 – 1.5]
 5400 [3700 – 8700] 5.0  [3.5 – 6.6] 1.9  [1.3 – 3.1]
 23 000 [18 000 – 31 000] 0.8  [0.6 – 1.0] 1.2  [0.9 – 1.5]
 … … … … … …
 34 000 [27 000 – 43 000] 5.2  [4.2 – 6.2] 5.3  [4.3 – 6.8]
 3900 [2200 – 7500] 2.0  [1.3 – 2.9] 0.6  [0.3 – 1.1]
 230 000 [200 000 – 260 000] 1.8  [1.6 – 2.0] 2.3  [2.0 – 2.5]
 70 000 [52 000 – 100 000] 1.3  [1.1 – 1.6] 1.7  [1.2 – 2.4]
 13 000 [11 000 – 16 000] 2.5  [2.0 – 3.0] 2.0  [1.7 – 2.4]
 1 300 000 [1 200 000 – 1 400 000] 6.3  [5.8 – 6.5] 8.4  [8.1 – 9.0]
 230 000 [210 000 – 250 000] 23.6  [22.3 – 25.2] 24.5  [23.1 – 26.1]
 46 000 [33 000 – 63 000] 1.5  [1.3 – 1.8] 3.1  [2.2 – 4.1]
 17 000 [14 000 – 20 000] 0.2   [0.2 – 0.3] 0.2  [0.2 – 0.3]
 760 000 [690 000 – 840 000] 11.0  [10.0 – 12.1] 13.8  [12.7 – 15.1]
 80 000 [66 000 – 98 000] 1.0  [0.8 – 1.3] 1.6  [1.3 – 1.9]
 8600 [7100 – 11 000] 0.7  [0.6 – 0.9] 0.6  [0.5 – 0.7]
 3100 [2100 – 4200] 1.0  [0.7 – 1.3] 0.4  [0.3 – 0.5]
 800 000 [720 000 – 870 000] 11.5  [10.6 – 12.2] 9.4  [8.7 – 10.3]
 150 000 [130 000 – 180 000] 13.1  [11.1 – 15.5] 16.1  [13.6 – 19.0]
 49 000 [40 000 – 61 000] 0.8  [0.7 – 1.0] 1.0  [0.8 – 1.3]
 2 400 000 [2 100 000 – 2 700 000] 3.6  [3.3 – 4.0] 3.8  [3.4 – 4.2]
 150 000 [140 000 – 170 000] 2.9  [2.5 – 3.3] 3.7  [3.4 – 4.4]
 31 000 [26 000 – 35 000] 0.9  [0.7 – 1.0] 0.6  [0.6 – 0.7]
 24 000 [13 000 – 38 000] 1.6  [1.4 – 2.1] 1.1  [0.6 – 1.7]
 4 400 000 [4 300 000 – 4 500 000] 17.8  [17.2 – 18.3] 17.1  [16.7 – 17.5]
 130 000 [120 000 – 140 000] 25.9  [24.9 – 27.0] 23.6  [22.4 – 24.8]
 98 000 [76 000 – 120 000] 3.2  [2.5 – 3.8] 3.6  [2.8 – 4.3]
 840 000 [760 000 – 920 000] 6.5  [5.9 – 6.9] 7.0  [6.4 – 7.4]
 1 200 000 [1 100 000 – 1 300 000] 5.6  [5.3 – 6.1] 7.1  [6.7 – 7.7]
 730 000 [670 000 – 790 000] 13.5  [12.8 – 14.1] 14.3  [13.7 – 15.0]
 1 500 000 [1 400 000 – 1 700 000] 14.3  [13.4 – 15.4] 23.7  [22.8 – 24.9]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Children (0–14)Women (15+)Women (15+)
200920012009
 15 900 000 [14 800 000 – 17 200 000] 13 600 000 [12 900 000 – 14 700 000] 2 500 000 [1 600 000 – 3 400 000]
 12 100 000 [11 100 000 – 13 200 000] 10 900 000 [10 100 000 – 11 700 000] 2 300 000 [1 400 000 – 3 100 000]
 110 000 [85 000 – 130 000] 77 000 [59 000 – 100 000] 22 000 [12 000 – 35 000]
 32 000 [27 000 – 37 000] 27 000 [23 000 – 33 000] 5400 [2900 – 7800]
 170 000 [160 000 – 190 000] 150 000 [140 000 – 160 000] 16 000 [9900 – 20 000]
 56 000 [44 000 – 70 000] 73 000 [60 000 – 92 000] 17 000 [8100 – 25 000]
 90 000 [78 000 – 100 000] 90 000 [81 000 – 99 000] 28 000 [17 000 – 40 000]
 320 000 [290 000 – 370 000] 260 000 [230 000 – 290 000] 54 000 [29 000 – 78 000]
 67 000 [57 000 – 78 000] 99 000 [86 000 – 120 000] 17 000 [8200 – 25 000]
 110 000 [88 000 – 160 000] 76 000 [54 000 – 98 000] 23 000 [12 000 – 35 000]
 <100 [<100 – <100] <100 [<100 – <100] … …
 40 000 [35 000 – 47 000] 36 000 [31 000 – 42 000] 7900 [4000 – 12 000]
 220 000 [190 000 – 260 000] 320 000 [280 000 – 370 000] 63 000 [32 000 – 91 000]
 … [220 000 – 300 000] … [160 000 – 220 000] … [33 000 – 86 000]
 11 000 [7600 – 14 000] 3100 [2100 – 5100] 1600 [<1000 – 2600]
 13 000 [9800 – 18 000] 14 000 [11 000 – 19 000] 3100 [1500 – 5000]
 … … … … … …
 25 000 [20 000 – 30 000] 20 000 [16 000 – 25 000] 3200 [1700 – 4800]
 9700 [6200 – 14 000] 2300 [1300 – 4400] … …
 140 000 [120 000 – 160 000] 130 000 [120 000 – 150 000] 27 000 [14 000 – 41 000]
 41 000 [34 000 – 50 000] 41 000 [30 000 – 61 000] 9000 [4300 – 14 000]
 12 000 [9300 – 14 000] 7800 [6400 – 9300] 2100 [1100 – 3200]
 760 000 [650 000 – 860 000] 780 000 [700 000 – 870 000] 180 000 [98 000 – 260 000]
 160 000 [140 000 – 180 000] 140 000 [130 000 – 160 000] 28 000 [17 000 – 37 000]
 19 000 [16 000 – 22 000] 27 000 [19 000 – 37 000] 6100 [3000 – 9900]
 7300 [5800 – 9000] 5400 [4500 – 6400] … …
 470 000 [410 000 – 530 000] 440 000 [390 000 – 500 000] 120 000 [68 000 – 170 000]
 40 000 [31 000 – 52 000] 48 000 [40 000 – 59 000] … …
 4000 [3200 – 4900] 2600 [2100 – 3200] … …
 2500 [1800 – 3400] <1000 [<1000 – 1200] … …
 760 000 [680 000 – 840 000] 470 000 [430 000 – 530 000] 130 000 [70 000 – 180 000]
 95 000 [79 000 – 110 000] 90 000 [76 000 – 110 000] 16 000 [9100 – 23 000]
 28 000 [23 000 – 36 000] 25 000 [20 000 – 32 000] … …
 1 700 000 [1 500 000 – 1 900 000] 1 400 000 [1 200 000 – 1 600 000] 360 000 [180 000 – 520 000]
 88 000 [76 000 – 98 000] 91 000 [83 000 – 110 000] 22 000 [11 000 – 34 000]
 32 000 [27 000 – 38 000] 18 000 [16 000 – 21 000] … …
 28 000 [22 000 – 35 000] 14 000 [7500 – 23 000] 2900 [1500 – 4500]
 3 300 000 [3 000 000 – 3 500 000] 2 600 000 [2 500 000 – 2 700 000] 330 000 [190 000 – 440 000]
 100 000 [91 000 – 110 000] 74 000 [69 000 – 82 000] 14 000 [8300 – 18 000]
 67 000 [54 000 – 83 000] 57 000 [45 000 – 72 000] 11 000 [3700 – 18 000]
 610 000 [540 000 – 680 000] 490 000 [430 000 – 560 000] 150 000 [80 000 – 210 000]
 730 000 [650 000 – 830 000] 720 000 [640 000 – 800 000] 160 000 [83 000 – 240 000]
 490 000 [440 000 – 550 000] 420 000 [380 000 – 470 000] 120 000 [64 000 – 160 000]
 620 000 [530 000 – 710 000] 890 000 [800 000 – 990 000] 150 000 [92 000 – 200 000]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Young men (15–24) prevalence (%)Young women (15–24) prevalence (%)Children (0–14)
200920092001
 2 000 000 [1 200 000 – 2 700 000] 0.6  [0.5 – 0.7] 0.3  [0.2 – 0.3]
 1 800 000 [1 100 000 – 2 500 000] 3.4  [3.0 – 4.2] 1.4  [1.2 – 1.7]
 14 000 [6900 – 24 000] 1.6  [1.1 – 2.2] 0.6  [0.4 – 0.9]
 3100 [1600 – 6600] 0.7  [0.5 – 1.1] 0.3  [0.2 – 0.4]
 14 000 [7800 – 19 000] 11.8  [9.0 – 15.9] 5.2  [3.7 – 7.3]
 24 000 [12 000 – 37 000] 0.8  [0.6 – 1.2] 0.5  [0.3 – 0.6]
 26 000 [16 000 – 36 000] 2.1  [1.6 – 2.7] 1.0  [0.8 – 1.2]
 33 000 [18 000 – 50 000] 3.9  [3.1 – 5.4] 1.6  [1.2 – 2.1]
 17 000 [8600 – 25 000] 2.2  [1.4 – 3.1] 1.0  [0.6 – 1.4]
 13 000 [6400 – 22 000] 2.5  [1.7 – 5.2] 1.0  [0.7 – 2.0]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 8300 [4200 – 12 000] 2.6  [2.1 – 3.6] 1.2  [0.9 – 1.6]
 59 000 [31 000 – 95 000] 1.5  [1.1 – 2.3] 0.7  [0.5 – 1.1]
 … [26 000 – 70 000] …  [0.9 – 1.5] …  [0.4 – 0.6]
 <500 [<200 – <1000] 5.0  [2.7 – 7.9] 1.9  [1.0 – 3.2]
 2300 [1200 – 4100] 0.4  [0.2 – 0.7] 0.2  [0.1 – 0.3]
 … … … … … …
 2000 [1200 – 3100] 3.5  [2.1 – 5.2] 1.4  [0.8 – 2.0]
 … … 2.4  [1.4 – 4.0] 0.9  [0.5 – 1.6]
 18 000 [9900 – 29 000] 1.3  [0.9 – 1.8] 0.5  [0.4 – 0.7]
 8400 [3500 – 18 000] 0.9  [0.6 – 1.3] 0.4  [0.3 – 0.6]
 <1000 [<1000 – 1400] 2.0  [1.5 – 2.9] 0.8  [0.5 – 1.1]
 170 000 [98 000 – 230 000] 4.1  [3.0 – 5.4] 1.8  [1.3 – 2.4]
 18 000 [11 000 – 23 000] 14.2  [11.2 – 19.2] 5.4  [4.1 – 7.4]
 4600 [2100 – 8400] 0.7  [0.2 – 1.2] 0.3  [0.1 – 0.5]
 … … 0.1  [<0.1 – 0.1] 0.1  [0.1 – 0.4]
 100 000 [57 000 – 140 000] 6.8  [5.3 – 9.2] 3.1  [2.3 – 4.2]
 … … 0.5  [0.2 – 0.9] 0.2  [0.1 – 0.4]
 … … 0.3  [0.1 – 0.5] 0.4  [0.2 – 1.4]
 … … 0.2  [0.1 – 0.3] 0.3  [0.2 – 0.4]
 53 000 [30 000 – 77 000] 8.6  [7.0 – 12.1] 3.1  [2.4 – 4.4]
 7900 [4400 – 11 000] 5.8  [3.7 – 8.6] 2.3  [1.3 – 3.6]
 … … 0.5  [0.4 – 0.6] 0.2  [0.2 – 0.3]
 270 000 [130 000 – 410 000] 2.9  [2.3 – 3.9] 1.2  [0.9 – 1.6]
 23 000 [11 000 – 38 000] 1.9  [1.3 – 2.3] 1.3  [0.9 – 1.6]
 … … 0.7  [0.5 – 1.0] 0.3  [0.2 – 0.4]
 <1000 [<500 – 2100] 1.5  [0.9 – 2.5] 0.6  [0.3 – 1.0]
 170 000 [97 000 – 220 000] 13.6  [12.3 – 15.0] 4.5  [4.1 – 5.0]
 7600 [4700 – 10 000] 15.6  [12.6 – 21.3] 6.5  [4.8 – 8.8]
 6700 [2700 – 11 000] 2.2  [1.5 – 3.1] 0.9  [0.6 – 1.2]
 150 000 [84 000 – 210 000] 4.8  [4.0 – 6.4] 2.3  [1.8 – 2.8]
 150 000 [83 000 – 210 000] 3.9  [3.1 – 5.3] 1.7  [1.3 – 2.3]
 100 000 [57 000 – 140 000] 8.9  [7.3 – 12.0] 4.2  [3.2 – 5.5]
 160 000 [100 000 – 210 000] 6.9  [5.3 – 9.3] 3.3  [2.5 – 4.4]
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ESTIMATED NEW HIV 
INFECTIONS
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults + children newly infectedAdult (15–49) incidence rateAdult (15–49) incidence rate
200920012009
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 2 600 000 [2 300 000 – 2 800 000]
 0.41  [0.36 – 0.46] 0.61  [0.54 – 0.65] 1 800 000 [1 600 000 – 2 000 000]
 0.21  [0.14 – 0.28] 0.22  [0.17 – 0.28] 22 000 [16 000 – 29 000]
 0.10  [<0.10 – 0.13] 0.11  [<0.10 – 0.15] 4900 [3400 – 6500]
 1.56  [1.11 – 2.27] 3.03  [2.64 – 3.48] 14 000 [10 000 – 20 000]
 <0.10  [<0.10 – 0.11] 0.11  [<0.10 – 0.16] 6800 [4300 – 11 000]
 …  [0.17 – 0.28] …  [0.34 – 0.47] … [11 000 – 17 000]
 0.53  [0.43 – 0.61] 0.59  [0.50 – 0.69] 58 000 [48 000 – 67 000]
 0.17  [<0.10 – 0.25] 0.56  [0.43 – 0.69] 5200 [3100 – 7100]
 …  [0.15 – 0.87] …  [0.39 – 0.55] … [12 000 – 47 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 0.28  [0.23 – 0.35] 0.43  [0.36 – 0.51] 6500 [5200 – 7900]
 0.11  [<0.10 – 0.20] 0.39  [0.30 – 0.51] 17 000 [11 000 – 27 000]
 …  [0.13 – 0.18] …  [0.13 – 0.18] … [49 000 – 67 000]
 …  [0.23 – 1.20] …  [0.38 – 0.83] … [1200 – 4500]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – 0.14] 1300 [<1000 – 2300]
 … … … … … …
 0.43  [0.10 – 0.61] 0.63  [0.46 – 0.85] 3600 [1300 – 5000]
 …  [0.21 – 0.83] …  [<0.10 – 0.22] … [1900 – 6400]
 0.15  [0.12 – 0.19] 0.18  [0.15 – 0.22] 22 000 [17 000 – 27 000]
 0.10  [<0.10 – 0.13] 0.15  [0.11 – 0.21] 6200 [3800 – 8400]
 0.21  [0.14 – 0.32] 0.32  [0.24 – 0.40] 2100 [1400 – 2900]
 0.53  [0.34 – 0.70] 0.55  [0.38 – 0.76] 110 000 [81 000 – 150 000]
 2.58  [2.18 – 3.04] 2.88  [2.53 – 3.40] 23 000 [20 000 – 27 000]
 …  [<0.10 – 0.17] …  [<0.10 – 0.22] … [<1000 – 3800]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1800 – 3700]
 0.95  [0.67 – 1.23] 1.35  [1.15 – 1.61] 73 000 [57 000 – 91 000]
 <0.10  [<0.10 – 0.12] <0.10  [<0.10 – 0.14] 4600 [1300 – 8300]
 …  [<0.10 – 0.11] …  [<0.10 – 0.11] … [<1000 – 1900]
 …  [<0.10 – 0.22] …  [<0.10 – 0.12] … [<1000 – 1800]
 1.19  [0.99 – 1.35] 1.77  [1.56 – 1.96] 130 000 [110 000 – 150 000]
 0.43  [<0.10 – 0.93] 2.29  [1.77 – 2.90] 5800 [2100 – 11 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.12] 6100 [4300 – 8400]
 0.38  [0.33 – 0.44] 0.39  [0.33 – 0.47] 340 000 [280 000 – 390 000]
 0.18  [<0.10 – 0.32] 0.34  [0.26 – 0.41] 8800 [3800 – 15 000]
 <0.10  [<0.10 – 0.11] 0.10  [<0.10 – 0.12] 6000 [4100 – 7900]
 0.14  [<0.10 – 0.35] 0.22  [0.16 – 0.29] 4700 [3000 – 9900]
 1.49  [1.27 – 1.76] 2.35  [2.14 – 2.60] 390 000 [340 000 – 440 000]
 2.66  [2.19 – 3.14] 4.07  [3.72 – 4.46] 14 000 [12 000 – 16 000]
 0.27  [0.15 – 0.39] 0.37  [0.28 – 0.48] 10 000 [6200 – 14 000]
 0.74  [0.62 – 0.85] 0.71  [0.61 – 0.82] 120 000 [100 000 – 140 000]
 0.45  [0.34 – 0.57] 0.64  [0.55 – 0.76] 100 000 [82 000 – 130 000]
 1.17  [0.96 – 1.40] 1.72  [1.52 – 1.95] 76 000 [62 000 – 89 000]
 0.84  [0.54 – 1.19] 1.94  [1.62 – 2.36] 62 000 [45 000 – 80 000]
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A1
ESTIMATED AIDS-RELATED 
DEATHS
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
AIDS-related deaths in adults + childrenAIDS-related deaths in adults + childrenAdults newly infected
200120092009
 2 200 000 [2 000 000 – 2 400 000] 1 800 000 [1 600 000 – 2 100 000] 1 800 000 [1 600 000 – 2 100 000]
 1 500 000 [1 300 000 – 1 600 000] 1 300 000 [1 100 000 – 1 500 000] 1 400 000 [1 200 000 – 1 600 000]
 17 000 [12 000 – 23 000] 11 000 [7700 – 16 000] 10 000 [6500 – 14 000]
 4000 [2700 – 5400] 2700 [1800 – 3700] 3100 [1900 – 5200]
 13 000 [9400 – 19 000] 5800 [2300 – 14 000] 15 000 [12 000 – 18 000]
 5000 [2800 – 7900] 7100 [4800 – 9700] 15 000 [11 000 – 19 000]
 … [7000 – 11 000] 15 000 [12 000 – 17 000] 14 000 [12 000 – 17 000]
 48 000 [39 000 – 56 000] 37 000 [29 000 – 46 000] 31 000 [25 000 – 37 000]
 3600 [1800 – 5200] 11 000 [8800 – 13 000] 15 000 [12 000 – 20 000]
 … [8000 – 39 000] 11 000 [8100 – 15 000] 8900 [5400 – 13 000]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 5100 [4100 – 6300] 5100 [4100 – 6400] 5800 [4800 – 7100]
 11 000 [5700 – 19 000] 36 000 [29 000 – 44 000] 51 000 [37 000 – 66 000]
 … [38 000 – 52 000] … [26 000 – 40 000] … [24 000 – 34 000]
 … [<1000 – 3800] <1000 [<1000 – 1400] <500 [<200 – <500]
 <1000 [<500 – 1700] 1700 [1000 – 2500] 1800 [1200 – 2600]
 … … … … … …
 3100 [<1000 – 4300] 2400 [1600 – 3400] 2000 [1500 – 2800]
 … [1600 – 5800] <1000 [<500 – 1200] <500 [<200 – <1000]
 18 000 [14 000 – 23 000] 18 000 [14 000 – 22 000] 16 000 [13 000 – 21 000]
 4800 [2600 – 6600] 4700 [3100 – 6900] 6300 [3000 – 14 000]
 1600 [1100 – 2300] 1200 [<1000 – 1600] <1000 [<1000 – <1000]
 92 000 [61 000 – 120 000] 80 000 [61 000 – 99 000] 120 000 [100 000 – 150 000]
 20 000 [17 000 – 24 000] 14 000 [10 000 – 18 000] 14 000 [12 000 – 18 000]
 … [<200 – 3100] 3600 [2800 – 4600] 3900 [2300 – 6200]
 … [1600 – 3400] 1700 [1400 – 2000] 1300 [1100 – 1600]
 56 000 [40 000 – 72 000] 51 000 [38 000 – 67 000] 68 000 [57 000 – 81 000]
 3400 [<500 – 6800] 4400 [3000 – 6100] 7200 [4200 – 11 000]
 … [<1000 – 1700] <1000 [<1000 – 1000] <500 [<500 – <1000]
 … [<1000 – 1800] <500 [<500 – <1000] <200 [<100 – <200]
 110 000 [91 000 – 120 000] 74 000 [57 000 – 92 000] 43 000 [34 000 – 53 000]
 4400 [<1000 – 9300] 6700 [2500 – 11 000] 8100 [6200 – 11 000]
 4600 [3200 – 6100] 4300 [3300 – 5600] 3300 [2500 – 4500]
 270 000 [230 000 – 310 000] 220 000 [170 000 – 260 000] 210 000 [130 000 – 260 000]
 6000 [1100 – 12 000] 4100 [<1000 – 9700] 15 000 [12 000 – 21 000]
 4800 [3100 – 6300] 2600 [1900 – 3500] 1800 [1500 – 2300]
 3900 [2300 – 8900] 2800 [2100 – 3700] <1000 [<500 – 2200]
 340 000 [300 000 – 400 000] 310 000 [260 000 – 390 000] 220 000 [180 000 – 260 000]
 12 000 [10 000 – 14 000] 7000 [4600 – 10 000] 6800 [5700 – 8400]
 8700 [5100 – 12 000] 7700 [5300 – 10 000] 6400 [4600 – 8400]
 100 000 [84 000 – 120 000] 64 000 [49 000 – 80 000] 89 000 [75 000 – 100 000]
 88 000 [66 000 – 110 000] 86 000 [69 000 – 110 000] 110 000 [94 000 – 130 000]
 59 000 [48 000 – 71 000] 45 000 [30 000 – 60 000] 68 000 [57 000 – 78 000]
 48 000 [31 000 – 66 000] 83 000 [70 000 – 97 000] 130 000 [110 000 – 160 000]
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ESTIMATED ORPHANS 
DUE TO AIDS
HIV PREVALENCE (%) 
IN MOST-AT-RISK 
GROUPS IN CAPITAL CITY
estimate estimate[low – high estimate] [low – high estimate]
Orphans (0–17)
Year Year YearHIV (%) HIV (%) HIV (%)
Injecting drug 
users
Female sex 
workers
Men who have 
sex with menOrphans (0–17) currently living
20012009
 16 600 000 [14 400 000 – 18 800 000] 10 000 000 [7 900 000 – 12 500 000] … … … … … …
 14 800 000 [12 800 000 – 17 000 000] 8 900 000 [6 900 000 – 11 200 000] … … … … … …
 140 000 [95 000 – 200 000] 65 000 [30 000 – 110 000] … … … … … …
 30 000 [18 000 – 53 000] 13 000 [5100 – 100 000] 2009 4.2 2009 24.7 … …
 93 000 [71 000 – 120 000] 56 000 [45 000 – 72 000] … … … … … …
 140 000 [100 000 – 170 000] 140 000 [100 000 – 190 000] … … 2005 16.3 … …
 200 000 [170 000 – 230 000] 130 000 [110 000 – 160 000] … … 2007 39.8 … …
 330 000 [270 000 – 420 000] 140 000 [91 000 – 230 000] … … 2009 35.5 … …
 140 000 [110 000 – 180 000] 82 000 [54 000 – 120 000] … … … … … …
 120 000 [79 000 – 170 000] 50 000 [26 000 – 91 000] … … 2009 20.0 … …
 <100 [<100 – <100] <100 [<100 – <100] … … … … … …
 51 000 [41 000 – 66 000] 51 000 [34 000 – 73 000] … … … … … …
 440 000 [330 000 – 550 000] 270 000 [170 000 – 440 000] … … … … … …
 … [350 000 – 510 000] … [290 000 – 450 000] … … … … … …
 4100 [2500 – 6400] <1000 [<500 – <1000] … … … … … …
 19 000 [12 000 – 28 000] 8 700 [4100 – 18 000] … … 2008 7.8 … …
 … … … … … … … … … …
 18 000 [12 000 – 25 000] 7 600 [5200 – 11 000] … … 2010 23.6 … …
 2800 [1400 – 6500] <1000 [<500 – 6400] … … … … … …
 160 000 [120 000 – 210 000] 60 000 [42 000 – 120 000] … … 2009 25.0 … …
 59 000 [34 000 – 120 000] 40 000 [12 000 – 100 000] … … 2008 32.7 … …
 9700 [7700 – 12 000] 2800 [1800 – 3900] … … 2009 39.6 … …
 1 200 000 [980 000 – 1 400 000] 820 000 [640 000 – 1 100 000] … … … … … …
 130 000 [110 000 – 160 000] 52 000 [41 000 – 68 000] … … … … … …
 52 000 [34 000 – 76 000] 19 000 [9900 – 33 000] … … … … … …
 11 000 [9 300 – 14 000] 9500 [7600 – 12 000] … … 2007 0.5 … …
 650 000 [540 000 – 780 000] 430 000 [330 000 – 550 000] … … 2006 70.7 … …
 59 000 [36 000 – 93 000] 35 000 [15 000 – 89 000] … … 2006 35.3 … …
 3600 [2700 – 4800] 1500 [<1000 – 2200] … … 2007 7.6 … …
 <1000 [<500 – <1000] <200 [<100 – <500] 2009 47.1 … … … …
 670 000 … 220 000 … … … … … … …
 70 000 [50 000 – 96 000] 30 000 [22 000 – 42 000] … … … … … …
 57 000 [44 000 – 73 000] 17 000 [12 000 – 24 000] … … 2009 35.6 … …
 2 500 000 [1 800 000 – 3 100 000] 1 300 000 [420 000 – 1 900 000] 2007 5.6 2007 32.7 2007 13.5
 130 000 [98 000 – 180 000] 170 000 [140 000 – 250 000] … … … … … …
 19 000 [15 000 – 25 000] 8700 [6600 – 11 000] … … 2006 19.8 2007 21.8
 15 000 [9 200 – 26 000] 2100 [1000 – 7000] … … 2005 8.5 … …
 1 900 000 [1 600 000 – 2 400 000] 580 000 [460 000 – 750 000] … … … … 2008 13.2
 69 000 [55 000 – 86 000] 29 000 [23 000 – 37 000] … … … … … …
 66 000 [47 000 – 89 000] 25 000 [12 000 – 45 000] … … 2005 44.5 … …
 1 200 000 [1 000 000 – 1 400 000] 1 100 000 [860 000 – 1 400 000] … … … … … …
 1 300 000 [1 100 000 – 1 500 000] 840 000 [690 000 – 1 000 000] … … … … … …
 690 000 [570 000 – 810 000] 580 000 [410 000 – 770 000] … … … … … …
 1 000 000 [910 000 – 1 200 000] 760 000 [630 000 – 940 000] … … … … … …
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A1
ESTIMATED PEOPLE 
LIVING WITH HIV
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults (15+)Adults + ChildrenAdults + Children
200920012009
 EAST ASIA 770 000 [560 000 – 1 000 000] 350 000 [250 000 – 480 000] 760 000 [560 000 – 1 000 000]
 China 740 000 [540 000 – 1 000 000] … [240 000 – 470 000] 730 000 [540 000 – 1 000 000]
 Democratic People’s Republic of Korea … … … … … …
 Japan 8100 [6300 – 10 000] 6500 [5200 – 8100] 8100 [6300 – 10 000]
 Mongolia <500 [<500 – <1000] <100 [<100 – <200] <500 [<500 – <1000]
 Republic of Korea 9500 [7000 – 13 000] 5200 [4100 – 6700] 9500 [7000 – 13 000]
 OCEANIA 57 000 [50 000 – 64 000] 29 000 [23 000 – 35 000] 54 000 [47 000 – 61 000]
 Australia 20 000 [15 000 – 25 000] 13 000 [10 000 – 16 000] 20 000 [15 000 – 25 000]
 Fiji <1000 [<500 – <1000] <200 [<100 – <500] <1000 [<500 – <1000]
 New Zealand 2500 [2000 – 3200] 1600 [1400 – 2100] 2400 [2000 – 3200]
 Papua New Guinea 34 000 [30 000 – 39 000] 14 000 [9400 – 21 000] 31 000 [27 000 – 35 000]
 SOUTH AND SOUTH-EAST ASIA 4 100 000 [3 700 000 – 4 600 000] 3 800 000 [3 500 000 – 4 200 000] 4 000 000 [3 600 000 – 4 400 000]
 Bangladesh 6300 [5200 – 8300] 1100 [<100 – 2400] 6200 [5100 – 8100]
 Bhutan <1000 [<1000 – 1500] <200 [<100 – <500] <1000 [<1000 – 1500]
 Cambodia 63 000 [42 000 – 90 000] 92 000 [63 000 – 130 000] 56 000 [38 000 – 82 000]
 India 2 400 000 [2 100 000 – 2 800 000] 2 500 000 [2 300 000 – 2 900 000] 2 300 000 [2 000 000 – 2 600 000]
 Indonesia 310 000 [200 000 – 460 000] 11 000 [<100 – 34 000] 300 000 [200 000 – 460 000]
 Lao People’s Democratic Republic 8500 [6000 – 13 000] <1000 [<100 – 1700] 8300 [5800 – 12 000]
 Malaysia 100 000 [83 000 – 120 000] 67 000 [57 000 – 80 000] 100 000 [83 000 – 120 000]
 Maldives <100 [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 Myanmar 240 000 [200 000 – 290 000] 250 000 [190 000 – 310 000] 230 000 [190 000 – 280 000]
 Nepal 64 000 [51 000 – 80 000] 60 000 [49 000 – 72 000] 60 000 [48 000 – 75 000]
 Pakistan 98 000 [79 000 – 120 000] 39 000 [32 000 – 48 000] 95 000 [76 000 – 120 000]
 Philippines 8700 [6100 – 13 000] 1700 [<100 – 4000] 8600 [6000 – 13 000]
 Singapore 3400 [2500 – 4400] 2800 [2200 – 3800] 3300 [2400 – 4300]
 Sri Lanka 2800 [2100 – 3800] 1300 [<1000 – 1900] 2800 [2100 – 3700]
 Thailand 530 000 [420 000 – 660 000] 640 000 [480 000 – 820 000] 520 000 [410 000 – 640 000]
 Viet Nam 280 000 [220 000 – 350 000] 140 000 [110 000 – 180 000] 270 000 [220 000 – 350 000]
 EASTERN EUROPE AND CENTRAL ASIA 1 400 000 [1 300 000 – 1 600 000] 760 000 [670 000 – 890 000] 1 400 000 [1 200 000 – 1 600 000]
 Armenia 1900 [1500 – 2400] 1400 [1100 – 1700] 1900 [1500 – 2300]
 Azerbaijan 3600 [2600 – 5200] 1300 [<500 – 1700] 3500 [2500 – 5100]
 Belarus 17 000 [13 000 – 20 000] 6300 [5100 – 7800] 16 000 [13 000 – 20 000]
 Georgia 3500 [2600 – 4900] 1200 [<100 – 1700] 3400 [2500 – 4800]
 Kazakhstan 13 000 [9000 – 19 000] 1800 [<1000 – 3400] 13 000 [8900 – 19 000]
 Kyrgyzstan 9800 [6500 – 16 000] <1000 [<100 – 11 000] 9700 [6400 – 16 000]
 Republic of Moldova 12 000 [9900 – 16 000] 12 000 [9900 – 16 000] 12 000 [9800 – 15 000]
 Russian Federation 980 000 [840 000 – 1 200 000] 430 000 [350 000 – 550 000] 960 000 [830 000 – 1 100 000]
 Tajikistan 9100 [6400 – 13 000] 4100 [3100 – 5300] 8900 [6300 – 12 000]
 Ukraine 350 000 [300 000 – 410 000] 290 000 [250 000 – 330 000] 350 000 [300 000 – 410 000]
 Uzbekistan 28 000 [18 000 – 46 000] <1000 [<100 – <100] 28 000 [18 000 – 45 000]
 WESTERN AND CENTRAL EUROPE 820 000 [720 000 – 910 000] 630 000 [570 000 – 700 000] 820 000 [720 000 – 910 000]
 Austria 15 000 [12 000 – 20 000] 5300 [3900 – 7000] 15 000 [12 000 – 20 000]
 Belgium 14 000 [11 000 – 18 000] 12 000 [9500 – 16 000] 14 000 [11 000 – 18 000]
 Bulgaria 3800 [2800 – 5200] 1 800 [1300 – 2300] 3800 [2700 – 5200]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adult (15–49) prevalence percentAdult (15–49) prevalence percentAdults (15+)
200120092001
 350 000 [250 000 – 480 000] 0.1  [0.1 – 0.1] <0.1  [<0.1 – <0.1]
 … [240 000 – 470 000] 0.1  [0.1 – 0.1] …  [<0.1 – 0.1]
 … … … … … …
 6400 [5200 – 8100] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 <100 [<100 – <200] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 5200 [4100 – 6700] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 28 000 [22 000 – 34 000] 0.3  [0.2 – 0.3] 0.2  [0.1 – 0.2]
 13 000 [9900 – 16 000] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 <200 [<100 – <500] 0.1  [0.1 – 0.2] <0.1  [<0.1 – 0.1]
 1600 [1400 – 2100] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 13 000 [9100 – 19 000] 0.9  [0.8 – 1.0] 0.5  [0.3 – 0.7]
 3 700 000 [3 400 000 – 4 100 000] 0.3  [0.3 – 0.3] 0.4  [0.3 – 0.4]
 1100 [<100 – 2300] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 <100 [<100 – <500] 0.2  [0.1 – 0.3] <0.1  [<0.1 – 0.1]
 83 000 [58 000 – 110 000] 0.5  [0.4 – 0.8] 1.2  [0.8 – 1.6]
 2 500 000 [2 200 000 – 2 800 000] 0.3  [0.3 – 0.4] 0.4  [0.4 – 0.5]
 11 000 [<100 – 34 000] 0.2  [0.1 – 0.3] <0.1  [<0.1 – <0.1]
 <1000 [<100 – 1700] 0.2  [0.2 – 0.4] <0.1  [<0.1 – 0.1]
 67 000 [56 000 – 80 000] 0.5  [0.4 – 0.6] 0.4  [0.3 – 0.5]
 <100 [<100 – <100] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 250 000 [190 000 – 310 000] 0.6  [0.5 – 0.7] 0.8  [0.6 – 0.9]
 57 000 [47 000 – 69 000] 0.4  [0.3 – 0.5] 0.5  [0.4 – 0.6]
 39 000 [32 000 – 47 000] 0.1  [0.1 – 0.1] 0.1  [<0.1 – 0.1]
 1600 [<100 – 3900] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 2700 [2100 – 3700] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 1300 [<1000 – 1900] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 610 000 [470 000 – 790 000] 1.3  [1.0 – 1.6] 1.7  [1.3 – 2.1]
 140 000 [110 000 – 170 000] 0.4  [0.3 – 0.5] 0.3  [0.2 – 0.3]
 750 000 [660 000 – 880 000] 0.8  [0.7 – 0.9] 0.4  [0.4 – 0.5]
 1400 [1100 – 1700] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 1200 [<500 – 1600] 0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 6300 [5000 – 7800] 0.3  [0.2 – 0.3] 0.1  [0.1 – 0.1]
 1200 [<100 – 1700] 0.1  [0.1 – 0.2] <0.1  [<0.1 – 0.1]
 1800 [<1000 – 3400] 0.1  [0.1 – 0.2] <0.1  [<0.1 – <0.1]
 <1000 [<100 – 11 000] 0.3  [0.2 – 0.5] <0.1  [<0.1 – 0.3]
 12 000 [9800 – 16 000] 0.4  [0.4 – 0.6] 0.4  [0.3 – 0.6]
 430 000 [350 000 – 550 000] 1.0  [0.9 – 1.2] 0.5  [0.4 – 0.6]
 4000 [3000 – 5200] 0.2  [0.1 – 0.3] 0.1  [0.1 – 0.1]
 290 000 [250 000 – 330 000] 1.1  [1.0 – 1.3] 0.9  [0.8 – 1.1]
 <1000 [<100 – <100] 0.1  [0.1 – 0.2] <0.1  [<0.1 – <0.1]
 620 000 [570 000 – 700 000] 0.2  [0.2 – 0.2] 0.2  [0.2 – 0.2]
 5300 [3900 – 7000] 0.3  [0.2 – 0.4] 0.1  [0.1 – 0.2]
 12 000 [9500 – 16 000] 0.2  [0.2 – 0.3] 0.2  [0.2 – 0.3]
 1800 [1300 – 2300] 0.1  [0.1 – 0.1] <0.1  [<0.1 – <0.1]
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A1
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Children (0–14)Women (15+)Women (15+)
200920012009
 220 000 [160 000 – 300 000] 98 000 [71 000 – 140 000] 8000 [3600 – 13 000]
 230 000 [160 000 – 300 000] … [67 000 – 130 000] … …
 … … … … … …
 2700 [2100 – 3400] 2200 [1700 – 2700] … …
 <200 [<100 – <200] <100 [<100 – <100] … …
 2900 [2200 – 4000] 1600 [1200 – 2000] … …
 25 000 [22 000 – 28 000] 12 000 [9400 – 16 000] 3100 [1500 – 4800]
 6200 [4800 – 7800] 3900 [3100 – 4900] … …
 <200 [<200 – <500] <100 [<100 – <100] … …
 <1000 [<1000 – 1000] <1000 [<500 – <1000] … …
 18 000 [16 000 – 21 000] 7600 [5100 – 11 000] 3100 [1600 – 4800]
 1 400 000 [1 400 000 – 1 700 000] 1 300 000 [1 300 000 – 1 600 000] 150 000 [97 000 – 200 000]
 1900 [1500 – 2400] <500 [<100 – <1000] … …
 <500 [<200 – <500] <100 [<100 – <100] … …
 35 000 [23 000 – 52 000] 51 000 [34 000 – 71 000] … …
 880 000 [730 000 – 1 000 000] 880 000 [780 000 – 1 000 000] … …
 88 000 [58 000 – 130 000] 3200 [<100 – 9600] … …
 3500 [2400 – 5500] <500 [<100 – <500] … …
 11 000 [8600 – 15 000] 6100 [4100 – 8100] … …
 <100 [<100 – <100] <100 [<100 – <100] … …
 81 000 [67 000 – 96 000] 67 000 [53 000 – 83 000] … …
 20 000 [16 000 – 25 000] 19 000 [15 000 – 22 000] … …
 28 000 [23 000 – 35 000] 11 000 [9000 – 13 000] … …
 2600 [1800 – 3900] <500 [<100 – 1100] … …
 1000 [<1000 – 1300] <1000 [<1000 – 1100] … …
 <1000 [<500 – <1000] <500 [<200 – <500] … …
 210 000 [160 000 – 260 000] 220 000 [160 000 – 300 000] … …
 81 000 [63 000 – 100 000] 39 000 [31 000 – 50 000] … …
 690 000 [600 000 – 790 000] 330 000 [290 000 – 390 000] 18 000 [8600 – 29 000]
 <1000 [<500 – <1000] <500 [<500 – <1000] … …
 2100 [1500 – 3000] <1000 [<500 – <1000] … …
 8300 [6700 – 10 000] 2300 [1900 – 2900] … …
 1500 [1100 – 2100] <500 [<100 – <1000] … …
 7700 [5300 – 11 000] 1100 [<1000 – 2000] … …
 2800 [1900 – 4700] <500 [<100 – 3200] … …
 5100 [4100 – 6600] 3700 [2900 – 4800] … …
 480 000 [400 000 – 570 000] 190 000 [160 000 – 250 000] 15 000 [6800 – 24 000]
 2700 [1900 – 3700] 1100 [<1000 – 1500] … …
 170 000 [140 000 – 200 000] 130 000 [110 000 – 150 000] … …
 8000 [4900 – 13 000] <500 [<100 – <100] … …
 240 000 [210 000 – 270 000] 180 000 [160 000 – 200 000] 1400 [<1000 – 1800]
 4600 [3500 – 5900] 1600 [1100 – 2100] … …
 4400 [3400 – 5500] 3700 [2900 – 4800] … …
 1100 [<1000 – 1500] <500 [<500 – <1000] … …
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Young men (15–24) prevalence (%)Young women (15–24) prevalence (%)Children (0–14)
200920092001
 2800 [1200 – 5400] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … …  [<0.1 – <0.1] …  [<0.1 – <0.1]
 … … … … … …
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 <1000 [<500 – 1600] 0.2  [0.2 – 0.3] 0.1  [0.1 – 0.3]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 <1000 [<500 – 1500] 0.8  [0.6 – 1.2] 0.3  [0.2 – 0.5]
 100 000 [67 000 – 140 000] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.1]
 … … 0.1  [0.1 – 0.3] 0.1  [<0.1 – 0.2]
 … … 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.2]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.1]
 … … 0.2  [0.1 – 0.3] 0.1  [0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] 0.1  [0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … 0.3  [0.2 – 0.3] 0.3  [0.3 – 0.4]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.6]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … …  [0.4 – 0.7] …  [0.4 – 0.5]
 … … 0.1  [<0.1 – 0.1] 0.1  [0.1 – 0.1]
 4000 [2000 – 6100] 0.2  [0.2 – 0.3] 0.1  [0.1 – 0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … 0.1  [0.1 – 0.1] <0.1  [<0.1 – 0.1]
 … … 0.1  [0.1 – 0.1] <0.1  [<0.1 – 0.1]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 … … 0.2  [0.1 – 0.3] 0.1  [<0.1 – 0.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … 0.1  [0.1 – 0.1] 0.1  [<0.1 – 0.1]
 2000 [<1000 – 3100] 0.3  [0.3 – 0.4] 0.2  [0.1 – 0.2]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 … … 0.3  [0.2 – 0.4] 0.2  [0.1 – 0.2]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 2200 [1300 – 3100] 0.1  [<0.1 – 0.1] 0.1  [0.1 – 0.2]
 … … 0.2  [0.1 – 0.3] 0.3  [0.1 – 0.9]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
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A1
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults + children newly infectedAdult (15–49) incidence rateAdult (15–49) incidence rate
200920012009
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 82 000 [48 000 – 140 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [47 000 – 140 000]
 … … … … … …
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <500 [<200 – <500]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <100 [<100 – <200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <1000 [<500 – 1000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 4500 [3400 – 6000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 1500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <200]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <200]
 <0.10  [<0.10 – 0.13] 0.13  [0.11 – 0.16] 3200 [2100 – 4800]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 270 000 [240 000 – 320 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 1400 [1000 – 2400]
 …  [<0.10 – 0.13] …  [<0.10 – <0.10] … [<200 – <1000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – 0.11] 1700 [<1000 – 4200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 140 000 [110 000 – 160 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [29 000 – 87 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 3400]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 10 000 [8400 – 13 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 17 000 [14 000 – 20 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 4800 [2700 – 7800]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [7300 – 15 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 2100 [1200 – 4900]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <500 [<200 – <1000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 12 000 [9800 – 15 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [16 000 – 38 000]
 <0.10  [<0.10 – <0.10] 0.14  [0.11 – 0.16] 130 000 [110 000 – 160 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <500 [<200 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1100]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 1500 [1100 – 2200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <1000 [<500 – 1200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 1900 [1200 – 3600]
 <0.10  [<0.10 – 0.22] <0.10  [<0.10 – <0.10] 2600 [1400 – 6500]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <1000 [<1000 – 1200]
 …  [<0.10 – 0.14] …  [0.17 – 0.25] … [67 000 – 120 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 1400 [<1000 – 2300]
 …  [<0.10 – 0.12] …  [0.10 – 0.16] … [16 000 – 32 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [3100 – 11 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 31 000 [23 000 – 40 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 2100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
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ESTIMATED AIDS-RELATED 
DEATHS
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
AIDS-related deaths in adults + childrenAIDS-related deaths in adults + childrenAdults newly infected
200120092009
 81 000 [47 000 – 140 000] 36 000 [25 000 – 50 000] 15 000 [9400 – 28 000]
 … [46 000 – 140 000] 26 000 [24 000 – 49 000] … [9100 – 28 000]
 … … … … … …
 <500 [<200 – <500] <100 [<100 – <500] <100 [<100 – <200]
 <100 [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 <1000 [<500 – 1000] <500 [<500 – <1000] <500 [<100 – <500]
 3700 [2600 – 5300] 1400 [<1000 – 2400] <1000 [<500 – 1100]
 … [<1000 – 1500] <100 [<100 – <1000] <100 [<100 – <200]
 … [<100 – <200] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <200] <100 [<100 – <100] <100 [<100 – <100]
 2400 [1400 – 4100] 1300 [<1000 – 1900] <1000 [<500 – <1000]
 250 000 [220 000 – 300 000] 260 000 [230 000 – 300 000] 230 000 [210 000 – 280 000]
 1400 [<1000 – 2400] <200 [<100 – <500] <100 [<100 – <200]
 … [<200 – <1000] <100 [<100 – <100] <100 [<100 – <100]
 1200 [<200 – 3500] 3100 [<1000 – 5600] 7400 [5000 – 11 000]
 120 000 [100 000 – 150 000] 170 000 [150 000 – 200 000] 140 000 [120 000 – 170 000]
 … [29 000 – 86 000] 8300 [3800 – 15 000] <200 [<100 – 1900]
 … [<1000 – 3100] <200 [<100 – <500] <100 [<100 – <100]
 10 000 [8400 – 13 000] 5800 [4500 – 7200] 3900 [3000 – 5200]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 16 000 [14 000 – 19 000] 18 000 [13 000 – 23 000] 16 000 [12 000 – 20 000]
 4300 [2300 – 7200] 4700 [3800 – 5700] 4000 [3200 – 4900]
 … [6700 – 14 000] 5800 [4500 – 7400] 1400 [<1000 – 1900]
 2100 [1200 – 4800] <200 [<100 – <500] <100 [<100 – <500]
 … [<100 – <500] <100 [<100 – <200] <100 [<100 – <500]
 <500 [<200 – <1000] <200 [<100 – <500] <100 [<100 – <100]
 12 000 [9500 – 14 000] 28 000 [21 000 – 37 000] 52 000 [39 000 – 68 000]
 … [15 000 – 37 000] 14 000 [9500 – 20 000] 5500 [3900 – 7500]
 130 000 [100 000 – 150 000] 76 000 [60 000 – 96 000] 18 000 [14 000 – 23 000]
 <500 [<200 – <500] <100 [<100 – <200] <100 [<100 – <100]
 … [<500 – 1100] <200 [<200 – <500] <100 [<100 – <100]
 1500 [1100 – 2200] <1000 [<500 – <1000] <200 [<100 – <500]
 <1000 [<500 – 1200] <100 [<100 – <200] <100 [<100 – <200]
 1900 [1200 – 3600] <500 [<200 – <1000] <100 [<100 – <100]
 2600 [1400 – 6500] <500 [<100 – <500] <100 [<100 – 3300]
 <1000 [<1000 – 1200] <1000 [<1000 – 1100] <1000 [<500 – <1000]
 … [64 000 – 110 000] … … … …
 1300 [<1000 – 2200] <500 [<500 – <1000] <200 [<200 – <500]
 … [16 000 – 32 000] 24 000 [20 000 – 29 000] 13 000 [9400 – 16 000]
 … [3100 – 11 000] <500 [<200 – 1000] <100 [<100 – <100]
 31 000 [23 000 – 39 000] 8500 [6800 – 19 000] 7300 [5700 – 11 000]
 … [<1000 – 2100] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <500] <100 [<100 – <500] <100 [<100 – <100]
 … [<500 – <1000] <200 [<200 – <500] <100 [<100 – <200]
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A1
HIV PREVALENCE (%) 
IN MOST-AT-RISK 
GROUPS IN CAPITAL CITY
estimate estimate[low – high estimate] [low – high estimate]
Orphans (0–17)
Year Year YearHIV (%) HIV (%) HIV (%)
Injecting drug 
users
Female sex 
workers
Men who have 
sex with menOrphans (0–17) currently living
20012009
ESTIMATED ORPHANS 
DUE TO AIDS
 52 000 [35 000 – 78 000] 18 000 [10 000 – 37 000] … … … … … …
 … … … … 2009 9.3 2009 0.6 2009 5.0
 … … … … … … … … … …
 … … … … … … … … 2009 4.0
 … … … … … … … … 2009 1.8
 … … … … … … … … … …
 6300 [4000 – 10 000] 2700 [1900 – 4400] … … … … … …
 … … … … 2008 1.5 2008 0.1 … …
 … … … … … … … … … …
 … … … … 2004 0.3 … … … …
 … … … … … … 2009 7.4 2009 4.4
 1 000 000 [820 000 – 1 100 000] 500 000 [420 000 – 620 000] … … … … … …
 … … … … 2007 1.6 2007 0.3 … …
 … … … … … … … … … …
 … … … … 2007 24.4 … … 2005 4.5
 … … … … 2009 9.2 2009 4.9 2009 7.3
 … … … … 2007 52.4 2007 7.8 2007 5.2
 … … … … … … … … … …
 … … … … … 22.1 … … 2009 3.9
 … … … … … … … … … …
 … … … … 2008 36.3 2008 18.1 2008 28.8
 … … … … 2009 20.7 2008 2.2 2009 3.8
 … … … … 2008 20.8 2009 1.0 … …
 … … … … 2009 0.2 2009 0.2 2009 1.0
 … … … … … … … … 2009 2.6
 … … … … … … … … 2009 0.5
 … … … … 2009 38.7 2009 2.8 2009 13.5
 … … … … 2009 18.4 2009 3.2 2010 16.7
 73 000 [59 000 – 91 000] 15 000 [9000 – 22 000] … … … … … …
 … … … … … … … … … …
 … … … … 2008 10.3 2008 1.7 2008 1.0
 … … … … 2009 13.7 2009 6.4 2009 2.7
 … … … … 2008 2.2 2009 2.0 2007 3.6
 … … … … 2009 2.9 2009 1.3 2009 0.3
 … … … … 2009 14.3 2009 1.6 … …
 … … … … … … … … … …
 37 000 [27 000 – 50 000] 1200 [<1000 – 1700] 2009 15.6 2009 4.5 2009 8.3
 … … … … 2008 17.6 2008 2.8 … …
 … … … … 2009 22.9 … … 2009 8.6
 … … … … 2009 11.0 2009 2.2 2009 6.8
 26 000 [22 000 – 42 000] 50 000 [41 000 – 60 000] … … … … … …
 … … … … 2009 4.0 … … … …
 … … … … 2008 8.7 2009 0.4 2010 5.6
 … … … … 2008 6.8 2008 0.7 2008 3.3
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults (15+)Adults + ChildrenAdults + Children
200920012009
 Croatia <1000 [<1000 – 1 100] <1000 [<500 – <1000] <1000 [<1000 – 1100]
 Czech Republic 2000 [1700 – 2300] 1300 [1200 – 1600] 2000 [1700 – 2300]
 Denmark 5300 [4000 – 6300] 3300 [2800 – 3800] 5300 [4000 – 6300]
 Estonia 9900 [8000 – 12 000] 4700 [3800 – 5700] 9800 [8000 – 12 000]
 Finland 2 600 [2200 – 3100] 1600 [1300 – 1900] 2600 [2200 – 3100]
 France 150 000 [120 000 – 190 000] 120 000 [100 000 – 140 000] 150 000 [120 000 – 190 000]
 Germany 67 000 [56 000 – 75 000] 49 000 [42 000 – 56 000] 67 000 [56 000 – 75 000]
 Greece 8800 [7300 – 11 000] 8100 [6800 – 9500] 8800 [7300 – 11 000]
 Hungary 3000 [2200 – 3900] 2800 [2100 – 3700] 3000 [2200 – 3900]
 Iceland <1000 [<500 – <1000] <500 [<500 – <500] <1000 [<500 – <1000]
 Ireland 6900 [5200 – 8700] 4500 [3400 – 5900] 6900 [5200 – 8700]
 Israel 7500 [5600 – 9900] 5200 [3900 – 6800] 7500 [5600 – 9900]
 Italy 140 000 [110 000 – 180 000] 130 000 [99 000 – 170 000] 140 000 [110 000 – 180 000]
 Latvia 8600 [6300 – 12 000] 4700 [3500 – 6 200] 8600 [6300 – 11 000]
 Lithuania 1200 [<1000 – 1600] <1000 [<1000 – <1000] 1200 [<1000 – 1600]
 Luxembourg <1000 [<1000 – 1200] <1000 [<500 – <1000] <1000 [<1000 – 1200]
 Malta <500 [<500 – <500] <500 [<200 – <500] <500 [<500 – <500]
 Netherlands 22 000 [17 000 – 32 000] 18 000 [14 000 – 24 000] 22 000 [17 000 – 32 000]
 Norway 4000 [3000 – 5400] 3000 [2300 – 4100] 4000 [3000 – 5400]
 Poland 27 000 [20 000 – 34 000] 21 000 [16 000 – 28 000] 27 000 [20 000 – 34 000]
 Portugal 42 000 [32 000 – 53 000] 31 000 [24 000 – 41 000] 42 000 [32 000 – 53 000]
 Romania 16 000 [12 000 – 20 000] 16 000 [12 000 – 20 000] 15 000 [11 000 – 20 000]
 Serbia 4900 [3500 – 7100] 1900 [<500 – 2800] 4900 [3400 – 7100]
 Slovakia <500 [<500 – <500] <200 [<200 – <500] <500 [<500 – <500]
 Slovenia <1000 [<500 – <1000] <500 [<200 – <500] <1000 [<500 – <1000]
 Spain 130 000 [120 000 – 150 000] 120 000 [100 000 – 130 000] 130 000 [120 000 – 150 000]
 Sweden 8100 [6100 – 11 000] 6300 [4900 – 8700] 8100 [6100 – 11 000]
 Switzerland 18 000 [13 000 – 24 000] 13 000 [9500 – 17 000] 18 000 [13 000 – 24 000]
 Turkey 4600 [3400 – 6100] 1700 [1300 – 2300] 4500 [3300 – 6100]
 United Kingdom of Great Britain 
 and Northern Ireland 85 000 [66 000 – 110 000] 43 000 [35 000 – 54 000] 85 000 [66 000 – 110 000]
 MIDDLE EAST AND NORTH AFRICA 460 000 [400 000 – 530 000] 180 000 [150 000 – 210 000] 440 000 [380 000 – 510 000]
 Algeria 18 000 [13 000 – 24 000] 6800 [4900 – 9000] 17 000 [12 000 – 24 000]
 Djibouti 14 000 [10 000 – 18 000] 12 000 [9000 – 16 000] 13 000 [9400 – 16 000]
 Egypt 11 000 [8400 – 17 000] 3300 [2900 – 5300] 10 000 [8100 – 16 000]
 Iran (Islamic Republic of) 92 000 [74 000 – 120 000] 54 000 [45 000 – 65 000] 91 000 [72 000 – 110 000]
 Lebanon 3600 [2700 – 4800] 3800 [2900 – 5100] 3400 [2600 – 4600]
 Morocco 26 000 [19 000 – 34 000] 14 000 [11 000 – 18 000] 25 000 [19 000 – 33 000]
 Oman 1100 [<1000 – 1400] <500 [<500 – <1000] 1100 [<1000 – 1400]
 Qatar <200 [<100 – <200] <100 [<100 – <100] <200 [<100 – <200]
 Somalia 34 000 [25 000 – 48 000] 11 000 [<500 – 14 000] 32 000 [23 000 – 46 000]
 Sudan 260 000 [210 000 – 330 000] 72 000 [35 000 – 98 000] 250 000 [200 000 – 310 000]
 Tunisia 2400 [1800 – 3300] <1000 [<500 – 1000] 2400 [1700 – 3300]
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A1
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adult (15–49) prevalence percentAdult (15–49) prevalence percentAdults (15+)
200120092001
 <1000 [<500 – <1000] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 1300 [1200 – 1600] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 3300 [2800 – 3800] 0.2  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 4700 [3800 – 5700] 1.2  [1.0 – 1.5] 0.6  [0.5 – 0.8]
 1600 [1300 – 1900] 0.1  [0.1 – 0.1] 0.1  [<0.1 – 0.1]
 120 000 [100 000 – 140 000] 0.4  [0.3 – 0.5] 0.3  [0.3 – 0.4]
 49 000 [42 000 – 56 000] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 8000 [6800 – 9500] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 2800 [2100 – 3700] <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 <500 [<500 – <500] 0.3  [0.2 – 0.4] 0.2  [0.2 – 0.3]
 4500 [3400 – 5900] 0.2  [0.2 – 0.3] 0.2  [0.1 – 0.2]
 5100 [3900 – 6800] 0.2  [0.1 – 0.2] 0.1  [0.1 – 0.2]
 130 000 [99 000 – 170 000] 0.3  [0.2 – 0.3] 0.3  [0.2 – 0.4]
 4700 [3500 – 6200] 0.7  [0.5 – 0.9] 0.4  [0.3 – 0.5]
 <1000 [<1000 – <1000] 0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 <1000 [<500 – <1000] 0.3  [0.2 – 0.4] 0.3  [0.2 – 0.3]
 <500 [<200 – <500] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 18 000 [14 000 – 24 000] 0.2  [0.1 – 0.3] 0.2  [0.1 – 0.3]
 3000 [2300 – 4100] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.2]
 21 000 [16 000 – 28 000] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.1]
 31 000 [24 000 – 41 000] 0.6  [0.4 – 0.7] 0.5  [0.4 – 0.6]
 16 000 [12 000 – 20 000] 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.2]
 1900 [<500 – 2700] 0.1  [0.1 – 0.2] <0.1  [<0.1 – 0.1]
 <200 [<200 – <500] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 <500 [<200 – <500] <0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 110 000 [100 000 – 130 000] 0.4  [0.3 – 0.4] 0.4  [0.4 – 0.5]
 6300 [4900 – 8700] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.2]
 13 000 [9500 – 17 000] 0.4  [0.3 – 0.5] 0.3  [0.2 – 0.4]
 1700 [1300 – 2300] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 43 000 [35 000 – 53 000] 0.2  [0.2 – 0.3] 0.1  [0.1 – 0.2]
 170 000 [150 000 – 200 000] 0.2  [0.2 – 0.3] 0.1  [0.1 – 0.1]
 6700 [4800 – 9000] 0.1  [0.1 – 0.1] <0.1  [<0.1 – <0.1]
 11 000 [8600 – 15 000] 2.5  [1.9 – 3.2] 2.9  [2.2 – 3.9]
 3200 [2900 – 5300] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 54 000 [44 000 – 64 000] 0.2  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 3700 [2800 – 5000] 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.2]
 14 000 [10 000 – 18 000] 0.1  [0.1 – 0.2] 0.1  [0.1 – 0.1]
 <500 [<500 – <500] 0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
 <100 [<100 – <100] <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 10 000 [<500 – 13 000] 0.7  [0.5 – 1.0] 0.3  [<0.1 – 0.3]
 68 000 [34 000 – 89 000] 1.1  [0.9 – 1.4] 0.4  [0.2 – 0.5]
 <1000 [<500 – 1000] <0.1  [<0.1 – 0.1] <0.1  [<0.1 – <0.1]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Children (0–14)Women (15+)Women (15+)
200920012009
 <500 [<500 – <500] <200 [<200 – <500] … …
 <1000 [<1000 – <1000] <500 [<500 – <500] … …
 1400 [1100 – 1700] <1000 [<1000 – 1000] … …
 3000 [2400 – 3800] 1400 [1100 – 1700] … …
 <1000 [<1000 – <1000] <500 [<500 – <1000] … …
 48 000 [38 000 – 59 000] 37 000 [31 000 – 44 000] … …
 12 000 [11 000 – 14 000] 9000 [7700 – 10 000] … …
 2700 [2200 – 3200] 2500 [2100 – 2900] … …
 <1000 [<1000 – 1300] <1000 [<1000 – 1200] … …
 <200 [<200 – <500] <100 [<100 – <200] … …
 2000 [1500 – 2600] 1300 [1000 – 1800] … …
 2200 [1700 – 2900] 1500 [1200 – 2100] … …
 48 000 [36 000 – 61 000] 42 000 [32 000 – 56 000] … …
 2600 [1900 – 3500] 1400 [1000 – 1800] … …
 <500 [<500 – <500] <500 [<200 – <500] … …
 <500 [<500 – <500] <200 [<200 – <500] … …
 <100 [<100 – <200] <100 [<100 – <100] … …
 6900 [5200 – 9700] 5400 [4200 – 7400] … …
 1200 [<1000 – 1600] <1000 [<1000 – 1200] … …
 8200 [6200 – 11 000] 6400 [4800 – 8500] … …
 13 000 [9900 – 16 000] 9400 [7300 – 12 000] … …
 4700 [3500 – 5900] 4600 [3600 – 5900] … …
 1200 [<1000 – 1600] <500 [<100 – <1000] … …
 <100 [<100 – <200] <100 [<100 – <100] … …
 <200 [<200 – <500] <100 [<100 – <100] … …
 32 000 [27 000 – 36 000] 28 000 [23 000 – 32 000] … …
 2500 [1900 – 3400] 1900 [1500 – 2700] … …
 5700 [4100 – 7500] 4000 [3000 – 5200] … …
 1400 [1000 – 1800] <1000 [<500 – <1000] … …
 
 26 000 [20 000 – 32 000] 13 000 [10 000 – 16 000] … …
 210 000 [180 000 – 240 000] 74 000 [61 000 – 87 000] 21 000 [13 000 – 28 000]
 5200 [3700 – 7200] 2000 [1500 – 2600] … …
 7400 [5300 – 9500] 6600 [5000 – 9000] … …
 2400 [2500 – 4900] <1000 [<1000 – 1600] … …
 26 000 [20 000 – 33 000] 15 000 [12 000 – 18 000] … …
 1100 [<1000 – 1400] 1100 [<1000 – 1500] … …
 8100 [6000 – 11 000] 4300 [3300 – 5600] … …
 <500 [<500 – <500] <200 [<200 – <200] … …
 <100 [<100 – <100] <100 [<100 – <100] … …
 15 000 [11 000 – 21 000] 4700 [<200 – 6300] … …
 140 000 [110 000 – 180 000] 39 000 [20 000 – 53 000] … …
 <1000 [<1000 – 1000] <500 [<100 – <500] … …
 Croatia
 Czech Republic
 Denmark
 Estonia
 Finland
 France
 Germany
 Greece
 Hungary
 Iceland
 Ireland
 Israel
 Italy
 Latvia
 Lithuania
 Luxembourg
 Malta
 Netherlands
 Norway
 Poland
 Portugal
 Romania
 Serbia
 Slovakia
 Slovenia
 Spain
 Sweden
 Switzerland
 Turkey
 United Kingdom of Great Britain 
 and Northern Ireland
 MIDDLE EAST AND NORTH AFRICA
 Algeria
 Djibouti
 Egypt
 Iran (Islamic Republic of)
 Lebanon
 Morocco
 Oman
 Qatar
 Somalia
 Sudan
 Tunisia
ESTIMATED PEOPLE 
LIVING WITH HIV
197Annex 1: HIV and AIDS estimates and data, 2009 and 2001 | 2010 GLOBAL REPORT
A1
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Young men (15–24) prevalence (%)Young women (15–24) prevalence (%)Children (0–14)
200920092001
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [0.1 – 0.1]
 … … 0.2  [0.2 – 0.3] 0.3  [0.2 – 0.4]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.6]
 … … <0.1  [<0.1 – <0.1] 0.1  [0.1 – 0.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.4]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … 0.1  [<0.1 – 0.2] 0.1  [<0.1 – 0.4]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
 … … 0.2  [0.1 – 0.4] 0.3  [0.1 – 0.9]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … 0.1  [<0.1 – 0.1] 0.1  [0.1 – 0.2]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.1]
 … … 0.1  [0.1 – 0.1] 0.2  [0.1 – 0.2]
 … … <0.1  [<0.1 – 0.1] <0.1  [<0.1 – 0.2]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.6]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … 0.1  [<0.1 – 0.2] 0.2  [0.1 – 0.6]
 7100 [3800 – 13 000] 0.2  [0.2 – 0.3] 0.1  [0.1 – 0.1]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.2]
 … … 1.9  [1.0 – 2.9] 0.8  [0.4 – 1.3]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – <0.1]
 … … 0.6  [0.4 – 1.1] 0.4  [0.3 – 0.7]
 … … 1.3  [0.9 – 1.8] 0.5  [0.4 – 0.7]
 … … <0.1  [<0.1 – <0.1] <0.1  [<0.1 – 0.1]
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults + children newly infectedAdult (15–49) incidence rateAdult (15–49) incidence rate
200920012009
ESTIMATED NEW HIV 
INFECTIONS
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<200 – <500]
 …  [<0.10 – 0.14] …  [0.13 – 0.21] … [<1000 – 1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 6900 [3900 – 10 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 3300 [2500 – 4200]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<200 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<200 – <500]
 …  [<0.10 – <0.10] … … … [1700 – 6200]
 <0.10  [<0.10 – 0.10] <0.10  [<0.10 – 0.11] <1000 [<500 – 1200]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] <100 [<100 – <200]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1300]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 2300]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <200]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [2200 – 4100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1500 – 6000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 75 000 [61 000 – 92 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1100 – 3700]
 0.25  [0.10 – 0.34] 0.29  [0.18 – 0.51] 1300 [<1000 – 1800]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 2900]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [5600 – 11 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1200 – 5800]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<200 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<100 – <100]
 …  [<0.10 – 0.29] …  [<0.10 – <0.10] … [4200 – 13 000]
 …  [0.17 – 0.35] …  [<0.10 – 0.10] … [38 000 – 74 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
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A1
ESTIMATED AIDS-RELATED 
DEATHS
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
AIDS-related deaths in adults + childrenAIDS-related deaths in adults + childrenAdults newly infected
200120092009
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<200 – <500] <100 [<100 – <200] <100 [<100 – <100]
 … [<1000 – 1000] <500 [<500 – <1000] <200 [<100 – <200]
 … [<100 – <200] <100 [<100 – <100] <100 [<100 – <100]
 6800 [3900 – 10 000] 1700 [1400 – 3900] 1200 [<1000 – 3000]
 3300 [2500 – 4200] <1000 [<1000 – 1900] <1000 [<500 – <1000]
 … [<200 – <500] <500 [<200 – <500] <500 [<500 – <500]
 … [<100 – <100] <200 [<100 – <200] <500 [<200 – <500]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <500] <100 [<100 – <200] <100 [<100 – <100]
 … [<200 – <500] <100 [<100 – <200] <100 [<100 – <100]
 … [1700 – 6200] <1000 [<1000 – 4100] 1300 [<1000 – 2400]
 <1000 [<500 – 1200] <1000 [<500 – <1000] <200 [<100 – <500]
 <100 [<100 – <200] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<500 – 1100] <100 [<100 – <500] <100 [<100 – <100]
 … [<100 – <500] <100 [<100 – <200] <100 [<100 – <100]
 … [<500 – 1300] <200 [<100 – <1000] <100 [<100 – <200]
 … [<1000 – 2300] <500 [<100 – 1300] <500 [<500 – <500]
 … [<500 – 1000] <1000 [<500 – 1200] <500 [<200 – <1000]
 … [<500 – <1000] <200 [<100 – <500] <500 [<100 – <500]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <200] <100 [<100 – <100] <100 [<100 – <100]
 … [2200 – 4100] 1600 [1200 – 2000] 1800 [1500 – 2100]
 … [<100 – <500] <100 [<100 – <500] <100 [<100 – <100]
 … [<500 – 1000] <100 [<100 – <500] <200 [<100 – <500]
 … [<500 – <1000] <200 [<100 – <500] <100 [<100 – <200]
 
 … [<100 – <100] <1000 [<500 – 1600] <500 [<200 – <500]
 68 000 [55 000 – 84 000] 24 000 [20 000 – 27 000] 8300 [6300 – 11 000]
 … [1000 – 3600] <1000 [<1000 – 1100] <500 [<200 – <500]
 1100 [<500 – 1500] 1000 [<1000 – 1400] <1000 [<500 – 1400]
 … [<1000 – 2700] <500 [<500 – <1000] <200 [<100 – <500]
 … [5400 – 11 000] 6400 [5200 – 8000] 2000 [1600 – 2600]
 … [<100 – <500] <500 [<500 – <500] <500 [<200 – <500]
 … [<100 – <100] 1200 [<1000 – 1600] <1000 [<1000 – 1000]
 … [<200 – <500] <100 [<100 – <100] <100 [<100 – <100]
 … [<100 – <100] <100 [<100 – <100] <100 [<100 – <100]
 … [3700 – 11 000] 1600 [1200 – 2300] <1000 [<100 – <1000]
 … [34 000 – 67 000] 12 000 [9200 – 15 000] 3500 [<1000 – 6700]
 … [<500 – <1000] <100 [<100 – <200] <100 [<100 – <100]
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ESTIMATED ORPHANS 
DUE TO AIDS
 … … … … … … … … … …
 … … … … 2009 0.1 … … 2009 2.6
 … … … … … … … … 2009 11.8
 … … … … 2007 62.5 2006 7.7 2007 1.7
 … … … … 2009 0.7 … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … 2009 2.6
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … 2007 22.6 … … 2008 4.0
 … … … … 2008 8.0 … … … …
 … … … … 2008 1.8 … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … 2008 14.0 … … … …
 … … … … 2009 1.1 2009 1.0 2009 4.4
 … … … … 2008 4.8 … … 2008 6.1
 … … … … … … … … … …
 … … … … … … … … 2009 1.6
 … … … … 2008 19.5 2008 0.9 2008 10.2
 … … … … … … … … … …
 … … … … 2006 10.9 … … 2007 8.1
 … … … … … … … … … …
 … … … … … … … … … …
 96 000 [73 000 – 120 000] 36 000 [22 000 – 63 000] … … … … … …
 … … … … … … … … … …
 … … … … … … 2008 20.3 … …
 … … … … … … 2006 0.9 2006 5.6
 … … … … … … … … … …
 … … … … … … … … 2008 1.0
 … … … … 2009 2.1 2009 2.4 … …
 … … … … … … … … … …
 … … … … … … … … … …
 … … … … … … 2008 5.5 … …
 … … … … … … 2008 0.9 … …
 … … … … 2009 3.1 2009 0.4 2009 4.8
 Croatia
 Czech Republic
 Denmark
 Estonia
 Finland
 France
 Germany
 Greece
 Hungary
 Iceland
 Ireland
 Israel
 Italy
 Latvia
 Lithuania
 Luxembourg
 Malta
 Netherlands
 Norway
 Poland
 Portugal
 Romania
 Serbia
 Slovakia
 Slovenia
 Spain
 Sweden
 Switzerland
 Turkey
 United Kingdom of Great Britain 
 and Northern Ireland
 MIDDLE EAST AND NORTH AFRICA
 Algeria
 Djibouti
 Egypt
 Iran (Islamic Republic of)
 Lebanon
 Morocco
 Oman
 Qatar
 Somalia
 Sudan
 Tunisia
HIV PREVALENCE (%) 
IN MOST-AT-RISK 
GROUPS IN CAPITAL CITY
estimate estimate[low – high estimate] [low – high estimate]
Orphans (0–17)
Year Year YearHIV (%) HIV (%) HIV (%)
Injecting drug 
users
Female sex 
workers
Men who have 
sex with menOrphans (0–17) currently living
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ESTIMATED PEOPLE 
LIVING WITH HIV
 NORTH AMERICA 1 500 000 [1 200 000 – 2 000 000] 1 200 000 [960 000 – 1 400 000] 1 500 000 [1 200 000 – 2 000 000]
 Canada 68 000 [53 000 – 83 000] 49 000 [40 000 – 62 000] 68 000 [53 000 – 83 000]
 Mexico 220 000 [180 000 – 280 000] 180 000 [150 000 – 210 000] 220 000 [180 000 – 270 000]
 United States of America 1 200 000 [930 000 – 1 700 000] 940 000 [730 000 – 1 200 000] 1 200 000 [930 000 – 1 700 000]
 CARIBBEAN 240 000 [220 000 – 270 000] 240 000 [210 000 – 270 000] 220 000 [200 000 – 250 000]
 Bahamas 6600 [2600 – 11 000] 5900 [3900 – 8500] 6100 [2400 – 11 000]
 Barbados 2100 [1800 – 2500] <1000 [<1000 – 1 000] 2100 [1800 – 2500]
 Cuba 7100 [5700 – 8900] 2600 [1900 – 3400] 7000 [5600 – 8800]
 Dominican Republic 57 000 [49 000 – 66 000] 54 000 [45 000 – 65 000] 54 000 [45 000 – 62 000]
 Haiti 120 000 [110 000 – 140 000] 130 000 [110 000 – 160 000] 110 000 [95 000 – 130 000]
 Jamaica 32 000 [21 000 – 45 000] 32 000 [23 000 – 41 000] 31 000 [20 000 – 43 000]
 Trinidad and Tobago 15 000 [11 000 – 19 000] 10 000 [7900 – 14 000] 14 000 [11 000 – 19 000]
 CENTRAL AND SOUTH AMERICA 1 400 000 [1 200 000 – 1 600 000] 1 100 000 [1 000 000 – 1 300 000] 1 400 000 [1 200 000 – 1 600 000]
 Argentina 110 000 [88 000 – 140 000] 80 000 [66 000 – 99 000] 110 000 [87 000 – 140 000]
 Belize 4800 [4000 – 5700] 3600 [3000 – 4200] 4400 [3600 – 5300]
 Bolivia 12 000 [9000 – 16 000] 12 000 [9100 – 16 000] 11 000 [8400 – 15 000]
 Brazil … [460 000 – 810 000] … [380 000 – 560 000] … [450 000 – 800 000]
 Chile 40 000 [32 000 – 51 000] 24 000 [19 000 – 31 000] 39 000 [31 000 – 50 000]
 Colombia 160 000 [120 000 – 210 000] 210 000 [170 000 – 260 000] 150 000 [120 000 – 200 000]
 Costa Rica 9800 [7500 – 13 000] 4400 [3400 – 5900] 9600 [7300 – 12 000]
 Ecuador 37 000 [28 000 – 50 000] 36 000 [27 000 – 47 000] 36 000 [27 000 – 49 000]
 El Salvador 34 000 [25 000 – 44 000] 25 000 [19 000 – 33 000] 32 000 [24 000 – 42 000]
 Guatemala 62 000 [47 000 – 82 000] 31 000 [23 000 – 41 000] 60 000 [45 000 – 79 000]
 Guyana 5900 [2700 – 8800] 7800 [5300 – 12 000] 5500 [2400 – 8200]
 Honduras 39 000 [26 000 – 51 000] 44 000 [33 000 – 61 000] 37 000 [24 000 – 49 000]
 Nicaragua 6900 [5200 – 9100] 3700 [2900 – 4800] 6700 [5000 – 8900]
 Panama 20 000 [14 000 – 36 000] 26 000 [17 000 – 50 000] 20 000 [13 000 – 36 000]
 Paraguay 13 000 [9800 – 16 000] 9200 [7200 – 13 000] 12 000 [9600 – 16 000]
 Peru 75 000 [58 000 – 100 000] 82 000 [65 000 – 100 000] 73 000 [56 000 – 98 000]
 Suriname 3700 [2700 – 5300] 3300 [2300 – 4500] 3600 [2700 – 5100]
 Uruguay 9900 [8400 – 12 000] 7000 [5900 – 8200] 9600 [8100 – 11 000]
 Venezuela … … … … … …
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults (15+)Adults + ChildrenAdults + Children
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adult (15–49) prevalence percentAdult (15–49) prevalence percentAdults (15+)
200120092001
 1 200 000 [950 000 – 1 400 000] 0.5  [0.4 – 0.7] 0.4  [0.4 – 0.5]
 49 000 [40 000 – 62 000] 0.3  [0.2 – 0.4] 0.3  [0.2 – 0.3]
 180 000 [150 000 – 210 000] 0.3  [0.3 – 0.4] 0.3  [0.2 – 0.4]
 930 000 [730 000 – 1 200 000] 0.6  [0.4 – 0.8] 0.5  [0.4 – 0.7]
 220 000 [200 000 – 250 000] 1.0  [0.9 – 1.1] 1.1  [1.0 – 1.2]
 5400 [3400 – 7600] 3.1  [1.2 – 5.4] 3.1  [1.9 – 4.4]
 <1000 [<1000 – 1000] 1.4  [1.2 – 1.6] 0.5  [0.4 – 0.6]
 2600 [1900 – 3400] 0.1  [0.1 – 0.1] <0.1  [<0.1 – 0.1]
 50 000 [43 000 – 60 000] 0.9  [0.7 – 1.0] 0.9  [0.8 – 1.1]
 120 000 [100 000 – 140 000] 1.9  [1.7 – 2.2] 2.6  [2.3 – 3.0]
 31 000 [22 000 – 39 000] 1.7  [1.1 – 2.5] 1.9  [1.3 – 2.4]
 10 000 [7800 – 14 000] 1.5  [1.1 – 2.0] 1.2  [0.9 – 1.6]
 1 100 000 [1 000 000 – 1 200 000] 0.5  [0.4 – 0.6] 0.5  [0.4 – 0.5]
 79 000 [65 000 – 97 000] 0.5  [0.3 – 0.6] 0.4  [0.3 – 0.5]
 3300 [2800 – 3800] 2.3  [2.0 – 2.8] 2.2  [1.9 – 2.6]
 11 000 [8600 – 15 000] 0.2  [0.1 – 0.3] 0.2  [0.2 – 0.3]
 … [360 000 – 550 000] …  [0.3 – 0.6] …  [0.3 – 0.5]
 24 000 [18 000 – 30 000] 0.4  [0.3 – 0.5] 0.3  [0.2 – 0.3]
 210 000 [160 000 – 260 000] 0.5  [0.4 – 0.7] 0.8  [0.7 – 1.1]
 4400 [3300 – 5800] 0.3  [0.2 – 0.4] 0.2  [0.1 – 0.2]
 35 000 [26 000 – 46 000] 0.4  [0.3 – 0.6] 0.5  [0.4 – 0.6]
 24 000 [18 000 – 32 000] 0.8  [0.6 – 1.1] 0.8  [0.6 – 1.0]
 30 000 [22 000 – 40 000] 0.8  [0.6 – 1.0] 0.5  [0.4 – 0.7]
 7000 [4600 – 11 000] 1.2  [0.5 – 1.9] 1.4  [0.9 – 2.2]
 42 000 [31 000 – 57 000] 0.8  [0.5 – 1.0] 1.2  [0.9 – 1.6]
 3600 [2800 – 4700] 0.2  [0.1 – 0.3] 0.1  [0.1 – 0.2]
 25 000 [16 000 – 49 000] 0.9  [0.6 – 1.5] 1.4  [0.9 – 2.7]
 9000 [7000 – 12 000] 0.3  [0.2 – 0.4] 0.3  [0.2 – 0.4]
 81 000 [64 000 – 99 000] 0.4  [0.3 – 0.5] 0.5  [0.4 – 0.6]
 3200 [2300 – 4400] 1.0  [0.7 – 1.4] 1.0  [0.7 – 1.4]
 6800 [5800 – 8000] 0.5  [0.4 – 0.6] 0.4  [0.3 – 0.4]
 … … … … … …
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Children (0–14)Women (15+)Women (15+)
200920012009
 390 000 [310 000 – 510 000] 270 000 [220 000 – 320 000] 4500 [4000 – 5800]
 21 000 [16 000 – 25 000] 15 000 [12 000 – 18 000] … …
 59 000 [47 000 – 75 000] 41 000 [33 000 – 49 000] … …
 310 000 [220 000 – 430 000] 210 000 [160 000 – 270 000] … …
 120 000 [100 000 – 140 000] 120 000 [100 000 – 140 000] 17 000 [8500 – 26 000]
 3700 [1500 – 6400] 3300 [2100 – 4600] … …
 <1000 [<1000 – <1000] <500 [<500 – <500] … …
 2200 [1700 – 2700] <1000 [<1000 – 1000] … …
 32 000 [26 000 – 37 000] 29 000 [24 000 – 35 000] … …
 67 000 [56 000 – 78 000] 73 000 [61 000 – 87 000] 12 000 [5700 – 18 000]
 10 000 [6700 – 14 000] 9900 [7300 – 13 000] … …
 4700 [3500 – 6100] 3300 [2600 – 4300] … …
 490 000 [420 000 – 590 000] 370 000 [330 000 – 420 000] 36 000 [25 000 – 50 000]
 36 000 [28 000 – 45 000] 25 000 [20 000 – 30 000] … …
 2600 [2100 – 3100] 1900 [1600 – 2200] … …
 3600 [2700 – 4800] 3500 [2700 – 4600] … …
 … [180 000 – 330 000] … [140 000 – 210 000] … …
 12 000 [9700 – 15 000] 7200 [5500 – 9300] … …
 50 000 [38 000 – 65 000] 65 000 [51 000 – 80 000] … …
 2800 [2100 – 3600] 1300 [<1000 – 1700] … …
 11 000 [8400 – 15 000] 11 000 [8200 – 14 000] … …
 11 000 [8500 – 14 000] 8000 [6000 – 11 000] … …
 20 000 [15 000 – 26 000] 9600 [7200 – 13 000] … …
 2800 [1100 – 4200] 3800 [2400 – 5700] … …
 12 000 [7900 – 16 000] 13 000 [9700 – 18 000] … …
 2100 [1600 – 2800] 1100 [<1000 – 1400] … …
 6300 [4200 – 11 000] 7600 [4900 – 15 000] … …
 3800 [2900 – 4800] 2700 [2100 – 3700] … …
 18 000 [14 000 – 25 000] 15 000 [12 000 – 19 000] … …
 1100 [<1000 – 1600] <1000 [<1000 – 1300] … …
 3100 [2600 – 3600] 2100 [1800 – 2500] … …
 … … … … … …
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Young men (15–24) prevalence (%)Young women (15–24) prevalence (%)Children (0–14)
200920092001
 5200 [2900 – 7700] 0.2  [0.1 – 0.3] 0.2  [0.2 – 0.4]
 … … 0.1  [<0.1 – 0.2] 0.1  [<0.1 – 0.5]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.2]
 … … 0.2  [0.1 – 0.3] 0.3  [0.2 – 0.5]
 18 000 [9100 – 27 000] 0.8  [0.6 – 1.0] 0.4  [0.3 – 0.7]
 … … 3.1  [0.8 – 6.6] 1.4  [0.5 – 2.8]
 … … 1.1  [0.8 – 1.4] 0.9  [0.7 – 1.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … 0.7  [0.4 – 0.9] 0.3  [0.1 – 0.4]
 12 000 [6300 – 19 000] 1.3  [1.0 – 1.8] 0.6  [0.4 – 0.8]
 … … 0.7  [0.3 – 1.4] 1.0  [0.4 – 3.1]
 … … 0.7  [0.3 – 1.2] 1.0  [0.4 – 3.3]
 30 000 [20 000 – 42 000] 0.2  [0.1 – 0.3] 0.2  [0.2 – 0.5]
 … … 0.2  [0.1 – 0.3] 0.3  [0.1 – 0.8]
 … … 1.8  [1.4 – 2.7] 0.7  [0.5 – 1.1]
 … … 0.1  [<0.1 – 0.1] 0.1  [<0.1 – 0.3]
 … … …  [0.1 – 0.4] …  [0.1 – 0.3]
 … … 0.1  [0.1 – 0.3] 0.2  [0.1 – 0.7]
 … … 0.1  [0.1 – 0.3] 0.2  [0.1 – 0.7]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.3]
 … … 0.2  [0.1 – 0.3] 0.2  [0.1 – 0.8]
 … … 0.3  [0.1 – 0.5] 0.4  [0.2 – 1.3]
 … … 0.3  [0.2 – 0.6] 0.5  [0.2 – 1.4]
 … … 0.8  [0.2 – 1.5] 0.6  [0.2 – 1.0]
 … … 0.2  [0.1 – 0.4] 0.3  [0.1 – 1.1]
 … … 0.1  [0.1 – 0.1] 0.1  [0.1 – 0.2]
 … … 0.3  [0.1 – 0.5] 0.4  [0.2 – 1.3]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.6]
 … … 0.1  [0.1 – 0.2] 0.2  [0.1 – 0.3]
 … … 0.4  [0.2 – 0.7] 0.6  [0.2 – 2.0]
 … … 0.2  [0.1 – 0.3] 0.3   [0.1 – 1.0]
 … … … … … …
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estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
Adults + children newly infectedAdult (15–49) incidence rateAdult (15–49) incidence rate
200920012009
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 70 000 [44 000 – 130 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 3800]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [8800 – 21 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 54 000 [24 000 – 110 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – 0.11] 17 000 [13 000 – 21 000]
 …  [<0.10 – 0.62] …  [<0.10 – 0.43] … [<200 – 1200]
 …  [<0.10 – 0.16] …  [<0.10 – 0.13] … [<200 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – 0.10] 3600 [1600 – 5000]
 0.15  [0.10 – 0.19] 0.19  [0.15 – 0.23] 8800 [6500 – 11 000]
 0.13  [<0.10 – 0.27] 0.19  [0.10 – 0.25] 2100 [<1000 – 4200]
 …  [<0.10 – 0.21] …  [0.10 – 0.19] … [<1000 – 1800]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 92 000 [70 000 – 120 000]
 <0.10  [<0.10 – <0.10] <0.10  [<0.10 – <0.10] 7500 [4100 – 11 000]
 0.20  [0.13 – 0.32] 0.30  [0.23 – 0.35] <500 [<500 – <1000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 1600]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [18 000 – 70 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1400 – 4300]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [2800 – 16 000]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1100]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [1100 – 6200]
 …  [<0.10 – 0.11] …  [<0.10 – 0.14] … [1200 – 4000]
 …  [<0.10 – 0.15] …  [<0.10 – 0.12] … [3600 – 11 000]
 …  [<0.10 – 0.17] …  [<0.10 – <0.10] … [<100 – <1000]
 …  [<0.10 – <0.10] …  [<0.10 – 0.13] … [<1000 – 3700]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – 1300]
 …  [<0.10 – 0.11] …  [<0.10 – 0.14] … [<1000 – 2200]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<1000 – 1600]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [2300 – 6700]
 <0.10  [<0.10 – <0.10] 0.11  [<0.10 – 0.16] <500 [<100 – <500]
 …  [<0.10 – <0.10] …  [<0.10 – <0.10] … [<500 – <1000]
 … … … … … …
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ESTIMATED AIDS-RELATED 
DEATHS
estimate estimate estimate[low – high estimate] [low – high estimate] [low – high estimate]
AIDS-related deaths in adults + childrenAIDS-related deaths in adults + childrenAdults newly infected
200120092009
 69 000 [43 000 – 120 000] 26 000 [22 000 – 44 000] 30 000 [26 000 – 35 000]
 … [<1000 – 3800] <1000 [<500 – <1000] <1000 [<500 – <1000]
 … [8300 – 20 000] … [6400 – 12 000] … [9800 – 15 000]
 54 000 [24 000 – 110 000] 17 000 [13 000 – 36 000] 17 000 [14 000 – 23 000]
 15 000 [12 000 – 19 000] 12 000 [8500 – 15 000] 19 000 [16 000 – 23 000]
 … [<100 – 1100] <500 [<200 – <1000] <1000 [<500 – <1000]
 … [<200 – <500] <100 [<100 – <100] <100 [<100 – <100]
 … [<500 – <1000] <100 [<100 – <500] <200 [<100 – <200]
 3200 [1300 – 4400] 2300 [1300 – 3400] 3900 [2900 – 5500]
 7600 [5400 – 10 000] 7100 [5200 – 9400] 12 000 [9200 – 14 000]
 2000 [<1000 – 4000] 1200 [<500 – 2100] 2700 [2100 – 3500]
 … [<1000 – 1700] <1000 [<500 – <1000] <1000 [<500 – <1000]
 87 000 [66 000 – 120 000] 58 000 [43 000 – 70 000] 53 000 [44 000 – 65 000]
 7400 [4100 – 11 000] 2900 [1600 – 4500] 2800 [1600 – 4100]
 <500 [<500 – <1000] <500 [<500 – <500] <500 [<200 – <500]
 … [<500 – 1500] <1000 [<1000 – 1200] <1000 [<1000 – 1100]
 … [17 000 – 69 000] … [2000 – 25 000] … [7200 – 24 000]
 … [1200 – 4000] … [<1000 – 2200] … [<500 – 1200]
 … [2300 – 16 000] 14 000 [11 000 – 18 000] 13 000 [9800 – 17 000]
 … [<500 – 1000] <500 [<100 – <1000] <100 [<100 – <200]
 … [<100 – <100] 2200 [1300 – 3300] 2800 [2100 – 3700]
 … [1000 – 3800] 1400 [<1000 – 2100] <1000 [<200 – 1100]
 … [3200 – 10 000] 2600 [1600 – 3700] 1500 [1000 – 2100]
 … [<100 – <1000] <500 [<100 – <1000] <1000 [<1000 – 1300]
 … [<1000 – 3400] 2500 [1700 – 3400] 3700 [2800 – 5000]
 … [<500 – 1300] <500 [<200 – <500] <200 [<200 – <500]
 … [<1000 – 2100] 1500 [<1000 – 3600] 1600 [<1000 – 3200]
 … [<1000 – 1600] <500 [<500 – <1000] <500 [<500 – <1000]
 … [2100 – 6300] 5000 [3800 – 6600] 6300 [5200 – 7900]
 <200 [<100 – <500] <200 [<200 – <500] <500 [<200 – <500]
 … [<500 – <1000] … … … …
 … … … … … …
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HIV PREVALENCE (%) 
IN MOST-AT-RISK 
GROUPS IN CAPITAL CITY
estimate estimate[low – high estimate] [low – high estimate]
Orphans (0–17)
Year Year YearHIV (%) HIV (%) HIV (%)
Injecting drug 
users
Female sex 
workers
Men who have 
sex with menOrphans (0–17) currently living
20012009
ESTIMATED ORPHANS 
DUE TO AIDS
 140 000 [110 000 – 180 000] 210 000 [160 000 – 260 000] … … … … … …
 … … … … 2008 12.7 … … 2008 14.7
 … … … … 2009 5.0 2009 0.9 2009 10.2
 … … … … … … … … … …
 140 000 [110 000 – 170 000] 100 000 [63 000 – 170 000] … … … … … …
 … … … … … … … … 2009 25.6
 … … … … … … … … … …
 … … … … … … 2009 0.1 2009 0.7
 … … … … … … 2008 4.8 2004 10.7
 … … … … … … 2009 5.3 … …
 … … … … … … 2009 4.9 2007 31.8
 … … … … … … … … … …
 240 000 [200 000 – 280 000] 190 000 [150 000 – 240 000] … … … … … …
 … … … … 2008 11.9 2008 1.9 2008 11.8
 … … … … … … … … … …
 … … … … … … … … 2008 11.6
 … … … … 2009 5.9 … … 2009 12.6
 … … … … … … … … 2009 20.3
 … … … … … … 2008 1.6 … …
 … … … … … … … … 2009 12.7
 … … … … … … … … … …
 … … … … … … 2009 4.1 2009 9.8
 … … … … … … 2006 1.0 2006 18.3
 … … … … … … 2009 16.6 2009 19.4
 … … … … … … 2006 2.3 2006 6.6
 … … … … … … … … 2009 4.2
 … … … … … … … … … …
 … … … … … … 2008 1.8 2008 9.6
 … … … … … … … … 2009 10.1
 … … … … … … … … … …
 … … … … … … … … 2008 9.1
 … … … … … … … … … …
 NORTH AMERICA
 Canada
 Mexico
 United States of America
 CARIBBEAN
 Bahamas
 Barbados
 Cuba
 Dominican Republic
 Haiti
 Jamaica
 Trinidad and Tobago
 CENTRAL AND SOUTH AMERICA
 Argentina
 Belize
 Bolivia
 Brazil
 Chile
 Colombia
 Costa Rica
 Ecuador
 El Salvador
 Guatemala
 Guyana
 Honduras
 Nicaragua
 Panama
 Paraguay
 Peru
 Suriname
 Uruguay
 Venezuela
208 Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
All countries, regardless of their economic or 
epidemiological status, were requested to report on all 
indicators, where appropriate. Countries were expected to 
consider each indicator in light of the individual dynamics 
of their epidemic. When countries chose not to report 
on a particular indicator, they were asked to provide 
an explanation as to why they chose not to report. Th is 
allowed for an analysis that diff erentiates between an 
absence of data, the inapplicability of particular indicators 
to particular country situations, or the non-relevance 
of the particular issue, such as orphans and vulnerable 
children in low-prevalence settings.
RESPONSE RATES
In 2010, 182 countries (94% of UN Member States) 
submitted Country Progress Reports to UNAIDS. Th e 
proportion of Member States submitting such reports 
has increased consistently over each of the four rounds of 
reporting, as seen in fi gures 1 and 2. In the fi rst round of 
reporting slightly more than half (54%) of Member States 
reported, increasing to 64% in 2006 and 77% in 2008. 
All but two regions have response rates above 90%. Th ere 
was a substantial increase in the numbers of reports 
received from Western and Central Europe, which resulted 
in an increase in the response rate for this region from 
67% in 2008 to 88% in 2010. No change in response rate 
was observed in East Asia with three of the fi ve countries 
in the region submitting reports, as was the case in 2008. 
Th e most remarkable increase in response rates was seen 
in North Africa and the Middle East, where the percentage 
of Member States submitting Country Progress Reports 
jumped from 45% in 2008 to 95% in 2010.
Monitoring progress in national responses 
to HIV
In adopting the 2001 Declaration of Commitment on 
HIV/AIDS, Member States of the United Nations agreed 
to systematically review and regularly report on their 
progress in realizing universal access to HIV prevention, 
treatment care and support by 2010. As part of that review 
process and on behalf of the United Nations Secretary-
General, the United Nations Joint Programme on 
HIV/AIDS (UNAIDS) requests Member States to submit 
biennial reports to UNAIDS—the Country Progress 
Reports—against a set of standardized core indicators.
Th e information provided by Country Progress Reports 
represents the most comprehensive and readily accessible 
data on the status of the epidemic and progress being 
made by countries in the response. Th e primary purpose 
of this annex is to compile that data in one place, thus 
providing a transparent monitoring of progress towards 
the targets set in the Declaration of Commitment and the 
Millennium Development Goals. Th e data compiled allow 
a deeper understanding of the global, as well as regional 
and national responses to the epidemic. 
INDICATORS
Core indicators for reporting have been consolidated and 
refi ned in each round of reporting since 2003, when the 
fi rst UNGASS Progress Report, Follow-up to the 2001 
UNGASS: Progress Report on the Global Response to 
HIV/AIDS, was published. Th is ongoing work is done 
in collaboration with global partners and the UNAIDS 
Monitoring and Evaluation Reference Group (MERG), 
which sets the international standards for monitoring and 
evaluation. Details on how the indicators were constructed 
are available on the UNAIDS Web site in the document 
UNGASS Monitoring the Declaration of Commitment 
on HIV/AIDS: Guidelines on the Construction of Core 
Indicators (March 2009). 
ANNEX 2 COUNTRY PROGRESS INDICATORS 2004 TO 2010
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Figure A2.1
Response rates by region and reporting round*
UNGASS Submissions by region (UN Member States 
reporting/total number of UN Member States)
* Includes all country progress reports submitted to UNAIDS, 
including late or incomplete submissions
% 10 20 30 40 50 60 70 80 90 100
Caribbean (13)
Central and South America (19)
Eastern Europe and Central Asia (12)
Sub- Saharan Africa (45)
South and South-East Asia (19)
East Asia (5)
Oceania (14)
Western and Central Europe (42)
North America (3)
North Africa and Middle East (20)
Global
2008 (153/192) 2010 (182/192)2004 (102/191) 2006 (143/192)
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Table A2.1 
Countries that did not provide reports on the implementation of 
the Declaration of Commitment in 2010 (n=10)
Andorra Iceland San Marino
Democratic People’s Republic of Korea Iraq Turkmenistan
Republic of Korea Kiribati
France Liechtenstein
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Table A2.2 
Countries that provided reports on the implementation of 
the Declaration of Commitment in 2010 (n=182)
Afghanistan Djibouti Luxembourg Samoa
Albania Dominica Madagascar Sao Tome and Principe
Algeria Dominican Republic Malawi Saudi Arabia 
Angola Ecuador Malaysia Senegal 
Antigua and Barbuda Egypt Maldives Serbia
Argentina El Salvador Mali Seychelles
Armenia Equatorial Guinea Malta Sierra Leone 
Australia Eritrea Marshall Islands Singapore 
Austria Estonia Mauritania Slovakia 
Azerbaijan Ethiopia Mauritius Slovenia 
Bahamas Fiji Mexico Solomon Islands
Bahrain Finland Micronesia, Federated States of Somalia 
Bangladesh Gabon Moldova South Africa 
Barbados Gambia Monaco Spain 
Belarus Georgia Mongolia Sri Lanka 
Belgium Germany Montenegro Sudan 
Belize Ghana Morocco Suriname 
Benin Greece Mozambique Swaziland 
Bhutan Grenada Myanmar Sweden 
Bolivia Guatemala Namibia Switzerland 
Bosnia and Herzegovina Guinea Nauru Syrian Arab Republic 
Botswana Guinea-Bissau Nepal Tajikistan 
Brazil Guyana Netherlands Thailand 
Brunei Darussalam Haiti New Zealand The Former Yugoslav Republic of 
Macedonia
Bulgaria Honduras Nicaragua Timor-Leste
Burkina Faso Hungary Niger Togo 
Burundi India Nigeria Tonga
Cambodia Indonesia Norway Trinidad and Tobago 
Cameroon Iran, Islamic Republic of Oman Tunisia 
Canada Ireland Pakistan Turkey 
Cape Verde Israel Palau Tuvalu
Central African Republic Italy Panama Uganda 
Chad Jamaica Papua New Guinea Ukraine 
Chile Japan Paraguay United Arab Emirates 
China Jordan Peru United Kingdom of Great Britain and 
Northern Ireland
Colombia Kazakhstan Philippines United Republic of Tanzania
Comoros Kenya Poland United States of America
Congo, Republic of the Kuwait Portugal Uruguay 
Costa Rica Kyrgyzstan Qatar Uzbekistan 
Côte d’Ivoire Lao People’s Democratic Republic Romania Vanuatu
Croatia Latvia Russian Federation Venezuela 
Cuba Lebanon Rwanda Viet Nam 
Cyprus Lesotho Saint Kitts and Nevis Yemen 
Czech Republic Liberia Saint Lucia Zambia 
Democratic Republic of the Congo Libyan Arab Jamahiriya Saint Vincent and the Grenadines Zimbabwe 
Denmark Lithuania  
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www.AIDSInfoOnline.org
To facilitate the use of AIDS-related data in countries and globally, UNAIDS has developed AIDSInfoOnline. 
AIDSInfoOnline is a data visualization and dissemination tool, based on the DevInfo project. It contains data from 
multiple agencies, including WHO, Measure DHS, UNAIDS and UNICEF. AIDSInfoOnline is populated with 
multisectoral HIV data, including AIDS spending, epidemiological estimates, country-reported programmatic data and 
National Composite Policy Index responses from government and civil society. 
AIDSInfoOnline’s data visualization capabilities allow for rapid production of charts, maps and tables, along with export 
of data and graphics to numerous formats for presentation and analysis. AIDSInfoOnline allows comparison of similar 
indicators from multiple sources. It is provided free of charge and installable on a PC or as a web-based service.
Under development for AIDSInfoOnline are e-learning materials to familiarize users with the tool and its advanced 
features, continued sourcing of relevant and complementary data into the database and assistance and guidance to 
regional and national entities that want to establish HIV/AIDS data hubs.
AIDSInfoOnline aims to be the leading source of HIV/AIDS data globally and provide its users with the most 
innovative, interactive exploration of that data.
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DATA VALIDATION
A comprehensive review of the national Reports was 
conducted by evaluation specialists at UNAIDS to ensure 
the completeness, accuracy and harmonization of data 
in relation to the core indicators. UNAIDS contacted 
150 countries with follow-up data questions. Th e 
majority of issues regarding reported data were resolved 
through these communications. Data issues that were not 
resolved as of the publication date were not included in 
the data analyses summarized in this report. 
In addition, a reconciliation process took place for data 
reported to UNAIDS, the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, UNICEF, the US President’s 
Emergency Plan for AIDS Relief, WHO and Measure 
DHS (data collected through the Demographic and 
Health Survey programme). As a result of discrepancies 
identifi ed in this reconciliation, direct communications 
were undertaken with national focal points for UNGASS 
reporting in 113 countries to obtain clarifi cation and 
resolution of outstanding questions. Over 85% of these 
113 countries responded with clarifying information.
Due to their complex nature, separate validation 
processes were undertaken for the National AIDS 
Spending Matrix and the National Composite Policy 
Index, a questionnaire that assesses progress in the 
development of national HIV policies and strategies. 
A comprehensive data review was undertaken at 
UNAIDS to check the completeness and accuracy of 
the funding matrices submitted. One hundred and 
eleven countries were contacted with follow-up data 
questions, the majority of which were resolved through 
these communications. Th e Policy Index reports were 
checked for internal consistency and completeness of the 
response. Confusing or illogical values were corrected; 
countries were contacted in cases of substantial missing 
data and multiple, non-consolidated Policy Index 
submissions. To resolve data issues relating to the Policy 
Index, 67 countries were contacted, the majority of 
countries responded.  
NATIONAL COMPOSITE POLICY INDEX (NCPI)
Th e National Composite Policy Index, (NCPI), is a 
questionnaire completed through a review of relevant 
documents and interviewing people most knowledgeable 
about the topics covered. One part1 of the NCPI is 
completed by government offi  cials, while another part2 
is completed by representatives from civil society and 
bilateral or multilateral organizations. Th e recommended 
consultative process for completing the NCPI aims to 
foster an environment conducive to including both 
government and nongovernment perspectives in the 
consolidated NCPI response that is eventually submitted 
by the government as part of its UNGASS report. It is 
strongly recommended that a fi nal workshop is organized 
with key stakeholders, including representatives from 
networks of people living with HIV and from populations 
at higher risk of HIV and other vulnerable populations, 
to present, discuss and validate the NCPI responses 
and write-up before the fi nal submission. In general, 
NCPI responses provided by the government are oft en 
more optimistic than those provided by nongovernment 
respondents. 
As there are over 200 data points for each country NCPI, 
not all data are included in the data tables presented in 
this report, but are available alongside individual country 
reports on the UNAIDS website and on AIDSInfoOnline.
org. Validated data from 171 UN member states were 
included in the analyses summarized in this report.
CHALLENGES IN MONITORING KEY POPULATIONS 
AT RISK
Ensuring country-level representative samples and 
establishing a global information system regarding 
programme coverage and risk behaviours for key 
populations at higher risk for HIV3 present signifi cant 
technical and ethical challenges. Methods are being 
developed to improve sampling of these oft en hard-to-
reach populations, such as respondent-driven sampling. 
While new methods may lead to samples that are more 
representative, it is recognized that obtaining a truly 
representative national sample may never be feasible. 
However, even though countries may not be able to 
attest to the national representativeness of samples used 
for surveys of key populations at higher risk for HIV, 
repeated measures using the same sampling frame and 
methodology can produce reliable data on trends in 
behaviours and service coverage.
1 Government offi cials complete questions on the national strategic plan, political support, and key policies and strategies of HIV programmes.
2 Nongovernment representatives complete questions on the country’s human rights context in relation to HIV; civil society involvement in the HIV 
response; and key policies and strategies of HIV programmes.
3 These groups were previously referred to as most-at-risk populations.
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Th e data from behavioural surveillance surveys (BSS), 
which are oft en obtained from urban convenience samples 
in programme catchment areas, are likely to produce a bias 
when measuring service coverage and risk behaviours. In 
order to enable the monitoring of trends countries were 
advised to keep theses biases constant by using a consistent 
methodology and sampling frame. In order to better 
understand potential biases and accurately interpret the 
data obtained in these surveys countries were encouraged 
to report data for these indicators that had been reviewed 
and endorsed by technical experts within the country, such 
as monitoring and evaluation technical working groups or 
national research councils. 
During the global data analysis, a number of 
methodological diff erences among countries were 
observed in the approach for data collection on key 
populations at risk. Th ese diff erences mostly relate to 
group defi nitions, measurement tools and time periods 
applied for the data collection. All recognized diff erences 
are systematically presented in the footnotes provided in 
the tables.
On a country level, it is important to interpret these 
indicator data alongside the country-reported NCPI, 
which provides an overview of the policy environment 
and programmatic response regarding key populations 
at risk in a given country, from the perspective of both 
the government and nongovernmental groups and civil 
society. 
NATIONAL CONSULTATION
While they are perhaps most pronounced in monitoring 
the behaviours and service coverage of key populations at 
risk of HIV, methodological challenges aff ect any eff orts 
to obtain national estimates of behaviours and services. It 
is therefore important to assess potential biases and other 
weaknesses of all available data in order to obtain the most 
robust assessment possible of the status of the national 
response.
Countries are strongly encouraged to undertake a 
consultation process with all relevant stakeholders to 
review and consolidate national-level data. Th e purpose of 
this consultation is to collectively assess the strengths and 
weaknesses of these data, and to obtain consensus on the 
interpretation of these data. Such discussions allow for a 
better understanding of national responses, and contribute 
to a strengthening of multisectoral responses. 
Th e vast majority of Country Progress Reports received 
provided information about the consultation process that 
was used for the validation and interpretation of the data 
reported. Th ese reports are available in full and unaltered 
on the UNAIDS website at www.unaids.org. 
COUNTRY DATA TABLES
Th e following tables present data submitted to UNAIDS in 
Country Progress Reports, as a part of the monitoring of 
progress towards the Declaration of Commitment. Where 
indicators and methods were consistent across reporting 
years, all available data from previous years are provided 
in order to allow the reader to examine changes over time. 
Where possible the year that the data were collected was 
diff erentiated from the year of reporting. Th e percentages 
and numbers in the tables are rounded to the nearest whole 
number. Some of the Country Progress Report data were 
still under review with countries at the time of production 
of this reference report. Where this is the case, it has been 
explicitly footnoted in the Indicator Data Tables. 
Countries may not have submitted data for a given 
indicator because either (1) no data were available with 
which to construct the indicator according to the UNGASS 
defi nition, (2) the country uses an alternate methodology 
or indicator for tracking this particular issue, or (3) the 
country chose not to report on the indicator because it was 
considered not relevant to the county’s epidemic. In some 
instances an alternative source was used to provide values 
when a country submission was not received for that 
indicator. An example of this is the blood safety indicator, 
where supplementary values were provided by the World 
Health Organization (Department of Blood Transfusion 
Safety). Where no data were reported for a given indicator, 
and no data for that country are available from another 
comparable source, that country has been excluded from 
the relevant data table. 
Values printed in the tables are those endorsed by 
countries. In some instances these values diff er from 
those originally submitted as a result of the reconciliation 
process. As such, some values in these data tables may 
diff er from those published in individual Country Progress 
Reports.
In addition to data reported by countries, values for these 
countries from the most recent Demographic and Health 
Survey or Multiple Indicator Cluster survey are provided. 
In the absence of confi dence intervals and detailed 
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methodological notes with which to interpret original 
country submissions, these values allow for some very 
simple data triangulation. However, in many instances 
the DHS or Multiple Indicator Cluster Survey was used 
as the source of country reporting, which should not be 
misinterpreted as a convergence of values from diff erent 
sources rather than a repetition of the same data.
MONITORING PROGRESS TOWARDS MILLENNIUM 
DEVELOPMENT GOAL 6
Progress towards Millennium Development Goal 
(MDG) 6, “to halt and begin to reverse the HIV epidemic”, 
is monitored using data contained in Country Progress 
Report submissions received from Member States of 
the United Nations. Th ese reports include data on 
25 standardized core indicators for use in monitoring 
progress towards the Declaration of Commitment made in 
the 2001 United Nations General Assembly Special Session 
on HIV/AIDS (UNGASS).
Th is report describes and presents individual country 
data for the 25 UNGASS indicators. fi ve of which are also 
explicitly included in the core set of indicators used for 
monitoring progress towards MDG 6 and are available in 
the MDG database at www.mdgs.un.org. Data for these 
fi ve indicators are sourced from Country Progress Reports 
and provided to the United Nations Statistics Division 
by UNAIDS, UNICEF and WHO. Table A2.3 shows the 
response rates for these indicators over the four rounds of 
UNGASS reporting.
Table A2.3 
Response rates for the indicators for monitoring 
progress towards Millennium Development Goal 6: 
to halt and begin to reverse the HIV epidemic
2004 2006 2008 2010
ANTIRETROVIRAL 
THERAPY
Number of 
responding 
countries
113 118 117 154
Response rate 60% 61% 61% 80%
ORPHANS’ 
SCHOOL 
ATTENDANCE
Number of 
responding 
countries
N/A N/A 50 46
Response rate N/A N/A 26% 24%
YOUNG 
PEOPLES’ 
KNOWLEDGE
Number of 
responding 
countries
38 16 110 119
Response rate 20% 8% 57% 62%
CONDOM USE Number of 
responding 
countries
34 20 91 106
Response rate 18% 10% 47% 55%
PREVALENCE Number of 
responding 
countries
N/A N/A 91 106
Response rate N/A N/A 47% 55%
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National commitment indicators
AIDS SPENDING 
As the national and international response to AIDS 
continues to scale up, it is increasingly important to 
accurately track in detail both where the funds originate 
and how they are spent at the national level. Th e data are 
used to measure national commitment and action, which 
is an important component of the UNGASS Declaration 
of Commitment on HIV/AIDS. When aggregated across 
multiple countries, the data help to evaluate the status of 
the response globally. In addition, the data help national-
level decision-makers monitor the scope and eff ectiveness 
of their programmes, and provide the basis for resource 
allocation and improved strategic planning processes.
Since diff erent countries can choose from among diff erent 
methodologies and tools to monitor the fl ow of AIDS 
funding (e.g. National AIDS Spending Assessments 
(NASA), AIDS sub-account of the National Health 
Accounts (NHA) and ad hoc Resource Flows Surveys), the 
National AIDS Spending Matrix includes a spreadsheet 
that allows fi nancial data from any of these three 
methodologies to be easily entered, reviewed and reported. 
While NASA provide information on expenditures on 
activities performed outside the health system, methods 
have been developed to allow comparison between NASA 
and NHA for AIDS health expenditures. Both tools can 
therefore track AIDS-health expenditures. A similar 
alignment process was undertaken for the UNFPA/
UNAIDS/Netherlands Interdisciplinary Demographic 
Institute Resource Flows Project. 
Defi nition
Domestic and international AIDS spending by categories 
and fi nancing sources 
Methodology
Th is indicator is measured using a National AIDS 
Spending Assessment, which documents actual 
expenditures classifi ed by eight AIDS spending categories 
and by three main sources of fi nancing, including public 
expenditure from its own sources (i.e. such government 
revenues as taxes) and from international sources. 
Spending categories 
1. Prevention.
2. Care and treatment. 
3. Orphans and vulnerable children.
4. Programme management and administration 
strengthening. 
5. Incentives for human resources. 
6. Social protection and social services (excluding orphans 
and vulnerable children). 
7. Enabling environment and community development.
8. Research (excluding operations research included under 
programme management).
Financing sources 
1. Domestic public. 
2. International. 
3. Domestic private (optional for UNGASS reporting).
Table A2.4
Response rates for AIDS spending
2004 2006 2008 2010
AIDS SPENDING Number of 
responding 
countries
N/A 95 106 137
Response rate N/A 50% 55% 71%
In 2010, 137 countries (71% of UN Member States) 
reported on domestic and international AIDS spending. 
Response rates for this indicator increased consistently 
over each round of reporting: 95 countries reported in 
2006, 106 in 2008 and 137 in 2010. Eastern Europe and 
Central Asia, Central and South America, South and 
South East Asia and sub-Saharan Africa are the regions 
with the highest response rate, with more than 80% of the 
countries on these regions reporting on HIV spending. 
Not all countries reported a complete spending matrix. 
Some countries reported only total spending (11%) hence 
spending fi gures were not disaggregated among the 
eight AIDS spending categories (Prevention, Treatment 
and care, OVC, etc.). Out of the 122 countries that did 
report on spending using the AIDS Spending Categories, 
112 countries reported spending on some or all of the sub 
categories of the eight AIDS Spending Categories such 
as: Antiretroviral therapy, Home-based care, Prevention 
of mother-to-child transmission or Blood safety among 
others. 
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GOVERNMENT HIV AND AIDS POLICIES—NATIONAL 
COMPOSITE POLICY INDEX 
Purpose 
To assess progress in the development and implementation 
of national-level HIV policies, strategies and laws. 
Th e NCPI is an extensive questionnaire with close to 
200 questions. It is the most comprehensive standardized 
questionnaire available to asses the following broad areas 
of policy, strategy and programme implementation for the 
HIV response:
Part A—completed by government respondents
1. Strategic plan
2. Political support 
3. Prevention
4. Treatment, care and support
5. Monitoring and evaluation
Part B—completed by civil society respondents
1. Human rights
2. Civil society involvement
3. Prevention
4. Care and support 
Although the NCPI is oft en referred to as an ‘indicator’ 
or index, it is not used in that sense. Th e NCPI provides a 
unique opportunity for the variety of stakeholders to take 
stock of progress made and to discuss what still needs to 
be done to support an eff ective and effi  cient HIV response. 
Many of the Country Progress reports received in 2010 
describe the role the NCPI has had in strengthening 
in-country collaboration and increasing shared ownership 
of the HIV response.
Th e NCPI is an integral part of the UNGASS set of 
indicators and has been so since the fi rst reporting round. 
Some of the questions have been the same since 2004 and 
the majority of the questions are similar in this reporting 
round to what they were in 2006 and 2008. Th is makes it 
possible to do trend analyses. 
Many of the standardized responses are complemented 
with open text boxes. Th ese text boxes facilitate a better 
understanding of the current country situation, provide 
examples of good practice for others to learn from and can 
pinpoint issues for further improvement. 
Out of the 182 countries that submitted UNGASS reports, 
171 countries (94%) also submitted the NCPI. Th is is an 
inspiring increase (in 2004 only 88 countries submitted 
NCPI reports). All countries except one submitted 
both part A and part B in this year’s round of reporting. 
Representatives from around 2000 organizations, the 
majority being civil society organizations, took part in the 
preparation of the reports.
Table A2.5
Response rates for the National Composite 
Policy Index
2004 2006 2008 2010
NATIONAL 
COMPOSITE 
POLICY INDEX
Number of 
responding 
countries
88 95 137 171
Response rate 47% 50% 71% 89%
Full NCPI reports including the answers from both the 
standardized responses and the text boxes are found next 
to the individual country reports on the UNAIDS web site. 
A small subset of the information available is presented in 
the following tables. Full access to NCPI data is available 
through www.AIDSInfoOnline.org.
Indicators for health sector interventions
BLOOD SAFETY
HIV is effi  ciently transmitted via transfusion of unsafe 
blood and blood products. Th e establishment of systems to 
ensure that all donated blood is screened for transfusion-
transmissible infections, including HIV (and also hepatitis 
B and C) is a core component of every national blood 
programme. Globally, however, there are signifi cant 
variations in the extent to which donated blood is 
screened, the screening strategies adopted and the overall 
quality and eff ectiveness of the blood screening process. 
As a result, in many countries the recipients of blood and 
blood products remain at unacceptable risk of acquiring 
life-threatening infections that could easily be prevented.
Purpose
To assess progress in ensuring a safe blood supply. Th e 
indicator applies to all countries and it is measured 
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annually using the WHO Global Database on Blood Safety 
protocol. 
Defi nition
Th e percentage of donated blood units screened for HIV in 
a quality-assured manner.
Numerator: number of donated blood units screened for 
HIV in blood centres/blood screening laboratories that 
have both: (1) followed documented standard operating 
procedures and (2) participated in an external quality 
assurance scheme.
Denominator: total number of blood units donated.
Table A2.6
Response rates for blood safety
2004 2006 2008 2010
BLOOD SAFETY Number of 
responding 
countries
N/A N/A 130 165
Response rate N/A N/A 68% 86%
ANTIRETROVIRAL THERAPY
Purpose
To assess the progress of countries in providing 
antiretroviral combination therapy to adults and children 
with advanced HIV infection. Th e indicator is applicable 
to all countries and data for the numerator is collected 
continuously (monthly or quarterly) with the denominator 
estimated.
Defi nition
Percentage of adults and children with advanced HIV 
infection receiving antiretroviral therapy.
Numerator: number of adults and children with advanced 
HIV infection who are currently receiving antiretroviral 
therapy in accordance with the nationally approved 
treatment protocol (or WHO/UNAIDS standards) at the 
end of the reporting period.
Denominator: estimated number of adults and children 
with advanced HIV infection.
All analyses of this indicator refl ect numerators which 
were reconciled between UNAIDS, WHO and UNICEF. 
To ensure comparability between countries, denominators 
estimated using the UNAIDS/WHO Reference group on 
Estimates, Modelling and Projections methodology were 
used for all analyses. Th e country-reported denominators 
are also presented in the data table.
Table A2.7
Response rates for HIV treatment
2004 2006 2008 2010
HIV TREATMENT Number of 
responding 
countries
113 118 117 154
Response rate 60% 61% 61% 80%
RETENTION ON ANTIRETROVIRAL THERAPY AFTER 
12 MONTHS 
Th e goals of any programme of antiretroviral therapy 
(ART) are to increase survival and quality of life among 
infected individuals. As ART is scaled up in countries 
around the world, it is also important to understand why 
and how many people drop out of treatment programmes. 
Th ese data can be used to demonstrate the eff ectiveness of 
those programmes and highlight obstacles to expanding 
and improving them.
Purpose 
To assess progress in retaining infected adults and children 
on ART.
Defi nition
Percentage of adults and children with HIV known to be 
on treatment 12 months aft er initiation of antiretroviral 
therapy.
Numerator: number of adults and children who are on 
ART at 12 months aft er initiating treatment.
Denominator: total number of adults and children who 
initiated ART who were expected to achieve 12-month 
outcomes within the reporting period, including those 
who have died since starting ART, those who have stopped 
ART and those recorded as lost to follow-up at month 12. 
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Th is indicator refl ects retention rates on ART, rather than 
survival rates. To determine survival rates individuals who 
stopped ART or were lost to follow-up would need to be 
excluded. In cases where it is known that a reported data 
value is not consistent with this defi nition, this has been 
footnoted in the data tables. 
Table A2.8
Response rates for survival (retention) on 
antiretroviral therapy 
2004 2006 2008 2010
SURVIVAL ON 
ANTIRETROVIRAL 
THERAPY 
Number of 
responding 
countries
N/A 11 106 143
Response rate N/A 6% 55% 74%
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION
In the absence of any preventive interventions, infants 
born to and breastfed by HIV-infected women have 
roughly a one-in-three chance of acquiring infection 
themselves. Th is can happen during pregnancy, 
during labour and delivery or aft er delivery through 
breastfeeding. Comprehensive programmes to reduce 
the number of children who become infected with HIV 
utilize four strategies, known as the “four prongs” for the 
prevention of mother-to-child transmission. Th ese are: 
primary prevention of HIV for women of child bearing 
age; prevention of unwanted pregnancies for women 
living with HIV; antiretroviral prophylaxis for the mother; 
and antiretroviral prophylaxis for the child. Th e risk of 
mother-to-child transmission can be further reduced 
through the implementation of safe delivery practices 
and safe breastfeeding. Th is indicator measures one of the 
four prongs—the provision of prophylactic antiretroviral 
therapy to the mother.
Purpose 
To assess progress in preventing vertical transmission of 
HIV.
Defi nition
Percentage of HIV-infected pregnant women who received 
antiretrovirals to reduce the risk of mother-to-child 
transmission.
Numerator: number of HIV-infected pregnant women 
who received antiretrovirals during the last 12 months to 
reduce mother-to-child transmission.
Denominator: estimated number of HIV-infected pregnant 
women in the last 12 months.
All analyses of this indicator refl ect numerators which 
were reconciled between UNAIDS, WHO and UNICEF. 
To ensure comparability between countries, denominators 
estimated using the UNAIDS/WHO Reference group on 
Estimates, Modelling and Projections methodology were 
used for all analyses. Th e country-reported denominators 
are also presented in the data table.
For data representing 2007, some countries did not report 
data refl ecting 12 months and in these instances the data 
were projected in order to refl ect a consistent time period.4
Table A2.9
Response rates for prevention of mother to child 
transmission
2004 2006 2008 2010
PREVENTION 
OF MOTHER 
TO CHILD 
TRANSMISSION
Number of 
responding 
countries
52 45 100 135
Response rate 28% 24% 52% 70%
Th e data tables include additional data on the prevention 
of mother-to-child transmission provided by the World 
Health Organization. Th ese data were gathered through 
the joint WHO/UNICEF/UNAIDS monitoring of progress 
towards Universal Access in the Health Sector.
CO-MANAGEMENT OF TUBERCULOSIS AND HIV
Tuberculosis (TB) is one of the most common causes 
of morbidity and mortality in people living with HIV, 
including those on antiretroviral therapy. Intensifi ed TB 
case-fi nding and access to quality diagnosis and treatment 
of TB in accordance with international/national guidelines 
are essential for improving the quality and quantity of life 
for people living with HIV. 
4 Method for projection – all values reported that represent less than 12 month period are projected taking the number of HIV positive pregnant women 
on antiretrovirals per month and dividing by the number of months the data represents and multiplying by 12 months.
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Purpose 
To assess progress in detecting and treating TB in people 
living with HIV.
Defi nition
Percentage of estimated HIV-positive incident TB cases 
that received treatment for TB and HIV.
Numerator: number of adults with advanced HIV 
infection who are currently receiving antiretroviral 
combination therapy in accordance with the nationally 
approved treatment protocol (or WHO/UNAIDS 
standards) and who were started on TB treatment (in 
accordance with national TB programme guidelines) 
within the reporting year.
Denominator: estimated number of incident TB cases in 
people living with HIV.
Table A2.10
Response rates for co-management of 
tuberculosis and HIV 
2004 2006 2008 2010
CO-MANAGE-
MENT OF 
TUBERCULOSIS 
AND HIV
Number of 
responding 
countries
N/A N/A 88 119
Response rate N/A N/A 46% 62%
General population indicators
SUPPORT FOR CHILDREN AFFECTED BY HIV AND 
AIDS
Care and support for orphaned children comes from 
families and communities. As the number of orphaned and 
vulnerable children continues to grow, those supporting 
families and communities themselves require support.
Purpose 
To assess progress in providing support to households 
that are caring for orphaned and vulnerable children 
aged 0–17.
Defi nition
Percentage of orphaned and vulnerable children aged 0–17 
whose households received free basic external support in 
caring for the child.
Numerator: number of orphaned and vulnerable children 
who live in households that received at least one of four 
types of support for each child.
Denominator: total number of orphaned and vulnerable 
children aged 0–17.
For the purposes of this indicator an orphan is defi ned as a 
child below the age of 18 who has lost one or both parents. 
A child made vulnerable by HIV is below the age of 18, 
and:
(i), has lost one or both parents; or
(ii), has a chronically ill parent (regardless of whether the 
parent lives in the same household as the child); or
(iii), lives in a household where, in the last 12 months, at 
least one adult died and was sick for three of the four 
months before he or she died; or
(iv), lives in a household where at least one adult was 
seriously ill for at least three of the past 12 months. 
A number of countries chose to report on this indicator 
using data obtained through HIV testing programmes. 
Th ese data are not comparable to data obtained through 
general population-based surveys.
Table A2.11
Response rates for support for children affected 
by HIV and AIDS 
2004 2006 2008 2010
SUPPORT FOR 
CHILDREN 
AFFECTED BY 
HIV AND AIDS
Number of 
responding 
countries
N/A 8 36 42
Response rate N/A 4% 19% 22%
ORPHANS SCHOOL ATTENDANCE
AIDS claims young adults just at the time in their lives 
when they are forming families and bringing up children. 
As a result, orphan prevalence is rising steadily in many 
countries, while fewer relatives within the prime adult 
ages mean that orphaned children face an increasingly 
uncertain future. Orphanhood is frequently accompanied 
by prejudice and increased poverty, factors that can 
further jeopardize children’s chances of completing 
school education and may lead to the adoption of 
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survival strategies that increase vulnerability to HIV. It is 
important therefore to monitor the extent to which AIDS 
support programmes succeed in securing the educational 
opportunities of orphaned children.
Purpose 
To assess progress towards preventing relative 
disadvantage in school attendance among orphans 
compared to non-orphans.
Defi nition
Current school attendance among orphans and 
non-orphans aged 10–14.
Part A: Current school attendance of orphans aged 10–14
 Numerator: number of children who have lost 
both parents and who attend school.
 Denominator: number of children who have lost 
both parents.
Part B:  Current school attendance of children aged 10–14 
both of whose parents are alive and who live with 
at least one parent.
 Numerator: number of children whose two parents 
are alive who are living with at least one parent and 
who attend school.
 Denominator: number of children whose two 
parents are alive who are living with at least one 
parent.
Table A2.12
Response rates for orphans’ school attendance
2004 2006 2008 2010
ORPHANS’ 
SCHOOL 
ATTENDANCE
Number of 
responding 
countries
N/A N/A 50 46
Response rate N/A N/A 26% 24%
LIFE SKILLS-BASED HIV EDUCATION IN SCHOOLS
Life skills-based education uses participatory exercises 
to teach behaviours to young people that help them deal 
with the challenges and demands of everyday life. Such 
education can include decision-making and problem-
solving skills, creative and critical thinking, self-awareness, 
communication and interpersonal relations. It can also 
teach young people how to cope with their emotions 
and causes of stress. When adapted specifi cally for HIV 
education in schools, a life skills-based approach helps 
young people understand and assess the individual, social 
and environmental factors that raise and lower the risk of 
HIV transmission. When properly implemented, it can 
have a positive eff ect on behaviours, including delay in 
sexual debut and reduction in number of sexual partners.
Purpose 
To assess progress towards implementation of life skills-
based HIV education in all schools.
Defi nition 
Percentage of schools that provided life skills-based HIV 
education in the last academic year.
Numerator: number of schools that provided life skills-
based HIV education in the last academic year. 
Denominator: number of schools surveyed. 
Table A2.13
Response rates for life skills-based HIV 
education in schools 
2004 2006 2008 2010
LIFE SKILLS-
BASED HIV 
EDUCATION IN 
SCHOOLS
Number of 
responding 
countries
N/A N/A 74 99
Response rate N/A N/A 39% 52%
YOUNG PEOPLE’S KNOWLEDGE ABOUT HIV 
PREVENTION
HIV epidemics are sustained primarily through sexual 
transmission of infection to successive generations of 
young people. Sound knowledge about HIV and AIDS 
is an essential prerequisite—albeit insuffi  cient in itself—
for adoption of behaviours that reduce the risk of HIV 
transmission.
Purpose 
To assess progress towards comprehensive knowledge of 
the essential facts about HIV transmission.
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Defi nition
Percentage of young people aged 15–24 who both correctly 
identify ways of preventing the sexual transmission of HIV 
and reject major misconceptions about HIV transmission.
Numerator: number of respondents aged 15–24 years 
who gave the correct answer to all fi ve of the following 
questions: 
1. Can the risk of HIV transmission be reduced by having 
sex with only one uninfected partner who has no other 
partners?
2. Can a person reduce the risk of getting HIV by using a 
condom every time they have sex?
3. Can a healthy-looking person have HIV? 
4. Can a person get HIV from mosquito bites?
5. Can a person get HIV by sharing food with someone 
who is infected? 
Denominator: number of all respondents aged 15–24.
Table A2.14
Response rates for young peoples’ knowledge
2004 2006 2008 2010
YOUNG 
PEOPLES’ 
KNOWLEDGE
Number of 
responding 
countries
38 16 110 119
Response rate 20% 8% 57% 62%
HIV TESTING IN THE GENERAL POPULATION
HI V testing and counselling is a critical element in the 
HIV response, as it facilitates HIV treatment and care 
and other prevention. In addition, testing increases the 
awareness of people living with HIV of their own status 
and encourages them to take protective measures. Finally, 
HIV testing increases social awareness of HIV and 
can reduce stigma and discrimination towards people 
living with HIV. Trends in the uptake of HIV testing 
and counselling can be assessed based on the results of 
successive surveys conducted in the same country over 
time. It should be noted that while this indicator measures 
the proportion of the general population who have been 
tested in a 12 month period, this should not be taken 
to imply that all people should be tested annually. Th e 
frequency with which people should be tested should be 
determined based on their individual behaviour patterns 
and the nature of the HIV epidemic in their country.
Purpose 
To assess progress in implementing HIV testing and 
counselling.
Defi nition
Percentage of women and men aged 15–49 who received an 
HIV test in the last 12 months and who know their results.
Numerator: number of respondents aged 15–49 who have 
been tested for HIV during the last 12 months and who 
know their results.
Denominator: number of all respondents aged 15–49.
A number of countries chose to report on this indicator 
using data obtained through HIV testing programmes. 
Th ese data are not comparable to data obtained through 
general population-based surveys and are footnoted in the 
data table.
Table A2.15
Response rates for HIV testing in the general 
population 
2004 2006 2008 2010
HIV TESTING IN 
THE GENERAL 
POPULATION
Number of 
responding 
countries
N/A N/A 102 116
Response rate N/A N/A 53% 60%
SEX BEFORE THE AGE OF 15 
A HIV prevention strategy adopted by many countries is 
to delay the age at which young people fi rst have sex and 
discourage premarital sexual activity because it reduces 
their potential exposure to HIV. Th ere is also evidence 
to suggest that fi rst having sex at a later age reduces 
susceptibility to infection per act of sex, at least for women.
Purpose 
To assess progress in increasing the age at which young 
women and men aged 15–24 fi rst have sex.
Defi nition
Percentage of young women and men aged 15–24 who 
have had sexual intercourse before the age of 15.
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Numerator: number of respondents aged 15–24 who 
report the age at which they fi rst had sexual intercourse as 
under 15 years. 
Denominator: number of all respondents aged 15–24. 
Table A2.16
Response rates for sex before the age of 15
2004 2006 2008 2010
SEX BEFORE THE 
AGE OF 15
Number of 
responding 
countries
N/A 23 108 117
Response rate N/A 12% 56% 61%
HIGHER-RISK SEX 
Th e spread of HIV is, for the most part, a function of 
unprotected sex. Individuals who have multiple partners 
(concurrently or sequentially) have a higher risk of HIV 
transmission than individuals that do not link into a wider 
sexual network. 
Purpose 
To assess progress in reducing the percentage of people 
who have higher-risk sex.
Defi nition
Percentage of women and men aged 15–49 who have had 
sexual intercourse with more than one partner in the last 
12 months.
Numerator: number of respondents aged 15–49 who have 
had sexual intercourse with more than one partner in the 
last 12 months .
Denominator: number of all respondents aged 15–49. 
Table A2.17
Response rates for higher-risk sex 
2004 2006 2008 2010
HIGHER-RISK SEX Number of 
responding 
countries
12 19 97 108
Response rate 6% 10% 51% 56%
CONDOM USE DURING HIGHER-RISK SEX
Condom use is eff ective in protecting against HIV and 
other infections transmitted through sexual intercourse. 
Condom use rates are an important measure of protection 
against HIV, especially among people with multiple sexual 
partners.
Purpose 
To assess progress towards preventing exposure to HIV 
through unprotected sex with non-regular partners.
Defi nition
Percentage of women and men aged 15–49 who had 
more than one partner in the past 12 months who used a 
condom during their last sexual intercourse.
Numerator: number of respondents aged 15–49 who 
reported having had more than one sexual partner in the 
last 12 months who also reported that a condom was used 
the last time they had sex. 
Denominator: number of respondents aged 15–49 who 
reported having had more than one sexual partner in the 
last 12 months. 
Table A2.18
Response rates for condom use during higher-
risk sex 
2004 2006 2008 2010
CONDOM USE 
DURING HIGHER-
RISK SEX
Number of 
responding 
countries
34 20 91 106
Response rate 18% 10% 47% 55%
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Indicators for key populations at higher risk 
of HIV 
KNOWLEDGE ABOUT HIV PREVENTION AMONG KEY 
POPULATIONS AT RISK
Concentrated epidemics are sustained by sexual 
transmission of HIV in paid sex and between men who 
have sex with men or transmission through the use of 
contaminated injecting equipment. Accurate information 
about HIV and AIDS is an essential prerequisite if people 
are going to adopt behaviours that reduce their risk of 
infection. Th is indicator should be calculated separately for 
each population that is considered to be at higher risk of 
HIV: sex workers, injecting drug users and men who have 
sex with men.
Purpose 
To assess progress in building knowledge of the essential 
facts about HIV transmission among key populations at 
risk.
Defi nition
Percentage of key populations at risk who both correctly 
identify ways of preventing the sexual transmission of HIV 
and reject major misconceptions about HIV transmission.
Numerator: number of respondents from populations at 
higher risk of HIV who gave the correct answer to all fi ve 
of the following questions.
1. Can the risk of HIV transmission be reduced by having 
sex with only one uninfected partner who has no other 
partners?
2. Can a person reduce the risk of getting HIV by using a 
condom every time they have sex?
3. Can a healthy-looking person have HIV? 
4. Can a person get HIV from mosquito bites?
5. Can a person get HIV by sharing food with someone 
who is infected? 
Denominator: number of respondents from populations 
at higher risk of HIV who gave answers, including “don’t 
know”, to all fi ve questions.
Table A2.19
Response rates for knowledge of key 
populations at risk 
2004 2006 2008 2010
SEX WORKERS Number of 
responding 
countries
N/A 21 67 84
Response rate N/A 11% 35% 44%
MEN WHO HAVE 
SEX WITH MEN
Number of 
responding 
countries
N/A 16 47 54
Response rate N/A 8% 24% 28%
INJECTING DRUG 
USERS
Number of 
responding 
countries
N/A 16 33 43
Response rate N/A 8% 17% 22%
HIV TESTING IN KEY POPULATIONS AT HIGHER RISK 
OF HIV
HIV testing and counselling is a critical element in the 
HIV response, as it facilitates HIV treatment and care 
and prevention activities. In addition, testing increases 
the awareness of people living with HIV of their own 
status and encourages them to take protective measures. 
Finally, HIV testing increases social awareness of HIV 
and can reduce stigma and discrimination towards people 
living with HIV. Trends in the uptake of HIV testing 
and counselling can be assessed based on the results 
of successive surveys conducted in the same country 
over time. Th e frequency with which people should be 
tested should be determined based on their individual 
behaviour patterns and the nature of the HIV epidemic 
in their country. In some epidemiological contexts it may 
be appropriate for members of key populations at higher 
risk of HIV to be tested annually. It should be noted that 
HIV testing should be voluntary and confi dential, and 
that due care should be taken to protect the rights of 
those tested. Th is is particularly important in contexts 
where the behaviours of key populations at risk of HIV 
are illegal or heavily stigmatized and where any breeches 
of confi dentiality can have serious legal and social 
ramifi cations.
Purpose 
To assess progress in implementing HIV testing and 
counselling among key populations at risk.
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Defi nition
Percentage of respondents from key populations at risk 
who received an HIV test in the last 12 months and who 
know their results.
Numerator: number of respondents from key populations 
at risk who have been tested for HIV during the last 
12 months and who know the results.
Denominator: number of respondents from key 
populations at risk included in the sample.
Table A2.20
Response rates for HIV testing in key 
populations at risk
2004 2006 2008 2010
SEX WORKERS Number of 
responding 
countries
N/A 21 87 96
Response rate N/A 11% 45% 50%
MEN WHO HAVE 
SEX WITH MEN
Number of 
responding 
countries
N/A 22 70 83
Response rate N/A 12% 36% 43%
INJECTING DRUG 
USERS
Number of 
responding 
countries
N/A 18 44 59
Response rate N/A 9% 23% 31%
PREVENTION PROGRAMME COVERAGE FOR KEY 
POPULATIONS AT HIGHER RISK OF HIV
Key populations at risk are oft en diffi  cult to reach with 
HIV prevention programmes. However, in order to 
prevent the spread of HIV among these populations as well 
as into the general population, it is important that they 
access these services. Th is indicator should be calculated 
separately for each population that is considered to be at 
higher risk of HIV: sex workers, injecting drug users and 
men who have sex with men.
Purpose
To assess progress in implementing HIV prevention 
programmes for key populations at risk.
Defi nition
Percentage of key populations at risk reached with HIV 
prevention programmes.
Numerator: number of respondents from key populations 
at risk who replied “yes” to both (all three for injecting 
drug users) of the following questions:
Do you know where you can go if you wish to receive an 
HIV test?
In the last twelve months, have you been given condoms?
(for injecting drug users) In the last twelve months, have 
you been given sterile needles and syringes?
Denominator: total number of respondents from key 
populations at risk surveyed.
Table A2.21
Response rates for HIV prevention programmes 
for key populations at risk
2004 2006 2008 2010
SEX WORKERS Number of 
responding 
countries
N/A 27 63 74
Response rate N/A 14% 33% 39%
MEN WHO HAVE 
SEX WITH MEN
Number of 
responding 
countries
N/A 18 43 53
Response rate N/A 9% 22% 28%
INJECTING DRUG 
USERS
Number of 
responding 
countries
N/A 22 30 39
Response rate N/A 12% 16% 20%
CONDOM USE BY SEX WORKERS
Various factors increase the risk of exposure to HIV 
among sex workers, including multiple, non-regular 
partners and more frequent sexual intercourse. However, 
sex workers can substantially reduce the risk of HIV 
transmission, both from clients and to clients, as well as to 
regular partners, through consistent and correct condom 
use. 
Purpose 
To assess progress in preventing exposure to HIV among 
sex workers through unprotected sex with clients.
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Defi nition
Percentage of female and male sex workers reporting the 
use of a condom with their most recent client.
Numerator: number of respondents who reported that 
a condom was used with their last client in the last 
12 months. 
Denominator: number of respondents who reported 
having commercial sex in the last 12 months. 
Table A2.22
Response rates for condom use by sex workers
2004 2006 2008 2010
CONDOM USE BY 
SEX WORKERS
Number of 
responding 
countries
N/A 32 91 101
Response rate N/A 17% 47% 53%
CONDOM USE BY MEN WHO HAVE SEX WITH MEN
Condoms can substantially reduce the risk of sexual 
transmission of HIV. Consequently, consistent and 
correct condom use is important for men who have sex 
with men because of the high risk of HIV transmission 
during unprotected anal sex. In addition, men who have 
anal sex with men may also have female partners. Hence 
condom use during male-to-male sex may be an important 
determinant of spousal transmission. 
Purpose 
To assess progress in preventing exposure to HIV among 
men who have unprotected anal sex with a male partner.
Defi nition
Percentage of men reporting the use of a condom the last 
time they had anal sex with a male partner.
Numerator: number of respondents who reported that a 
condom was used the last time they had anal sex. 
Denominator: number of respondents who reported 
having had anal sex with a male partner in the last six 
months.
Table A2.23
Response rates for condom use by men who 
have sex with men
2004 2006 2008 2010
CONDOM USE BY 
MEN WHO HAVE 
SEX WITH MEN
Number of 
responding 
countries
N/A 29 68 82
Response rate N/A 15% 35% 43%
CONDOM USE BY INJECTING DRUG USERS
Safer sexual practices among injecting drug users are 
essential, even in countries where other modes of 
HIV transmission predominate. Th e high risk of HIV 
transmission from contaminated injecting equipment 
places the sexual partners of injecting drug users at 
higher risk of HIV. Condom use by injecting drug users 
is therefore an important aspect of the prevention of HIV 
sexual transmission.
Purpose 
To assess progress in preventing sexual transmission of 
HIV.
Defi nition
Percentage of injecting drug users reporting the use of a 
condom the last time they had sexual intercourse.
Numerator: number of respondents who reported that a 
condom was used the last time they had sex.
Denominator: number of respondents who report having 
had sexual intercourse in the last month.
Table A2.24
Response rates for condom use by injecting 
drug users
2004 2006 2008 2010
CONDOM USE 
BY INJECTING 
DRUG USERS
Number of 
responding 
countries
N/A N/A 43 51
Response rate N/A N/A 22% 27%
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SAFE INJECTING PRACTICES BY INJECTING 
DRUG USERS
Safer injecting practices among injecting drug users are 
essential, even in countries where other modes of HIV 
transmission predominate, due to the high risk of HIV 
transmission from contaminated injecting equipment. 
Harm-reduction programmes aim to prevent HIV 
transmission among injecting drug users through a 
range of services which seek to reduce illicit drug use, 
reduce injecting frequency and reduce the re-use of used 
injecting equipment. While this indicator is designed to 
measure the behavioural outcome of services aimed at 
reducing the use of contaminated injecting equipment, any 
behaviour changes that are observed may not necessarily 
be attributable to such services.
Purpose 
To assess progress in preventing injecting drug 
use-associated HIV transmission.
Defi nition
Percentage of injecting drug users reporting the use of 
sterile injecting equipment the last time they injected. 
Numerator: number of respondents who report using 
sterile injecting equipment the last time they injected 
drugs.
Denominator: number of respondents who report 
injecting drugs in the last month. 
Table A2.25
Response rates for safe injecting practices 
2004 2006 2008 2010
SAFE INJECTING 
PRACTICES
Number of 
responding 
countries
N/A N/A 44 55
Response rate N/A N/A 23% 29%
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Total reported 
domestic 
public and 
international 
expenditure 
million USD
Public InternationalSurvey 
Year
Domestic 
public (%)
Bilaterals (%) Global Fund 
(%)
UN (%) All other 
multilaterals 
(%)
All other 
international 
sources (%)
SHARE BY FINANCING SOURCECOUNTRY REPORTS OF 
DOMESTIC AND 
INTERNATIONAL AIDS 
SPENDING BY SERVICE 
CATEGORIES AND 
FINANCING SOURCES
Caribbean          
 Antigua and Barbuda1 2008 0.329 78.9% 0.0% 21.1% 0.0% 0.0% 0.0% 
 Antigua and Barbuda1 2009 0.391 66.3% 0.0% 33.7% 0.0% 0.0% 0.0% 
 Bahamas 2008 4.442 89.7% 2.8% 0.0% 3.4% 0.0% 4.0% 
 Bahamas 2009 4.889 90.0% 0.0% 0.0% 3.8% 0.0% 6.2% 
 Barbados 2009 11.903 67.3% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Cuba 2007 44.509 80.3% 0.0% 19.7% 0.0% 0.0% 0.0% 
 Cuba 2008 46.616 79.7% 0.0% 20.3% 0.0% 0.0% 0.0% 
 Cuba 2009 76.893 81.5% 0.0% 18.0% 0.0% 0.0% 0.5% 
 Dominica5 2008 0.178 17.3% 42.2% 31.7% 8.5% 0.0% 0.3% 
 Dominica5 2009 0.178 17.3% 42.2% 31.7% 8.5% 0.0% 0.3% 
 Dominican Republic8 2008 23.416 34.8% 6.8% 53.9% 2.9% 0.2% 1.3% 
 Grenada 2008 0.484 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Grenada 2009 0.194 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Saint Kitts and Nevis 2007 1.343 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Saint Kitts and Nevis 2008 1.487 92.3% 0.0% 7.7% 0.0% 0.0% 0.0% 
 Saint Kitts and Nevis 2009 1.210 89.4% 0.0% 10.6% 0.0% 0.0% 0.0% 
 Saint Vincent and 
 the Grenadines 2008 1.625 11.4% 0.0% 3.3% 0.0% 85.3% 0.0% 
 Saint Vincent and 
 the Grenadines 2009 2.629 8.4% 0.0% 5.3% 1.1% 85.1% 0.0% 
 Trinidad and Tobago 2007 9.716 96.8% 0.0% 0.0% 0.0% 1.6% 1.6% 
 Trinidad and Tobago 2008 15.033 90.6% 0.0% 0.2% 3.8% 0.0% 5.3% 
 Trinidad and Tobago 2009 13.533 84.4% 0.0% 0.0% 5.2% 10.3% 0.1% 
Central and South America        
 Argentina 2007 209.455 97.4% 0.0% 2.4% 0.3% 0.0% 0.0% 
 Argentina 2008 248.773 97.4% 0.0% 2.3% 0.2% 0.0% 0.0% 
 Belize 2009 2.024 32.2% 0.0% 10.2% 8.6% 42.9% 6.1% 
 Bolivia 2008 5.394 17.5% 8.2% 46.8% 14.8% 1.2% 11.5% 
 Bolivia 2009 7.418 12.6% 4.9% 58.6% 14.0% 0.0% 9.9% 
 Brazil2 2007 575.139 99.5% 0.1% 0.0% 0.4% 0.0% 0.0% 
 Brazil2 2008 623.134 99.0% 0.1% 0.0% 0.5% 0.0% 0.4% 
 Chile4 2008 88.012 99.0% 0.1% 0.8% 0.1% 0.0% 0.0% 
 Colombia 2007 69.262 99.1% 0.0% 0.0% 0.9% 0.0% 0.0% 
 Colombia 2008 103.557 99.5% 0.0% 0.0% 0.5% 0.0% 0.0% 
 Colombia 2009 108.792 99.5% 0.0% 0.0% 0.5% 0.0% 0.0% 
 Costa Rica 2008 19.885 93.1% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Ecuador 2008 25.972 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Ecuador 2009 31.900 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 El Salvador 2007 38.261 90.8% 1.3% 4.5% 0.3% 2.2% 0.9% 
 El Salvador 2008 39.227 79.7% 4.7% 7.1% 1.9% 0.0% 6.5% 
 Guatemala 2007 43.648 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Guatemala 2008 51.350 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Honduras 2007 18.420 43.2% 13.6% 28.4% 6.7% 0.2% 7.8% 
 Honduras 2008 24.320 38.3% 14.3% 36.1% 4.7% 0.0% 6.6% 
 Nicaragua 2007 12.665 45.4% 54.6% 0.0% 0.0% 0.0% 0.0% 
 Nicaragua 2008 14.909 42.3% 57.7% 0.0% 0.0% 0.0% 0.0% 
 Panama 2008 13.628 86.6% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Paraguay 2008 9.298 65.3% 14.9% 12.4% 5.8% 0.4% 1.2% UNGASS Indicator 1
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Orphans and 
vulnerable 
children 
Other HIV 
expenditures 
Prevention Care and Treatment Programme Support 
Monitoring 
and 
evaluation
Planning, 
coordination 
and 
programme 
management
Total for 
programme 
management 
and admin-
istration 
strengthen-
ing
Total for 
prevention
Male and 
female 
condom social 
marketing and 
public and 
commercial 
sector 
provision
Communica-
tion for social 
and behav-
ioral change
Prevention 
of mother 
to child 
transmission 
Voluntary 
counseling 
and testing 
Total for care 
and treatment 
Programmes 
for sex workers 
and their 
clients for 
MSM and for 
harm reduction 
for IDUs 
Antiretroviral 
therapy 
TOTAL HIV EXPENDITURES ON SELECTED SERVICES (MILLION CURRENT USD DOLLARS)
           
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
0.708 0.007 0.241 NA/NR 0.035 0.182 3.492 0.693 NA/NR 0.033 NA/NR NA/NR 0.208
0.399 NA/NR 0.245 NA/NR NA/NR 0.102 3.093 0.292 NA/NR 1.114 NA/NR NA/NR 0.281
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
8.967 5.584 0.801 NA/NR 2.582 NA/NR 32.604 11.314 NA/NR 0.176 0.176 NA/NR 2.762
5.543 0.313 0.088 0.102 4.167 0.003 15.420 13.163 0.014 21.148 2.758 NA/NR 4.491
16.422 2.124 0.061 0.106 10.537 0.044 26.035 15.184 0.044 31.945 12.072 NA/NR 2.447
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
5.450 0.481 0.497 0.283 0.561 0.721 7.220 2.657 0.024 9.036 4.650 0.329 1.686
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
0.033 NA/NR NA/NR NA/NR NA/NR NA/NR 0.012 NA/NR NA/NR 1.290 0.015 0.019 0.008
0.035 0.017 0.007 NA/NR 0.003 NA/NR 0.184 0.090 NA/NR 1.228 0.050 NA/NR 0.040
0.106 0.013 0.012 NA/NR 0.013 NA/NR 0.065 0.028 NA/NR 1.010 0.025 NA/NR 0.029
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
4.535 2.329 0.033 0.350 0.001 0.194 3.481 2.535 NA/NR 1.310 0.111 NA/NR 0.390
6.864 3.335 0.132 0.211 NA/NR 0.340 5.016 3.350 NA/NR 2.870 0.455 0.004 0.283
5.739 3.290 0.005 0.051 NA/NR 0.471 6.538 4.221 0.048 0.774 0.618 NA/NR 0.434
            
28.705 3.065 NA/NR 0.017 2.867 5.826 156.449 46.787 0.269 10.302 8.418 0.044 13.730
35.216 4.665 NA/NR 0.010 2.813 5.795 186.732 50.532 0.353 5.823 3.667 0.016 20.649
0.541 0.246 0.011 NA/NR 0.031 0.035 0.402 0.198 0.043 0.800 0.618 0.080 0.238
2.178 0.193 NA/NR 0.004 0.096 0.369 1.384 0.164 0.010 0.566 0.158 0.174 1.256
2.775 0.727 NA/NR 0.072 NA/NR 0.126 2.303 0.404 0.008 0.753 0.187 0.170 1.580
82.027 15.222 8.896 0.022 37.915 3.694 438.853 362.674 0.036 19.692 6.561 2.274 34.531
41.759 16.241 7.967 0.100 0.092 3.799 522.611 427.759 NA/NR 23.447 6.063 2.324 35.316
20.321 0.550 1.952 2.349 0.348 1.332 57.672 53.450 0.005 0.784 0.681 0.033 9.230
9.193 0.821 1.731 0.122 0.388 1.043 56.118 24.853 0.077 1.664 0.272 0.164 2.210
20.788 1.066 3.583 0.107 0.232 2.713 77.010 33.783 0.075 3.594 1.675 0.185 2.092
21.464 2.426 2.577 0.127 0.644 1.996 83.036 37.316 0.073 2.037 0.565 0.214 2.182
6.480 NA/NR NA/NR NA/NR NA/NR NA/NR 11.987 NA/NR NA/NR 0.576 NA/NR NA/NR 0.842
13.596 NA/NR NA/NR NA/NR NA/NR NA/NR 9.093 NA/NR 0.043 1.534 NA/NR NA/NR 1.706
16.195 NA/NR NA/NR NA/NR NA/NR NA/NR 12.250 NA/NR 0.052 1.643 NA/NR NA/NR 1.759
11.209 0.962 1.355 0.286 1.037 0.534 21.090 7.103 0.347 3.409 1.230 0.390 2.206
8.338 0.845 0.682 0.441 0.071 0.435 25.957 8.163 0.130 3.588 2.025 0.061 1.214
10.447 NA/NR NA/NR NA/NR NA/NR NA/NR 28.613 NA/NR 0.035 3.998 NA/NR NA/NR 0.555
14.000 NA/NR NA/NR NA/NR NA/NR NA/NR 30.927 NA/NR 0.039 5.835 NA/NR NA/NR 0.548
9.844 1.060 2.483 0.358 0.493 0.968 4.727 1.482 0.582 2.388 0.852 0.195 0.878
14.420 1.408 0.881 0.764 0.591 1.286 5.749 3.139 0.609 1.883 0.490 0.448 1.660
3.703 NA/NR NA/NR NA/NR NA/NR NA/NR 2.234 NA/NR NA/NR 1.519 NA/NR NA/NR 5.209
4.669 NA/NR NA/NR NA/NR NA/NR NA/NR 2.261 NA/NR 0.029 2.428 NA/NR NA/NR 5.522
0.922 NA/NR NA/NR NA/NR NA/NR NA/NR 11.302 NA/NR 0.093 0.658 NA/NR NA/NR 0.652
1.164 0.164 0.427 NA/NR 0.078 0.053 6.990 1.902 0.024 0.623 0.417 0.097 0.497
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 Paraguay 2009 11.418 67.6% 10.4% 14.5% 5.1% 2.1% 0.3% 
 Peru 2007 34.892 37.6% 7.2% 13.1% 4.1% 0.0% 37.9% 
 Peru 2008 41.056 45.3% 1.1% 36.8% 2.7% 0.0% 14.1% 
 Peru 2009 43.639 54.8% 0.0% 36.4% 1.1% 0.0% 7.8% 
 Uruguay 2007 7.534 90.9% 0.0% 0.0% 5.2% 3.8% 0.1% 
 Venezuela 2007 79.818 99.9% 0.0% 0.0% 0.1% 0.0% 0.0% 
 Venezuela 2008 71.723 99.8% 0.0% 0.0% 0.2% 0.0% 0.0% 
 Venezuela 2009 78.801 99.9% 0.0% 0.0% 0.1% 0.0% 0.0% 
East Asia          
 China 2008 323.834 72.9% 4.0% 13.6% 2.4% 0.0% 7.1% 
 China 2009 353.535 76.0% 3.1% 13.0% 2.0% 0.0% 5.8% 
 Japan 2009 73.197 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Mongolia 2008 5.044 31.2% 1.8% 46.1% 14.2% 2.8% 3.9% 
 Mongolia 2009 4.664 24.8% 4.8% 57.5% 4.2% 5.7% 2.9% 
Eastern Europe and Central Asia        
 Armenia 2008 2.605 21.4% 0.5% 56.9% 9.2% 0.0% 12.0% 
 Armenia 2009 2.301 27.5% 1.1% 51.6% 10.7% 0.0% 9.1% 
 Azerbaijan 2008 5.002 63.7% 2.1% 25.4% 5.9% 0.0% 2.9% 
 Azerbaijan 2009 6.062 68.4% 0.4% 19.1% 4.6% 0.0% 7.6% 
 Belarus 2008 18.616 72.7% 0.0% 19.3% 2.3% 2.1% 3.5% 
 Belarus 2009 16.660 68.1% 0.0% 24.8% 3.6% 0.0% 3.5% 
 Georgia 2008 8.043 15.8% 13.1% 58.1% 6.9% 0.0% 6.1% 
 Georgia 2009 8.387 26.6% 7.5% 59.4% 3.1% 0.0% 3.3% 
 Kazakstan 2009 22.778 71.4% 4.7% 22.7% 1.2% 0.0% 0.0% 
 Kyrgyzstan 2008 8.796 16.5% 5.5% 58.5% 3.0% 10.8% 5.7% 
 Kyrgyzstan 2009 9.987 18.1% 20.0% 45.3% 6.4% 6.5% 3.6% 
 Republic of Moldova 2008 12.871 38.6% 0.4% 23.2% 10.1% 27.7% 0.0% 
 Republic of Moldova 2009 11.482 48.3% 0.9% 32.8% 11.1% 6.9% 0.0% 
 Russian Federation11 2008 777.021 90.2% 0.1% 8.4% 1.3% 0.0% 0.0% 
 Tajikistan 2008 6.178 16.5% 0.0% 59.2% 7.2% 6.8% 10.3% 
 Tajikistan 2009 7.479 15.4% 0.0% 61.6% 4.5% 8.6% 9.9% 
 Ukraine 2007 77.575 60.3% 8.7% 23.6% 2.7% 3.6% 1.1% 
 Ukraine 2008 100.004 59.5% 8.7% 26.8% 1.7% 1.7% 1.6% 
 Uzbekistan 2009 15.940 51.7% 0.0% 40.6% 3.0% 4.7% 0.0% 
Middle East and North Africa        
 Algeria 2008 3.802 69.8% 0.4% 27.5% 2.4% 0.0% 0.0% 
 Algeria 2009 2.721 93.7% 4.2% 0.0% 2.0% 0.0% 0.0% 
 Djibouti 2007 3.691 0.0% 0.0% 7.1% 27.1% 65.8% 0.0% 
 Djibouti 2008 3.221 0.0% 0.0% 57.3% 11.8% 30.9% 0.0% 
 Djibouti 2009 2.007 0.0% 0.0% 30.5% 69.5% 0.0% 0.0% 
 Egypt 2007 5.737 59.7% 16.3% 0.0% 10.7% 0.6% 12.7% 
 Egypt 2008 7.538 50.3% 3.7% 17.8% 12.9% 1.2% 14.0% 
 Iran (Islamic 
 Republic of) 2008 36.011 87.6% 0.0% 8.7% 3.7% 0.0% 0.0% 
 Jordan 2009 3.099 40.2% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Kuwait 2007 4.219 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Kuwait 2008 4.696 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Kuwait 2009 4.578 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Lebanon 2007 4.400 72.7% 0.0% 0.0% 10.2% 0.0% 17.0% 
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1.342 0.187 0.171 0.031 0.091 0.147 8.698 1.899 0.021 0.940 0.667 0.106 0.416
7.393 1.012 NA/NR 2.196 0.033 1.044 10.689 4.841 0.171 1.562 0.727 0.359 15.075
14.135 0.860 NA/NR 2.493 0.022 4.355 16.864 10.541 1.120 1.992 1.130 0.756 6.944
13.550 0.410 NA/NR 4.870 0.000 3.521 22.307 18.359 0.679 2.230 1.181 0.794 4.873
1.607 0.163 0.299 0.014 0.152 0.064 4.823 4.187 NA/NR 0.076 0.021 NA/NR 1.028
3.471 0.138 NA/NR 0.159 0.437 0.960 75.245 73.636 NA/NR 0.172 NA/NR NA/NR 0.930
5.662 0.133 NA/NR 0.116 0.385 0.835 64.145 59.561 NA/NR 0.263 NA/NR NA/NR 1.653
6.013 0.095 NA/NR 0.309 NA/NR 0.697 69.644 65.588 NA/NR 0.325 NA/NR NA/NR 2.819
           
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
2.756 0.149 0.145 0.015 0.099 NA/NR 0.600 0.004 0.005 1.371 0.564 0.046 0.311
2.589 0.085 0.101 0.006 0.022 NA/NR 0.104 0.005 0.005 1.649 0.407 0.024 0.315
            
1.100 0.104 0.197 0.253 0.023 0.089 0.705 0.142 NA/NR 0.425 0.257 0.080 0.375
0.894 0.051 0.153 0.172 0.024 0.082 0.690 0.156 NA/NR 0.305 0.163 0.071 0.413
3.512 0.152 0.003 0.422 0.089 0.393 0.621 0.065 0.000 0.241 0.084 0.005 0.629
3.940 0.101 0.002 0.248 0.050 0.468 0.917 0.114 NA/NR 0.343 0.081 0.024 0.861
12.365 0.323 0.890 0.995 0.000 0.213 2.578 1.060 0.094 2.010 0.291 0.142 1.569
10.057 0.101 0.833 1.341 0.000 0.461 2.856 1.028 0.100 2.370 0.269 0.201 1.278
3.218 0.260 0.424 1.380 0.259 0.090 2.408 1.352 NA/NR 0.591 0.081 0.011 1.826
2.995 0.132 0.500 1.534 0.024 0.098 2.794 0.954 NA/NR 1.278 0.060 0.018 1.320
15.923 0.373 0.662 2.996 NA/NR 0.291 2.463 0.689 NA/NR 4.042 0.595 0.423 0.351
5.547 0.257 0.188 2.921 0.020 0.035 0.351 0.086 0.067 1.883 0.022 0.061 0.949
6.422 0.261 1.863 2.265 0.020 0.157 0.781 0.031 0.065 1.683 0.005 0.154 1.037
8.966 0.070 0.452 0.402 0.048 0.088 2.060 0.673 0.138 1.259 0.221 0.106 0.448
6.565 0.049 0.443 0.667 NA/NR 0.058 2.634 1.299 0.078 1.081 0.096 0.117 1.125
181.902 7.859 10.100 8.083 2.002 9.398 447.312 228.410 64.972 45.272 5.244 0.763 37.563
2.930 0.094 0.104 0.485 NA/NR 0.168 0.407 0.055 NA/NR 2.397 0.791 0.137 0.444
2.878 0.112 0.181 0.794 NA/NR 0.208 0.722 0.068 NA/NR 3.065 0.738 0.185 0.814
28.679 0.592 7.377 8.779 0.955 1.964 37.445 7.669 0.504 5.406 1.131 0.706 5.541
22.808 0.936 3.806 9.687 1.481 1.867 48.799 21.632 2.562 21.256 2.978 2.176 4.578
3.153 0.031 0.141 0.014 NA/NR 0.228 4.250 0.134 1.029 4.556 0.227 0.154 2.951
            
0.432 0.361 0.003 0.034 0.013 NA/NR 2.788 2.430 NA/NR 0.107 0.069 0.003 0.475
0.736 0.071 0.002 0.006 0.004 NA/NR 1.819 1.681 NA/NR 0.078 0.060 NA/NR 0.087
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
2.420 0.345 0.350 0.194 NA/NR 0.002 1.325 0.824 0.005 0.747 0.027 0.007 1.239
2.601 0.295 0.301 0.307 NA/NR 0.010 1.492 0.464 0.007 1.324 0.147 0.093 2.115
20.402 NA/NR NA/NR NA/NR NA/NR NA/NR 4.302 NA/NR NA/NR 4.639 NA/NR NA/NR 6.667
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 1.508 1.508 NA/NR 2.711 0.273 NA/NR 0.000
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 1.785 1.785 NA/NR 2.910 0.293 NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 1.860 1.860 NA/NR 2.718 0.276 NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
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 Lebanon 2008 7.300 43.8% 0.0% 0.0% 44.5% 0.0% 11.6% 
 Lebanon 2009 4.450 71.9% 0.0% 0.0% 5.6% 0.0% 22.5% 
 Morocco 2007 10.313 50.3% 5.8% 29.3% 7.8% 2.9% 3.9% 
 Morocco 2008 12.566 44.4% 3.7% 36.7% 7.9% 0.0% 7.3% 
 Oman 2009 0.812 76.5% 0.0% 0.0% 23.5% 0.0% 0.0% 
 Saudi Arabia 2009 19.389 99.7% 0.0% 0.0% 0.3% 0.0% 0.0% 
 Somalia5 2008 5.995 0.2% 0.0% 83.5% 13.0% 2.9% 0.4% 
 Somalia5 2009 5.982 0.0% 0.0% 83.7% 13.0% 2.9% 0.4% 
 Syrian Arab Republic 2007 1.638 91.5% 0.0% 0.0% 7.3% 0.0% 1.2% 
 Syrian Arab Republic 2008 1.986 88.1% 1.3% 0.0% 9.9% 0.0% 0.8% 
 Syrian Arab Republic 2009 1.977 91.1% 1.1% 0.0% 6.4% 0.0% 1.3% 
 United Arab Emirates 2009 17.584 99.8% 0.0% 0.0% 0.2% 0.0% 0.0% 
 Yemen 2009 4.956 2.5% 0.0% 83.5% 14.0% 0.0% 0.0% 
North America          
 Mexico 2008 266.037 99.4% 0.1% 0.0% 0.2% 0.0% 0.3% 
 Mexico 2009 218.421 99.4% 0.1% 0.0% 0.4% 0.0% 0.2% 
Oceania          
 Fiji 2007 1.849 20.1% 49.6% 0.1% 25.9% 1.0% 3.3% 
 Fiji 2008 2.506 15.9% 44.1% 3.6% 24.6% 11.4% 0.4% 
 Fiji 2009 2.100 11.8% 35.7% 15.9% 27.6% 8.0% 1.0% 
 Marshall Islands 2008 0.578 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Marshall Islands 2009 0.539 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Micronesia, 
 Federated States of 2008 0.355 0.0% 68.2% 8.1% 0.0% 12.5% 11.3% 
 Micronesia, 
 Federated States of 2009 0.540 0.0% 45.9% 14.3% 0.0% 31.4% 8.3% 
 Nauru 2008 0.081 43.7% 0.0% 54.2% 2.1% 0.0% 0.0% 
 Nauru 2009 0.097 53.8% 0.0% 46.2% 0.0% 0.0% 0.0% 
 Palau 2007 0.057 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 
 Palau 2008 0.057 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 
 Palau 2009 0.067 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 
 Samoa 2009 0.792 78.1% 0.0% 21.9% 0.0% 0.0% 0.0% 
 Solomon Islands 2008 0.598 16.4% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Solomon Islands 2009 0.575 18.8% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Tonga 2008 0.210 0.0% 0.0% 47.2% 16.0% 36.8% 0.0% 
 Tonga 2009 0.279 26.5% 1.0% 42.2% 5.5% 24.8% 0.0% 
 Tuvalu 2008 0.054 11.8% 0.0% 88.2% 0.0% 0.0% 0.0% 
 Tuvalu 2009 0.038 16.6% 0.0% 83.4% 0.0% 0.0% 0.0% 
 Vanuatu 2008 1.092 6.6% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Vanuatu 2009 1.115 6.5% NA/NR NA/NR NA/NR NA/NR NA/NR 
South and South-East Asia         
 Afghanistan 2008 3.241 4.0% 7.8% 0.0% 5.8% 82.3% 0.0% 
 Afghanistan 2009 5.159 2.6% 5.5% 21.1% 8.4% 62.4% 0.0% 
 Bangladesh 2008 37.265 0.0% 13.1% 38.6% 43.0% 5.4% 0.0% 
 Bangladesh 2009 26.938 0.0% 17.4% 38.4% 36.9% 7.4% 0.0% 
 Cambodia 2007 53.259 11.4% 45.8% 31.1% 10.5% 0.0% 1.2% 
 Cambodia 2008 51.847 10.1% 39.9% 36.8% 9.1% 4.1% 0.0% 
 India6 2008 145.590 16.5% 19.1% 41.1% 0.7% 22.6% 0.0% 
 India6 2009 140.002 16.5% 19.1% 41.1% 0.7% 22.6% 0.0% 
 Indonesia 2007 58.671 26.3% 57.2% 6.2% 9.2% 1.1% 0.0% 
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NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
3.911 0.812 0.502 0.491 0.171 0.012 4.457 1.666 NA/NR 1.680 1.006 0.374 0.264
4.685 0.797 0.475 0.962 0.325 0.106 4.848 1.429 NA/NR 1.612 1.210 0.300 1.421
0.217 0.044 NA/NR NA/NR NA/NR 0.039 0.297 0.134 0.045 0.162 NA/NR NA/NR 0.091
5.968 NA/NR 5.146 NA/NR NA/NR NA/NR 10.094 9.209 NA/NR 3.264 NA/NR NA/NR 0.063
1.088 0.264 0.023 NA/NR 0.004 NA/NR 1.040 0.048 0.016 2.400 0.697 0.263 1.451
1.088 0.264 0.023 NA/NR 0.004 NA/NR 1.040 0.048 0.016 2.400 0.697 0.263 1.438
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 1.027 0.424 NA/NR 0.506 0.486 NA/NR 0.104
0.007 NA/NR 0.007 NA/NR NA/NR NA/NR 1.211 0.502 NA/NR 0.596 0.576 NA/NR 0.172
0.050 NA/NR 0.050 NA/NR NA/NR NA/NR 1.381 0.548 NA/NR 0.461 0.461 NA/NR 0.085
0.018 NA/NR NA/NR NA/NR NA/NR NA/NR 2.826 2.390 NA/NR 14.638 NA/NR NA/NR 0.102
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
           
50.606 6.496 3.569 1.765 0.440 13.897 200.711 156.923 0.014 8.617 4.178 0.121 6.089
48.242 3.252 3.751 1.680 0.507 15.805 163.405 122.275 0.012 5.537 3.738 0.124 1.226
           
0.800 0.382 0.051 0.019 0.002 0.044 0.091 NA/NR NA/NR 0.486 0.348 0.083 0.472
0.917 0.141 0.027 0.015 0.022 0.056 0.095 NA/NR NA/NR 0.713 0.569 0.025 0.782
0.635 0.264 0.002 0.017 0.050 0.001 0.079 NA/NR NA/NR 0.704 0.582 0.041 0.681
0.302 NA/NR NA/NR NA/NR NA/NR NA/NR 0.000 NA/NR NA/NR 0.275 NA/NR NA/NR 0.000
0.158 NA/NR NA/NR NA/NR NA/NR NA/NR 0.084 NA/NR NA/NR 0.289 NA/NR NA/NR 0.008
0.184 0.015 0.009 NA/NR 0.000 NA/NR 0.040 NA/NR NA/NR 0.033 0.016 0.012 0.098
0.170 0.004 0.012 NA/NR 0.005 NA/NR 0.041 NA/NR NA/NR 0.110 0.043 0.010 0.219
0.040 0.007 0.002 NA/NR 0.002 NA/NR NA/NR NA/NR NA/NR 0.041 0.032 NA/NR 0.000
0.030 0.006 0.001 NA/NR 0.001 NA/NR NA/NR NA/NR NA/NR 0.058 0.038 0.005 0.009
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 0.031 0.013 NA/NR 0.027
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 0.014 0.014 NA/NR 0.038 0.034 NA/NR 0.005
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 0.018 0.018 NA/NR 0.036 0.028 NA/NR 0.013
0.765 NA/NR NA/NR NA/NR NA/NR NA/NR 0.027 0.027 NA/NR NA/NR NA/NR NA/NR NA/NR
0.204 0.018 0.000 0.005 0.022 0.009 0.038 NA/NR NA/NR 0.158 0.061 0.015 0.198
0.122 0.028 NA/NR NA/NR NA/NR NA/NR 0.014 NA/NR NA/NR 0.134 0.015 0.008 0.305
0.013 NA/NR NA/NR NA/NR 0.001 NA/NR 0.103 NA/NR NA/NR 0.015 0.015 NA/NR 0.078
0.021 0.005 NA/NR NA/NR 0.001 NA/NR 0.104 NA/NR NA/NR 0.032 0.027 0.004 0.123
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 0.054 NA/NR NA/NR NA/NR NA/NR NA/NR 0.000
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 0.038 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
            
1.472 0.069 0.003 0.725 NA/NR 0.009 0.019 NA/NR NA/NR 0.615 0.365 0.013 1.135
2.456 0.154 0.275 0.950 0.001 0.016 0.107 NA/NR 0.001 1.162 0.435 0.063 1.433
25.566 NA/NR NA/NR NA/NR NA/NR NA/NR 2.408 NA/NR NA/NR 7.175 NA/NR NA/NR 2.117
17.334 NA/NR NA/NR NA/NR NA/NR NA/NR 2.403 NA/NR NA/NR 6.378 NA/NR NA/NR 0.823
23.273 2.269 1.537 4.078 2.912 1.524 13.482 7.052 2.788 9.494 7.134 0.919 4.222
19.929 2.538 0.821 2.477 4.077 0.742 14.809 4.467 2.225 10.280 6.836 0.901 4.605
98.974 18.647 21.843 NA/NR 3.178 0.071 24.171 23.636 NA/NR 21.535 NA/NR 4.314 0.910
71.989 9.524 14.110 NA/NR 0.316 0.002 52.245 52.152 NA/NR 15.468 NA/NR 1.500 0.299
24.369 0.532 0.008 1.961 0.136 0.017 9.270 0.083 NA/NR 20.191 0.030 0.056 4.841
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 Indonesia 2008 49.563 40.0% 39.5% 11.7% 4.5% 3.0% 1.1% 
 Lao People’s 
 Democratic Republic 2007 5.147 1.3% 19.4% 36.0% 20.3% 7.9% 15.0% 
 Lao People’s 
 Democratic Republic 2008 5.017 2.0% 13.5% 39.6% 29.9% 6.9% 8.1% 
 Lao People’s 
 Democratic Republic 2009 5.997 1.9% 19.4% 42.0% 22.2% 3.5% 11.0% 
 Malaysia 2008 24.289 98.8% 0.0% 0.0% 1.2% 0.0% 0.0% 
 Malaysia 2009 27.700 98.4% 0.0% 0.0% 1.1% 0.0% 0.5% 
 Myanmar 2007 32.763 3.6% 0.0% 0.0% 0.0% 0.0% 96.4% 
 Myanmar 2008 32.802 4.7% 0.0% 0.0% 0.0% 0.0% 95.3% 
 Nepal 2007 17.662 3.5% 67.8% 14.9% 7.5% 0.0% 6.3% 
 Pakistan 2008 14.195 68.5% 2.8% 7.7% 18.5% 2.5% 0.0% 
 Pakistan 2009 19.999 78.4% 0.5% 5.5% 13.3% 1.8% 0.6% 
 Philippines 2007 4.827 33.5% 47.3% 0.6% 16.5% 1.7% 0.3% 
 Philippines 2008 6.577 25.5% 9.0% 44.0% 16.7% 4.0% 0.9% 
 Philippines 2009 10.466 16.2% 7.3% 63.9% 11.7% 0.7% 0.2% 
 Singapore 2007 11.350 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Singapore 2008 15.338 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Singapore 2009 16.088 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Sri Lanka 2008 1.568 29.5% 0.0% 17.3% 13.9% 39.2% 0.0% 
 Sri Lanka 2009 1.555 33.2% 0.0% 28.4% 18.6% 19.8% 0.0% 
 Thailand 2007 199.645 82.7% 0.5% 16.0% 0.8% 0.0% 0.0% 
 Thailand 2008 209.123 85.4% 1.2% 12.9% 0.5% 0.0% 0.0% 
 Thailand 2009 213.775 93.3% 0.9% 5.1% 0.6% 0.0% 0.0% 
 Timor Leste 2008 1.827 0.0% 0.0% 87.9% 12.1% 0.0% 0.0% 
 Timor Leste 2009 1.803 1.2% 0.0% 96.7% 0.0% 0.0% 2.1% 
 Viet Nam 2007 66.281 12.0% 67.5% 3.5% 4.6% 11.8% 0.6% 
 Viet Nam 2008 108.814 8.0% 74.0% 3.5% 4.2% 9.8% 0.5% 
 Viet Nam 2009 102.988 2.1% 87.1% 0.1% 1.8% 8.1% 0.8% 
Sub-Saharan Africa          
 Angola 2008 31.766 75.8% 0.0% 21.2% 0.4% 2.5% 0.0% 
 Angola 2009 24.839 64.6% 0.0% 32.5% 1.7% 1.2% 0.0% 
 Benin 2007 16.836 27.1% 28.0% 17.8% 17.9% 6.2% 3.0% 
 Benin 2008 20.770 19.9% 21.7% 28.7% 18.2% 5.5% 6.0% 
 Benin 2009 28.789 45.2% 9.4% 25.8% 11.7% 3.5% 4.3% 
 Botswana 2008 339.868 67.3% 21.3% 0.0% 0.4% 0.0% 10.9% 
 Burkina Faso 2007 36.336 25.0% 36.3% 15.2% 13.3% 5.1% 5.1% 
 Burkina Faso 2008 48.011 25.3% 21.3% 25.0% 14.4% 4.0% 10.1% 
 Burundi 2007 25.964 29.5% 21.3% 27.1% 12.5% 0.2% 9.3% 
 Burundi 2008 26.060 22.5% 25.2% 22.1% 12.4% 1.0% 16.9% 
 Cameroon 2007 36.559 18.7% 9.7% 54.1% 8.8% 0.0% 8.7% 
 Cameroon 2008 39.972 17.6% 18.7% 47.7% 10.5% 0.0% 5.4% 
 Cape Verde 2008 2.570 1.2% 92.9% 0.0% 3.4% 2.1% 0.3% 
 Cape Verde 2009 1.111 1.7% 85.9% 0.0% 3.5% 1.4% 7.6% 
 Central African 
 Republic 2007 10.332 4.6% 18.8% 37.6% 36.2% 0.0% 2.7% 
 Central African 
 Republic 2008 20.282 3.5% 13.3% 47.3% 33.7% 0.0% 2.2% 
 Chad 2007 8.617 34.1% 37.5% 7.8% 14.5% 3.1% 3.0% 
 Chad 2008 13.895 16.1% 41.2% 15.8% 17.6% 6.7% 2.6% 
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24.703 0.649 3.021 5.641 0.183 0.003 7.325 5.504 0.032 10.307 3.528 1.353 7.197
2.582 0.393 0.026 0.443 0.561 0.189 0.339 0.182 0.015 1.065 0.608 0.119 1.145
1.571 0.211 0.079 0.107 0.029 0.049 0.791 0.643 0.016 1.330 0.722 0.123 1.309
2.160 0.406 0.083 0.343 0.085 0.101 0.962 0.503 0.099 1.466 0.679 0.158 1.310
11.000 NA/NR NA/NR NA/NR NA/NR NA/NR 9.861 9.286 0.000 3.429 3.429 NA/NR 0.000
13.459 NA/NR NA/NR NA/NR NA/NR NA/NR 10.447 9.559 0.000 3.529 3.529 NA/NR 0.265
16.844 1.310 0.031 8.032 NA/NR 1.132 11.758 5.556 0.419 2.191 0.195 0.142 1.552
15.546 NA/NR 0.041 8.301 NA/NR 1.672 12.680 10.629 0.674 1.578 0.608 0.245 2.324
8.187 0.638 0.487 2.186 NA/NR 0.126 2.936 0.667 0.159 5.110 1.553 0.253 1.269
9.709 2.317 NA/NR 3.739 NA/NR NA/NR 1.443 1.443 NA/NR 2.360 2.360 NA/NR 0.683
15.522 3.483 NA/NR 8.288 NA/NR NA/NR 1.521 1.521 NA/NR 2.521 2.521 NA/NR 0.436
3.845 0.017 0.025 0.090 2.763 0.009 0.151 0.005 NA/NR 0.473 0.023 0.018 0.358
3.462 0.109 0.096 0.522 0.082 0.004 0.679 0.081 0.123 1.334 0.282 0.012 0.979
5.860 0.077 0.278 0.607 0.000 0.037 0.911 0.184 0.036 2.703 0.481 0.122 0.956
2.721 NA/NR NA/NR NA/NR NA/NR NA/NR 7.965 NA/NR NA/NR 0.664 NA/NR NA/NR 0.000
4.241 NA/NR NA/NR NA/NR NA/NR NA/NR 9.330 NA/NR NA/NR 1.767 NA/NR NA/NR 0.000
4.125 NA/NR NA/NR NA/NR NA/NR NA/NR 9.075 NA/NR NA/NR 2.888 NA/NR NA/NR 0.000
1.030 NA/NR NA/NR 0.064 NA/NR NA/NR 0.071 0.047 NA/NR 0.088 0.087 NA/NR 0.379
0.917 NA/NR NA/NR 0.130 NA/NR NA/NR 0.076 0.054 NA/NR 0.102 0.099 NA/NR 0.459
28.186 0.188 5.497 1.029 2.529 3.542 143.334 93.625 3.006 19.449 10.948 1.511 5.669
45.287 0.920 0.694 0.566 1.529 4.110 137.646 61.295 1.507 11.984 6.425 0.143 12.699
29.259 1.424 1.096 1.418 0.708 3.893 162.604 92.680 1.535 7.421 0.575 0.274 12.956
0.570 0.211 0.060 NA/NR NA/NR 0.016 0.019 0.019 NA/NR 1.003 0.728 NA/NR 0.236
0.358 0.053 0.008 NA/NR 0.003 0.002 0.061 0.061 NA/NR 1.166 0.694 NA/NR 0.218
24.553 4.874 3.459 0.051 0.007 2.226 25.900 12.670 0.578 9.326 2.607 2.540 5.924
39.344 7.050 4.911 0.117 0.051 4.226 42.324 21.245 1.818 16.312 3.714 7.628 9.016
35.872 3.736 5.634 0.012 NA/NR 4.573 47.383 21.868 3.231 10.278 1.755 6.781 6.223
           
12.215 1.733 0.897 0.244 1.418 5.430 13.105 4.615 NA/NR 5.562 1.793 NA/NR 0.884
7.263 1.292 1.418 0.453 0.604 2.030 8.636 3.714 NA/NR 7.135 2.544 0.531 1.806
4.667 0.472 1.134 NA/NR 0.785 0.937 6.776 2.664 0.231 4.228 3.718 0.091 0.935
5.745 1.017 0.937 NA/NR 1.349 0.431 5.902 4.408 0.500 7.295 5.003 1.029 1.328
9.530 0.359 1.078 NA/NR 1.335 1.197 6.578 3.645 0.727 9.721 6.763 0.518 2.233
29.766 2.160 8.566 NA/NR 3.127 5.621 165.330 48.827 80.607 49.952 40.913 2.617 14.213
7.064 2.132 0.544 NA/NR 0.948 1.010 13.060 9.248 2.930 9.130 4.185 0.765 4.153
12.956 1.945 1.993 0.362 1.630 0.918 15.661 6.495 2.632 10.487 6.528 1.780 6.275
5.899 1.015 0.766 0.073 0.941 0.861 7.420 3.210 2.616 7.175 5.783 1.195 2.852
5.736 0.783 0.865 0.069 0.846 0.857 8.684 2.501 2.664 6.134 4.719 0.792 2.842
10.000 1.646 0.946 0.004 0.931 1.376 15.297 11.474 2.251 5.920 2.907 0.369 3.092
11.435 2.313 1.561 NA/NR 2.780 0.565 16.036 11.055 3.148 6.089 5.260 0.486 3.263
0.749 0.253 0.012 NA/NR NA/NR NA/NR 1.233 0.624 0.074 0.366 NA/NR NA/NR 0.147
0.153 NA/NR NA/NR NA/NR NA/NR NA/NR 0.415 0.214 0.133 0.381 0.212 0.137 0.029
2.387 0.224 NA/NR NA/NR 0.878 0.176 4.207 1.008 0.113 2.915 1.890 0.151 0.710
3.031 0.493 0.195 0.000 1.208 0.178 8.230 NA/NR 0.979 5.665 3.672 0.454 2.377
3.324 0.704 0.158 0.039 0.970 0.116 3.210 3.035 0.025 1.417 1.235 0.077 0.640
5.323 1.821 0.033 NA/NR 1.903 0.300 4.088 3.036 0.188 3.402 2.252 0.133 0.894
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 Congo 2007 9.442 10.2% 1.9% 51.3% 14.7% 21.8% 0.0% 
 Congo 2008 11.629 11.0% 5.8% 34.9% 2.8% 45.5% 0.0% 
 Congo 2009 17.395 52.5% 4.1% 25.0% 2.1% 16.4% 0.0% 
 Cote d’Ivoire 2007 67.012 9.1% 72.6% 13.4% 4.5% 0.0% 0.4% 
 Cote d’Ivoire 2008 62.011 8.4% 76.8% 11.4% 2.4% 0.0% 0.9% 
 Democratic Republic 
 of the Congo 2008 85.964 3.6% 13.9% 40.0% 18.5% 16.8% 7.3% 
 Equatorial Guinea 2007 1.310 74.0% 6.7% 0.0% 19.3% 0.0% 0.0% 
 Equatorial Guinea 2008 2.827 33.5% 7.1% 41.9% 17.4% 0.0% 0.0% 
 Equatorial Guinea 2009 2.797 32.8% 4.2% 55.3% 7.6% 0.0% 0.0% 
 Eritrea 2008 14.457 5.9% 2.7% 46.7% 18.7% 26.0% 0.0% 
 Eritrea 2009 13.661 8.9% 4.7% 30.1% 23.8% 32.5% 0.0% 
 Gabon 2007 10.471 58.2% 2.6% 24.0% 10.9% 4.4% 0.0% 
 Gabon 2008 11.852 87.4% 4.6% 3.5% 4.4% 0.0% 0.0% 
 Gabon 2009 12.263 77.1% 2.1% 15.3% 5.5% 0.0% 0.0% 
 Gambia 2007 4.893 4.5% 0.8% 51.4% 17.3% 4.3% 21.6% 
 Gambia 2008 4.985 3.6% 1.9% 63.2% 14.6% 0.1% 16.7% 
 Ghana 2007 52.308 21.5% 12.9% 46.2% 1.0% 16.1% 2.3% 
 Ghana 2008 37.928 14.1% 11.9% 29.2% 7.2% 18.7% 19.0% 
 Guinea 2007 7.402 0.6% 35.5% 7.1% 21.9% 18.1% 16.9% 
 Guinea 2008 13.184 2.0% 19.9% 14.0% 15.8% 33.1% 15.3% 
 Guinea 2009 10.231 6.5% 25.7% 21.7% 23.6% 0.0% 22.5% 
 Guinea-Bissau 2008 3.648 7.3% 24.1% 11.0% 42.8% 3.3% 11.5% 
 Guinea-Bissau 2009 5.256 4.5% 28.1% 45.9% 19.0% 0.1% 2.3% 
 Kenya 2007 418.582 13.7% 68.3% 6.3% 1.5% 0.0% 10.2% 
 Kenya 2008 659.866 11.2% 79.3% 1.5% 2.4% 0.1% 5.6% 
 Kenya 2009 687.258 14.2% 75.2% 2.8% 2.2% 0.0% 5.5% 
 Lesotho 2007 53.737 37.2% 16.0% 16.1% 16.3% 3.9% 10.5% 
 Lesotho 2008 81.315 56.9% 18.5% 8.9% 5.0% 0.1% 10.6% 
 Madagascar 2008 11.954 45.3% 36.2% 0.5% 18.1% 0.0% 0.0% 
 Malawi 2008 106.722 1.8% 19.9% 65.1% 3.2% 1.6% 8.4% 
 Malawi 2009 103.907 1.4% 26.4% 54.7% 2.5% 6.0% 8.9% 
 Mali 2007 40.800 12.5% 19.2% 30.6% 31.3% 6.1% 0.3% 
 Mali 2008 40.390 10.9% 16.3% 25.9% 37.6% 8.8% 0.5% 
 Mozambique 2007 104.542 5.7% 68.0% 5.0% 8.5% 1.0% 11.8% 
 Mozambique 2008 144.946 3.5% 70.0% 2.8% 8.0% 5.9% 9.8% 
 Niger 2007 14.522 4.4% 10.0% 24.2% 37.5% 23.2% 0.7% 
 Niger 2008 12.457 4.5% 12.6% 25.5% 40.1% 5.6% 11.8% 
 Nigeria 2007 299.242 14.7% 65.9% 6.6% 3.1% 9.8% 0.0% 
 Nigeria 2008 394.664 7.6% 80.8% 6.9% 1.5% 3.1% 0.0% 
 Rwanda 2007 74.565 8.2% 62.7% 15.1% 4.3% 3.8% 5.9% 
 Rwanda 2008 110.812 5.5% 58.1% 24.3% 2.5% 2.9% 6.7% 
 Sao Tome and Principe 2007 0.098 47.5% 0.0% 0.0% 0.0% 23.0% 29.5% 
 Sao Tome and Principe 2008 0.093 45.8% 0.0% 0.0% 0.0% 19.5% 34.7% 
 Sao Tome and Principe 2009 1.065 3.6% 0.0% 60.5% 31.9% 0.4% 3.5% 
 Senegal 2008 25.570 25.0% 40.7% 30.4% 3.9% 0.0% 0.0% 
 Seychelles 2007 0.479 96.1% 0.0% 0.0% 3.9% 0.0% 0.0% 
 Seychelles 2008 0.573 83.9% 0.0% 0.0% 12.1% 2.0% 1.9% 
 Seychelles 2009 0.575 80.4% 4.3% 0.0% 15.3% 0.0% 0.0% 
 Sierra Leone 2007 9.173 2.2% 15.0% 24.6% 20.1% 34.7% 3.3% 
237
A2
Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
Orphans and 
vulnerable 
children 
Other HIV 
expenditures 
Prevention Care and Treatment Programme Support 
Monitoring 
and 
evaluation
Planning, 
coordination 
and 
programme 
management
Total for 
programme 
management 
and admin-
istration 
strengthen-
ing
Total for 
prevention
Male and 
female 
condom social 
marketing and 
public and 
commercial 
sector 
provision
Communica-
tion for social 
and behav-
ioral change
Prevention 
of mother 
to child 
transmission 
Voluntary 
counseling 
and testing 
Total for care 
and treatment 
Programmes 
for sex workers 
and their 
clients for 
MSM and for 
harm reduction 
for IDUs 
Antiretroviral 
therapy 
TOTAL HIV EXPENDITURES ON SELECTED SERVICES (MILLION CURRENT USD DOLLARS)
3.787 0.091 0.455 0.009 1.015 0.287 1.145 0.422 0.956 2.586 1.764 0.083 0.968
4.118 0.008 0.243 0.080 0.961 0.217 0.332 NA/NR 2.044 3.694 2.119 0.280 1.440
2.826 0.078 0.441 0.032 0.374 0.412 8.557 6.038 0.874 3.953 1.422 0.371 1.184
18.448 0.925 1.118 1.698 5.043 1.005 28.610 NA/NR 1.962 15.310 8.249 1.007 2.681
19.417 1.726 1.477 2.011 4.966 0.239 17.631 NA/NR 1.631 18.411 9.406 0.675 4.922
18.115 0.801 1.730 0.291 2.978 1.727 25.521 NA/NR 4.703 28.544 21.112 1.600 9.082
0.013 0.006 NA/NR NA/NR NA/NR 0.003 0.007 NA/NR NA/NR 1.169 0.197 0.003 0.120
0.329 0.117 0.001 NA/NR 0.017 0.084 0.228 0.178 0.046 2.029 0.683 0.078 0.195
0.258 0.060 NA/NR NA/NR 0.022 0.078 0.231 0.213 NA/NR 2.190 1.165 NA/NR 0.117
3.574 0.340 0.459 NA/NR 0.200 0.061 3.943 0.408 1.384 3.200 0.257 0.588 2.356
3.641 0.680 NA/NR NA/NR 0.273 0.118 4.130 NA/NR 1.155 2.464 NA/NR 0.136 2.270
3.728 0.055 0.198 0.042 0.235 0.006 3.333 2.214 0.344 2.494 0.784 0.301 0.573
4.542 NA/NR NA/NR 0.032 0.065 NA/NR 2.524 1.819 0.117 4.358 0.290 0.165 0.310
4.488 0.045 NA/NR 0.022 0.080 0.010 3.898 3.196 0.110 3.478 0.173 0.065 0.289
0.700 0.209 0.085 NA/NR NA/NR 0.106 0.651 0.163 0.265 2.046 0.227 0.434 1.231
0.563 0.067 0.124 NA/NR NA/NR 0.183 1.019 0.225 0.227 2.048 0.170 0.374 1.129
6.336 1.742 0.339 0.577 1.190 NA/NR 21.026 6.119 0.153 18.466 2.292 0.482 6.327
8.307 2.596 2.303 0.080 0.043 0.514 9.554 NA/NR 0.422 11.562 2.823 1.091 8.083
3.675 NA/NR NA/NR NA/NR NA/NR NA/NR 1.820 NA/NR 0.020 1.322 NA/NR NA/NR 0.565
4.087 NA/NR NA/NR NA/NR NA/NR NA/NR 2.875 NA/NR 0.001 4.965 NA/NR NA/NR 1.256
2.650 NA/NR NA/NR NA/NR NA/NR NA/NR 5.626 NA/NR 0.192 1.063 NA/NR NA/NR 0.700
1.238 0.577 0.274 0.000 0.041 0.196 1.009 0.801 0.052 0.944 0.712 0.004 0.406
1.001 0.389 0.042 0.176 0.017 0.224 1.495 1.140 0.109 1.949 1.753 0.019 0.701
87.310 13.472 30.670 0.581 4.075 15.043 257.239 147.934 31.067 36.432 23.880 0.000 6.533
158.619 45.742 32.005 0.500 4.758 29.333 379.551 226.436 50.887 67.159 39.811 0.061 3.650
181.152 39.484 41.119 0.500 6.246 29.847 376.273 207.071 55.427 68.239 39.060 0.061 6.167
4.802 0.246 1.848 NA/NR 0.473 1.377 25.393 17.211 4.699 7.918 5.007 0.612 10.924
9.869 0.409 1.694 NA/NR 0.531 4.125 41.210 9.995 10.839 14.968 3.979 0.868 4.429
5.003 1.179 0.151 0.247 1.328 0.008 0.112 NA/NR NA/NR 4.959 3.421 0.478 1.881
20.598 2.398 7.043 0.243 NA/NR 4.132 33.459 6.379 7.623 24.246 6.450 3.627 20.796
17.704 0.868 3.058 0.335 NA/NR 3.602 39.925 0.781 4.448 23.127 8.409 2.940 18.702
10.857 2.324 1.334 0.216 1.498 0.597 9.413 6.352 1.341 12.292 8.676 0.438 6.897
11.987 0.895 3.169 0.525 1.001 0.665 7.787 4.805 1.544 12.397 8.003 0.728 6.675
25.779 4.774 2.440 0.000 0.029 5.166 28.690 14.308 8.983 32.587 25.987 2.160 8.503
38.543 4.581 4.481 0.462 0.003 8.681 41.850 21.237 13.022 35.818 28.114 2.501 15.714
5.168 0.091 1.335 0.207 0.850 0.062 3.700 2.752 0.586 3.910 3.671 0.124 1.158
2.822 0.035 0.358 0.008 0.749 0.025 2.615 1.288 0.639 4.837 4.485 0.325 1.545
37.654 4.606 3.741 0.228 2.336 7.501 135.088 67.342 5.715 102.825 33.919 11.476 17.959
57.949 8.043 7.852 0.527 2.025 12.599 185.912 79.196 9.972 117.521 38.549 13.137 23.310
17.115 2.176 2.069 NA/NR 0.628 2.710 27.794 1.671 9.359 10.791 5.809 1.879 9.506
29.308 1.895 1.981 NA/NR 1.425 3.131 44.670 14.411 12.850 13.273 6.588 3.415 10.711
0.052 0.009 0.010 0.001 0.014 NA/NR NA/NR NA/NR NA/NR 0.028 0.028 NA/NR 0.019
0.044 0.004 0.014 0.003 0.015 0.001 NA/NR NA/NR NA/NR 0.026 0.026 NA/NR 0.023
0.453 0.123 0.112 0.004 0.052 0.005 0.069 0.015 0.035 0.119 0.045 NA/NR 0.389
7.148 1.028 1.766 0.645 1.773 1.100 4.373 3.699 1.478 10.460 6.733 1.304 2.112
0.029 NA/NR NA/NR NA/NR NA/NR 0.014 0.327 0.171 NA/NR 0.119 0.119 NA/NR 0.005
0.098 0.027 NA/NR 0.012 NA/NR 0.008 0.271 0.141 0.123 0.020 0.020 NA/NR 0.062
0.133 0.025 NA/NR NA/NR NA/NR 0.008 0.212 0.102 0.091 0.073 0.018 NA/NR 0.066
5.611 1.554 0.113 0.215 0.312 0.224 1.043 0.663 0.193 1.545 1.075 0.196 0.779
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Total reported 
domestic 
public and 
international 
expenditure 
million USD
Public InternationalSurvey 
Year
Domestic 
public (%)
Bilaterals (%) Global Fund 
(%)
UN (%) All other 
multilaterals 
(%)
All other 
international 
sources (%)
SHARE BY FINANCING SOURCECOUNTRY REPORTS OF 
DOMESTIC AND 
INTERNATIONAL AIDS 
SPENDING BY SERVICE 
CATEGORIES AND 
FINANCING SOURCES
1  Antigua and Barbuda 2008 
and 2009 expenditures for HIV 
patients’ hospitalization, ARV, 
and out-patient clinic visits for 
care and treatment are not 
reported.
2 Brazil sub-national spending 
at state, federal district and 
municipal level is not reported, 
except for acquisition of 
opportunistic infection drugs.
3 Bulgaria opportunistic infection 
treatment expenditures not 
reported.
4 Chilean armed forces HIV-related 
expenditures were not reported.
5 The country reported biannual 
fi gures for HIV spending. The 
expenditures were therefore 
divided in two and distributed 
equally over the two years.
6 India: The values reported refl ect 
only NACO’s (public) spending 
from the budgetary funds. The 
extra budgetary expenditures 
by donors and others is not 
refl ected in the table provided 
and is still under compilation and 
analysis in a separate study.
7 Montenegro spending includes 
only the budgeted activities of 
the GFATM project proposal.
8 Dominican Republic: Blood 
safety expenditures were not 
reported.
9 Switzerland: Only central 
government funding is reported.
10 Timor Leste: Original submission 
for 2008 was for a one and a 
half year period (Aug. 2007 – 
Dec. 2008). The current fi gure for 
2008 was derived by adjusting all 
fi gures by 2/3.
11 Blood safety spending reported 
by Russia included expenditures 
such as equipment upgrades; 
some of which were not HIV 
related.
 South Africa 2008 1,694.000 77.0% 21.3% 0.7% 0.2% 0.4% 0.4% 
 South Africa 2009 2,088.000 72.7% 26.3% 0.2% 0.3% 0.2% 0.3% 
 Swaziland 2007 49.447 39.6% NA/NR NA/NR NA/NR NA/NR NA/NR 
 Togo 2007 10.203 9.5% 4.1% 56.5% 10.8% 1.3% 17.7% 
 Togo 2008 15.368 7.0% 15.3% 47.4% 6.5% 23.7% 0.1% 
 Uganda 2007 270.011 2.5% 92.7% 0.0% 4.9% 0.0% 0.0% 
 Uganda 2008 296.650 13.0% 83.0% 0.8% 3.2% 0.0% 0.0% 
 Zimbabwe 2008 27.344 1.3% 34.7% 0.0% 2.4% 0.0% 61.7% 
 Zimbabwe 2009 39.548 19.5% 21.4% 17.1% 1.1% 0.0% 40.9% 
Western and Central Europe        
 Belgium 2008 111.777 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Bosnia and Herzegovina 2008 2.760 10.9% 0.0% 70.8% 12.5% 5.9% 0.0% 
 Bosnia and Herzegovina 2009 3.584 8.4% 0.0% 76.4% 10.8% 4.4% 0.0% 
 Bulgaria3 2007 6.666 50.8% 0.0% 43.4% 5.9% 0.0% 0.0% 
 Bulgaria3 2008 9.212 66.0% 0.6% 30.6% 2.8% 0.0% 0.0% 
 Bulgaria3 2009 10.702 52.7% 0.2% 44.4% 2.7% 0.0% 0.0% 
 Croatia 2007 8.908 99.1% 0.0% 0.0% 0.9% 0.0% 0.0% 
 Croatia 2008 9.957 98.3% 0.0% 0.0% 1.7% 0.0% 0.0% 
 Croatia 2009 10.367 98.2% 0.0% 0.0% 1.8% 0.0% 0.0% 
 Czech Republic 2007 56.998 97.6% 0.0% 0.0% 0.0% 0.0% 2.4% 
 Czech Republic 2008 64.279 98.0% 0.0% 0.0% 0.0% 0.0% 2.0% 
 Czech Republic 2009 69.311 96.6% 0.0% 0.0% 0.0% 0.0% 3.4% 
 Estonia 2008 18.373 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Greece 2008 96.058 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Hungary5 2007 2.275 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Hungary 2008 3.673 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Hungary 2009 3.496 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Latvia 2009 2.264 94.4% 0.0% 0.0% 5.6% 0.0% 0.0% 
 Luxembourg 2009 7.356 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Montenegro7 2007 1.471 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 
 Montenegro7 2008 0.597 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 
 Montenegro7 2009 0.830 0.0% 0.0% 100.0% 0.0% 0.0% 0.0% 
 Poland 2007 41.202 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Poland 2008 62.586 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Poland 2009 55.520 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Romania 2008 87.241 92.7% 0.0% 6.0% 0.9% 0.0% 0.5% 
 Romania 2009 84.256 95.1% 0.0% 3.9% 0.5% 0.0% 0.4% 
 Spain 2007 551.413 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Spain 2008 916.739 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Spain 2009 1,031.381 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Sweden 2007 21.598 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Sweden 2008 22.155 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Sweden 2009 19.085 NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR 
 Switzerland9 2008 14.898 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 Switzerland9 2009 14.843 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 The former Yugoslav 
 Republic of Macedonia 2008 3.659 56.5% 0.7% 31.4% 10.8% 0.0% 0.7% 
 United Kingdom 2007 1,204.082 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
 United Kingdom 2008 925.714 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
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Orphans and 
vulnerable 
children 
Other HIV 
expenditures 
Prevention Care and Treatment Programme Support 
Monitoring 
and 
evaluation
Planning, 
coordination 
and 
programme 
management
Total for 
programme 
management 
and admin-
istration 
strengthen-
ing
Total for 
prevention
Male and 
female 
condom social 
marketing and 
public and 
commercial 
sector 
provision
Communica-
tion for social 
and behav-
ioral change
Prevention 
of mother 
to child 
transmission 
Voluntary 
counseling 
and testing 
Total for care 
and treatment 
Programmes 
for sex workers 
and their 
clients for 
MSM and for 
harm reduction 
for IDUs 
Antiretroviral 
therapy 
TOTAL HIV EXPENDITURES ON SELECTED SERVICES (MILLION CURRENT USD DOLLARS)
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
8.567 3.167 2.243 NA/NR 0.713 0.344 9.384 6.244 15.027 6.933 3.136 0.879 9.535
4.245 0.483 0.114 0.146 0.671 0.216 2.074 1.480 0.189 2.727 2.131 0.197 0.969
5.887 2.005 0.614 0.139 0.378 0.246 2.496 1.011 0.805 5.130 3.289 0.566 1.049
70.370 NA/NR NA/NR NA/NR NA/NR NA/NR 114.934 NA/NR 25.749 55.450 NA/NR NA/NR 3.508
64.185 NA/NR NA/NR NA/NR NA/NR NA/NR 147.367 NA/NR 15.246 65.502 NA/NR NA/NR 4.349
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
            
6.576 0.206 NA/NR 2.426 NA/NR NA/NR 102.713 79.482 NA/NR 2.488 NA/NR 0.358 0.000
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
2.880 0.418 0.553 0.598 NA/NR NA/NR 2.935 2.027 NA/NR 0.349 0.122 0.139 0.501
4.711 0.214 1.265 0.832 NA/NR NA/NR 3.502 2.831 NA/NR 0.321 0.108 0.136 0.677
5.710 0.198 1.645 1.084 0.122 NA/NR 3.421 2.713 0.200 0.881 0.514 0.350 0.489
2.219 NA/NR 0.284 0.580 NA/NR NA/NR 6.531 NA/NR NA/NR 0.159 0.111 NA/NR 0.000
2.128 NA/NR 0.272 0.615 NA/NR NA/NR 7.677 NA/NR NA/NR 0.153 0.107 NA/NR 0.000
2.287 NA/NR 0.307 0.869 NA/NR NA/NR 7.562 NA/NR NA/NR 0.152 NA/NR 0.100 0.366
32.921 0.103 0.456 8.289 0.003 2.446 15.687 10.779 NA/NR 0.147 0.030 0.010 8.243
34.591 0.088 0.415 8.565 NA/NR 2.442 19.867 12.204 NA/NR 0.617 0.031 0.009 9.204
36.831 0.022 0.326 8.309 0.003 2.629 21.537 13.746 0.026 0.477 0.024 0.016 10.440
5.989 NA/NR 0.523 2.671 NA/NR 0.024 12.010 NA/NR NA/NR 0.375 NA/NR 0.212 0.000
13.969 NA/NR 0.897 NA/NR NA/NR NA/NR 81.231 79.063 NA/NR 0.781 NA/NR NA/NR 0.077
1.733 0.029 0.052 0.124 0.003 NA/NR 0.449 0.051 NA/NR 0.075 NA/NR NA/NR 0.017
2.546 0.295 0.055 0.016 0.027 0.109 0.448 0.045 NA/NR 0.531 NA/NR NA/NR 0.148
2.492 0.293 0.052 0.068 0.026 NA/NR 0.423 0.042 NA/NR 0.493 NA/NR NA/NR 0.089
0.736 NA/NR NA/NR NA/NR NA/NR NA/NR 1.494 NA/NR NA/NR 0.034 NA/NR 0.012 0.000
1.661 NA/NR NA/NR NA/NR NA/NR NA/NR 4.942 4.517 NA/NR 0.023 0.003 0.021 0.730
0.812 NA/NR 0.065 0.322 NA/NR NA/NR 0.185 NA/NR NA/NR 0.277 0.277 NA/NR 0.197
0.313 NA/NR 0.025 0.126 NA/NR NA/NR NA/NR NA/NR NA/NR 0.168 0.168 NA/NR 0.116
0.480 NA/NR 0.027 0.197 NA/NR NA/NR 0.048 NA/NR NA/NR 0.154 0.154 NA/NR 0.147
4.237 0.261 0.149 2.774 NA/NR 0.682 36.614 35.292 0.013 0.018 NA/NR 0.017 0.319
5.420 0.430 0.784 0.148 NA/NR 0.881 56.035 56.035 NA/NR 0.023 0.013 0.003 1.107
2.661 0.211 0.409 0.145 NA/NR 0.960 51.726 51.726 NA/NR 0.025 0.013 0.003 1.108
4.726 NA/NR 0.003 0.411 0.037 NA/NR 54.667 54.040 0.003 0.748 0.030 0.054 27.097
3.372 0.066 0.066 0.459 0.070 NA/NR 54.767 54.067 0.001 0.388 0.017 NA/NR 25.727
36.532 NA/NR NA/NR NA/NR NA/NR NA/NR 500.918 500.918 NA/NR NA/NR NA/NR NA/NR 13.963
40.374 NA/NR NA/NR NA/NR NA/NR NA/NR 859.361 859.361 NA/NR NA/NR NA/NR NA/NR 17.004
21.649 NA/NR NA/NR NA/NR NA/NR NA/NR 997.670 997.670 NA/NR NA/NR NA/NR NA/NR 12.063
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR NA/NR
4.611 2.456 NA/NR 0.996 NA/NR NA/NR NA/NR NA/NR NA/NR 1.019 0.649 0.371 9.268
4.594 2.447 NA/NR 0.993 NA/NR NA/NR NA/NR NA/NR NA/NR 1.016 0.646 0.369 9.234
2.833 0.207 0.301 1.858 0.005 NA/NR 0.172 0.154 NA/NR 0.478 0.282 0.070 0.176
46.939 NA/NR NA/NR 4.082 NA/NR NA/NR 1,106.122 NA/NR NA/NR NA/NR NA/NR NA/NR 51.020
35.714 NA/NR NA/NR 2.857 NA/NR NA/NR 857.143 NA/NR NA/NR NA/NR NA/NR NA/NR 32.857
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 Yes/Agree  No/Disagree  Data not available  In progress  Not applicable Number SCALE: 0= low; 5 = High
National Composite 
Policy Index (NCPI)
2010
Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo, Republic of the
Costa Rica
HIV Prevention 
Services Implementation
Treatment 
Implementation
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 Yes/Agree  No/Disagree  Data not available  In progress  Not applicable Number SCALE: 0= low; 5 = High
National Composite 
Policy Index (NCPI)
2010
Croatia
Cuba
Cyprus
Czech Republic
Côte d’Ivoire
Democratic People’s 
Republic of Korea
Democratic Republic 
of Congo
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
HIV Prevention 
Services Implementation
Treatment 
Implementation
  A &/ B  A | B A B A A A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B
      4             
      4             
                   
      5             
      4             
                   
      3             
      1             
      4             
      4             
      3             
      5             
      3             
      3             
      5             
      5             
      2             
      4             
      4             
      3             
                   
      4             
      4             
      3             
      5             
      4             
      2             
      3             
      3             
      4             
      4             
      3             
      4             
      3             
      2             
                   
      2             
      1             
      4             
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242 Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
 Yes/Agree  No/Disagree  Data not available  In progress  Not applicable Number SCALE: 0= low; 5 = High
National Composite 
Policy Index (NCPI)
2010
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People’s Democratic 
Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macedonia, FYR
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia, Federated 
States of
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
HIV Prevention 
Services Implementation
Treatment 
Implementation
  A &/ B  A | B A B A A A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B
                   
                   
      4             
                   
      3             
      3             
      2             
      3             
      3             
                   
                   
      3             
       4             
      3             
      5             
      4             
                   
      2             
                   
      4             
      5             
      5             
      4             
      4             
      4             
      3             
      5             
                   
                   
                   
      4             
      2             
       1             
      4             
                   
      4             
      4             
      5             
      3             
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Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
 Yes/Agree  No/Disagree  Data not available  In progress  Not applicable Number SCALE: 0= low; 5 = High
National Composite 
Policy Index (NCPI)
2010
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of Korea
Romania
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and 
Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
HIV Prevention 
Services Implementation
Treatment 
Implementation
  A &/ B  A | B A B A A A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B
      3             
                   
                   
      4             
      5             
      3             
      4             
      4             
      4             
      3             
      3             
      5             
      2             
      3             
                   
                   
      3             
      3             
      5             
      3             
      3             
      3             
      5             
                   
      4             
                   
      5             
      4             
      2             
      3             
      3             
                   
      3             
      4             
      2             
      3             
      2             
      2             
                   
      2             
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 Yes/Agree  No/Disagree  Data not available  In progress  Not applicable Number SCALE: 0= low; 5 = High
National Composite 
Policy Index (NCPI)
2010
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Tajikistan
Thailand
Timor-Leste
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom of 
Great Britain and 
Northern Ireland
United Republic of 
Tanzania
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Yemen
Zambia
Zimbabwe
HIV Prevention 
Services Implementation
Treatment 
Implementation
  A &/ B  A | B A B A A A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B A | B
      4             
                   
      4             
      4             
      4             
      3             
      3             
      2             
      1             
      3             
      3             
      5             
      4             
      4             
                   
      2             
      3             
      2             
                   
      5             
      5             
      3             
      4             
       2             
                    
      3             
      4             
                   
      5             
      2             
      2             
      3             
      4             
      4             
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PERCENTAGE OF DONATED 
BLOOD UNITS SCREENED FOR 
HIV IN A QUALITY-ASSURED 
MANNER
 Afghanistan 39 52 
 Albania  100 
 Algeria 100 100 
 Angola  26 
 Antigua and Barbuda 33 100 
 Argentina 100 100 
 Armenia 100 100 
 Australia 100 100 
 Austria 100 2 100 
 Azerbaijan  100 
 Bahamas 100 100 
 Bahrain 100 2 100 
 Bangladesh  100 
 Barbados 100 100 
 Belarus 100 100 
 Belgium 100 100 
 Belize 100 100 
 Benin 99 99 
 Bhutan 50 2  
 Bolivia 88 69 
 Bosnia and 
 Herzegovina 0 0 
 Botswana 100 100 
 Brazil  100 
 Brunei Darussalam  100 3 
 Bulgaria 100 100 
 Burkina Faso 66 75 
 Burundi 100 100 
 Côte d’Ivoire 100 100 
 Cambodia 97 100 
 Cameroon  100 
 Canada 100 100 
 Cape Verde 61 100 
 Central African 
 Republic 76 84 
 Chad 100 100 
 China 100 100 
 Colombia 100 100 
 Comoros 100 62 
 Congo, 
 Republic of the 100 100 
 Costa Rica 100 100 
 Croatia 86 100 
 Cuba 100 100 
 Cyprus 100 100 
 Czech Republic 100 2 100 
 Democratic Republic 
 of the Congo 47 55 
 Denmark  100 
 Djibouti  100 
 Dominica 100 100 
 Dominican Republic 100 86 
 Ecuador 100 100 
 Egypt  100 
 El Salvador 100 100 
Indicator Value Indicator Value
20071 2009
UNGASS Indicator 3
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Indicator Value Indicator Value
20071 2009
 Equatorial Guinea  0 
 Eritrea 100 100 
 Estonia 100 100 
 Ethiopia 100 100 
 Fiji 100 100 
 Finland 100 100 
 Gabon 100 100 
 Georgia 0 0 
 Germany 100 100 
 Ghana 100 100 
 Greece  100 
 Grenada 91 100 
 Guatemala 100 75 
 Guinea 53 100 
 Guinea-Bissau 100 0 
 Guyana 100 100 
 Haiti 100 100 
 Honduras 46 48 
 Hungary 100 100 
 India 100 100 
 Indonesia  100 
 Iran, Islamic 
 Republic of 100 100 
 Ireland 100 100 
 Israel 100  
 Jamaica 100 100 
 Japan 100 100 
 Jordan 100 100 
 Kazakhstan 95 100 
 Kenya 100 100 
 Kuwait 100 2 100 
 Kyrgyzstan 88 52 
 Lao People’s 
 Democratic Republic 100 100 
 Latvia 100 100 
 Lebanon 100 100 
 Lesotho 100 100 
 Lithuania 100 100 
 Luxembourg 100 2 100 
 Madagascar 99 100 
 Malawi 99 100 
 Malaysia 100 100 
 Maldives 0 2 100 
 Mali 94 100 
 Malta 100 2  
 Marshall Islands 100 97 
 Mauritania 100 100 
 Mauritius 100 100 
 Mexico 100 100 
 Micronesia, 
 Federated States of  100 
 Moldova 74 100 
 Monaco  94 
 Mongolia 72 70 
 Montenegro 100 0 
PERCENTAGE OF DONATED 
BLOOD UNITS SCREENED FOR 
HIV IN A QUALITY-ASSURED 
MANNER
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Indicator Value Indicator ValueIndicator Value Indicator Value
20071 200712009 2009
 Morocco 100 100 
 Mozambique 36 70 
 Myanmar  76 
 Namibia 100 2 100 
 Nauru  100 
 Nepal 100 39 
 Netherlands 100 2 100 
 New Zealand 100 100 
 Nicaragua 90 100 
 Niger 100 26 
 Nigeria 100 100 
 Norway 100 2 100 
 Oman  0 
 Pakistan 87  
 Palau 100 100 
 Panama 100 100 
 Papua New Guinea 100 100 
 Paraguay 95 100 
 Peru 99 88 
 Philippines  96 
 Poland 100 2  
 Portugal  100 
 Qatar  100 
 Republic of Korea 100 2  
 Romania 100 100 
 Russian Federation  79 
 Rwanda 100 100 
 Saint Kitts and 
 Nevis 100 100 
 Saint Lucia 100 100 
 Saint Vincent and 
 the Grenadines 100 100 
 Samoa 100 2  
 Sao Tome and 
 Principe 0 100 
 Saudi Arabia  100 
 Senegal 78 86 
 Serbia 100 49 
 Seychelles 100 100 
 Sierra Leone 100 100 
 Singapore 100 100 
 Slovakia  100 
 Slovenia 100 100 
 Solomon Islands  79 
 Somalia  0 
 South Africa 100 100 
 Spain 100 100 
 Sri Lanka 42 100 
 Sudan  0 
 Suriname 100 100 
 Swaziland 100 100 
 Sweden 100 100 
 Switzerland 100 100 
 Syrian Arab 
 Republic  0 
 Tajikistan 97 100 
 Thailand 99 100 
 Timor-Leste 58 2 100 
 Togo 85 92 
 Tonga  100 
 Trinidad and 
 Tobago 100 100 
 Tunisia 100 100 
 Turkey 100 100 
 Uganda 100 100 
 Ukraine 0  
 United Arab 
 Emirates  100 
 United Kingdom 
 of Great Britain 
 and Northern 
 Ireland 100 100 
 United Republic
  of Tanzania 100 36 
 Uruguay 100 100 
 Uzbekistan  82 
 Vanuatu  91 
 Venezuela  100 
 Zambia 100 100 
 Zimbabwe 100 100 
1  Report date 2007, but data collection can vary from 2005-2007.
2 Data provided by WHO Department of Blood Transfusion Safety.
3 Data collection started before 2008.
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REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2008b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2009b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED NUMBER OF 
PEOPLE RECEIVING AND 
NEEDING ANTIRETROVIRAL 
THERAPY AND COVERAGE, 
2008-2009. LOW- AND 
MIDDLE-INCOME COUNTRIESa  Afghanistan  0 Dec 08  12 Dec 09 
 Albania  110 Dec 08  114 Dec 09 
 Algeria  1 111 Dec 08  1 526 Dec 09 
 Angola  14 139 f Dec 08  20 640 Dec 09 
 Argentina  40 240 f Dec 08  42 815 Dec 09 
 Armenia  100 Dec 08  179 Dec 09 
 Azerbaijan  159 Dec 08  238 Dec 09 
 Bangladesh  283 Dec 08  353 Dec 09 
 Belarus  1 249 Dec 08  1 776 Dec 09 
 Belize  630 Dec 08  855 Dec 09 
 Benin  12 078 Dec 08  15 401 Dec 09 
 Bhutan  30 Dec 08 …  
 Bolivia (Plurinational 
 State of)  758 f Dec 08  1 115 Dec 09 
 Bosnia and Herzegovina  33 Dec 08  38 Dec 09 
 Botswana  117 045 Dec 08  145 190 Dec 09 
 Brazil  194 984 f Dec 08 …  
 Bulgaria  251 Dec 08  327 Dec 09 
 Burkina Faso  21 103 Dec 08  26 448 Dec 09 
 Burundi  14 343 Dec 08  17 661 Dec 09 
 Cambodia  31 999 Dec 08  37 315 Dec 09 
 Cameroon  59 960 Dec 08  76 228 Dec 09 
 Cape Verde  360 Dec 08  611 Dec 09 
 Central African Republic  10 551 f Dec 08  14 474 Dec 09 
 Chad  17 900 f Oct 08  32 288 Dec 09 
 Chile  10 904 f Dec 08  12 762 Dec 09 
 China  48 254 Dec 08  65 481 Dec 09 
 Colombia  17 551 f Dec 08  16 302 Dec 09 
 Comoros  8 Dec 08  12 Dec 09 
 Congo  9 400 Dec 08  7 998 Dec 09 
 Cook Islands  1 Dec 08 …  
 Costa Rica  2 886 f Dec 08  3 064 Dec 09 
 Côte d’Ivoire  51 820 f Dec 08  72 011 Dec 09 
 Croatia  398 Dec 08  441 Dec 09 
 Cuba  3 999 Dec 08  5 034 Dec 09 
 Democratic People’s 
 Republic of Korea  0 Dec 06 …  
 Democratic Republic 
 of the Congo  24 645 f Dec 08  34 967 Dec 09 
 Djibouti  816 Dec 08  913 Dec 09 
 Dominica  36 f Dec 08  38 Dec 09 
 Dominican Republic  11 072 f Dec 08  13 785 Dec 09 
 Ecuador  3 728 Dec 08  5 538 Dec 09 
 Egypt  291 Dec 08  359 Dec 09 
 El Salvador  7 104 Dec 08  8 348 Dec 09 
 Equatorial Guinea  839 Dec 08  1 645 Dec 09 
 Eritrea  4 299 f Dec 08  4 955 Dec 09 
 Ethiopia  132 379 Dec 08  176 632 Dec 09 
 Fiji  39 Dec 08  52 Nov 09 
 Gabon  7 773 Dec 08  9 976 Dec 09 
 Gambia  770 Dec 08  921 Sep 09 
 Georgia  498 Dec 08  655 Dec 09 
 Ghana  21 548 f Dec 08  30 265 Dec 09 
UNGASS Indicator 4
MDG 6b indicator
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Estimate Estimate Estimate EstimateLow 
estimate
Low 
estimate
Low 
estimate
Low 
estimate
High 
estimate
High 
estimate
High 
estimate
High 
estimate
ESTIMATED 
NUMBER 
OF PEOPLE 
NEEDING 
ANTIRETROVIRAL 
THERAPY BASED 
ON COUNTRY 
REPORT, 2009d
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2010 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2010 GUIDELINES, 2009b
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2006 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2006 GUIDELINES, 2009b,e
…   …   …   …   …
…   …   …   …   …
 6 000  4 500  8 000 25% 19% 34%  3 700  2 700  4 900 42% 31% 56% …
 86 000  65 000  110 000 24% 19% 32%  59 000  43 000  79 000 35% 26% 48%  84 250
 61 000  42 000  74 000 70% 58% >95%  50 000  37 000  58 000 86% 74% >95% …
<1 000 <1 000 <1 000 24% 20% 29% <500 <500 <1 000 39% 32% 47%  352
 1 100 <1 000  1 400 21% 16% 29% <1 000 <500 <1 000 36% 26% 51%  418
 1 500 <1 000  2 000 23% 17% 39% <1 000 <500  1 200 40% 28% 71%  740
 6 000  4 700  7 800 29% 23% 37%  3 700  3 000  4 500 48% 40% 59%  2 852
 2 100  1 800  2 500 40% 34% 47%  1 500  1 200  1 800 57% 49% 69%  1 394
 29 000  24 000  34 000 53% 45% 64%  21 000  17 000  26 000 72% 59% 88%  20 396
<500 <200 <500 14% 10% 29% <200 <100 <200 26% 16% 53% …
 6 000  4 700  7 600 19% 15% 24%  3 900  3 100  5 000 28% 22% 36%  5 050
…   …   …   …    50
 170 000  150 000  190 000 83% 77% >95%  140 000  120 000  150 000 >95% 94% >95%  161 706
…g  220 000  390 000 … 50% 89% …g  190 000  300 000 … 65% 101% …
 1 400  1 100  1 800 23% 18% 30% <1 000 <1 000  1 100 38% 29% 50% …
 58 000  46 000  71 000 46% 37% 58%  44 000  34 000  55 000 60% 48% 77%  56 241
 91 000  79 000  100 000 19% 17% 22%  65 000  53 000  78 000 27% 23% 33%  57 438
 40 000  28 000  55 000 94% 68% >95%  33 000  24 000  44 000 >95% 86% >95%  40 483
 270 000  230 000  310 000 28% 25% 33%  190 000  150 000  220 000 41% 34% 51%  164 070
…   …   …   …   …
 74 000  64 000  85 000 19% 17% 23%  51 000  41 000  61 000 28% 24% 35%  40 334
 90 000  73 000  110 000 36% 30% 44%  61 000  47 000  79 000 53% 41% 68%  66 000
 20 000  17 000  24 000 63% 53% 76%  16 000  12 000  19 000 81% 68% >95%  15 520
…h  170 000  350 000 … 19% 38% …h  97 000  210 000 … 31% 67%  190 000
 95 000  79 000  120 000 17% 14% 21%  63 000  53 000  75 000 26% 22% 31%  22 924
<100 <100 <100 18% 13% 24% <100 <100 <100 29% 21% 40%  12
 35 000  30 000  41 000 23% 19% 27%  25 000  20 000  30 000 33% 26% 41% …
…   …   …   …   …
 4 500  3 100  6 100 68% 50% >95%  3 500  2 500  4 800 86% 64% >95% …
 260 000  220 000  300 000 28% 24% 32%  180 000  150 000  220 000 39% 33% 47%  164 000
<1 000 <500 <1 000 80% 62% >95% <500 <500 <1 000 >95% 75% >95% …
 3 500  2 900  4 100 >95% >95% >95%  2 900  2 400  3 400 >95% >95% >95%  5 034
<1 000 <1 000 <1 000 0%   <500 <500 <1 000 0%   …
…h  170 000  240 000 … 14% 21% …h  110 000  180 000 … 20% 32%  283 055
 6 400  4 700  8 200 14% 11% 20%  4 300  3 100  5 700 21% 16% 29%  4 235
…   …   …   …    13
 29 000  25 000  34 000 47% 41% 55%  22 000  18 000  25 000 64% 55% 77%  19 410
 19 000  14 000  26 000 30% 21% 40%  16 000  10 000  22 000 36% 25% 54%  13 128
 3 300  1 600  3 000 11% 12% 22%  1 900  1 600  3 000 19% 12% 22%  1 500
 16 000  10 000  22 000 53% 38% 84%  13 000  8 100  16 000 66% 51% >95% …
 6 600  4 700  8 800 25% 19% 35%  4 300  2 800  6 000 39% 27% 58%  3 108
 14 000  10 000  18 000 37% 28% 49%  9 700  7 300  13 000 51% 39% 68%  7 182
…h  280 000  390 000 … 45% 62% …h  200 000  310 000 … 58% 86%  336 160
<200 <200 <500 30% 23% 40% <200 <100 <200 52% 38% 73% …
 21 000  16 000  26 000 47% 38% 61%  15 000  12 000  19 000 66% 53% 86%  14 258
 5 000  3 100  7 300 18% 13% 30%  3 300  2 000  5 000 28% 18% 45%  1 500
 1 000 <1 000  1 300 65% 51% 91% <1 000 <500 <1 000 >95% 77% >95%  686
 130 000  110 000  150 000 24% 21% 28%  85 000  69 000  100 000 36% 29% 44%  70 988
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REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2008b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2009b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED NUMBER OF 
PEOPLE RECEIVING AND 
NEEDING ANTIRETROVIRAL 
THERAPY AND COVERAGE, 
2008-2009. LOW- AND 
MIDDLE-INCOME COUNTRIESa  Grenada  46 f Dec 08  54 Dec 09 
 Guatemala  9 694 Dec 08  10 362 Dec 09 
 Guinea  9 212 Dec 08  14 999 Dec 09 
 Guinea-Bissau  1 832 f Dec 08  2 764 Dec 09 
 Guyana  2 473 Dec 08  2 832 Dec 09 
 Haiti  19 990 f Dec 08  26 007 Dec 09 
 Honduras  6 288 Dec 08  7 075 Dec 09 
 Hungary  559 f Dec 08  547 Dec 09 
 India  234 581 i Dec 08  320 074 i Dec 09 
 Indonesia  10 606 f Dec 08  15 442 Nov 09 
 Iran (Islamic Republic of)  878 Sep 08  1 486 Jan 10 
 Iraq  4 Dec 08 …  
 Jamaica  4 444 f Dec 08  7 244 Dec 09 
 Jordan  58 Dec 08  63 Dec 09 
 Kazakhstan  707 Dec 08  1 035 Jan 10 
 Kenya  250 576 f Dec 08  336 980 Dec 09 
 Kiribati  6 Dec 08 …  
 Kyrgyzstan  89 Dec 08  231 Jan 10 
 Lao People’s 
 Democratic Republic  1 009 Dec 08  1 345 Dec 09 
 Latvia  334 Dec 08  439 Dec 09 
 Lebanon  285 f Dec 08  354 Dec 09 
 Lesotho  45 262 Dec 08  61 736 Dec 09 
 Liberia  2 017 f Dec 08  2 970 Dec 09 
 Libyan Arab Jamahiriya  1 000 Dec 07 …  
 Lithuania  127 Dec 08  145 Dec 09 
 Madagascar  162 Dec 08  214 Dec 09 
 Malawi  147 497 f Dec 08  198 846 Dec 09 
 Malaysia  8 197 Dec 08  9 962 Mar 10 
 Maldives  2 Dec 08  3 Dec 09 
 Mali  16 475 f Dec 08  21 100 Dec 09 
 Marshall Islands  4 Dec 08  4 Dec 09 
 Mauritania  1 072 f Dec 08  1 401 Dec 09 
 Mauritius  491 f Jan 08  652 Dec 09 
 Mexico  55 599 f Dec 08  60 911 Dec 09 
 Micronesia (Federated 
 States of)  2 f Dec 08  5 Dec 09 
 Mongolia  5 Dec 08  9 Dec 09 
 Montenegro  25 Dec 08  31 Mar 10 
 Morocco  2 207 Dec 08  2 647 Dec 09 
 Mozambique  128 330 Dec 08  170 198 Dec 09 
 Myanmar  15 191 Dec 08  21 138 Dec 09 
 Namibia  59 376 Dec 08  70 498 Sep 09 
 Nauru  0 Dec 08 …  
 Nepal  1 992 f Jul 08  3 226 Jul 09 
 Nicaragua  744 f Dec 08  1 063 Dec 09 
 Niger  2 846 Dec 08  6 445 Dec 09 
 Nigeria  238 659 Dec 08  302 973 Dec 09 
 Niue  0 Dec 08 …  
 Oman  412 Dec 08  486 Dec 09 
 Pakistan  875 f Dec 08  1 320 Dec 09 
 Palau  3 Dec 08  3 Dec 09 
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Estimate Estimate Estimate EstimateLow 
estimate
Low 
estimate
Low 
estimate
Low 
estimate
High 
estimate
High 
estimate
High 
estimate
High 
estimate
ESTIMATED 
NUMBER 
OF PEOPLE 
NEEDING 
ANTIRETROVIRAL 
THERAPY BASED 
ON COUNTRY 
REPORT, 2009d
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2010 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2010 GUIDELINES, 2009b
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2006 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2006 GUIDELINES, 2009b,e
…   …   …   …    59
 24 000  18 000  31 000 44% 33% 59%  16 000  12 000  21 000 63% 48% 84%  14 966
 38 000  30 000  46 000 40% 32% 50%  27 000  20 000  35 000 56% 43% 74%  22 500
 9 100  7 300  11 000 30% 25% 38%  6 000  4 700  7 600 46% 36% 59%  5 885
 2 900  1 700  4 200 >95% 68% >95%  2 700  1 700  3 700 >95% 76% >95%  3 390
 60 000  49 000  71 000 43% 37% 53%  43 000  34 000  52 000 61% 50% 76%  38 491
 21 000  16 000  27 000 33% 26% 44%  15 000  12 000  18 000 47% 38% 61%  13 356
 2 100  1 600  2 600 27% 21% 34%  1 600  1 200  2 000 35% 28% 44% …
1 200 000 1 100 000 1 400 000 26% 23% 28%  790 000  700 000  890 000 41% 36% 46%  580 000
 73 000  50 000  110 000 21% 14% 31%  45 000  26 000  64 000 34% 24% 58%  40 200
 40 000  33 000  48 000 4% 3% 4%  23 000  18 000  29 000 6% 5% 8%  16 540
…   …   …   …   …
 16 000  12 000  20 000 46% 36% 62%  11 000  8 500  13 000 67% 55% 85%  14 000
…   …   …   …   …
 3 800  2 600  5 400 27% 19% 40%  2 300  1 600  3 300 45% 31% 66%  1 900
 710 000  610 000  800 000 48% 42% 55%  520 000  430 000  610 000 65% 55% 79%  555 000
…   …   …   …   …
 1 900 <1 000  2 700 12% 9% 24%  1 000 <1 000  1 600 22% 15% 46%  450
 2 000  1 200  2 800 67% 48% >95%  1 300 <1 000  1 900 >95% 71% >95%  1 461
 3 600  2 700  4 600 12% 9% 16%  2 100  1 600  2 800 21% 16% 28% …
 1 900  1 500  2 500 18% 14% 24%  1 200 <1 000  1 600 29% 22% 37%  1 171
 130 000  110 000  140 000 48% 43% 54%  90 000  75 000  110 000 68% 58% 83%  122 818
 22 000  17 000  27 000 14% 11% 17%  15 000  11 000  19 000 20% 15% 27%  10 023
…   …   …   …   …
<1 000 <500 <1 000 27% 21% 34% <500 <500 <500 42% 32% 52%  274
 10 000  8 300  12 000 2% 2% 3%  6 000  4 900  7 600 4% 3% 4%  5 000
 440 000  370 000  500 000 46% 40% 53%  310 000  260 000  370 000 63% 53% 77%  305 805
 43 000  34 000  55 000 23% 18% 29%  26 000  22 000  31 000 38% 32% 44%  20 977
<100 <100 <100 17% 14% 23% <100 <100 <100 28% 22% 36%  71
 42 000  34 000  51 000 50% 41% 61%  32 000  26 000  40 000 65% 53% 81%  31 410
…   …   …   …    8
 5 700  4 700  6 900 25% 20% 30%  3 500  2 800  4 300 41% 33% 51%  2 790
 2 900  2 200  3 800 22% 17% 30%  1 700  1 300  2 300 38% 28% 51%  1 587
 110 000  89 000  130 000 54% 46% 68%  86 000  69 000  98 000 71% 62% 88%  74 000
…   …   …   …    5
<200 <100 <200 8% 6% 15% <100 <100 <100 15% 10% 31%  53
…   …   …   …    388
 9 800  7 500  13 000 27% 21% 35%  6 300  4 900  8 100 42% 33% 54%  5 266
 570 000  500 000  650 000 30% 26% 34%  380 000  310 000  470 000 45% 36% 55%  445 672
 120 000  98 000  140 000 18% 15% 22%  75 000  60 000  89 000 28% 24% 35%  74 058
 93 000  77 000  110 000 76% 62% 92%  70 000  56 000  86 000 >95% 82% >95%  76 727
…   …   …   …   …
 31 000  26 000  36 000 11% 9% 13%  19 000  16 000  23 000 17% 14% 21%  16 950
 2 600  2 100  3 300 40% 32% 51%  1 700  1 400  2 200 62% 49% 79%  1 580
 29 000  26 000  31 000 22% 21% 25%  19 000  15 000  23 000 33% 28% 42%  16 738
1 400 000 1 200 000 1 700 000 21% 18% 25%  990 000  790 000 1 200 000 31% 25% 38%  882 139
…   …   …   …   …
<500 <500 <1 000 >95% 83% >95% <500 <200 <500 >95% >95% >95%  513
 36 000  27 000  48 000 4% 3% 5%  21 000  16 000  27 000 6% 5% 8%  13 422
…   …   …   …   …
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REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2008b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2009b,c
MONTH AND 
YEAR OF 
REPORT
REPORTED NUMBER OF 
PEOPLE RECEIVING AND 
NEEDING ANTIRETROVIRAL 
THERAPY AND COVERAGE, 
2008-2009. LOW- AND 
MIDDLE-INCOME COUNTRIESa  Panama  3 972 f Dec 08  4 463 Dec 09 
 Papua New Guinea  5 195 Dec 08  6 751 Dec 09 
 Paraguay  1 613 Dec 08  2 073 Dec 09 
 Peru  10 232 f Dec 08  14 780 Dec 09 
 Philippines  532 Dec 08  750 Dec 09 
 Poland  3 822 Dec 08  4 329 Dec 09 
 Republic of Moldova  682 Dec 08  984 Dec 09 
 Romania  7 434 Dec 08  7 244 Dec 09 
 Russian Federation  54 900 Dec 08  75 900 Dec 09 
 Rwanda  63 149 Dec 08  76 726 Dec 09 
 Saint Kitts and Nevis …  …  
 Saint Lucia  85 f Dec 08  124 Dec 09 
 Saint Vincent and 
 the Grenadines  120 f Dec 08  162 Dec 09 
 Samoa  8 Dec 08 …  
 Sao Tome and Principe  109 Dec 08  169 Dec 09 
 Senegal  9 252 f Dec 08  12 249 Dec 09 
 Serbia  842 Dec 08  790 Dec 09 
 Seychelles  113 Dec 08  139 Dec 09 
 Sierra Leone  1 950 f Feb 09  3 660 Dec 09 
 Slovakia  97 Dec 08 …  
 Solomon Islands  3 f Dec 08  4 Dec 09 
 Somalia  413 Dec 08  578 Dec 09 
 South Africa  730 183 Dec 08  971 556 j Oct 09 
 Sri Lanka  142 f Dec 08  207 Dec 09 
 Sudan  1 151 k Dec 08  3 825 k Dec 09 
 Suriname  858 f Dec 08  996 Jul 09 
 Swaziland  32 701 Dec 08  47 241 Dec 09 
 Syrian Arab Republic  73 f Dec 08  99 Dec 09 
 Tajikistan  138 f Dec 08  322 Dec 09 
 Thailand  185 086 f Sep 08  216 118 Sep 09 
 The former Yugoslav 
 Republic of Macedonia  23 Dec 08  24 Dec 09 
 Timor-Leste  29 Dec 08  31 Dec 09 
 Togo  11 211 Dec 08  16 710 Dec 09 
 Tonga  2 Dec 08 …  
 Tunisia  326 f Dec 08  412 Dec 09 
 Turkey  900 Dec 08  1 000 Dec 09 
 Turkmenistan  0 Dec 08 …  
 Tuvalu  1 Dec 08  1 Dec 09 
 Uganda  153 718 Sep 08  200 413 Sep 09 
 Ukraine  10 629 f Dec 08  15 871 Dec 09 
 United Republic 
 of Tanzania  154 468 Dec 08  199 413 Dec 09 
 Uruguay …   2 510 Dec 09 
 Uzbekistan  1 200 Dec 08  1 753 Dec 09 
 Vanuatu  2 Dec 08  2 Dec 09 
 Venezuela (Bolivarian 
 Republic of)  27 240 f Dec 08  32 302 Dec 09 
 Viet Nam  25 597 Dec 08  37 995 Dec 09 
 Yemen  189 Dec 08  274 Dec 09 
 Zambia  219 576 f Dec 08  283 863 Dec 09 
 Zimbabwe  148 144 f Dec 08  218 589 Feb 10 
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Estimate Estimate Estimate EstimateLow 
estimate
Low 
estimate
Low 
estimate
Low 
estimate
High 
estimate
High 
estimate
High 
estimate
High 
estimate
ESTIMATED 
NUMBER 
OF PEOPLE 
NEEDING 
ANTIRETROVIRAL 
THERAPY BASED 
ON COUNTRY 
REPORT, 2009d
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2010 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2010 GUIDELINES, 2009b
ESTIMATED NUMBER OF PEOPLE 
NEEDING ANTIRETROVIRAL 
THERAPY BASED ON WHO 2006 
GUIDELINES, 2009b,d
ESTIMATED ANTIRETROVIRAL 
THERAPY COVERAGE BASED ON 
WHO 2006 GUIDELINES, 2009b,e
 12 000  8 200  22 000 37% 21% 54%  8 400  6 100  14 000 53% 32% 73%  20 836
 13 000  10 000  16 000 52% 42% 65%  8 800  6 500  11 000 77% 59% >95%  9 061
 5 600  4 200  7 400 37% 28% 49%  3 600  2 900  4 500 57% 46% 70%  3 066
 40 000  33 000  48 000 37% 31% 44%  26 000  22 000  31 000 57% 47% 67%  20 201
 2 000  1 000  2 800 37% 27% 75%  1 300 <1 000  1 800 60% 42% >95%  919
 20 000  14 000  27 000 22% 16% 31%  17 000  12 000  22 000 26% 19% 35%  5 000
 5 800  4 800  7 200 17% 14% 20%  3 500  2 900  4 400 28% 22% 34%  2 780
 9 000  5 300  13 000 81% 55% >95%  7 700  4 700  10 000 95% 71% >95%  7 244
…h  320 000  460 000 … 16% 24% …h  180 000  280 000 … 27% 42%  79 116
 88 000  71 000  100 000 88% 74% >95%  72 000  55 000  88 000 >95% 87% >95%  104 900
…   …   …   …   …
…   …   …   …    134
…   …   …   …    182
…   …   …   …   …
…   …   …   …    1 096
 24 000  20 000  28 000 51% 43% 62%  17 000  13 000  21 000 72% 58% 92%  16 198
 2 100  1 600  2 700 38% 30% 51%  1 400  1 100  1 800 55% 44% 75%  950
…   …   …   …    146
 20 000  16 000  24 000 18% 15% 23%  13 000  9 400  16 000 29% 22% 39%  7 277
<200 <200 <500 62% 46% 86% <200 <100 <200 78% 56% >95% …
…   …   …   …    4
 10 000  7 300  13 000 6% 4% 8%  6 300  4 200  8 700 9% 7% 14%  5 213
2 600 000 2 500 000 2 800 000 37% 35% 39% 1 700 000 1 500 000 2 000 000 56% 48% 65% 1 630 000
 1 100 <1 000  1 400 20% 15% 26% <1 000 <500 <1 000 33% 24% 45%  510
 74 000  60 000  90 000 5% 4% 6%  46 000  34 000  61 000 8% 6% 11%  45 466
 1 900  1 400  2 600 53% 39% 72%  1 300  1 000  1 700 76% 57% >95% …
 80 000  71 000  88 000 59% 53% 66%  56 000  47 000  65 000 85% 72% >95%  52 965
…   …   …   …   …
 3 000  2 300  3 900 11% 8% 14%  1 700  1 300  2 300 19% 14% 25%  579
 350 000  280 000  440 000 61% 50% 78%  290 000  230 000  350 000 76% 62% 95%  285 271
…   …   …   …    442
…   …   …   …    151
 58 000  44 000  73 000 29% 23% 38%  40 000  29 000  51 000 42% 33% 57%  33 030
…   …   …   …   …
<1 000 <1 000  1 000 53% 41% 72% <1 000 <500 <1 000 79% 60% >95%  470
 1 600  1 200  2 100 62% 48% 84%  1 100 <1 000  1 500 90% 67% >95%  1 400
…   …   …   …   …
…   …   …   …    1
 520 000  430 000  600 000 39% 33% 46%  380 000  300 000  450 000 53% 44% 67%  373 383
 160 000  140 000  190 000 10% 9% 11%  99 000  85 000  110 000 16% 14% 19%  33 016
 660 000  580 000  750 000 30% 27% 34%  450 000  380 000  550 000 44% 36% 53%  361 295
 5 100  4 300  6 100 49% 41% 59%  3 700  3 100  4 400 67% 57% 81%  3 018
…g   …   …g   …    2 850
…   …   …   …    2
…g   …   …g   …    161 510
 110 000  84 000  150 000 34% 26% 45%  85 000  67 000  110 000 45% 35% 56%  67 047
…   …   …   …    3 150
 440 000  380 000  510 000 64% 56% 75%  330 000  270 000  390 000 85% 72% >95%  416 533
 640 000  580 000  720 000 34% 30% 38%  450 000  390 000  520 000 49% 42% 57%  389 895
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REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2005-2008
MONTH AND 
YEAR OF 
REPORT
REPORTED 
NUMBER 
OF PEOPLE 
RECEIVING 
ANTIRETRO-
VIRAL THERAPY, 
2009
MONTH AND 
YEAR OF 
REPORT
REPORTED NUMBER OF 
PEOPLE RECEIVING AND 
NEEDING ANTIRETROVIRAL 
THERAPY AND COVERAGE, 
2008-2009. HIGH INCOME 
COUNTRIESa  Andorra  25 Dec 07 … 
 Antigua and Barbuda  148 Sep 07  98 Dec 09
 Australia  9 933 Dec 07 … 
 Austria  2 250 Dec 08  1 800 Sep 09
 Bahamas  1 244 Sep 07  1 506 Dec 09
 Bahrain …  … 
 Barbados  719 Dec 08  804 Dec 09
 Belgium  6 928 Dec 07 … 
 Brunei Darussalam  10 Dec 08  15 Jan 10
 Canada  27 000 Dec 08 … 
 Cyprus  151 Dec 07  187 Dec 09
 Czech Republic  570 Jun 07  706 Oct 09
 Denmark  3 000 Dec 08  3 000 Oct 09
 Estonia  772 Dec 07  1 263 Dec 09
 Finland  450 Aug 06 … 
 France  79 680 Dec 08 … 
 Germany  36 500 Dec 08  37 000 Jun 09
 Greece  3 746 Dec 07 … 
 Iceland  100 l <05 … 
 Ireland  1 600 Dec 05 … 
 Israel  2 876 Dec 08 … 
 Italy  95 000 Dec 08 … 
 Japan  48 Dec 06  94 Mar 09
 Kuwait …  131 Dec 09
 Luxembourg  344 Dec 08  434 Dec 09
 Malta  65 Jun 07  100 Dec 09
 Monaco  45 Dec 05 … 
 Netherlands  7 919 Apr 07 … 
 New Zealand …  1 204 Jun 09
 Norway  900 Dec 05 … 
 Portugal  12 366 Dec 08  18 107 Dec 09
 Qatar …  70 Jan 09
 Republic of Korea …  … 
 San Marino …  … 
 Saudi Arabia  865 Dec 08 … 
 Singapore …  … 
 Slovenia  157 Jul 07 … 
 Spain  82 710 Dec 08  79 500 Dec 09
 Sweden  2 800 Dec 06  4 185 Dec 09
 Switzerland …  … 
 Trinidad and Tobago  3 172 Dec 08  2 639 Dec 09
 United Arab Emirates  59 Sep 07 … 
 United Kingdom  39 556 Dec 07  39 704 Dec 09
 United States 
 of America  268 000 l <05 … 
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… Data not available or not applicable.
a Countries classifi ed by World Bank income status.
b Antiretroviral therapy data by age and available.
c Private sector data have been included in the total number of people on treatment, when available, but only South Africa and India have specifi ed how 
many of the total number number of people on treatment received it through private facilities.
d The needs estimates are based on the methods described in the explanatory notes.
e The coverage estimates are based on the estimated unrounded numbers of people receiving antiretroviral therapy and the estimated unrounded need 
for antiretroviral therapy (based on UNAIDS/WHO methodology). The ranges in coverage estimates are based on plausibility bounds in the denominator: 
that is, low and high estimates of need.
f Updated 2008 value. See last year’s annex (http://www.who.int/entity/hiv/data/tuapr2009_annex1.xls).
g Estimates of the number of people needing antitretroviral therapy are currently being reviewed and will be adjusted, as appropriate, based on ongoing 
data collection and analysis.
h At the request of the country, only ranges in the estimates are being presented.
i By December 2009, the government reported that 285 074 people were receiving antiretroviral therapy through the public sector sites. A further 
estimated 35 000 people were treated in the unorganized private sector – the same fi gure as in 2008. Overall, an estimated 320 074 people were 
receiving antiretroviral therapy by the end of 2009, including those enrolled through private facilities.
j The number collected from public sector health facilities only is 919 923 and was provided by the Department of Health based on routine monitoring 
data. The majority of these facilities report people currently on treatment. The main AIDS Disease Management organisation, Aid for AIDS, reported 
that they had 51 633 patients on treatment in 2009, and the government estimated that this represents the majority of people on treatment in the private 
sector.
k Two separate reports were received for 2009 from Sudan: northern Sudan, 1996; southern Sudan, 1829. The fi gure of 1151 for 2008 applies to northern 
Sudan only.
l ‘<05’ indicates that data exist but no update has been received since December 2004. These data should be interpreted cautiously, as they may refl ect 
the situation in early 2004 or even 2003.
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Month and 
year of 
report
Males % of total Females % of total
REPORTED NUMBER OF MALES AND FEMALES 
RECEIVING ANTIRETROVIRAL THERAPY
PEOPLE RECEIVING 
ANTIRETROVIRAL THERAPY 
IN LOW- AND MIDDLE-
INCOME COUNTRIES, AND 
ESTIMATED CHILDREN 
RECEIVING AND NEEDING 
ANTIRETROVIRAL THERAPY, 
AND COVERAGE, 2009. 
LOW- AND MIDDLE-INCOME 
COUNTRIESa
 Afghanistan  …  …  
 Albania  …  …  
 Algeria Dec 09 d  762 51%  739 49% 
 Angola Dec 08 d  2 444 31%  5 440 69% 
 Argentina Dec 08 d  26 791 64%  15 250 36% 
 Armenia Dec 09  114 64%  65 36% 
 Azerbaijan Dec 09  178 75%  60 25% 
 Bangladesh  …  …  
 Belarus Dec 09  1 032 58%  744 42% 
 Belize Dec 09  444 52%  411 48% 
 Benin Dec 09  6 468 42%  8 933 58% 
 Bhutan Dec 08  14 47%  16 53% 
 Bolivia (Plurinational 
 State of) Dec 09  721 65%  394 35% 
 Bosnia and Herzegovina Dec 09 d  26 70%  11 30% 
 Botswana Dec 09  56 566 39%  88 624 61% 
 Brazil Dec 08 d  106 769 57%  79 867 43% 
 Bulgaria Dec 09  223 68%  104 32% 
 Burkina Faso Dec 09  8 609 33%  17 839 67% 
 Burundi Dec 09  5 869 33%  11 792 67% 
 Cambodia Dec 09  17 873 48%  19 442 52% 
 Cameroon Dec 09  25 196 33%  51 032 67% 
 Cape Verde Dec 09  272 45%  339 55% 
 Central African Republic Dec 08 e  4 321 45%  5 229 55% 
 Chad Dec 09  11 888 37%  20 400 63% 
 Chile Dec 09  10 376 81%  2 386 19% 
 China Dec 09 d  38 350 59%  26 659 41% 
 Colombia Dec 09  12 254 75%  4 043 25% 
 Comoros Dec 09  6 50%  6 50% 
 Congo Dec 08 d,e  3 565 40%  5 347 60% 
 Cook Islands  …  …  
 Costa Rica  …  …  
 Côte d’Ivoire Dec 09  21 603 30%  50 408 70% 
 Croatia Dec 09  366 83%  75 17% 
 Cuba Dec 09  4 027 80%  1 007 20% 
 Democratic People’s 
 Republic of Korea  …  …  
 Democratic Republic 
 of the Congo  …  …  
 Djibouti Dec 09  451 49%  462 51% 
 Dominica Dec 09 d  10 91%  1 9% 
 Dominican Republic  …  …  
 Ecuador  …  …  
 Egypt  …  …  
 El Salvador Dec 08 e  4 262 60%  2 842 40% 
 Equatorial Guinea Dec 08 e  235 28%  604 72% 
 Eritrea Dec 09  2 153 43%  2 802 57% 
 Ethiopia Dec 09 d  90 527 45%  111 693 55% 
 Fiji Nov 09  25 48%  27 52% 
 Gabon Dec 09  3 492 35%  6 484 65% 
 Gambia  …  …  
 Georgia Dec 09  468 71%  187 29% 
 Ghana Dec 09 d  10 477 33%  20 954 67% 
UNGASS Indicator 4
MDG 6b indicator
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Month and 
year of 
report
Estimate EstimateAdults 
(15+)
Low 
estimate
Low 
estimate
% of total High 
estimate
High 
estimate
Children 
(<15)
% of total
REPORTED NUMBER OF ADULTS AND CHILDREN 
RECEIVING ANTIRETROVIRAL THERAPY
ESTIMATED NUMBER OF CHILDREN NEED-
ING ANTIRETROVIRAL THERAPY BASED 
ON UNAIDS/WHO METHODS, 2009b
ESTIMATED ANTIRETROVIRAL THERAPY 
COVERAGE AMONG CHILDREN, 
DECEMBER 2009c
Dec 09  12 100%  0 0% …   …  
Dec 09  99 87%  15 13% …   …  
Dec 09  1 429 94%  97 6% … <100 <500 … 36% >95%
Dec 09  19 092 93%  1 548 8%  12 000  6 300  18 000 13% 8% 25%
Dec 08 e  40 041 95%  2 000 5% … <500 <1 000 … >95% >95%
Dec 09  172 96%  7 4% … <100 <100 … 54% >95%
Dec 09  235 99%  3 1% … <100 <200 … 3% 9%
Dec 08 e  277 98%  6 2% … <100 <200 … 6% 16%
Dec 09  1 681 95%  95 5% … <100 <200 … 77% >95%
Dec 09  775 91%  80 9% … <200 <500 … 28% 66%
Dec 09  14 266 93%  1 135 7%  2 700  1 500  4 100 41% 28% 77%
Dec 08  29 97%  1 3% … <100 <100 … 8% 33%
Dec 09  1 065 96%  50 4% … <200 <1 000 … 8% 28%
Dec 09  37 97%  1 3% …   …  
Jan 09  136 700 94%  8 490 6%  9 400  8 200  11 000 90% 76% >95%
Dec 08 d  178 697 96%  7 939 4% … f  8 200  12 000 … 65% >95%
Dec 09  324 99%  3 1% … <100 <100 … 10% 33%
Dec 09  25 094 95%  1 354 5%  8 000  3 900  12 000 17% 11% 35%
Dec 09  16 065 91%  1 596 9%  14 000  8 500  20 000 11% 8% 19%
Dec 09  33 677 90%  3 638 10% …  2 800  6 100 … 60% >95%
Dec 09 e  73 114 96%  3 114 4%  28 000  15 000  41 000 11% 8% 20%
Dec 09  574 94%  37 6% …   …  
Dec 09  13 750 95%  724 5%  7 600  3 600  11 000 9% 6% 20%
Dec 09 d  31 514 98%  774 2%  12 000  6 600  19 000 6% 4% 12%
Dec 08 e  10 865 98%  186 2% … <500 <1 000 … 21% 59%
Dec 09  63 887 98%  1 594 2% …  2 100  7 600 … 21% 74%
 …  …  …  1 000  3 400 … <1% <1%
Jan 09  11 92%  1 8% … <100 <100 … 14% 50%
Dec 08 e  8 912 95%  488 5%  4 000  2 000  5 900 12% 8% 24%
Dec 08  1 100%  0 0% …   …  
Dec 09  3 003 98%  61 2% … <100 <200 … 33% >95%
Dec 09  67 662 94%  4 349 6%  29 000  14 000  42 000 15% 10% 30%
Dec 09  438 99%  3 1% … <100 <100 … 30% >95%
Dec 09  5 014 100%  20 0% … <100 <100 … 22% 59%
 …  …  … <100 <100 …  
Dec 08 e  20 470 83%  4 053 17% … g  17 000  46 000 … 9% 23%
Dec 09  889 97%  24 3% <1 000 <500 <1 000 4% 2% 8%
Dec 09  37 97%  1 3% …   …  
Dec 08 e  10 266 93%  782 7% … <1 000  2 900 … 27% 84%
Dec 09  5 131 93%  407 7% … <500  1 000 … 39% >95%
Dec 09  332 92%  27 8% … <100 <500 … 12% 36%
Dec 09  8 048 96%  300 4% …  1 100  1 500 … 20% 28%
Dec 09  1 618 98%  27 2% <1 000 <500  1 500 3% 2% 7%
Dec 09  4 631 93%  324 7%  1 500 <1 000  2 400 21% 14% 45%
Dec 09  166 640 94%  9 992 6% … g  27 000  74 000 … 14% 38%
Nov 09  51 98%  1 2% … <100 <100 … 20% >95%
Dec 09  9 701 97%  275 3%  1 600 <1 000  2 500 17% 11% 34%
Dec 08 e  461 60%  309 40% … <500  1 300 … 25% 88%
Dec 09  627 96%  28 4% … <100 <100 … 62% >95%
Dec 09  28 648 95%  1 617 5%  13 000  6 700  20 000 12% 8% 24%
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Month and 
year of 
report
Males % of total Females % of total
REPORTED NUMBER OF MALES AND FEMALES 
RECEIVING ANTIRETROVIRAL THERAPY
PEOPLE RECEIVING 
ANTIRETROVIRAL THERAPY 
IN LOW- AND MIDDLE-
INCOME COUNTRIES, AND 
ESTIMATED CHILDREN 
RECEIVING AND NEEDING 
ANTIRETROVIRAL THERAPY, 
AND COVERAGE, 2009. 
LOW- AND MIDDLE-INCOME 
COUNTRIESa
 Grenada Dec 09  27 53%  24 47% 
 Guatemala Dec 09  5 904 57%  4 458 43% 
 Guinea Dec 09  5 850 39%  9 149 61% 
 Guinea-Bissau Dec 09  840 30%  1 924 70% 
 Guyana Dec 08 e  1 113 45%  1 360 55% 
 Haiti Dec 09  10 871 42%  15 136 58% 
 Honduras Dec 09  3 323 47%  3 752 53% 
 Hungary Dec 08 d,e  467 84%  86 16% 
 India Dec 09 d  168 598 59%  115 036 41% 
 Indonesia Dec 08 e  7 934 75%  2 682 25% 
 Iran (Islamic Republic of) Jan 10  1 198 81%  288 19% 
 Iraq Dec 08  4 100%  0 0% 
 Jamaica  …  …  
 Jordan Dec 08 e  44 76%  14 24% 
 Kazakhstan Jan 10  691 67%  344 33% 
 Kenya Sep 09 d,e  107 401 36%  190 429 64% 
 Kiribati  …  …  
 Kyrgyzstan Jan 10  158 68%  73 32% 
 Lao People’s 
 Democratic Republic Dec 09  722 54%  623 46% 
 Latvia Dec 08 e  240 72%  94 28% 
 Lebanon  …  …  
 Lesotho Dec 09  22 471 36%  39 265 64% 
 Liberia Dec 09  1 079   1 891  
 Libyan Arab Jamahiriya  …  …  
 Lithuania Dec 09  113 78%  32 22% 
 Madagascar Dec 09  106   108  
 Malawi  …  …  
 Malaysia  …  …  
 Maldives Dec 09  3 100%  0 0% 
 Mali Dec 09  7 596 36%  13 504 64% 
 Marshall Islands Dec 09  1 25%  3 75% 
 Mauritania Dec 09  723 52%  678 48% 
 Mauritius  …  …  
 Mexico Dec 09  47 384 78%  13 527 22% 
 Micronesia (Federated 
 States of) Dec 09  2 40%  3 60% 
 Mongolia Dec 09  1 11%  8 89% 
 Montenegro Mar 10  26 84%  5 16% 
 Morocco Dec 09  1 372 52%  1 275 48% 
 Mozambique Sep 09 d,e  43 159 37%  72 854 63% 
 Myanmar Dec 09  11 987 57%  9 151 43% 
 Namibia Sep 09 d  26 212 37%  44 365 63% 
 Nauru Dec 08  0   0  
 Nepal Jul 09  1 928 60%  1 298 40% 
 Nicaragua Dec 09  679 64%  384 36% 
 Niger Dec 09  2 836 44%  3 609 56% 
 Nigeria Dec 09  105 122 35%  197 851 65% 
 Niue Dec 08  0   0  
 Oman Dec 08 e  262 64%  150 36% 
 Pakistan Dec 09  944 72%  376 28% 
 Palau Dec 09  1 33%  2 67% 
 Panama  …  …  
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Month and 
year of 
report
Estimate EstimateAdults 
(15+)
Low 
estimate
Low 
estimate
% of total High 
estimate
High 
estimate
Children 
(<15)
% of total
REPORTED NUMBER OF ADULTS AND CHILDREN 
RECEIVING ANTIRETROVIRAL THERAPY
ESTIMATED NUMBER OF CHILDREN NEED-
ING ANTIRETROVIRAL THERAPY BASED 
ON UNAIDS/WHO METHODS, 2009b
ESTIMATED ANTIRETROVIRAL THERAPY 
COVERAGE AMONG CHILDREN, 
DECEMBER 2009c
Dec 09  51 94%  3 6% …   …  
Dec 09  9 594 93%  768 7% … <1 000  2 500 … 31% 77%
Dec 09  14 325 96%  674 4%  4 400  2 100  6 900 15% 10% 32%
Dec 09  2 646 96%  118 4%  1 100 <1 000  1 700 10% 7% 21%
Dec 08 e  2 308 93%  165 7% … <200 <500 … 73% 92%
Dec 09  24 909 96%  1 098 4%  5 700  2 700  8 600 19% 13% 41%
Dec 09  6 356 90%  719 10% … <1 000  1 800 … 40% 81%
Dec 08 e  553 99%  6 1% … <100 <100 … 29% >95%
Dec 09 e  302 122 94%  17 952 6% …  30 000  76 000 … 24% 59%
Dec 08 e  10 260 97%  356 3% … <1 000  2 600 … 14% 48%
Jan 10  1 432 96%  54 4% … <500  1 300 … 4% 14%
Dec 08  4 100%  0 0% …   …  
Dec 09  6 808 94%  436 6% … <500 <1 000 … 52% >95%
Dec 08 e  56 97%  2 3% …   …  
Jan 10  844 82%  191 18% … <100 <200 … >95% >95%
Dec 09  308 610 92%  28 370 8%  89 000  48 000  130 000 32% 22% 59%
Dec 08  6 100%  0 0% …   …  
Jan 10  130 56%  101 44% … <100 <100 … >95% >95%
Dec 09  1 250 93%  95 7% … <100 <500 … 36% >95%
Dec 09  413 94%  26 6% … <100 <100 … 34% >95%
Dec 07 d,e …   9  … <100 <200 … 9% 28%
Dec 08 e  42 224 93%  3 038 7%  13 000  7 800  18 000 23% 17% 39%
Dec 09 e  2 704 91%  266 9%  2 900  1 400  4 500 9% 6% 19%
 …  …  …   …  
Dec 09  143 99%  2 1% … <100 <100 … 20% 67%
Dec 09  209 98%  5 2% … <500 <1 000 … 1% 2%
Dec 09  181 482 91%  17 364 9%  61 000  34 000  84 000 29% 21% 51%
Dec 08 e  7 696 94%  501 6% … <1 000 <1 000 … 88% 94%
Dec 09  3 100%  0 0% … <100 <100 … 0% 0%
Dec 09  19 834 94%  1 266 6% …  2 300  7 200 … 18% 55%
Dec 09  4 100%  0 0% …   …  
Dec 09  1 359 97%  42 3% … <200 <500 … 9% 28%
 …  …  … <100 <100 …  
Dec 09  59 317 97%  1 594 3% …  1 300  3 200 … 50% >95%
Dec 09  5 100%  0 0% …   …  
Dec 09  9 100%  0 0% … <100 <100 … 0% 0%
Mar 10  30 97%  1 3% …   …  
Dec 09  2 502 95%  145 5% … <200 <500 … 29% >95%
Dec 09  160 805 94%  9 393 6%  66 000  36 000  93 000 14% 10% 26%
Dec 09  19 603 93%  1 535 7% …  1 900  4 900 … 32% 83%
Sep 09  62 310 88%  8 188 12%  9 200  7 300  13 000 89% 65% >95%
Dec 08  0   0  …   …  
Jul 09  3 048 94%  178 6% … <1 000  2 600 … 7% 23%
Dec 09  1 007 95%  56 5% … <100 <200 … 34% 79%
Dec 09  6 187 96%  258 4% …  1 800  5 900 … 4% 15%
Dec 09  284 881 94%  18 092 6%  180 000  94 000  270 000 10% 7% 19%
Dec 08  0   0  …   …  
Dec 09  460 95%  26 5% … <100 <100 … >95% >95%
Dec 09  1 263 96%  57 4% … <1 000  2 300 … 2% 8%
Dec 09  3 100%  0 0% …   …  
Dec 09  4 207 94%  256 6% … <500 <500 … 79% >95%
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Month and 
year of 
report
Males % of total Females % of total
REPORTED NUMBER OF MALES AND FEMALES 
RECEIVING ANTIRETROVIRAL THERAPY
PEOPLE RECEIVING 
ANTIRETROVIRAL THERAPY 
IN LOW- AND MIDDLE-
INCOME COUNTRIES, AND 
ESTIMATED CHILDREN 
RECEIVING AND NEEDING 
ANTIRETROVIRAL THERAPY, 
AND COVERAGE, 2009 
LOW- AND MIDDLE-INCOME 
COUNTRIESa
 Papua New Guinea Dec 09  2 936 43%  3 815 57% 
 Paraguay Dec 08 d  1 022 69%  461 31% 
 Peru Dec 09  10 346 70%  4 434 30% 
 Philippines Dec 09  726 97%  24 3% 
 Poland Dec 09  3 130 72%  1 199 28% 
 Republic of Moldova Dec 09  571 58%  413 42% 
 Romania Dec 09  3 538 49%  3 706 51% 
 Russian Federation  …  …  
 Rwanda Dec 09  29 795 39%  46 931 61% 
 Saint Kitts and Nevis  …  …  
 Saint Lucia Dec 09  59 48%  65 52% 
 Saint Vincent and 
 the Grenadines Dec 09  87 54%  75 46% 
 Samoa  …  …  
 Sao Tome and Principe Dec 09  62 37%  107 63% 
 Senegal Dec 09  4 427 36%  7 822 64% 
 Serbia Dec 09  598 76%  192 24% 
 Seychelles Dec 09  78 56%  61 44% 
 Sierra Leone Nov 08 d,e  1 542 37%  2 680 63% 
 Slovakia Dec 08  70 72%  27 28% 
 Solomon Islands Dec 09  1 25%  3 75% 
 Somalia  …  …  
 South Africa Oct 09 d  349 967 35%  649 939 65% 
 Sri Lanka Dec 09  120 58%  87 42% 
 Sudan Dec 09 d,h  1 141 57%  855 43% 
 Suriname  …  …  
 Swaziland Dec 09  17 300 37%  29 941 63% 
 Syrian Arab Republic Dec 09  66 67%  33 33% 
 Tajikistan Dec 09  218 68%  104 32% 
 Thailand  …  …  
 The former Yugoslav 
 Republic of Macedonia Dec 09  18 75%  6 25% 
 Timor-Leste Dec 09  15 48%  16 52% 
 Togo Dec 09  5 307 32%  11 403 68% 
 Tonga  …  …  
 Tunisia Dec 09  262 64%  150 36% 
 Turkey  …  …  
 Turkmenistan  …  …  
 Tuvalu Dec 09  1 100%  0 0% 
 Uganda Sep 09 d  64 604 37%  110 763 63% 
 Ukraine Dec 09  8 356 53%  7 515 47% 
 United Republic 
 of Tanzania Sep 09 d  70 558 36%  126 854 64% 
 Uruguay  …  …  
 Uzbekistan  …  …  
 Vanuatu Dec 09  0 0%  2 100% 
 Venezuela (Bolivarian 
 Republic of) Dec 09  23 338 72%  8 964 28% 
 Viet Nam Sep 09 d,e  16 854 72%  6 558 28% 
 Yemen Dec 08 e  123 65%  66 35% 
 Zambia Dec 09  124 189 44%  159 674 56% 
 Zimbabwe Dec 08 d  49 701 37%  85 625 63% 
… Data not available or not applicable.
a Countries classifi ed by World Bank income 
status.
b The needs estimates are based on the 
methods described in the explanatory notes 
to the annexes. The estimates for individual 
countries may differ according to the local 
methods used.
c The coverage estimates are based on the 
estimated unrounded numbers of children 
receiving antiretroviral therapy and the 
estimated unrounded need for antiretroviral 
therapy (based on UNAIDS/WHO 
methodology). The ranges in coverage 
estimates are based on plausibility bounds 
in the denominator: that is, low and high 
estimates of need. 
d Point estimates and ranges are given for 
countries with a generalized epidemic, 
whereas only ranges are given for countries 
with a low or concentrated epidemic. 
e The latest available breakdowns refer to 
partial or cumulative data sets and do not 
refl ect national-level data.
f The latest available breakdowns are not as 
recent as the latest reported national-level 
data.
g Estimates of the number of children 
needing antitretroviral therapy are currently 
being reviewed and will be adjusted, 
as appropriate, based on ongoing data 
collection and analysis.
h At the request of the country, only ranges in 
the estimates are being presented.
i Breakdowns by sex and age groups were 
only received for northern Sudan, therefore 
data should be interpreted cautiously.
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Month and 
year of 
report
Estimate EstimateAdults 
(15+)
Low 
estimate
Low 
estimate
% of total High 
estimate
High 
estimate
Children 
(<15)
% of total
REPORTED NUMBER OF ADULTS AND CHILDREN 
RECEIVING ANTIRETROVIRAL THERAPY
ESTIMATED NUMBER OF CHILDREN NEED-
ING ANTIRETROVIRAL THERAPY BASED 
ON UNAIDS/WHO METHODS, 2009b
ESTIMATED ANTIRETROVIRAL THERAPY 
COVERAGE AMONG CHILDREN, 
DECEMBER 2009c
Dec 09  6 324 94%  427 6%  1 700 <1 000  2 600 26% 17% 49%
Dec 08 e  1 483 92%  130 8% … <200 <500 … 49% >95%
Dec 09  14 263 97%  517 3% … <500  1 400 … 36% >95%
Dec 08 e  521 98%  11 2% … <100 <200 … 8% 30%
Dec 09  4 192 97%  137 3% … <100 <100 … >95% >95%
Dec 09  950 97%  34 3% … <100 <100 … 45% >95%
Dec 09  7 052 97%  192 3% … <500 <500 … 52% 71%
Dec 08 e  52 902 96%  1 998 4% …  3 400  12 000 … 17% 60%
Dec 09  70 047 91%  6 679 9%  11 000  7 000  17 000 60% 40% >95%
 …  …  …   …  
Dec 09  121 98%  3 2% …   …  
Dec 09  159 98%  3 2% …   …  
 …  …  …   …  
Dec 08 e  104 95%  5 5% …   …  
Dec 09  11 455 94%  794 6% …  1 600  4 300 … 18% 51%
Dec 09  779 99%  11 1% … <100 <100 … 55% >95%
Dec 09  130 94%  9 6% …   …  
Dec 09  3 423 94%  237 6%  1 700 <1 000  2 600 14% 9% 25%
Dec 08  97 100%  0 0% … <100 <100 … 0% 0%
Dec 09  4 100%  0 0% …   …  
Dec 08 e  404 98%  9 2% … <1 000  1 900 … 0% 1%
Oct 09  885 286 91%  86 270 9%  160 000  92 000  210 000 54% 41% 94%
Dec 09  196 95%  11 5% … <100 <100 … 34% 92%
Dec 09 d,h …   188   8 700  4 400  13 000 2% h 1% 4%
Dec 08 e  778 91%  80 9% … <100 <200 … 74% >95%
Dec 09  42 469 90%  4 772 10%  6 800  4 400  9 000 70% 53% >95%
Dec 09  91 92%  8 8% …   …  
Dec 09  313 97%  9 3% … <100 <200 … 5% 21%
Sep 09  208 042 96%  8 076 4% …  7 900  11 000 … 73% >95%
Dec 09  23 96%  1 4% …   …  
Dec 09  28 90%  3 10% …   …  
Dec 09  15 682 94%  1 028 6%  5 200  1 800  8 800 20% 12% 58%
Dec 08  2 100%  0 0% …   …  
Dec 09  400 97%  12 3% … <100 <100 … 35% 86%
Dec 07 d,e …   9  … <100 <100 … 10% 21%
 …  …  …   …  
Dec 09  1 100%  0 0% …   …  
Sep 08  187 000 93%  13 413 7%  76 000  41 000  110 000 18% 12% 33%
Dec 09  14 151 89%  1 720 11% …  1 500  2 500 … 69% >95%
Dec 08  186 591 94%  12 822 6%  75 000  38 000  110 000 17% 11% 34%
Dec 06  2 350 94%  160 6% … <100 <200 … 81% >95%
Dec 07 d,e …   225  … f   …  
Dec 09  1 50%  1 50% …   …  
Dec 09  31 518 98%  784 2% … f   …  
Dec 09  36 008 95%  1 987 5% …  1 700  3 700 … 54% >95%
Dec 08 e  265 97%  9 3% …   …  
Dec 09  262 743 93%  21 120 7%  59 000  32 000  82 000 36% 26% 65%
Feb 10  197 068 90%  21 521 10%  71 000  43 000  95 000 30% 23% 50%
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Females TotalBoth sexesMales
<15 15+
2005PERCENTAGE OF ADULTS AND 
CHILDREN WITH HIV KNOWN 
TO BE ON TREATMENT 
12 MONTHS AFTER INITIATION 
OF ANTIRETROVIRAL 
THERAPY1
 Albania      
 Algeria      
 Angola      
 Antigua and Barbuda      
 Argentina      
 Armenia      
 Austria      
 Azerbaijan      
 Bahamas      
 Bangladesh      
 Barbados 93 94   93 
 Belarus      
 Belize      
 Benin      
 Bolivia      
 Bosnia and Herzegovina      
 Botswana   92   
 Brazil      
 Brunei Darussalam      
 Bulgaria      
 Burkina Faso      
 Burundi      
 Cambodia      
 Cameroon      
 Cape Verde      
 Central African Republic      
 Chad      
 Chile      
 China      
 Colombia      
 Comoros      
 Costa Rica      
 Côte d’Ivoire      
 Croatia      
 Cuba      
 Cyprus      
 Democratic Republic 
 of the Congo      
 Djibouti      
 Dominica      
 Dominican Republic      
 Ecuador      
 Egypt      
 El Salvador      
 Equatorial Guinea      
 Eritrea      
 Ethiopia 90 86   89 
 Fiji      
 Finland      
 Gabon      
 Gambia      
 Georgia 85 100   88 
 Germany      
 Ghana      
 Greece      UNGASS Indicator 24
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Females FemalesTotal TotalBoth sexes Both sexesMales Males
<15 <1515+ 15+
2007 2009
         89 
         98 
     59 62 73 61 61 
53 57   55 2     78 
    90      
80 100  84 84 77 75  77 77 
     90 90   90 
57 43  86 86 3 72 94  77 77 
68 71 90 68 70 83 98 30 97 91 
         90 
93 96  95 95 89 89 100 88 89 
74 77 97 74 75 78 79 100 77 78 
         76 
    73 87 88 98 87 88 
97 96 100 97 97 81 75 75 79 79 
    100 3     72 
82 86   85 4     91 
     98 99 99 99 99 
     67   67 67 
89 93 33 97 91 91 86  90 90 
77 71 77 73 73 87 80 86 82 83 
77 82 77 81 80 88 91 88 90 90 
  94 87 88   94 87 87 
96 96 97 96 96 90 93 97 92 92 
93 86 100 88 89   92 88 88 
85 85 89 85 85     81 
     38 54 14 50 47 
    89     94 
84 91 96 85 85 81 86 86 82 82 
    76      
40 60 0 100 100 3 100 100 100 100 100 
    91     94 
86 91 82 90 89     67 
100 88 0 97 97 89 100  89 89 
96 96 100 96 96 93 98 100 94 94 
         11 
66 72 62 70 70     77 
    82 78 77  77 77 
     100 100  100 100 
  89 90 90     83 
         95 
       95 74 75 
    85   87 95 90 
         70 
    93      
    70     72 8 
  100 78 79 96 93  83 83 
    90     95 
50 62 63 58 58 83 88 50 87 86 
    92      
71 86 75 71 75 5 79 87 82 81 81 
77 80   78     79 
         90 
95 96 100 95 96 97 98 100 97 97 
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Females TotalBoth sexesMales
<15 15+
2005PERCENTAGE OF ADULTS AND 
CHILDREN WITH HIV KNOWN 
TO BE ON TREATMENT 
12 MONTHS AFTER INITIATION 
OF ANTIRETROVIRAL 
THERAPY1
 Grenada      
 Guatemala      
 Guinea      
 GuineaBissau      
 Guyana      
 Haiti      
 Honduras      
 Hungary      
 India      
 Indonesia      
 Iran, Islamic Republic of      
 Jamaica      
 Japan      
 Jordan      
 Kazakhstan      
 Kenya      
 Kuwait      
 Kyrgyzstan      
 Lao People’s Democratic 
 Republic      
 Lebanon      
 Lesotho     82 
 Lithuania      
 Luxembourg      
 Madagascar     100 
 Malawi     83 
 Malaysia      
 Maldives      
 Mali      
 Marshall Islands      
 Mauritania      
 Mauritius      
 Mexico      
 Micronesia, Federated 
 States of      
 Moldova      
 Mongolia      
 Montenegro      
 Morocco      
 Mozambique      
 Myanmar      
 Namibia     91 2 
 Nepal      
 New Zealand      
 Nicaragua      
 Niger      
 Nigeria     98 6 
 Oman      
 Pakistan      
 Palau      
 Panama      
 Papua New Guinea      
 Paraguay      
 Peru      
 Philippines      
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Females FemalesTotal TotalBoth sexes Both sexesMales Males
<15 <1515+ 15+
2007 2009
83 100 100 83 88 56 67 100 50 60 
    91 82 83 90 82 83 
     75 79 19 81 78 7 
    62 81 85 65 84 84 
70 78 97 73 75 70 75 65 73 72 
    84      
    91 76 81 95 78 79 
99 98 83 99 99 99 99 100 99 99 
    80     89 
         65 8 
78 79 75 78 78 69 72 68 70 70 
   88 88     92 
    100     99 8 
    98 95 100 100 95 96 
72 61 8 73 68 73 80 100 69 75 
    87     80 7 
     100 100 0 100 100 
70 57 100 66 68 67 85 82 66 73 
90 90 93 90 90 93 97 100 95 95 
    100     100 
74 75 79 73 74     81 
54 71  58 58 83 100  88 88 
     87 89  89 89 
    94 91 97 100 95 95 
    69   79 79 79 8 
    87     87 
     100   100 100 
72 72 72 72 72     72 
 100  100 100 3 50 50  50 50 
    92 92 97 93 95 95 
84 90  85 85 94 85  93 93 
     88 89 35 96 88 
     100 100  100 100 
82 93 88 87 87 90 85 100 88 88 
67   67 67 3 100   100 100 
75 20  60 60 3 83 50  75 75 8 
    93 89 93 100 91 91 
    97      
     90 85 94 87 88 
  82 69 71   80 80 80 
    85 88 94 98 90 91 
    98     98 8 
    100     67 
  36 47 47 95 95 67 96 95 
  92 95 95 67 72 70 70 70 
     84 79 100 83 83 
    87      
100 100  100 100 3     38 
    96   94 76 77 
67 56 10 67 61 91 91 67 91 82 
30 14 6 44 49     85 
85 87 95 85 85   82 87 86 
96 96  96 96     90 
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Females TotalBoth sexesMales
<15 15+
2005PERCENTAGE OF ADULTS AND 
CHILDREN WITH HIV KNOWN 
TO BE ON TREATMENT 
12 MONTHS AFTER INITIATION 
OF ANTIRETROVIRAL 
THERAPY1
 Portugal      
 Qatar      
 Romania      
 Russian Federation      
 Rwanda      
 Saint Kitts and Nevis      
 Saint Lucia     80 
 Saint Vincent and 
 the Grenadines      
 Sao Tome and Principe      
 Senegal      
 Seychelles      
 Sierra Leone      
 Slovakia      
 Solomon Islands      
 Somalia      
 South Africa      
 Sri Lanka      
 Sudan      
 Suriname      
 Swaziland      
 Sweden      
 Switzerland      
 Syrian Arab Republic      
 Tajikistan      
 Thailand      
 The former Yugoslav 
 Republic of Macedonia      
 TimorLeste      
 Togo      
 Trinidad and Tobago      
 Tunisia      
 Turkey      
 Tuvalu      
 Uganda      
 Ukraine 69 75 70 100 72 
 United Arab Emirates      
 United Kingdom of 
 Great Britain and 
 Northern Ireland      
 United Republic 
 of Tanzania      
 Uruguay      
 Uzbekistan      
 Venezuela      
 Viet Nam      
 Zambia      
 Zimbabwe      
1 Data values represent 1 cohort with 12 month minimum survival, with patients lost to 
followup and death included in the denominator, unless otherwise noted.
2 Represents cumulative survival.
3 Represents <10 persons alive and still on ART in last 12 months.
5 Represents 2006.
6 Represents 8 month survival.
7 Represents 2007.
8 Refl ects greater than 12 months survival.
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Females FemalesTotal TotalBoth sexes Both sexesMales Males
<15 <1515+ 15+
2007 2009
         84
     100 100 0 100 100
         93
         79
    91     95 8
    100 100  100  100
100 97 100 98 98 100 100 100 100 100
43 80 50 63 62 90 82 100 86 86
65 82 100 74 75 100 83  88 88
79 94   89     85
62 43 100 53 55 94 94 100 93 94
    81 84 84   84
     89 93  90 90
     100 100  100 100
         72
    53     
    64 96 86  93 93
         57
    80   57 63 62
63 65 65 64 64   78 77 77
     99 98 100 99 99
92 84  89 89     
     100 100  100 100
55 61  57 57 54 71  58 58
85 85 88 85 85 78 93 90 85 85 8
43 50  44 44 3 71 100  78 78
         78
90 90 90 90 90     95
       9 77 86
93 90   92   100 96 96 8
26 16 3 24 23     
     100   100 100
    88     86
73 83 91 76 78     85
         99
     92 84 79 89 89
         65
    74    87 87
       84 80 81
     86 80 87 84 84
  93 81 82   81 84 84
87 90 92 88 88     
    93 72 77   75
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NUMBER OF 
PREGNANT WOMEN 
LIVING WITH HIV 
WHO RECEIVED 
ANTIRETROVIRALS 
FOR PREVENTING 
MOTHER-TO-CHILD 
TRANSMISSION
PERIODPREVENTING MOTHER-TO-
CHILD TRANSMISSION OF HIV 
IN LOW- AND MIDDLE-INCOME 
COUNTRIES, 2009a
 Afghanistan …  
 Albania …  
 Algeria   65 Jan 09–Dec 09 
 Angola  3 053 Jan 09–Dec 09 
 Argentina  2 039 Jan 08–Dec 08 
 Armenia   13 Jan 09–Dec 09 
 Azerbaijan   11 Jan 09–Dec 09 
 Bangladesh   7 Jan 08–Dec 08 
 Belarus   194 Jan 09–Dec 09 
 Belize   63 Jan 09–Dec 09 
 Benin  1 703 Jan 09–Dec 09 
 Bhutan   19 Jan 08–Dec 08 
 Bolivia (Plurinational 
 State of)   105 Jan 09–Dec 09 
 Bosnia and Herzegovina   1 Jan 08–Dec 08 
 Botswana  12 406 Jan 09–Dec 09 
 Brazil  5 988 Jan 09–Dec 09 
 Bulgaria   9 Jan 09–Dec 09 
 Burkina Faso  2 084 Jan 09–Dec 09 
 Burundi  1 837 Jan 09–Dec 09 
 Cambodia   798 Jan 09–Dec 09 
 Cameroon  9 092 Jan 09–Dec 09 
 Cape Verde   61 Jan 09–Dec 09 
 Central African Republic  2 157 Jan 09–Dec 09 
 Chad   989 Jan 09–Dec 09 
 Chile   121 Jan 09–Dec 09 
 China  1 554 Jan 09–Dec 09 
 Colombia   519 Jan 09–Dec 09 
 Comoros   1 Jan 09–Dec 09 
 Congo   441 Jan 09–Dec 09 
 Cook Islands …  
 Costa Rica   31 Jan 08–Dec 08 
 Côte d’Ivoire  11 064 Jan 09–Dec 09 
 Croatia   2 Jan 09–Dec 09 
 Cuba   50 Jan 09–Dec 09 
 Democratic People’s 
 Republic of Korea …  
 Democratic Republic of 
 the Congo  2 232 Jan 09–Dec 09 
 Djibouti   63 Jan 09–Dec 09 
 Dominica   2 Jan 09–Dec 09 
 Dominican Republic   949 Jan 09–Dec 09 
 Ecuador   477 Jan 09–Dec 09 
 Egypt   11 Jan 09–Dec 09 
 El Salvador   170 Jan 08–Dec 08 
 Equatorial Guinea   365 Jan 09–Dec 09 
 Eritrea   464 Jan 09–Dec 09 
 Ethiopia  6 721 Jan 09–Dec 09 
 Fiji   5 Jan 09–Nov 09 
 Gabon   577 Jan 09–Dec 09 
 Gambia   885 Jan 09–Sep 09 
 Georgia   12 Jan 09–Dec 09 
 Ghana  3 643 Jan 09–Dec 09 UNGASS Indicator 5
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Estimate EstimateLow 
estimate
Low 
estimate
High 
estimate
High 
estimate
ESTIMATED NUMBER OF PREGNANT 
WOMEN LIVING WITH HIV NEEDING 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSION 
BASED ON UNAIDS/WHO METHODSb
ESTIMATED PERCENTAGE OF 
PREGNANT WOMEN LIVING 
WITH HIV WHO RECEIVED 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSIONc
…   …  
…   …  
… <200 <500 … 14% 59%
 16 000  8 400  25 000 19% 12% 36%
… <1 000  2 400 … 86% >95%
… <100 <100 … 65% >95%
… <100 <500 … 5% 17%
… <100 <200 … 4% 13%
… <100 <500 … >95% >95%
… <200 <500 … 22% 61%
 3 700  1 900  5 800 46% 29% 92%
… <100 <100 … 95% >95%
… <200 <500 … 22% 83%
…   …  
 13 000  6 900  17 000 >95% 74% >95%
…  3 700  12 000 … 49% >95%
… <100 <100 … 23% 82%
 6 500  3 500  11 000 32% 19% 60%
 15 000  8 400  21 000 12% 9% 22%
… <1 000  3 000 … 26% >95%
 34 000  18 000  50 000 27% 18% 50%
…   …  
 6 300  3 200  9 500 34% 23% 67%
 16 000  8 300  29 000 6% 3% 12%
… <500 <1 000 … 15% 55%
…  2 600  11 000 … 14% 59%
… <1 000  3 900 … 13% 55%
… <100 <100 … 10% 33%
 3 800  1 900  5 600 12% 8% 23%
…   …  
… <100 <200 … 17% 53%
 20 000  10 000  31 000 54% 36% >95%
… <100 <100 … 15% 67%
… <100 <200 … 39% >95%
… <100 <100 …  
…d  20 000  54 000 … 4% 11%
<1 000 <500  1 000 10% 6% 21%
…   …  
… <1 000  3 000 … 32% 95%
… <500 <1 000 … 48% >95%
… <200 <500 … 3% 10%
… <500 <1 000 … 19% 71%
 1 400 <1 000  2 300 26% 16% 50%
 1 400 <1 000  2 200 34% 21% 71%
…d  17 000  51 000 … 13% 40%
… <100 <100 … 28% >95%
 1 900 <1 000  2 900 30% 20% 60%
… <1 000  2 000 … 43% >95%
… <100 <100 … 19% 86%
 13 000  6 900  20 000 27% 18% 53%
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NUMBER OF 
PREGNANT WOMEN 
LIVING WITH HIV 
WHO RECEIVED 
ANTIRETROVIRALS 
FOR PREVENTING 
MOTHER-TO-CHILD 
TRANSMISSION
PERIODPREVENTING MOTHER-TO-
CHILD TRANSMISSION OF HIV 
IN LOW- AND MIDDLE-INCOME 
COUNTRIES, 2009a
 Grenada   2 Jan 09–Dec 09 
 Guatemala   440 Jan 09–Dec 09 
 Guinea   783 Jan 09–Dec 09 
 Guinea-Bissau   383 Jan 09–Dec 09 
 Guyana   183 Jan 09–Dec 09 
 Haiti  2 960 Jan 09–Dec 09 
 Honduras   255 Jan 09–Dec 09 
 Hungary   5 Jan 09–Dec 09 
 India  11 319 Jan 09–Dec 09 
 Indonesia   196 Jan 08–Dec 08 
 Iran (Islamic Republic of)   25 Mar 08–Feb 09 
 Iraq   0 Jan 08–Dec 08 
 Jamaica   379 Jan 09–Dec 09 
 Jordan   0 Jan 09–Dec 09 
 Kazakhstan   193 Jan 09–Dec 09 
 Kenya  58 591 Jan 09–Dec 09 
 Kiribati   0 Jan 08–Dec 08 
 Kyrgyzstan   58 Jan 09–Dec 09 
 Lao People’s 
 Democratic Republic   24 Jan 09–Dec 09 
 Latvia   56 Jan 09–Dec 09 
 Lebanon …  
 Lesotho  8 846 Jan 09–Dec 09 
 Liberia   377 Jan 09–Dec 09 
 Libyan Arab Jamahiriya …  
 Lithuania   12 Jan 09–Dec 09 
 Madagascar   17 Jan 09–Dec 09 
 Malawi  33 156 Jan 09–Dec 09 
 Malaysia   300 Jan 09–Dec 09 
 Maldives   0 Jan 09–Dec 09 
 Mali  1 710 Jan 09–Dec 09 
 Marshall Islands   1 Oct 08–Sep 09 
 Mauritania   68 Jan 09–Dec 09 
 Mauritius   41 Jan 09–Dec 09 
 Mexico   124 Jan 09–Dec 09 
 Micronesia (Federated 
 States of) …  
 Mongolia   1 Jan 09–Dec 09 
 Montenegro   0 Jan 09–Dec 09 
 Morocco   90 Jan 09–Dec 09 
 Mozambique  68 248 Jan 09–Dec 09 
 Myanmar  2 398 Jan 09–Dec 09 
 Namibia  6 744 Apr 08–Mar 09 
 Nauru …  
 Nepal   56 Jul 08–Jun 09 
 Nicaragua   91 Jan 09–Dec 09 
 Niger  1 737 Jan 09–Dec 09 
 Nigeria  44 723 Jan 09–Dec 09 
 Niue …  
 Oman   9 Jan 09–Dec 09 
 Pakistan   25 Jan 09–Dec 09 
 Palau …  
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Estimate EstimateLow 
estimate
Low 
estimate
High 
estimate
High 
estimate
ESTIMATED NUMBER OF PREGNANT 
WOMEN LIVING WITH HIV NEEDING 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSION 
BASED ON UNAIDS/WHO METHODSb
ESTIMATED PERCENTAGE OF 
PREGNANT WOMEN LIVING 
WITH HIV WHO RECEIVED 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSIONc
…   …  
… <1 000  2 900 … 15% 56%
 4 600  2 300  7 200 17% 11% 34%
 1 600 <1 000  2 400 24% 16% 49%
… <100 <500 … 88% >95%
 5 000  2 600  7 500 60% 39% >95%
… <500  1 300 … 20% 82%
… <100 <100 … 14% 63%
…  23 000  65 000 … 17% 48%
…  1 100  4 600 … 4% 17%
… <500  1 300 … 2% 7%
…   …  
… <200 <1 000 … 46% >95%
…   …  
… <200 <1 000 … 38% >95%
 81 000  41 000  120 000 73% 50% >95%
…   …  
… <100 <500 … 23% >95%
… <200 <500 … 5% 20%
… <100 <200 … 52% >95%
… <100 <100 …  
 14 000  8 400  18 000 64% 48% >95%
 2 400  1 100  3 700 16% 10% 33%
…   …  
… <100 <100 … 92% >95%
… <500  1 100 … 1% 5%
 57 000  31 000  83 000 58% 40% >95%
… <100 <1 000 … 55% >95%
… <100 <100 … 0% 0%
…  2 100  6 700 … 26% 82%
…   …  
… <200 <1 000 … 12% 37%
… <100 <200 … 33% >95%
…  1 500  4 500 … 3% 9%
   …  
… <100 <100 … 10% 33%
…   …  
… <200 <1 000 … 13% 49%
 97 000  53 000  130 000 70% 51% >95%
…  1 800  5 600 … 43% >95%
 7 700  4 100  11 000 88% 61% >95%
…   …  
… <1 000  2 100 … 3% 10%
… <100 <500 … 45% >95%
…  2 300  7 000 … 25% 74%
 210 000  110 000  300 000 22% 15% 42%
…   …  
… <100 <100 … 29% >95%
…  1 000  3 700 … 1% 2%
…   …  
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NUMBER OF 
PREGNANT WOMEN 
LIVING WITH HIV 
WHO RECEIVED 
ANTIRETROVIRALS 
FOR PREVENTING 
MOTHER-TO-CHILD 
TRANSMISSION
PERIODPREVENTING MOTHER-TO-
CHILD TRANSMISSION OF HIV 
IN LOW- AND MIDDLE-INCOME 
COUNTRIES, 2009a
 Panama   118 Jan 09–Dec 09 
 Papua New Guinea   263 Jan 09–Dec 09 
 Paraguay   148 Jan 09–Dec 09 
 Peru   550 Jan 09–Dec 09 
 Philippines   3 Jan 09–Dec 09 
 Poland   81 Jan 09–Dec 09 
 Republic of Moldova   109 Jan 09–Dec 09 
 Romania   152 Jan 09–Dec 09 
 Russian Federation  9 380 Jan 09–Dec 09 
 Rwanda  7 030 Jan 09–Dec 09 
 Saint Kitts and Nevis   1 Jan 09–Dec 09 
 Saint Lucia   6 Jan 09–Dec 09 
 Saint Vincent and 
 the Grenadines   14 Jan 09–Dec 09 
 Samoa …  
 Sao Tome and Principe   11 Jan 09–Dec 09 
 Senegal   917 Jan 09–Dec 09 
 Serbia   2 Jan 08–Dec 08 
 Seychelles   12 Jan 09–Dec 09 
 Sierra Leone   637 Jan 09–Dec 09 
 Slovakia   2 Jan 09–Dec 09 
 Solomon Islands   1 Jan 09–Dec 09 
 Somalia   0 Jan 09–Dec 09 
 South Africa  188 200 Jan 09–Dec 09 
 Sri Lanka   4 Jan 09–Dec 09 
 Sudan   245 Jan 09–Dec 09 
 Suriname   83 Jan 08–Dec 08 
 Swaziland  8 182 Jan 09–Dec 09 
 Syrian Arab Republic   2 Jan 09–Dec 09 
 Tajikistan   25 Jan 09–Dec 09 
 Thailand  5 457 Oct 08–Sep 09 
 The former Yugoslav 
 Republic of Macedonia   0 Jan 09–Dec 09 
 Timor-Leste   1 Jan 08–Dec 08 
 Togo  1 451 Jan 09–Dec 09 
 Tonga …  
 Tunisia   3 Jan 09–Dec 09 
 Turkey   4 Jan 06–Dec 06 
 Turkmenistan …  
 Tuvalu …  
 Uganda  46 948 Jan 09–Dec 09 
 Ukraine  3 645 Jan 09–Dec 09 
 United Republic 
 of Tanzania  58 833 Jan 09–Dec 09 
 Uruguay   70 Jan 08–Dec 08 
 Uzbekistan   304 Jan 09–Dec 09 
 Vanuatu …  
 Venezuela (Bolivarian 
 Republic of)   233 Jan 09–Dec 09 
 Viet Nam  1 372 Jan 09–Dec 09 
 Yemen   13 Jan 09–Dec 09 
 Zambia  47 175 Jan 09–Dec 09 
 Zimbabwe  28 208 Jan 09–Dec 09 
a Countries classifi ed by World Bank income status.
b The needs estimates are based on the methods described in 
the explanatory notes. The estimates for individual countries 
may differ according to the local methods used.
c The coverage estimates are based on the numbers of 
pregnant women living with HIV receiving antiretrovirals and 
the estimated unrounded need for antiretrovirals (based on 
UNAIDS/WHO methods). The ranges in coverage estimates are 
based on plausibility bounds in the denominator: that is, low 
and high estimates of need. Point estimates and ranges are 
given for countries with a generalized epidemic, whereas only 
ranges are given for countries with a low-level or concentrated 
epidemic.
d The data may include double-counting.
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Estimate EstimateLow 
estimate
Low 
estimate
High 
estimate
High 
estimate
ESTIMATED NUMBER OF PREGNANT 
WOMEN LIVING WITH HIV NEEDING 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSION 
BASED ON UNAIDS/WHO METHODSb
ESTIMATED PERCENTAGE OF 
PREGNANT WOMEN LIVING 
WITH HIV WHO RECEIVED 
ANTIRETROVIRALS FOR PREVENTING 
MOTHER-TO-CHILD TRANSMISSIONc
… <200 <1 000 … 19% >95%
 2 000 <1 000  3 000 13% 9% 27%
… <200 <500 … 38% >95%
… <500  1 700 … 33% >95%
… <100 <500 … 1% 4%
… <100 <500 … 27% >95%
… <100 <200 … 71% >95%
… <100 <500 … 76% >95%
…  5 100  16 000 … 57% >95%
 11 000  5 400  16 000 65% 43% >95%
…   …  
…   …  
…   …  
…   …  
…   …  
…  2 000  5 900 … 16% 45%
… <100 <100 … 3% 10%
…   …  
 3 300  1 800  5 100 19% 12% 36%
… <100 <100 … 50% >95%
…   …  
…  1 000  3 700 … 0% 0%
 210 000  120 000  290 000 88% 66% >95%
… <100 <100 … 9% 31%
 14 000  7 300  22 000 2% 1% 3%
… <100 <200 … 82% >95%
 9 300  5 700  12 000 88% 68% >95%
…   …  
… <100 <500  9% 36%
…  4 900  8 300 … 66% >95%
…     
…   …  
 5 600  2 200  9 400 26% 15% 67%
…   …  
… <100 <100 … 6% 25%
… <100 <200 … 3% 13%
…   …  
…   …  
 88 000  48 000  130 000 53% 37% >95%
…  1 200  4 800 … 76% >95%
 84 000  45 000  120 000 70% 48% >95%
… <100 <500 … 31% >95%
…d   …  
…   …  
…d   …  
…  1 700  4 700 … 29% 79%
…   …  
 68 000  37 000  94 000 69% 50% >95%
 50 000  28 000  69 000 56% 41% >95%
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Reported 
number
Estimated 
coverage
PREGNANT WOMEN TESTED FOR HIVMATERNAL AND INFANT HIV 
TESTING AND INFANT 
PROPHYLAXIS IN LOW- AND 
MIDDLE-INCOME COUNTRIESa
 Afghanistan …  
 Albania …  
 Algeria …  
 Angola  203 463 26% 
 Argentina  598 123d 87% 
 Armenia  40 679 86% 
 Azerbaijan  172 153d >95% 
 Bangladesh   91 <1% 
 Belarus  150 186e >95% 
 Belize  6 310 85% 
 Benin  171 532f 49% 
 Bhutan …  
 Bolivia (Plurinational 
 State of)  73 369 28% 
 Bosnia and Herzegovina  1 012 3% 
 Botswana  44 386h 93% 
 Brazil 2 381 280d 79% 
 Bulgaria …  
 Burkina Faso  310 583 42% 
 Burundi  113 053 40% 
 Cambodia  153 884 42% 
 Cameroon  291 473 41% 
 Cape Verde  8 500 71% 
 Central African Republic  43 775 28% 
 Chad  32 119 6% 
 Chile  144 772 57% 
 China 3 741 337k 20% 
 Colombia  353 764 39% 
 Comoros  1 034 5% 
 Congo  28 699 23% 
 Cook Islands …  
 Costa Rica …  
 Côte d’Ivoire  342 698 47% 
 Croatia …  
 Cuba  122 611e >95% 
 Democratic People’s 
 Republic of Korea …  
 Democratic Republic 
 of the Congo  253 297 9% 
 Djibouti  9 371 39% 
 Dominica   947 … 
 Dominican Republic  114 046 51% 
 Ecuador  286 211e >95% 
 Egypt  1 750g <1% 
 El Salvador  65 712 53% 
 Equatorial Guinea  16 228 63% 
 Eritrea  46 544d 25% 
 Ethiopia  488 554 16% 
 Fiji  9 041d 52% 
 Gabon  9 321 23% 
 Gambia  31 071 50% 
 Georgia  58 769d >95% 
 Ghana  388 254 51% 
Supplemental data received obtained by 
World Health Organization through the 
monitoring of progress towards Universal 
Access in the Health Sector
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Reported 
number
Reported 
number
Reported 
number
Estimated 
coverage
Estimated 
coverage
Estimated 
coverage
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING ANTIRETROVI-
RALS FOR PREVENTING MOTHER-TO-
CHILD TRANSMISSION
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING CO-TRIMOX-
AZOLE PROPHYLAXIS WITHIN TWO 
MONTHS OF BIRTH
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING A VIROLOGICAL 
TEST BY TWO MONTHS OF AGE
...  ...  … 
…  …  … 
…  …  … 
 2 435 15%  2 435 15% … 
 2 280d >95%  2 160d >95% … 
  9 75%   2 17%   0 0%
  14d 11%   13d 10%   15d 12%
  12 12%   16 16% … 
  195 >95%   148 >95%   192 >95%
  51 26% …    53 27%
 1 473 39%  1 473 39% … 
  13d >95%   7d 58% … 
  28g 10%   27d 10%   23d 8%
  0 …   0 …   0 …
 14 073i >95%  8 232j 65% … 
 7 511d >95% …   2 306d 32%
…  …  … 
 2 140 33%  1 815 28%   199 3%
 1 332 9%  1 332 9% … 
  730 45%   203g 12% … 
 8 378 25%  8 378 25%  8 940 26%
  67 …   67 …   67 …
 1 380 22%   887 14%   40 1%
  676 4%   676 4% … 
...  …  … 
 1 701 28% …  … 
  248 12% …    83 4%
  1 17%   1 17%   0 0%
  615 16%   548 15%   444 12%
...  …  … 
  38 33%   44 38%   44 38%
 6 696 33% …  … 
…  …  … 
  0 0%   1g 1%   50 67%
...  …  … 
 2 232 6%   396 1% … 
  36d 6%   22 4% … 
  1 …   1 …   1 …
 1 133 59% …    391d 20%
  315 56% …    5 1%
  2g 1% …    5g 3%
  216 42%   176 34% … 
  164 11% …  … 
  424d 31%   225d 17% … 
 5 025 15%  1 076 3%  1 375 4%
  1d 10%   2d 20%   1d 10%
  312 16%   219d 12% … 
  230 20%   99 8% … 
  19d 58%   19d 58%   19d 58%
 1 730m 13% …  … 
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Reported 
number
Estimated 
coverage
PREGNANT WOMEN TESTED FOR HIV
 Grenada  1 229 60% 
 Guatemala  102 957 23% 
 Guinea  39 893 10% 
 Guinea-Bissau  13 864o 21% 
 Guyana  14 283e >95% 
 Haiti  154 835 57% 
 Honduras  103 562 51% 
 Hungary  8 357d 8% 
 India 5 717 819 21% 
 Indonesia  10 026 <1% 
 Iran (Islamic Republic of)   158q <1% 
 Iraq  1 550d <1% 
 Jamaica  28 659d 55% 
 Jordan   0 0% 
 Kazakhstan  434 548e >95% 
 Kenya  961 990 63% 
 Kiribati  1 159 … 
 Kyrgyzstan  171 480e >95% 
 Lao People’s Democratic 
 Republic  3 094 2% 
 Latvia  20 608 88% 
 Lebanon …  
 Lesotho  29 626 50% 
 Liberia  32 659 22% 
 Libyan Arab Jamahiriya …  
 Lithuania  30 057 95% 
 Madagascar  140 261 20% 
 Malawi  316 000 52% 
 Malaysia  403 287s 73% 
 Maldives  3 911 67% 
 Mali  86 814 16% 
 Marshall Islands …  
 Mauritania  6 371d 6% 
 Mauritius  15 026 83% 
 Mexico  757 863d 37% 
 Micronesia (Federated 
 States of) …  
 Mongolia …  
 Montenegro …  
 Morocco  2 723d <1% 
 Mozambique  672 020 77% 
 Myanmar  182 760 18% 
 Namibia  51 970 88% 
 Nauru …  
 Nepal  65 791 9% 
 Nicaragua  81 686 58% 
 Niger  158 695 19% 
 Nigeria  820 865 13% 
 Niue …  
 Oman  30 875 50% 
 Pakistan  10 277 <1% 
 Palau …  
 Panama  59 334 85% 
MATERNAL AND INFANT HIV 
TESTING AND INFANT 
PROPHYLAXIS IN LOW- AND 
MIDDLE-INCOME COUNTRIESa
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Reported 
number
Reported 
number
Reported 
number
Estimated 
coverage
Estimated 
coverage
Estimated 
coverage
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING ANTIRETROVI-
RALS FOR PREVENTING MOTHER-TO-
CHILD TRANSMISSION
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING CO-TRIMOX-
AZOLE PROPHYLAXIS WITHIN TWO 
MONTHS OF BIRTH
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING A VIROLOGICAL 
TEST BY TWO MONTHS OF AGE
  2 …   2 …   0 …
  159d 9%   222d 13% … 
  231n 5%   801n 17% … 
  143d 9% …    0 0%
  206 >95%   97p >95% … 
…    448d 9% … 
  255 35% …    309 42%
  5 26%   5 26% … 
 11 593 27% …  … 
  165d 6%   25g 1% … 
  24d 3%   20d 3%   7d 1%
  0d …   0d … … 
  605d >95% …  … 
  0 …   0 …   0 …
  198 68%   204 70%   188 64%
 39 482 49%  4 043 5% … 
  0 …   0 …   0 …
  60 51%   70 59%   0 0%
  18d 7%   17d 7% … 
…    52 84% … 
  0 0% …  … 
 4 240 31%  1 542d 11%  4 621 33%
  194 8%   45r 2%   109r 5%
...  …  … 
  12 >95% …    10 >95%
  8 1% …  … 
 23 773 41%  28 079 49% … 
  163 54%   163 54%   163 54%
  0 0%   0 0%   0 0%
  810 19%   722 17%   531 13%
...  …  … 
  15d 4%   18g 5% … 
  53 73%   48 66% … 
  58d 2% …  … 
...  …  … 
  1 17%   1 17%   1 17%
  1g … …  … 
  20d 5%   19d 5%   4d 1%
 41 266 43% …  … 
 1 697 46%   858 23% … 
 7 120 93% …  … 
...  …  … 
  89 7%   75 6%   10 1%
  81 63%   81 63%   81 63%
  708 15%   309 6% … 
 15 905 8%  3 927t 2%  6 101r 3%
...  …  … 
  4 21%   4 21%   4 21%
  16 1%   0 0%   15 1%
...  …  … 
  154d,u 56%   62d,u 23% … 
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Reported 
number
Estimated 
coverage
PREGNANT WOMEN TESTED FOR HIV
 Papua New Guinea  43 942 21% 
 Paraguay  73 123 47% 
 Peru  599 012e >95% 
 Philippines …v  
 Poland …  
 Republic of Moldova  45 557e >95% 
 Romania  100 589 47% 
 Russian Federation 1 468 091d,w 95% 
 Rwanda  294 457 71% 
 Saint Kitts and Nevis …  
 Saint Lucia …  
 Saint Vincent and 
 the Grenadines  2 635e >95% 
 Samoa …  
 Sao Tome and Principe  6 475e >95% 
 Senegal  166 830 35% 
 Serbia  5 665d 5% 
 Seychelles  1 650 … 
 Sierra Leone  99 256 44% 
 Slovakia …  
 Solomon Islands   41d <1% 
 Somalia  1 131 <1% 
 South Africa 1 099 712e >95% 
 Sri Lanka  13 475 4% 
 Sudan  33 127x 3% 
 Suriname  8 885d 91% 
 Swaziland  25 769 73% 
 Syrian Arab Republic   4g <1% 
 Tajikistan  76 297 39% 
 Thailand  797 047 82% 
 The former Yugoslav 
 Republic of Macedonia …  
 Timor-Leste   71d <1% 
 Togo  42 101 20% 
 Tonga …  
 Tunisia …  
 Turkey …  
 Turkmenistan …  
 Tuvalu …  
 Uganda  968 157* 64% 
 Ukraine  555 535e >95% 
 United Republic of Tanzania 1 194 172 66% 
 Uruguay  47 428d 95% 
 Uzbekistan  414 346*** 74% 
 Vanuatu  1 499d,† 21% 
 Venezuela (Bolivarian 
 Republic of) …  
 Viet Nam  480 814‡ 32% 
 Yemen  4 211 <1% 
 Zambia  532 484e >95% 
 Zimbabwe  175 223 46% 
MATERNAL AND INFANT HIV 
TESTING AND INFANT 
PROPHYLAXIS IN LOW- AND 
MIDDLE-INCOME COUNTRIESa
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Reported 
number
Reported 
number
Reported 
number
Estimated 
coverage
Estimated 
coverage
Estimated 
coverage
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING ANTIRETROVI-
RALS FOR PREVENTING MOTHER-TO-
CHILD TRANSMISSION
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING CO-TRIMOX-
AZOLE PROPHYLAXIS WITHIN TWO 
MONTHS OF BIRTH
INFANTS BORN TO WOMEN LIVING 
WITH HIV RECEIVING A VIROLOGICAL 
TEST BY TWO MONTHS OF AGE
  251 13%   19 1% … 
  148 62%   85 36% … 
  426 43% …  … 
  2 1%   3 2%   2 1%
  69 41%   69 41%   69 41%
  118 >95%   33 37%   112 >95%
  192 >95%   7 6%   192 >95%
 8 744d >95% …  … 
 6 684 62%  7 222 67%  5 646 52%
...  …  … 
...  …  … 
  15 …   14 …   14 …
...  …  … 
  17 …   17 … … 
  433 11% …    339 9%
  1 2%   0 0%   1 2%
  7 …   7 …   0 …
  518d 16%   363d 11%   0d 0%
…  …  … 
  1d …   0d  … 
  6 0%   0 0% … 
 119 395d 56%  43 394 20% … 
  4 15%   4 15%   0 0%
  56y <1%   34z <1% … 
  91d >95% …    9 16%
 7 655 82%  9 189 >95% … 
...  …  … 
  19 12%   23 15%   1g 1%
 5 722 88%  2 074 32% … 
…  …  … 
  1d … …  … 
 1 508 27%   945 17%   614 11%
...  …  … 
  1 4%   0 0%   0 0%
…  …  … 
…  …  … 
...  …  … 
 24 554 28% …   5 607 6%
 3 840 >95%  3 021 >95%  2 033 69%
 43 119 51%  8 348** 10%  11 345 13%
…  …  … 
  399 … …    2 …
  0d … …  … 
  274 … …  … 
 1 511 48%   944 30% … 
  10 …   8 …   0 …
 26 743 39%  25 139 37%  35 824 53%
 17 331 35%  13 852 28% … 
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a Countries classifi ed by World Bank income status.
b No reference b.
c No reference c. 
d The latest reported data are to December 2008.
e The reported number of pregnant women tested for HIV was higher than the estimated number of pregnant women, implying a coverage of >100%.  
Last year, coverage was already >95% in these countries, thus in the regional and global analysis, data are adjusted.
f Data are from 323 out of 364 maternity hospitals with PMTCT services.
g The latest reported data are to December 2007.
h Number of tests were reported, as tests for women who tested more than once at ANC, labour/delivery and postpartum cannot be deduplicated.
i The data may include double-counting.
j The data cannot specify whether data reported were for infants within two months of birth, but the policy is for all infants to start co-trimoxazole at 6 
weeks of age.  Data suggest that around two-thirds of infants who started cotrimoxazole, started within two months of birth.
k Data are collected from 453 priority counties out of a total of 2860.
l No reference l.
m Data reported in 2009 is lower than reported value of 2 450 in 2008.  This is due to the transition from the old regimen of single-dose nevirapine to the 
new regimen of single-dose nevirapine at birth and Zidovudine and Lamivudine for 1 or 6 weeks as relevant, which were both still used in 2008. Now only 
the new regimen is used and is still being scaled up.
n Only partial data were collected.
o Data are based on the number of pregnant women having access to antenatal clinics/maternity hospitals who know their HIV status.
p Data are collected on a monthly data reporting form at 6 weeks, not at 2 months.  Therefore, some infants may be lost to follow up.
q The latest data reported are to August 2007.
r Data may be under-reported.
s Only public data were reported, which represent about 70% of total ANC cases.
t Four out of ten Implementing partners reported for this indicator.
u The data are from three of four paediatric care clinics.
v A data value of 26 was reported.  The data value was from one site only and for the period September-November 2009.
w Russian Federation reported 4 827 215 pregnant women being tested for HIV. As the number of pregnant women tested likely refl ects double or triple 
counting, 95% of the estimated number of births in Russia (1 545 359) was used as a proxy and most likely represents the total number of tests conducted 
among pregnant women.
x Two separate reports were received from Sudan: Northern Sudan reported 19 986 for the period between January-December 2009; southern Sudan 
reported 13 141 to November 2009, giving a total of 33 127.
y Two separate reports were received from Sudan: Northern Sudan reported 34 for the period between January-December 2009; southern Sudan reported 
22 to November 2009, giving a total of 56.
z Two separate reports were received from Sudan: Northern Sudan reported 34 for the period between January-December 2009; southern Sudan reported 
“no data” stating that services have just been initiated and co-trimoxazole was initially not part of the supplies for PMTCT. Data for southern Sudan are 
expected to be ready in next reporting period.
* The data are reported for the period July 2008-July 2009.
** Data are under-reported.
*** In 2009, there was a substantial increase in the number of pregnant women tested for HIV, up from the last reported value of 58 063 in 2007. Previously, 
only those pregnant women with risky behaviour or those who had sexual partners with risky behaviour were recommended for VCT. Now all pregnant 
women are now recommended for VCT; however, only 77% of pregnant women were reached through VCT by the end of 2009.
† Data were collected from Northern District Hospital, Vila Central Hospital, Leneakel Hospital, Lolowai Hospital and Norsup Hospital.
‡ Data are based on total number tested and received results.
MATERNAL AND INFANT HIV 
TESTING AND INFANT 
PROPHYLAXIS IN LOW- AND 
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2007 2009
% of patients 
treated
Adults 
treated
Adults 
treated
% of patients 
treated
TREATMENT FOR TB AND HIVPERCENTAGE OF 
ESTIMATED HIV-POSITIVE 
INCIDENT TB CASES THAT 
RECEIVED TREATMENT FOR 
TB AND HIV
 Afghanistan 2 <1 4 1 
 Albania   4  
 Algeria 82 87 1 111 99 
 Angola   359 20 
 Argentina 415 55 250 83 
 Armenia 15 59 1 6  
 Austria   12 100 
 Azerbaijan 3 4 62 53 
 Bahamas 26 81 15 100 
 Barbados 2 100   
 Belarus 136 72 138 73 
 Belize 9 69   
 Benin 157 31 629 16 
 Bolivia 60 41 94 51 
 Bosnia and 
 Herzegovina   25 25 
 Brazil   3333 26 5 
 Brunei Darussalam   1 50 
 Bulgaria 32 2 23  
 Burkina Faso 199 1 503 4 
 Burundi   594 3 
 Cote d’Ivoire 994 10 1633 31 
 Cambodia   526 5 
 Cameroon   117 3 
 Cape Verde 3 3 61 61 
 Central African 
 Republic 3671 15 414 36 
 Chad   7560 70 
 China 901 13   
 Colombia   343 45 
 Comoros   0 0 
 Costa Rica 13 100 36 100 
 Croatia 3 100   
 Cuba 46 90 31 97 
 Czech Republic   3 60 
 Democratic Republic 
 of the Congo 162 <1 724 5 
 Djibouti   170 23 
 Dominica 1 100 2 67 
 Dominican Republic 322 115 1 260 42 
 Ecuador 150 40   
 Egypt   3 2 
 El Salvador 63 100 37 50 
 Equatorial Guinea   205 11 5 
 Ethiopia 2658 13 4515 41 
 Fiji 2 40 0  
 Finland 0   90 
 Gabon 521 13 366 33 
 Georgia 34 71 76 67 
 Ghana   531  
 Grenada 0 2 1 100 
 Guatemala 109 33 342 11 
 Guinea 245 61 335 6 
 Guinea-Bissau   171 10 UNGASS Indicator 6
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2007 2009
% of patients 
treated
Adults 
treated
Adults 
treated
% of patients 
treated
TREATMENT FOR TB AND HIVPERCENTAGE OF 
ESTIMATED HIV-POSITIVE 
INCIDENT TB CASES THAT 
RECEIVED TREATMENT FOR 
TB AND HIV
 Guyana   75 94 
 Haiti 61 5 2409 24 
 Honduras 383 71 203 33 
 Hungary 7 <1 3 1 100 
 India 19 400 23 2693 4 
 Indonesia   2976 3 
 Iran, Islamic 
 Republic of 52 20 120 32 
 Jamaica 18 72   
 Japan 10 83 16 94 
 Jordan 0  0  
 Kazakhstan 76 33 103 43 
 Kenya   14116 23 
 Kuwait   0 0 
 Kyrgyzstan   177 52 
 Lao People’s 
 Democratic Republic   85  
 Latvia 27 57 8 13 
 Lebanon 3 148 1   
 Lesotho   2235 27 
 Liberia   926  
 Lithuania 5 38 5 38 
 Malawi 18 910 70 4929 16 
 Malaysia 72 33 390 30 
 Malta   6 100 
 Marshall Islands   2 100 
 Mauritania 95 86 1, 4 55 6 
 Mauritius 3 16 7 100 
 Mexico 806 78 216 77 
 Moldova 23 10 63 39 
 Morocco 88 73 103 22 
 Mozambique 1008 4 1 5622 10 
 Myanmar   959 11 5 
 Nepal 321 46 1   
 New Zealand   8 100 
 Nicaragua 13 14 40 77 
 Niger 197 1 271 3 
 Nigeria 28 625 56 18 788 69 
 Oman   3 100 
 Panama 270 5 171 35 
 Papua New Guinea 320 35 127 20 
 Paraguay 20 14 72  
 Peru 93 11 529 71 
 Philippines 99 49  80 
 Poland 70 176 1   
 Portugal   309 100 
 Qatar   0  
 Russian Federation 463 39 1, 4 6679 40 
 Rwanda   1148 9 
 Saint Kitts and Nevis 2 100   
 Saint Lucia 2 50 1 100 
 Saint Vincent and 
 the Grenadines 4 100 3 27 
 Sao Tome and Principe 0 2 10 77 
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2007 2009
% of patients 
treated
Adults 
treated
Adults 
treated
% of patients 
treated
TREATMENT FOR TB AND HIVPERCENTAGE OF 
ESTIMATED HIV-POSITIVE 
INCIDENT TB CASES THAT 
RECEIVED TREATMENT FOR 
TB AND HIV
 Senegal 319 15 259 6 
 Seychelles 11 100 2 100
 Slovakia   0 0
 Slovenia 0 2  
 Somalia 14 2 59 3
 South Africa 159 382 50 3 42 576 42
 Sri Lanka   3 10
 Sudan   823 8
 Suriname   15 60
 Sweden   57 100
 Syrian Arab Republic   0 
 Tajikistan 6 8 52 14
 Thailand 2260 23 1 4151 26
 The former Yugoslav 
 Republic of Macedonia 2 2  
 Togo 44 2 1 94 4
 Trinidad and Tobago   6 6
 Tunisia   11 55
 Turkey 47 2  
 Uganda   18 062 60
 Ukraine 411 15 740 21
 United Kingdom of 
 Great Britain and 
 Northern Ireland   310 100
 United Republic 
 of Tanzania 188 12 5918 30
 Uruguay 20 25 18 18
 Venezuela   81 22
 Viet Nam 390 15 1818 28
 Yemen   25 
 Zambia 21103 35 6951 41
1  Estimate of denominator provided by WHO (Global Tuberculosis Control 
Report 2008).
2 No denominator is available.
3 Denominator is the total number of TB cases reported in 2007.
4  For Mauritania, data available for 2 year period only, thus indicator for 
2007 assumes cases evenly spread over each year. For Russian Federation, 
data reported from 4 geographical regions only – Ulyanovskaya oblast, 
Saratovskaya oblast, Tverskaya oblast, and Altayskiy kray
5 Data collection started before 2008.
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TB patients 
(new and 
re-treatment) 
with an HIV 
test result 
recorded in 
the TB register 
TB patients 
(new and 
re-treatment) 
recorded as 
HIV-positive
HIV-positive 
TB patients 
started or 
continued on 
co-trimoxazole 
preventive 
therapy (CPT) 
HIV-positive 
TB patients 
started or 
continued on 
antiretroviral 
therapy (ART) 
People 
registered as 
HIV-positive 
screened for 
TB at least 
once during 
year
People registered 
as HIV-positive 
given isoniazid 
prophylaxis 
(treatment 
of latent TB 
infection)
Survey 
YearTREATMENT AND HIV 
TESTING OF TB PATIENTS
 Afghanistan 2009 1175 5  5 93 
 Albania 2009 211 6 4 6 51 3
 American Samoa 2009 4 0 0 0 0 0
 Andorra 2009 0 0 0 0 0 0
 Angola 2009 2023 306 42 29  
 Antigua and 
 Barbuda 2009 4 0 0 0 1 0
 Argentina 2009 131 115    
 Armenia 2009 521 17 8 6 167 0
 Australia 2009 297 15    
 Bahamas 2009 46 15 6 9  
 Bahrain 2009 256 9 0 1  
 Bangladesh 2009 662 36 35 36 57 
 Barbados 2009 2 0 0 0  0
 Belarus 2009  190    
 Belize 2009 89 17 17 17  
 Benin 2009 3845 629    
 Bolivia (Plurinational 
 State of) 2009 1105 38 8 29  
 Bosnia and 
 Herzegovina 2009      
 Botswana 2009 6128 4036 1467 1467 15 9112 11732
 Brazil 2009 39 744 8668  7935 8668 
 Burkina Faso 2009 4817 981 959 503  
 Burundi 2009 2857 1305 617 423 768 617
 Cambodia 2009 28 246 3597 1081 526  66
 Cameroon 2009 18 677 7494 0 0 18 677 0
 Cape Verde 2009 282 57    0
 Central African 
 Republic 2009 3749 1230 808 427  0
 Chad 2009 0 0 0 0 0 0
 China 2009 63 227 2511 2176 1072  
 China, Hong 
 Kong SAR 2009 3993 40 9 11 606 78
 China, Macao SAR 2009 336 1 0 0 17 1
 Colombia 2009 5031 1018  237  
 Comoros 2009 117 0 0 0 1 0
 Congo 2009 205 99 99 99  
 Cook Islands 2009 0 0 0 0 0 0
 Costa Rica 2009 476 41   41 
 Côte d’Ivoire 2009 17 253 5207 3674 1633 88 0
 Cuba 2009 687 3 0 3 1249 1561
 Democratic 
 People’s Republic 
 of Korea 2009 0 0 0 0 0 0
 Democratic 
 Republic of 
 the Congo 2009 20 630 4173 1435 656 5161 0
 Djibouti 2009 1819 197 0 152  
 Dominica 2009 4 1 0 1 12 2
 Ecuador 2009 2262 443  443  
 Egypt 2009 3204 11 11 11 89 1
 El Salvador 2009 1650 204 58 71 67 97
 Equatorial Guinea 2009 720 121 0 0  
 Estonia 2009 380 39 0 21  0
Supplemental data obtained by 
the World Health Organization 
through annual reporting of 
national tuberculosis programmes 
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TB patients 
(new and 
re-treatment) 
with an HIV 
test result 
recorded in 
the TB register 
TB patients 
(new and 
re-treatment) 
recorded as 
HIV-positive
HIV-positive 
TB patients 
started or 
continued on 
co-trimoxazole 
preventive 
therapy (CPT) 
HIV-positive 
TB patients 
started or 
continued on 
antiretroviral 
therapy (ART) 
People 
registered as 
HIV-positive 
screened for 
TB at least 
once during 
year
People registered 
as HIV-positive 
given isoniazid 
prophylaxis 
(treatment 
of latent TB 
infection)
Survey 
YearTREATMENT AND HIV 
TESTING OF TB PATIENTS
 Ethiopia 2009 56 040 11098 7516 4515 24112 2403
 Fiji 2009 144 0 0 0 30 0
 French Polynesia 2009 12 0 0 0  0
 Gabon 2009 1130 667 348 348  
 Gambia 2009 2045 326  35 1238 
 Ghana 2009 9870 2218 1601 531 10730 0
 Grenada 2009 5 1 1 1 1 0
 Guam 2009 63 0 0 0 7 0
 Guatemala 2009 1920 342 342 342 525 250
 Guinea 2009 5444 1288 520 84  
 Guyana 2009 562 156 116 87 893 162
 Honduras 2009 1619 192 192 170 764 96
 India 2009 258 037 31058   280903 
 Indonesia 2009 2782 479  201 2812 0
 Iran (Islamic 
 Republic of) 2009 700 223 28 47 11400 418
 Iraq 2009 6121 1 1 0 7 0
 Israel 2009 20 20  8 20 
 Jamaica 2009 96 29    
 Jordan 2009 387 0 0 0 15 2
 Kenya 2009 96 676 42294 38989 14250 14116 
 Kiribati 2009 152 0 0 0  
 Kuwait 2009 933 4 4 4 11 0
 Kyrgyzstan 2009 6615 88  12  58
 Lao People’s 
 Democratic 
 Republic 2009 686 179 159   
 Latvia 2009 830 73  44  0
 Lebanon 2009 298 25 25 25 97 19
 Lesotho 2009 10 563 8084 7636 2235  
 Liberia 2009 5964 72 30 35 0 0
 Libyan Arab 
 Jamahiriya 2009 950 144   148 
 Lithuania 2009  14    
 Malawi 2009 19 289 13329 12748 6185 0 0
 Malaysia 2009 15 192 1644 164 164 2156 0
 Mali 2009 3760 585 263 61  0
 Malta 2009 30 4    
 Marshall Islands 2009 98 2 0 2 4 0
 Mauritania 2009 199 23    
 Mauritius 2009 110 7 7 5 210 0
 Mexico 2009 4196 945 945 216 2368 676
 Micronesia 
 (Federated 
 States of) 2009 49 0 0 0 0 0
 Monaco 2009      
 Mongolia 2009 3993 0 0 0 53 0
 Montenegro 2009 91 0 0 0 1 0
 Montserrat 2009      
 Morocco 2009 77 0 0 0 4972 0
 Mozambique 2009 38 087 25 056 22183 5622 24330 2429
 Myanmar 2009 4174 1015 981 681 489 333
 Namibia 2009 9849 5676 5192 1995 87529 17737
 Nauru 2009     0 0
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TB patients 
(new and 
re-treatment) 
with an HIV 
test result 
recorded in 
the TB register 
TB patients 
(new and 
re-treatment) 
recorded as 
HIV-positive
HIV-positive 
TB patients 
started or 
continued on 
co-trimoxazole 
preventive 
therapy (CPT) 
HIV-positive 
TB patients 
started or 
continued on 
antiretroviral 
therapy (ART) 
People 
registered as 
HIV-positive 
screened for 
TB at least 
once during 
year
People registered 
as HIV-positive 
given isoniazid 
prophylaxis 
(treatment 
of latent TB 
infection)
Survey 
YearTREATMENT AND HIV 
TESTING OF TB PATIENTS
 New Zealand 2009 137 4    
 Nicaragua 2009 1081 30 30 30 60 60
 Niger 2009 2424 300    
 Nigeria 2009 64 246 16 813 7730 5486 195 112 1853
 Niue 2009 0 0 0 0 0 0
 Northern 
 Mariana Islands 2009 32 0 0 0 1 0
 Oman 2009 334 3 3 3 116 0
 Pakistan 2009 4714 7 7 7 2917 0
 Palau 2009 19 0 0 0  0
 Panama 2009 1494 107  107  196
 Papua New 
 Guinea 2009 1305 196    
 Paraguay 2009 239 133 0 72 273 0
 Peru 2009 11 893 697  121  1361
 Philippines 2009 1136 1 0 0  1
 Puerto Rico 2009 59 8 3 3 4 0
 Qatar 2009 619 0 0 0 5 0
 Romania 2009 5755 209  169  188
 Russian Federation 2009 204 624 7442  1448 235 753 10451
 Rwanda 2009 7448 2529 2329 1239 12 152 0
 Saint Kitts and 
 Nevis 2009 4 0 0 0  
 Saint Lucia 2009 11 4  4  
 Saint Vincent and 
 the Grenadines 2009 13 7  1  1
 Samoa 2009 0 0 0 0  
 San Marino 2009      
 Sao Tome and 
 Principe 2009 79 10 10 3 10 2
 Saudi Arabia 2009 1929 49    
 Senegal 2009 6906 455 386 123  0
 Seychelles 2009 15 3 3 2 52 0
 Sierra Leone 2009 8625 987    
 Singapore 2009 1121 52    
 Solomon Islands 2009 0 0 0 0 8 0
 Somalia 2009 698 96 89 7  0
 South Africa 2009 197 448 114 523 80 954 48 314 433 662 23583
 Sudan 2009 16 168 692 296 375 1482 
 Suriname 2009 154 49 6 25  
 Swaziland 2009 8272 6895    
 Tajikistan 2009 3714 49 0 22 435 0
 Thailand 2009 49 955 8202 5930 4151 25 172 127
 The Former 
 Yugoslav Republic 
 of Macedonia 2009 43 0 0 0 12 0
 Timor-Leste 2009 108 0 0 0 12 2
 Togo 2009 1429 357  94  0
 Tonga 2009 8 0 0 0 1 0
 Trinidad and 
 Tobago 2009 306 95 22 17 335 4
 Tunisia 2009 130 2 0 2 35 24
 Tuvalu 2009 0 0 0 0 0 0
 Uganda 2009 31 695 17 131 14 731 3766 57 679 
 Ukraine 2009  3380  915  
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TREATMENT AND HIV 
TESTING OF TB PATIENTS
TB patients 
(new and 
re-treatment) 
with an HIV 
test result 
recorded in 
the TB register 
TB patients 
(new and 
re-treatment) 
recorded as 
HIV-positive
HIV-positive 
TB patients 
started or 
continued on 
co-trimoxazole 
preventive 
therapy (CPT) 
HIV-positive 
TB patients 
started or 
continued on 
antiretroviral 
therapy (ART) 
People 
registered as 
HIV-positive 
screened for 
TB at least 
once during 
year
People registered 
as HIV-positive 
given isoniazid 
prophylaxis 
(treatment 
of latent TB 
infection)
Survey 
Year
 United Republic 
 of Tanzania 2009 56 162 21 031 19 007 6639 5526 153
 United States 
 of America 2009 7032 703    
 Uruguay 2009 666 109 0 18  
 Uzbekistan 2009 21 453 357 89 37 3022 1056
 Vanuatu 2009 11 0 0 0 3 0
 Venezuela 
 (Bolivarian 
 Republic of) 2009 4856 487 0 102 30 158 102
 Viet Nam 2009 34 907 5934 5265 354 7092 1500
 Wallis and Futuna 
 Islands 2009 9 0 0 0 0 0
 West Bank and 
 Gaza Strip 2009 35 0 0 0 0 0
 Yemen 2009      
 Zambia 2009 34 992 23 584 15 041 10 009  
 Zimbabwe 2009 28 006 21 967    
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2005 2007PERCENTAGE OF ORPHANED 
AND VULNERABLE CHILDREN 
AGED 0-17 WHOSE HOUSE-
HOLDS RECEIVED FREE BASIC 
EXTERNAL SUPPORT IN 
CARING FOR THE CHILD
Survey year Survey yearCoverage Coverage
 Angola     
 Barbados     
 Benin   2006 69 1 
 Botswana 2004 34   
 Burkina Faso   2007 5 1 
 Burundi   2006 50 1 
 Côte d’Ivoire   2006 9 1 
 Cameroon   2006 9 
 Central African Republic   2006 20 2 
 Chad     
 Congo, Republic of the     
 Costa Rica   2006 100 1 
 Croatia   2007 100 1 
 Cuba     
 Democratic Republic 
 of the Congo     
 Djibouti     
 Dominican Republic   2007 4 1 
 Eritrea   2007  
 Ethiopia 2004 4 2004 4 
 Finland    99 
 Gabon   2007 10 
 Ghana   2006 2 1 
 Guinea   2007 17 1 
 Guinea-Bissau   2006 8 
 Haiti   2006 5 
 Honduras     
 Indonesia     
 Kenya  10   
 Lesotho 2004 25   
 Madagascar 2003 7   
 Malawi   2006 53 2 
 Mali 2005 39 2007 45 1 
 Mozambique     
 Namibia   2007 17 
 Nigeria   2007 10 1 
 Rwanda   2005 13 
 Saint Lucia   2007 69 1 
 Saint Vincent and 
 the Grenadines     
 Senegal   2007 44 1 
 Seychelles   2006 100 1 
 Sierra Leone   2005 1 
 South Africa   2007 67 1 
 Swaziland   2007 41 
 Togo  10 2006 60 2 
 Turkey   2006 100 1 
 Uganda   2006 11 
 United Republic 
 of Tanzania   2006 51 1 
 Zambia 2005 13 2007 16 
 Zimbabwe   2006 31 
UNGASS Indicator 10
MDG 6a indicator
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2009 MOST RECENT DHS 
(OR MICS)3
Survey year Survey yearCoverage Coverage
2009 17  
2009 100  
2009 7  
2008 31  
2008 5  
2009 7  
2009 27 2005 9
2009 16  
2006 7 2006 7
2009 35  
2009   
   
   
2009 100  
2007 9 2007 9
2009 14  
2008 37  
   
2004 3  
2009 100  
2010 20  
2008 7  
2009 17  
   
2005 5 2005 5
2009 0  
2007 13  
2007 21  
   
2010   
2006 19  
2009 17  
2008 22  
2006 17 2006 17
2008 6 2008 6
2005 13 2005 13
2009 83  
2008   
2007 43  
   
2005 1  
2009 75  
2006 41 2007 41
2007 60  
   
2010  2006 11
2008 16  
2006 16 2007 16
2009 21 2005-06 28
1 Methodology not harmonized with UNGASS 2008 
guidelines.
2 Differs from value provided by UNICEF.
3 Demographic Health Survey (or Multiple Indicator 
Cluster Survey).
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2005 2007 20092003
Survey 
year
Ratio Ratio Survey 
year
Ratio Survey 
year
Ratio
ORPHANS SCHOOL ATTENDENCERATIO OF ORPHANS TO 
NON-ORPHANS AGED 10-14 
ATTENDING SCHOOL
 Angola 0.90   2001 0.90 2009 0.87
 Argentina    2005 1.03  
 Bahamas      2009 1.00
 Belize      2006 0.66
 Benin    2006 0.85 2009 0.00
 Bolivia    2003 0.741   
 Botswana 0.99      
 Burkina Faso    2007 0.87 2007 1.15
 Burundi 0.70   2005 0.85  
 Côte d’Ivoire 0.83   2005 1.213  2009 0.69
 Cambodia    2006 0.83 2005 0.83
 Cameroon 0.94   2006 0.89 2006 0.91
 Central African 
 Republic 0.91   2006 0.96 2006 0.97
 Chad 0.96   2004 1.03 2004 1.17
 Colombia    2005 0.851   
 Comoros 0.59      
 Congo, 
 Republic of the    2005 1.12 2009 0.88
 Croatia    2007 1.00   
 Cuba    2005 1.00  2009 1.00
 Democratic 
 Republic of 
 the Congo 0.72   2007 0.771  2007 0.77
 Dominican Republic      2006 0.71
 Equatorial Guinea 0.95      
 Eritrea    2002 0.831   
 Ethiopia 0.60   2004  2004 0.90
 Finland     >0.99  
 Gabon 0.98   2007 1.14 2010 0.84
 Gambia 0.85   2006 0.87  
 Ghana 0.93   2006 1.044  2008 0.76
 Guinea 1.13   2005 0.731   
 Guinea-Bissau 1.03   2006 0.97  
 Guyana    2005 0.951   
 Haiti    2000 0.871  2005 0.86
 Honduras      2005 1.08
 India    2006 0.721   
 Indonesia    2002 0.841  2007 0.94
 Iran, Islamic 
 Republic of      2008 0.81
 Japan      2008 1.00
 Kenya 0.74 2005 0.97 2003 0.951  2007 1.05
 Lesotho 0.87   2007 0.95  
 Madagascar 0.65 2003 0.80 2004 0.83 2009 1.00
 Malawi 0.93 2004 0.97   2006 0.97
 Mali 0.72     2006 0.87
 Mauritania      2007 0.72
 Moldova      2010 0.52
 Mozambique 0.47   2004 0.80 2008 0.91
 Namibia 0.92 2005 0.97 2007 1.00 2006 1.01
 Nicaragua    2007 0.88  
 Niger 1.07   2006 0.67 2006 0.66
 Nigeria 0.87   2007 0.86  2008 1.17
UNGASS Indicator 12
MDG 6a indicator
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2005 2007 20092003
Survey 
year
Ratio Ratio Survey 
year
Ratio Survey 
year
Ratio
ORPHANS SCHOOL ATTENDENCERATIO OF ORPHANS TO 
NON-ORPHANS AGED 10-14 
ATTENDING SCHOOL
 Papua New 
 Guinea    2007 0.86 2006 0.86
 Rwanda 0.80   2005 0.82 2005 0.82
 Saint Lucia    2007 1.76 2 2009 1.38
 Saint Vincent and 
 the Grenadines      2008 1.00
 Senegal 0.74   2007 1.25 2  
 Sierra Leone 0.71   2005 0.83 2008 0.62
 Somalia 0.65   2006 0.78  
 South Africa 0.95   2007 0.812 2008 0.99
 Spain      2007 0.00
 Sudan 0.96     2006 0.80
 Swaziland 0.91   2007 0.97 2006 0.97
 Thailand    2006 0.93 2005 0.99
 Togo 0.96   2007 0.94 2007 0.96
 Turkey    2007 0.70 2  
 Uganda 0.95   2000 0.95 2010 0.00
 United Republic 
 of Tanzania 0.74   2007 0.64 2008 
 Zambia 0.87 2005 0.17 2005 1.02 2 2006 0.92
 Zimbabwe 0.85   2006 0.95  
1 Demographic and Health Survey value provided by MEASURE DHS (www.measuredhs.com).
2 Data collection method differs from the UNGASS recommended methodology.
3 Differs from value provided by UNICEF.
4 Multiple Indicator Cluster Survey based on small denominators, typically 25-49 unweighted cases.
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2007 2009PERCENTAGE OF SCHOOLS 
THAT PROVIDED LIFE SKILLS-
BASED HIV EDUCATION IN 
THE LAST ACADEMIC YEAR
 Afghanistan  1 
 Angola 1  
 Antigua and 
 Barbuda 13 100 
 Argentina  3 
 Azerbaijan 19 100 
 Bahamas 72 78 
 Bangladesh  0 
 Barbados 41 85 
 Belarus 79 13 
 Belize  38 
 Bosnia and 
 Herzegovina 24  
 Botswana 100 100 
 Brazil  63 1 
 Bulgaria 6 17 
 Burkina Faso 1 10 
 Burundi 64 66 
 Côte d’Ivoire 1 2 
 Cambodia 26 34 
 Cameroon  6 1 
 Cape Verde 100 100 
 Central African 
 Republic 15 27 
 Chad 4 75 
 Comoros 15 27 
 Congo, 
 Republic of the 82 63 
 Costa Rica 100 100 
 Croatia 5 5 
 Cuba 71 94 
 Czech Republic  59 
 Democratic 
 Republic of 
 the Congo 0 68 
 Djibouti  38 
 Dominica 100 100 
 Dominican 
 Republic 1 8 
 Ecuador  63 
 El Salvador 4 100 
 Eritrea 26 31 
 Ethiopia 70 38 
 Finland 95 100 
 Gabon 35 35 1 
 Gambia 33  
 Germany 50 1 
 Ghana 58 79 
 Grenada 0 94 
 Guatemala  2 
 Guinea  82 
 Guyana  62 
 Haiti  13 UNGASS Indicator 11
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2007 20072009 2009
 Honduras 39 11 
 India  31 
 Indonesia 10  
 Iran, Islamic 
 Republic of 0 
 Jamaica 24 44
 Japan 72 100
 Kazakhstan  81
 Kenya  100
 Kyrgyzstan  84
 Lao People’s 
 Democratic 
 Republic 32 74
 Lesotho  88
 Liberia  2
 Luxembourg  100
 Malaysia  0 1
 Mali  49
 Mexico 27 
 Moldova 93 0
 Montenegro  27
 Namibia 79 
 Nepal 6 8
 Nicaragua 8 88
 Niger 8 82
 Nigeria 34 23
 Oman  100
 Pakistan 6 
 Papua New 
 Guinea 25 100
 Portugal  100 1
 Romania 64 67
 Russian 
 Federation 82 92
 Saint Kitts and 
 Nevis  45
 Saint Lucia 91 59
 Saint Vincent and 
 the Grenadines 87 100
 Sao Tome and 
 Principe 100 
 Serbia 1 
 Seychelles 100 100
 Singapore  100
 South Africa 96 100
 Sudan  13
 Suriname  0
 Swaziland 51 85
 Sweden  100
 Tajikistan  5
 Timor-Leste  0
 Togo 0 0
 Turkey 100 
 Tuvalu  100
 Ukraine 57 59
 Uruguay  90
 Uzbekistan  100
 Vanuatu  8
 Venezuela  100
 Viet Nam  34
 Yemen  4
 Zambia 60 
 Zimbabwe 100 100
1 Data collection started before 2008.
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Females Survey 
year
Males Females
15-24 15-2415-24
2003 2005YOUNG WOMEN AND MEN 
AGED 15-24 WHO CORRECTLY 
IDENTIFY WAYS OF 
PREVENTING THE SEXUAL 
TRANSMISSION OF HIV 
AND WHO REJECT MAJOR 
MISCONCEPTIONS
 Albania <1    
 Algeria     
 Angola   43 35 
 Antigua and Barbuda     
 Argentina     
 Armenia     
 Azerbaijan 2    
 Bangladesh     
 Barbados     
 Belarus     
 Belize     
 Benin   11 8 
 Bolivia 22    
 Bosnia and 
 Herzegovina     
 Botswana 28    
 Brazil     
 Bulgaria     
 Burkina Faso     
 Burundi 24 2004 4 4 
 Côte d’Ivoire 16    
 Cambodia 37    
 Cameroon 16 2004 34 27 
 Cape Verde     
 Central African 
 Republic 5    
 Chad 5    
 Chile     
 China     
 Colombia     
 Comoros 10    
 Congo, 
 Republic of the     
 Costa Rica     
 Croatia     
 Cuba 52    
 Cyprus     
 Democratic Republic 
 of the Congo     
 Djibouti     
 Dominican Republic 33    
 Ecuador     
 Egypt     
 El Salvador     
 Equatorial Guinea 4    
 Eritrea     
 Estonia     
 Ethiopia     
 Gabon     
 Gambia 15    
 Georgia     
 Germany     
 Ghana  2003 40 36 
 Greece     UNGASS Indicator 13
MDG 6a indicator
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
2007 2009 MOST RECENT DHS (OR MICS)1
    2008 22 36    
2006  16 16 2006  16    
2006 25 21 23 2009 32 25 28   
2005   48       
2005 83 89 86 2008   93   
2007 42 34 36     2005 15% 23%
    2006 5 5 5 2006 5% 5%
2005 24 21 22 2008 22 13 18   
    2009 52 49 50   
2007 70 65 68 2009 68 72 70   
2006 26 26 26 2009 47 53 50   
2006 35 16 20 2008 34 34 34 2006 35% 16%
    2008 28 30 24 2008 28% 25%
2006  44        
    2008 39 45 42   
    2008 53 50 52   
2006 18 21 19 2009 21 25 23   
2007 45 46 45 2008 29 21 25 2003 23% 15%
2005  31  2007 45 39 35   
2005 28 18 22 2009 17 13 15 2005 28% 18%
2006 45 49 47 2005 45 50 48 2005 45% 50%
2006  32 32 2004 35 27 30 2004 35% 27%
2005 37 38 38 2009 65 68 67 2005 36% 36%
2006 31 22 24 2006 26 17 20 2006 27% 17%
2004 20 8 11 2004 20 8 11 2004 20% 8%
2007    2009 78 85 82   
2007 50 55 42 2008   85   
        2005  
          
2005 22 10 13 2009 22 8 14 2009 22% 8%
2006 43 42 42       
2006 16 25 20       
2006 55 61 58 2008      
2007 10 11 10       
2006 29 22 26 2007 21 15 17 2007 21% 15%
    2008 23 18 21   
2007 34 41 37 2007 34 41 37 2007 34% 41%
2006 31 27 29       
    2007 18 5 11   
    2008  27    
    2006   2   
    2008 77 78 77 2002  37%
2007 28 37 32 2007 28 37 32   
2005 33 21 24 2005 33 21  2005 33% 21%
2007 58 60 59 2010 58 53 55   
2005 34 25 29       
2005  4        
2007    2009      
    2008 34 28  2008 34% 28%
2007 27 23 25 2009 27 50 38   
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Females Survey 
year
Males Females
15-24 15-2415-24
2003 2005YOUNG WOMEN AND MEN 
AGED 15-24 WHO CORRECTLY 
IDENTIFY WAYS OF 
PREVENTING THE SEXUAL 
TRANSMISSION OF HIV 
AND WHO REJECT MAJOR 
MISCONCEPTIONS
 Grenada     
 Guatemala     
 Guinea     
 Guinea-Bissau 8    
 Guyana 36    
 Haiti 14    
 Honduras     
 India     
 Indonesia 7    
 Iran, Islamic 
 Republic of     
 Jamaica     
 Japan     
 Kazakhstan     
 Kenya 26 2005 80 58 
 Kyrgyzstan     
 Latvia     
 Lesotho 18    
 Liberia     
 Lithuania     
 Madagascar  2003 16 19 
 Malawi 34 2005 36 24 
 Malaysia     
 Mali     
 Marshall Islands     
 Mauritania     
 Mauritius     
 Mexico     
 Micronesia     
 Moldova 19    
 Mongolia 32 2005 3 5 
 Montenegro     
 Morocco     
 Mozambique     
 Myanmar     
 Namibia     
 Nepal     
 Nicaragua     
 Niger 5    
 Nigeria     
 Norway     
 Oman     
 Palau     
 Panama     
 Papua New Guinea     
 Peru     
 Philippines     
 Russian Federation     
 Rwanda 23    
 Saint Kitts and Nevis     
 Saint Lucia     
 Saint Vincent and 
 the Grenadines     
 Samoa     
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
2007 2009 MOST RECENT DHS (OR MICS)1
2006 43 40 41       
2002 10 9 9 2008 24 22 23   
2007 20 12 16 2009 23 20 22 2005 23% 17%
2006  18  2008 13 13 13   
2005 34 44 39 2008   46 2005 47% 53%
2006 40 32 35 2005 40 34 35 2005 40% 34%
2005 39 89 77 2005  30  2005-06  30%
2006 33 24 28 2009 44 35 40 2005-06 36% 20%
    2007 14 15 14   
    2008 15 17 16   
2004 23 47 35 2008 38 43 40   
2004    2008      
2007 18 20 19 2008 29 32 30   
    2008 55 48  2003 47% 34%
2006 30 33 32 2009 33 37 35   
2007 3 3 3       
    2009    2004 19% 27%
    2006 67 57 62 2007 27% 21%
    2009 50 34 41   
2006 46 45 45 2008 57 54  2003-04 16% 19%
    2006 42 42 42 2004 36% 24%
    2008   23   
2006 22 18 20 2006 59 54 55 2006 22% 18%
2006 8 4 6 2007 39 27 32 2007 39% 27%
    2007 14 5 7   
2004   22       
2002 18 18        
 0   2006-07      
2006 26 27 26 2008 39 42 41 2005 na na
2005 17 15 16 2009 19 16 18   
2006    2007      
2007    2007    2003 na 12%
2004 39 25 28     2009 34% 36%
    2007 47 48 48   
2007 62 65 63 2006 62 65  2006 62% 65%
2006 44 28 32 2006 44 28 32 2006 44% 28%
2007  81 81     2001  22%
2006 16 13 14 2006 16 13 14 2006 16% 13%
2005 25 20 23 2007 27 21 24 2008 33% 22%
    2008 66 67 65   
    2007 4 4 4   
2006  27  2008 0 27 27   
    2009 12 15 14   
    2007 26 17 22   
2006   55 2008 28 20 23 2007  19%
        2008  21%
2007 33 35 34 2009 35 39 37   
2005 54 51 52 2005 54 51 52 2005 54% 51%
2006   52 2005   52   
2006 61 57 59 2005 61 57 60   
2006 59 40 49 2008 59 40 49   
    2008      
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Females Survey 
year
Males Females
15-24 15-2415-24
2003 2005YOUNG WOMEN AND MEN 
AGED 15-24 WHO CORRECTLY 
IDENTIFY WAYS OF 
PREVENTING THE SEXUAL 
TRANSMISSION OF HIV 
AND WHO REJECT MAJOR 
MISCONCEPTIONS
 Sao Tome and Principe 11    
 Senegal     
 Serbia     
 Seychelles     
 Sierra Leone 16    
 Singapore     
 Solomon Islands     
 Somalia  2004 13 8 
 South Africa 20    
 Spain     
 Sri Lanka     
 Sudan     
 Suriname 27    
 Swaziland 27    
 Sweden     
 Tajikistan     
 Thailand     
 The former Yugoslav 
 Republic of Macedonia     
 Timor-Leste     
 Togo 20    
 Tonga     
 Trinidad and Tobago 33    
 Tunisia     
 Turkey     
 Turkmenistan     
 Tuvalu     
 Uganda 28    
 Ukraine     
 United Kingdom of 
 Great Britain and 
 Northern Ireland     
 United Republic 
 of Tanzania 26    
 Uruguay     
 Uzbekistan 3    
 Vanuatu     
 Viet Nam 25    
 Zambia 26 2005 46 41 
 Zimbabwe  2003 56 54 
1 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
2007 2009 MOST RECENT DHS (OR MICS)1
2006    2008    2008-09 43% 43%
2005 24 19 22 2005 24 19 23 2005 24% 19%
2006 20 21 20 2006 20 21 20   
2003 59 67 63       
2007    2008 28 17  2008 28% 17%
2007 15 20 17       
    2008      
2006  4 4 2006  4    
    2008 30 27 29   
    2008      
2007 10 7 8 2006  17    
    2006  7 7   
2006  41 41 2006  41    
2007 52 52 52 2006 52 52 52 2007 52% 52%
    2009 59 61 60   
2007 11 11 11 2008 11 9 10   
2006 47 33 40 2006 44 30 37   
2007 19 26 22 2007 18 25 22   
    2008 21 36    
2007 59 44 51 2007 59 44 51   
    2008      
2007   56       
 26 29 27 2009 5 11 8   
2007 35 39 37       
        2000  3%
2005    2007 61 39 48   
2006 38 32 33 2010    2006 38% 32%
2007 39 42 40 2009 40 41 40 2007 43% 45%
    2007   65   
    2008 42 39 40 2007-08 42% 39%
2007 52 48 50 2008 23 44 34   
    2009 14 11 13   
    2008      
2005 50 42 46 2009 44 41 42 2005 50% 42%
2007 37 34 35 2007 37 34 35 2007 37% 34%
2006 46 44 45 2009  53  2005-06 46% 44%
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Survey 
year
Males Females
15-24 15-24
20051PERCENTAGE OF YOUNG 
WOMEN AND MEN AGED 
15-24 WHO HAVE HAD 
SEXUAL INTERCOURSE 
BEFORE THE AGE OF 15
 Albania    
 Angola  47 24 
 Antigua and Barbuda    
 Argentina    
 Armenia    
 Azerbaijan    
 Bahamas    
 Bangladesh    
 Barbados  36 26 
 Belarus    
 Belize    
 Benin  16 9 
 Bolivia    
 Bosnia and 
 Herzegovina    
 Botswana    
 Brazil    
 Bulgaria    
 Burkina Faso    
 Burundi  14 6 
 Côte d’Ivoire 2004 13 15 
 Cambodia  <1 <1 
 Cameroon 2004 23 35 
 Cape Verde    
 Central African 
 Republic 2004 10 10 
 Chad    
 Chile    
 Colombia    
 Comoros    
 Congo, 
 Republic of the 2003 10 10 
 Costa Rica    
 Cuba    
 Cyprus    
 Czech Republic    
 Democratic Republic 
 of the Congo    
 Djibouti    
 Dominican Republic    
 Ecuador    
 El Salvador    
 Eritrea    
 Estonia    
 Ethiopia  40 42 
 Fiji    
 Finland    
 Gabon    
 Gambia    
 Georgia    
 Germany    
 Ghana    
 Greece    
 Grenada    
 Guatemala    UNGASS Indicator 15
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
20071 20091 MOST RECENT DHS (OR MICS)2
    2008 1 1    
2006 36 28 32 2009 37 23 30   
2006   25       
2005 27 19 23 2008   19   
2007 11 <1 3     2005 3 0
    2006 1 1  2006 1 1
    2009 70 41 58   
2005 4 1 2 2008 12 31 24 2007 1 
    2009 22 16 20   
2007 8 4 5 2009 7 2 4   
2006 11 6 9 2009 11 5 8   
2006 13 12 12  22 13 17 2006 13 12
    2008 13 7 8 2008 13 7
2006  1  2009 17  18   
    2008 5 3 4   
    2008 41 29 35   
2006 13 7 10 2009 11 5 8   
2007 3 7 6 2008 9 7 8 2003 4 7
2005  3  2007 5 3 4   
2005 15 19 18 2009   21 2005 15 19
2006 <1 1 1 2005 0 1 1 2005 0 1
2006  14  2004 23 35 31 2004 11 20
2005 41 24 30 2009 26 13 26 2005 41 24
2006 20 33 30 2006 36 52 48 2006 13 25
2004 19 39 35 2004 10 26  2004 10 26
2006 12 6 9 2009 13 8 11   
2007   37     2005  13
    1996 16 8 10   
2005 27 24 24  25 20 22 2009 25 20
2006 15 7 11       
2006 33 15 24 2008 32 15 24   
2007 15 1 8       
    2008 3 4 3   
2006 31 23 28 2007 18 18 18 2007 18 18
    2008 11 2 7   
2007 24 33 29 2007 24 15 19 2007 24 15
2004  10        
2003 54 21 27 2008  11    
        2002  13
2007 10 11 10 2007 11 11 11   
2005 2 16 12 2005 2 16  2005 2 16
2007   50       
    2009 27 30 28   
2007 38 14 25 2010 28 8 15 2000 42 24
2006  5        
2005  2 2       
2006 10 12 11 2005 12 14 13   
    2008 4 8  2008 4 8
2007 35 7 24 2009 22 10 16   
2006 32 20 25       
2002 20 9 11 2008 16 8 11 1999  10
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Survey 
year
Males Females
15-24 15-24
20051PERCENTAGE OF YOUNG 
WOMEN AND MEN AGED 
15-24 WHO HAVE HAD 
SEXUAL INTERCOURSE 
BEFORE THE AGE OF 15
 Guinea 2005 16 18 
 Guinea-Bissau    
 Guyana    
 Haiti    
 Honduras    
 India    
 Indonesia    
 Iran, Islamic Republic of    
 Jamaica    
 Japan    
 Kazakhstan    
 Kenya 2005 20 17 
 Kyrgyzstan    
 Latvia    
 Lebanon    
 Lesotho 2004 27 14 
 Liberia    
 Lithuania    
 Luxembourg    
 Madagascar 2003 22 31 
 Malawi    
 Malaysia    
 Mali    
 Malta    
 Marshall Islands    
 Mauritania    
 Mauritius    
 Mexico    
 Micronesia, Federated 
 States of    
 Moldova 2005 34 24 
 Mongolia 2005 3 <1 
 Montenegro    
 Morocco    
 Mozambique    
 Myanmar    
 Namibia    
 Nepal    
 Nicaragua    
 Niger    
 Nigeria 2005 5 15 
 Norway    
 Pakistan    
 Palau    
 Panama    
 Papua New Guinea    
 Paraguay    
 Peru    
 Philippines    
 Portugal    
 Romania    
 Russian Federation 2004 17 8 
 Rwanda    
 Saint Kitts and Nevis    
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
2007 20 31 25 2009 25 29 26 2005 17 22
2006  22  2008 26 16 21   
2005 30 12 21 2009 19 10 14 2009  
2006 43 15 23 2005 43 15 23 2005 43 15
2005 19 11 13 2006 19 11 13 2005-06  11
2006 2 4 3 2009 2 10 0 2005-06 2 10
    2007 0 0 0 2007  
2005    2007 7 1 4   
2004    2008 57 16 36   
2004 8 9 9       
2007 20 3 9 2008 7 0 4   
2003 29 14 21 2008 22 11  2003 29 14
2007 9 <1 5 2009 6 0 3   
2007 16 9 12       
2004   4 2004   4   
2005 12 6 8     2004 13 6
    2006 8 17 13 2007 9 17
2006 22 10 16 2008 18 7 13   
    2006 18 15 16   
2006 33 39 36 2009 9 18  2003-04 9 15
2006    2004 14 15 15 2004 14 15
    2001   5   
2006 5 25 6 2006 5 25 21 2006 5 25
    2009 7 6 7   
2006 17 10 14 2007 27 14 19 2007 27 14
2007  14 14 2007  14 14   
2004 3 1 2 2008 10 5 7   
2005 4 4 4 2005 4 4 4   
    2006   22   
2006 8 1 4 2008 13 1 7 2005 9 1
2005 3 <1 1 2009 2 0 1   
2007 4 2 3 2007      
2007 8 1 5 2007 8 1 5 1992  0
2004 26 28 28 2009 25 25 25 2009 25 25
    2007 1 1 1   
2007 18 7 12 2006 18 7  2006 18 7
        2006 4 8
2007  14 14     2001  12
2006 8 39 25 2006 5 30  2006 5 30
2005 5 15 10 2007 7 17 12 2008 6 16
    2009 8 10 9   
2006 1 <1        
2006  5  2008 17 15 10   
    2009 30 21 24   
2007 4 4 4 2007 8 7 8   
    2008  64    
2007  6  2008 12 7 8 2007  6
        2008  2
    2008 11 6 8   
2006 17 3 10       
2007 12 3 7 2009 10 3 6   
2005 13 4 7 2005 13 4 7 2005 13 4
2006 36 10 22 2005 36 10 22   
20071 20091 MOST RECENT DHS (OR MICS)2
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Survey 
year
Males Females
15-24 15-24
20051PERCENTAGE OF YOUNG 
WOMEN AND MEN AGED 
15-24 WHO HAVE HAD 
SEXUAL INTERCOURSE 
BEFORE THE AGE OF 15
 Saint Lucia    
 Saint Vincent and 
 the Grenadines 2005 63 37 
 Samoa    
 Sao Tome and Principe    
 Senegal    
 Serbia    
 Sierra Leone    
 Singapore    
 Solomon Islands    
 South Africa    
 Spain    
 Sri Lanka    
 Sudan    
 Suriname    
 Swaziland    
 Sweden    
 Switzerland    
 Tajikistan    
 Thailand  11 7 
 The former Yugoslav 
 Republic of Macedonia    
 Togo    
 Trinidad and Tobago    
 Tunisia    
 Turkmenistan    
 Tuvalu    
 Uganda    
 Ukraine    
 United Kingdom of 
 Great Britain and 
 Northern Ireland    
 United Republic 
 of Tanzania    
 Uruguay    
 Uzbekistan    
 Viet Nam    
 Zambia    
 Zimbabwe  9 8 
1 Methodology may vary for individual countries.
2 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Survey 
year
Survey 
year
Survey 
year
Males Males MalesFemales Females FemalesBoth sexes Both sexes
15-24 15-2415-24 15-2415-24 15-24
2006 32 20 26 2005 32 20 26   
2006 31 14 22 2008 31 14 22   
    2008 11 5 9   
2006        2008-09 12 9
2005 12 9 10 2005 12 9 10 2005 12 9
    2006 4 1 2   
2005 25  25 2008 11 25  2008 11 25
2007 3 2 2       
    2008 44 22 29   
2005 5 12 8 2008 11 6 9   
2003 18 11 15 2008 30 18    
2007   3 2006  1    
    2009   41   
2006   8 2006  9    
2007 5 7 6 2006 5 7 6 2007 5 7
2007 15 21 19 2009 19 24 22   
2007 10 7 8 2007 9 7 8   
2006 1 <1 1 2008 1 0 0   
2006 21 5 13 2006 8 1 5   
2007 8 1 5 2007 9 1 5   
2007 13 10 11 2007 13 10 11 1998 0 19
2007   12       
 7 <1 4 2009 52 14 36   
        2000  0
    2007 15 2 7   
2006 12 16 15 2010    2006 12 16
2007 7 3 5 2009 4 0 2 2007 2 1
2001 14 12 13 2001 14 12 13   
2005 10 13 11 2008 10 11 10 2007-08 10 11
2007 25 10 18 2008 44 30 37   
    2009 1 0 1 1996  1
2005 1 <1 <1 2009 0 0 0 2005 0 1
2007 16 14 15 2006 16 13 14 2007 16 14
2006 5 5 5 2007 4 5 5 2005-06 5 5
20071 20091 MOST RECENT DHS (OR MICS)2
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
 Albania      
 Angola      
 Antigua and Barbuda      
 Armenia 2000 9 <1 4 4 
 Azerbaijan      
 Bangladesh      
 Belarus      
 Belize      
 Benin 1996  2   
 Bolivia      
 Bosnia and Herzegovina      
 Botswana      
 Brazil      
 Bulgaria      
 Burkina Faso 1999 13 1 9 6 
 Burundi      
 Côte d’Ivoire 1998 33 5 19 19 
 Cambodia 2000  <1   
 Cameroon 1998 41 10 25 25 
 Canada      
 Cape Verde      
 Central African Republic      
 Chad 1997 19 1 11 8 
 Chile      
 Colombia 2000  3   
 Comoros      
 Congo, Republic of the      
 Costa Rica      
 Cuba      
 Cyprus      
 Czech Republic      
 Democratic Republic 
 of the Congo      
 Djibouti      
 Dominican Republic 1996 16 2 4 6 
 Eritrea      
 Estonia      
 Ethiopia 2000 7 1 3 5 
 Gabon 2000 24 14 20 18 
 Gambia      
 Germany      
 Ghana      
 Greece      
 Grenada      
 Guatemala      
 Guinea 1999 26 4 15 15 
 Guinea-Bissau      
 Guyana      
 Haiti 2000 24 1 11 13 
 Honduras      
 Hungary      
 India      
 Indonesia      
UNGASS Indicator 16
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20074
           
     2006 51 25 38 54 46 26
     2006   55   
2005 9 <1 6 3       
           
     2005 18  18 25 25 14
     2007 33 14 21 27 32 15
     2006 13 2 4 2 8 2   
2001 22 1 7 8 2006 12 35 17 62 30 8
2003 15 1 10 7       
     2006  8  4 11 
           
           
           
2003 15 1 5 9 2007 14 1 7 2 6 9
           
2005 24 4 12 15 2005 31 4 16 15 18 16
2005 6 <1 2 4 2006 6 <1 3 1 4 3
2004 31 6 15 22 2004 40 8 18 17 20 17
     2006   13   
2005 36 3 19 19 2005 69 43 52 86 71 36
     2006 24 2 6 2 11 2 6 14 
2004 17 1 6 10 2004 17 1 8 4 9 10
     2006 12 2 7 6 14 6
2005  3   2007  4 3   35 3 
     2003 24 4 11   9
2005 24 7 15 16 2005 28 8 14 19 16 13
     2006 37 35 39   
     2006 35 10 23 22 29 22
     2007 25 6 15   
           
     2007 22 4 9 10 11 9
           
2002 23 2 13 13 2007 30 4 17 22 25 16
           
     2007 23 19 21 17 26 
2005 2 <1 1 2 2005 3 <1 2 1 2 2
     2007 51 38 43 53 36 43
     2006  1 2    
     2007 35 22 29   
2003 10 1 4 7 2006 22 2 40 2 26 2   
     2007 33 8 20 22 48 18
     2006 30 13 21 19 30 16
     2002 13  13 34 19 8
2005 25 2 11 14 2005 25 2 8 6 10 8
     2006    5 7 
2005 7 1 6 3 2005 9 1 5   
2005 23 1 11 13 2006 23 1 12 7 16 13
2006  1   2005 16 1 4   
           
2006 1 <1 1 1 2006 8 2 5 6 9 4
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
 Iran, Islamic Republic of      
 Jamaica      
 Japan      
 Kazakhstan      
 Kenya 1998 24 3 16 11 
 Kyrgyzstan      
 Lebanon      
 Lesotho      
 Liberia      
 Lithuania      
 Madagascar      
 Malawi 2000 15 1 6 9 
 Mali 1996 13    
 Malta      
 Marshall Islands      
 Mauritius      
 Mexico      
 Micronesia, Federated 
 States of      
 Moldova      
 Mongolia      
 Morocco      
 Mozambique      
 Myanmar      
 Namibia 2000 16 2 9 10 
 Nepal 2001 3    
 Nicaragua 2001  1   
 Niger 1998 10 1 7 5 
 Nigeria      
 Palau      
 Panama      
 Papua New Guinea      
 Paraguay      
 Peru 1996 23 <1 4 9 
 Philippines      
 Poland      
 Portugal      
 Russian Federation      
 Rwanda 2000 2 <1 1 2 
 Saint Kitts and Nevis      
 Saint Lucia      
 Saint Vincent and 
 the Grenadines      
 Sao Tome and Principe      
 Senegal      
 Serbia      
 Seychelles      
 Sierra Leone      
 Singapore      
 Solomon Islands      
 South Africa      
 Spain      
 Sri Lanka      
 Sudan      
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20074
           
     2004 48 11 29   
           
     2007 25 5 15 9 23 15
2003 12 2 7 7 2003 12 2 5 3 6 5
     2007 28 2 15 10 21 
     2004 24 4 17   
2004 21 8 11 16 2005 30 11 16   
           
     2007 43 26 41 <1 <1 41
2004 17 3 11 9 2004 20 3 7   
2004 9 1 4 6 2005 1 1 1 2 1 1
2001 17 1 5 11 2006 23 2 5 5 4 1
           
     2006 23 18 21 19 30 
     2004 9 1 5 4 5 6
     2003 8    6 9
           
2005 11 1 9 4 2007 16 2 8 11 19 5
     2005 54  54   
     2007 37 2 19 14 27 
2003 30 5 18 17 2004 52 24 29 60 34 19
           
     2007 16 3 9 10 15 7
           
     2007  2 2 1 2 2
     2006 9 1 2 5 4 2
2003 15 2 5 10 2005 19 2 10 3 10 14
     2006  9  36 13 5
           
     2007 13 2 8 6 11 7
           
2000  <1   2006 33 12    
2003 6          
     2005 8 5 7   
           
     2006 20 9 15 16 26 13
2005 3 <1 1 2 2005 3 <1 2 <1 1 2
     2006 53 19 36   
     2007 42 25 35   
     2006 25 10 17 13 32 9
           
2005 13 1 4 10 2005 25 4 8 7 11 7
     2006 42 11 26 32 24 <1
     2003 23 11 17   
     2005 9 36 21   
     2007 7 2 4 2 10 4
           
     2005 3 18 10 18 15 8
     2003 27 13 20   
     2007 3 <1 2 1 1 3
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
 Suriname      
 Swaziland      
 Sweden      
 Switzerland      
 Tajikistan      
 Thailand      
 Timor-Leste      
 Togo 1998 21 3 13 13 
 Tonga      
 Trinidad and Tobago      
 Tunisia      
 Turkey      
 Turkmenistan 2000  <1   
 Tuvalu      
 Uganda 1995 8 1 5 4 
 Ukraine      
 United Arab Emirates      
 United Kingdom of 
 Great Britain and 
 Northern Ireland      
 United Republic 
 of Tanzania 1999 29 9 17 20 
 United States of America      
 Uruguay      
 Vanuatu      
 Viet Nam      
 Zambia 1996 27 4 18 12 
 Zimbabwe 1999 13 2 6 8 
1 Data provided by MEASURE DHS.
2 15-24 years.
3 25-64 years only.
4 Methodology may vary for individual countries.
5 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20074
     2006   3   
     2007 14 2 13 15 17 15
     2007 23 23 23 33 34 11
     2007 18 10 14 25 26 10
     2006   6 3 9 
     2006 18 1 9 24 18 7
           
     2007 26 6 16 10 22 17
           
     2007 94 79 85   
           
     2007  15 15 19 20 11
           
           
2001 18 2 6 12 2006 21 2 12 3 9 16
     2007 21 7 14 18 23 11
           
     2001 25 15 20 30 35 16
2004 23 3 10 15 2006 20 5 13 46  
           
     2007 23 11 17 28 35 11
           
2005 14 2 6 9 2005 1 <1 <1 <1 1 <1
2002 21 2 10 13 2007 14 1 7 3 7 9
2006 9 1 4 6 2006 14 1 7 7 9 6
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PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20094
 Albania 2008 5 0 2 15  
 Angola 2009 25 3 10 31 27 
 Antigua and Barbuda       
 Armenia       
 Azerbaijan 2006 6  3 16 5 
 Bangladesh 2005 12  39 28 9 
 Belarus 2009 22 10 28 17 18 
 Belize 2009 15 5 11 27 14 
 Benin 2006 21 1 5 18 27 
 Bolivia 2008 12  10 21 11 
 Bosnia and 
 Herzegovina 2009 64     
 Botswana 2008 16 7 5 26 16 
 Brazil 2008 76 57 66 74 78 
 Bulgaria 2009 29 12 27 43  
 Burkina Faso 2008 27 2 24 26 27 
 Burundi 2007      
 Côte d’Ivoire 2005 31 5 32 33 30 
 Cambodia 2005 6 0 2 9 7 
 Cameroon 2004 40 9 35 45 40 
 Canada       
 Cape Verde 2009 54 42 93 80 36 
 Central African 
 Republic 2006 21 6 12 29  
 Chad 2004 17 1 7 20 21 
 Chile 2009 21 7 16 29 21 
 Colombia 2005  3    
 Comoros 2003 24 4    
 Congo, 
 Republic of the 2009 29 7 9 34 33 
 Costa Rica       
 Cuba 2008 34 12    
 Cyprus       
 Czech Republic 2008 29 21 47 36 26 
 Democratic People’s 
 Republic of Korea       
 Democratic Republic 
 of the Congo 2007 17 3 10 19 18 
 Djibouti 2008   70 90  
 Dominican Republic 2007 30 4 33 43 27 
 Equatorial Guinea 2006      
 Eritrea       
 Estonia 2007 23 21 14 31  
 Ethiopia 2005 3 0 0 2 4 
 Gabon 2010 57 33 54 63 55 
 Gambia       
 Germany 2009 13 7 23 30 10 
 Ghana 2008 11 1 3 10 15 
 Greece 2009 32 22 50 35 28 
 Grenada       
 Guatemala 2008 12 1 13 18 10 
 Guinea 2008      
 Guinea-Bissau 2008 37 10 31 41 41 
 Guyana 2009 10 1 8 18 9 
 Haiti 2005 23 1 13 29 26 UNGASS Indicator 16
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Survey 
year
Males Females
MOST RECENT DHS (OR MICS)5
Females
15-19 20-24 25-49 15-49 15-49
0 0    
4 4 2   
     
   2005 9 0
   2006 6 0
   2007  
9 26 5   
4 6 5   
1 1 0 2006 21 1
   2008 12 
     
4 13 7   
56 63 55   
10 14    
6 3 2 2003 15 1
     
7 6 3 2005 24 4
0 0 0 2005 6 0
20 11 6 2004 31 6
     
71 62 27 2005 36 3
5 7  2006  
1 1 1 2004 17 1
5 10 6   
4 6 2 2005  3
     
9 10 5 2009 29 7
     
     
     
43 28 18   
     
3 4 3 2007 17 3
56 85    
10 7 2 2007 24 3
     
   1995 6 
19 22    
0 0 0 2005 2 0
34 44 28 2000 46 14
     
14 17 5   
1 2 1 2008 11 1
28 27 17   
     
1 1 1   
   2005 25 2
9 13 9   
1 2 1 2009  1
1 2 1 2005 23 1
20094
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PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20094
 Honduras 2006 19 1 32 29 14 
 Hungary 2009 85 25    
 India 2009 9 3 1 5 1 
 Indonesia 2007 0  0 0 0 
 Iran, 
 Islamic Republic of 2008 12 1 11 14  
 Jamaica 2008 62 17 50 81 61 
 Japan 1999 22 7    
 Kazakhstan 2008 22 4 16 31 21 
 Kenya 2008 9 1 4 12 11 
 Kyrgyzstan 2009 22 1 16 32  
 Lebanon 2004      
 Lesotho       
 Liberia 2006 22 7 16 27 21 
 Lithuania 2008 26 8    
 Madagascar 2009   14 24 15 
 Malawi 2004 9 1 5 9 11 
 Mali 2006 25 6 93 64 20 
 Malta 2009 7 3 11 23 8 
 Marshall Islands 2007 32 15 59 47 16 
 Mauritius 2008 23 3 41 26  
 Mexico       
 Micronesia, 
 Federated States of 2006 45 18    
 Moldova 2009 18 2 17 29 15 
 Mongolia       
 Morocco 2007 37 2    
 Mozambique 2009 20 3 10 24 22 
 Myanmar 2006 13 0 1 11 17 
 Namibia 2006 11 2 6 17  
 Nepal       
 Nicaragua 2007  2    
 Niger 2006 9 1 76 27 5 
 Nigeria 2007 19 4 6 18 26 
 Palau 2008  9    
 Panama 2009 45 41 31 54 48 
 Papua New Guinea 2007 37 1 62 38 34 
 Paraguay 2008  6    
 Peru 2008 14 1 18 25 9 
 Philippines       
 Poland       
 Portugal 2007 27 9 45 43 23 
 Russian Federation 2008 21 9 32 36 16 
 Rwanda 2005 3 0 0 1 4 
 Saint Kitts and Nevis 2005      
 Saint Lucia 2007 42 25    
 Saint Vincent and 
 the Grenadines 2008 24 10 16 52 13 
 Sao Tome and Principe 2008 22 1 21 23  
 Senegal 2005 13 1 4 9 19 
 Serbia 2006 11 1 11 25 8 
 Seychelles       
 Sierra Leone 2008 21 5 12 23 34 
 Singapore       
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Survey 
year
Males Females
MOST RECENT DHS (OR MICS)5
Females
15-19 20-24 25-49 15-49 15-49
1 1 0 2005-06  1
     
0 0 0 2005-06 1 0
     
1 1    
17 23 14   
     
2 8 4   
1 2 1 2003 12 
0 2    
     
   2004 21 8
12 8 6 2007 18 6
     
3 2 2 2003-04 17 3
1 1 1 2004 9 1
21 9 2 2006 15 1
3 4 2   
31 22 7 2007 7 3
2 3    
     
     
3 5 1 2005 11 1
     
     
4 4 2 2009  3
0 0 0   
1 4  2006 11 2
   2006 2 0
1 2  2001  1
1 1 1 2006 12 1
3 5 4 2008 10 1
36 13 5   
23 41 46   
0 0 1   
7 8 4   
1 3 1 2004-08  1
   2003 6 
     
26 22 7   
14 13 8   
0 0 0 2000 2 0
     
     
10 15 5   
3 2   18 2
1 1 2 2005 13 1
1 4 1   
     
7 6 12 2008 16 4
     
20094
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PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAVE HAD SEXUAL 
INTERCOURSE WITH MORE 
THAN ONE PARTNER IN 
THE LAST 12 MONTHS
Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20094
 Solomon Islands 2008 91 24 71 82  
 South Africa 2008 19 4    
 Spain 2008      
 South Africa 2008 19 4    
 Sri Lanka       
 Suriname 2006  1    
 Swaziland 2006 14 1 26 30 20 
 Sweden 2009 42 51 37 47  
 Switzerland 2007 18 10    
 Tajikistan 2008 15 5 8 20 16 
 Thailand 2006 18 1    
 Timor-Leste 2008 92     
 Togo 2007 26 6 15 31 27 
 Tonga 2008   19   
 Trinidad and Tobago       
 Tunisia 2009 37 14    
 Turkey       
 Turkmenistan       
 Tuvalu 2007 5 1 13 18 1 
 Uganda 2010 29 4    
 Ukraine 2009 23 7 18 41 20 
 United Arab Emirates       
 United Kingdom of 
 Great Britain and 
 Northern Ireland 2008 15 8  25 13 
 United Republic 
 of Tanzania 2008 18 3 4 18 24 
 United States 
 of America       
 Uruguay 2007 23 11 40 52 14 
 Vanuatu 2008 53 27    
 Viet Nam 2009 2 0 1 5  
 Zambia 2007 14 1 5 14 18 
 Zimbabwe 2007 28 9 18 34 29 
1 Data provided by MEASURE DHS.
2 15-24 years.
3 25-64 years only.
4 Methodology may vary for individual countries.
5 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Survey 
year
Males Females
MOST RECENT DHS (OR MICS)5
Females
15-19 20-24 25-49 15-49 15-49
20094
45 32 6   
     
     
     
     
     
4 4 2 2007 14 2
49 53    
     
1 3 7   
24 18 7   
     
7 11 4 1998 21 3
10     
     
     
     
   2000  0
0 1 1   
   2006 21 2
3 10 7 2007 13 2
     
 24 5   
2 3 3 2007-08 18 3
     
16 16 9   
     
0 0  2005 1 0
2 1 1 2007 14 1
8 12 8 2005-06 9 1
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAD MORE THAN ONE 
SEXUAL PARTNER IN THE PAST 
12 MONTHS REPORTING THE 
USE OF A CONDOM DURING 
THEIR LAST SEXUAL 
INTERCOURSE
 Albania      
 Angola      
 Antigua and Barbuda      
 Argentina      
 Armenia 2000 32    
 Azerbaijan      
 Bangladesh      
 Belarus      
 Belize      
 Benin      
 Bolivia      
 Bosnia and Herzegovina      
 Botswana      
 Brazil      
 Bulgaria      
 Burkina Faso 1999 55 36 56  
 Burundi      
 Côte d’Ivoire 1998 45 23 53 34 
 Cambodia      
 Cameroon 1998 23 13 27 17 
 Canada      
 Cape Verde      
 Central African Republic      
 Chad 1997 20 10 22 17 
 Chile      
 Colombia 2000  22   
 Congo, Republic of the      
 Costa Rica      
 Cuba      
 Cyprus      
 Democratic Republic 
 of the Congo 1996 9 19 7 10 
 Djibouti      
 Dominican Republic      
 El Salvador      
 Equatorial Guinea      
 Eritrea      
 Estonia      
 Ethiopia 2000 20 11 43 10 
 Gabon 2000 40 26 41 29 
 Germany      
 Ghana      
 Greece      
 Grenada      
 Guatemala      
 Guinea 1999 24 9 31 17 
 Guinea-Bissau      
 Guyana      
 Haiti 2000 21 30 30 16 
 Honduras      
 Hungary      
 India      
 Indonesia      
 Iran, Islamic Republic of      UNGASS Indicator 17
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20076
     2005      
     2006 46 18 32 26 40 31
     2006   87   
     2005 48 44 46 48 44 
2005 58          
     2006      
     2005 35  35 42 31 36
     2007 62 60 61 76 68 49
           
           
           
     2006  72  73 71 
           
           
           
2003 43 44 68 33 2007 36 51 38 69 61 30
     2004 55 45 49   
2005 38 41 59 26 2005 52 34 44 47 45 42
2005 41    2006 40 12 39 83 73 23
2004 38 35 53 28 2006 55 41 48 61 62 43
      23 16 19   
2005 69 57 78 59 2005 72 46 58 70 61 47
     2006      
2004 20 7   2004 20 7    
     2006 30 18 28 32 34 25
2005  31         
2005 30 23   2005 43 21 30 24 29 35
     2006 15 11 13   12
     2006 41 33 39 72 53 30
     2007 63 53 61   
2002 35 33 45 27 2007 42 33 37 54 44 34
           
           
           
           
           
     2007 64 55 61 61 64 
2005 9    2005 52 24 43 38 47 34
     2007 72 2 70 2 71 2 65 2 73 2 71 2
     2007   58   
2003 22 33 39  2006 33 54    
     2007 71 55 67 61 58 75
     2006 68 52  61 63 
     2002    47 58 50
2005 24 20 38 17 2005 32 26 31 35 43 27
           
2005 53 56   2005 53 56 53   
2005 34 21 49 23 2006 34 21 33 41 53 23
2006  27   2006 38 32 37   
           
2006 23 12   2006 67 62 66 61 68 66
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031
 Jamaica      
 Japan      
 Kazakhstan      
 Kenya 1998 36 18 38 30 
 Kyrgyzstan      
 Lebanon      
 Lesotho      
 Liberia      
 Lithuania      
 Madagascar      
 Malawi 2000 14 15 26 7 
 Mali 1996 34    
 Malta      
 Marshall Islands      
 Mauritania      
 Mauritius      
 Mexico      
 Micronesia, 
 Federated States of      
 Moldova      
 Mongolia      
 Morocco      
 Mozambique      
 Myanmar      
 Namibia 2000 65 45 72 56 
 Nepal      
 Nicaragua 2001  19   
 Niger 1998 26 28   
 Nigeria      
 Palau      
 Panama      
 Papua New Guinea      
 Paraguay      
 Peru 2000  15   
 Philippines      
 Portugal      
 Russian Federation      
 Rwanda 2000 28 30   
 Saint Kitts and Nevis      
 Saint Lucia      
 Saint Vincent and 
 the Grenadines      
 Samoa      
 Sao Tome and Principe      
 Senegal      
 Serbia      
 Sierra Leone      
 Singapore      
 South Africa      
 Spain      
 Suriname      
 Swaziland      
 Sweden      
 Switzerland      
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20076
     2004 67 53 64   
           
     2007 82 82 82 88 93 77
2003 33 12 47 17 2003 33 12 30 48 47 17
     2007 81 75 80 85 78 
     2004 72 67 72   
2004 41 19 47 26 2004 41 19 34 49 40 26
           
     2007 46 20 44   44
2004 9 2 12 6 2004 13 5 8 8 8 8
2004 20 16 32 13 2004 47 30 38 35 47 33
2001 16 14 27 13 2006 38 17 20 19 29 34
           
     2006 19 15 18 17 19 
     2007 10  10   
     2004 44 46 44 50 43 43
     2003 20    78 14
           
2005 45 22 56 28 2007 48 60 49 45 50 52
     2005 34  34   
     2007 61 75 62 63 61 
2003 19 14 38 10 2003 19 14 18 28 28 10
           
     2007 74 66 68 79 76 60
     2006 54     
     2001  19    
     2006 7 8    
2003 22 13 34 17 2005 62 44 56 44 56 62
     2006  23    60
           
     2007 45 26 43 50 49 38
           
     2006   48 59 43 
2003 22    2003 22     
           
           
2005 8 14   2005 8 14 8   
     2006   67   
     2007 48 39 45   
     2006 62 52 59 59 59 
           
     2006  57 3  60 59 
2005 31 21 61 22 2005 62 37 52 39 51 59
     2006    73 78 
     2007 11 26 37   
     2007 51 0 42 50 14 51
     2005 67 47 64 80 72 56
     2003 50 42 46   
     2006   49   
     2007 56 57 56  62 51
           
     2007 62 52 58 83 61 48
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-24 25-49
20031
 Tajikistan      
 Thailand      
 Timor-Leste      
 Togo 1998 33 21 42 25 
 Tonga      
 Tunisia      
 Turkey      
 Tuvalu      
 Uganda 1995 18 8 24 9 
 Ukraine      
 United Kingdom of 
 Great Britain and 
 Northern Ireland      
 United Republic 
 of Tanzania 1999 22 16 25 17 
 Uruguay      
 Viet Nam      
 Zambia 1996 31 18 36 23 
 Zimbabwe 1999 40 46 56 30 
1 Data provided by MEASURE DHS.
2 data from two cities only.
3 female is 15-24 years only.
4 No reference 4.
5 No reference 5.
6 Methodology may vary for individual countries.
7 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Males MalesFemales FemalesBoth sexes Both sexesSurvey 
Year
Survey 
Year
15-49 15-4915-49 15-4915-24 15-4925-49 15-19 20-24 25-49
20051 20076
     2006   65 53 69 
     2006 53 14 51 63 49 50
           
     2007 73 69 73 72 76 71
           
           
     2007  58 53 52 71 45
           
2001 24 25   2006 42 41 42  30 41
     2007 75 61 72 77 64 72
     2001 10 5 7 15 15 5
2004 29 21 37 23 2005 50 38 44 38 41 
     2007 69 65 68 76 81 56
2005 58     1 0 0 0 1 0
2001 27 21 40 20 2007 50 37 46 39 49 48
2006 36 41 57 24 2006 71 47 64 50 67 68
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Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20096
 Albania 2008 40   50  
 Angola 2009 42 45 48 56 35 
 Antigua and Barbuda       
 Argentina 2008      
 Armenia       
 Azerbaijan 2006 26   26 24 
 Bangladesh 2005 33     
 Belarus 2009 70 68 80 71 54 
 Belize 2009 66 56 81 70 61 
 Benin 2006 17 21 49 43 11 
 Bolivia 2008 35  44 39 31 
 Bosnia and 
 Herzegovina 2009      
 Botswana 2008 82 80 83 88 79 
 Brazil 2008 43 34 76 58 33 
 Bulgaria 2009 71 64 71 70  
 Burkina Faso 2008 69 78 93 94 60 
 Burundi 2007      
 Côte d’Ivoire 2005 38 41 64 61 25 
 Cambodia 2005 41 9 86 72 24 
 Cameroon 2004 38 35 57 56 28 
 Canada       
 Cape Verde 2009 75 59 83 75 66 
 Central African 
 Republic 2006 60 41    
 Chad 2004 16 7 30 18 14 
 Chile 2009 55 38 57 55 48 
 Colombia 2005  31    
 Congo, 
 Republic of the 2009 28 29 49 37 24 
 Costa Rica       
 Cuba 2008 48 38    
 Cyprus       
 Democratic People’s 
 Republic of Korea       
 Democratic Republic 
 of the Congo 2007 16 7 28 19 12 
 Djibouti 2008   33 70  
 Dominican Republic 2007 45 35 72 57 35 
 El Salvador 2008  81    
 Equatorial Guinea 2006      
 Eritrea       
 Estonia 2007 61 42 66 59  
 Ethiopia 2005 9   24 5 
 Gabon 2010 35 22 30 40 34 
 Germany 2009 64 49 74 65 61 
 Ghana 2008 26  24 49 22 
 Greece 2009 23 17 33 25 20 
 Grenada       
 Guatemala 2008 62 24 79 68 47 
 Guinea 2008      
 Guinea-Bissau 2009 64 55 65 62 65 
 Guyana 2009 65 48 86 70 58 
 Haiti 2005 34 21 42 56 23 
 Honduras 2006  27    
 Hungary 2009 100  5 18 77 
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Survey 
year
Males Females
MOST RECENT DHS (OR MICS)7
Females
15-19 20-24 25-49 15-49 15-49
     
47 51 42   
     
     
   2005 58 
   2006 26 0
     
69 77 46   
58 77 50   
20 35 10 2006 17 21
     
   2008 35 
85 83 78   
52 37 30   
60 65    
76 86 75 2003 43 44
     
45 45 35 2005 38 41
0 100 2 2005 41 8
47 37 27 2004 38 35
     
78 60 41 2005 69 57
   2006  
   2004 16 7
49 34 31   
35 36 27 2005  31
24 26 33 2009 28 29
     
     
     
     
7 10 7 2007 16 8
47 90    
37 31 36 2007 45 35
83 79 81   
     
   1995 54 
56 33    
   2005 9 
24 30 18 2000 40 26
58 51 45   
   2008 26 18
23 24 11   
     
13 43 23   
   2005 24 20
57 46 66   
  48 2009 65 48
31 18 19 2005 34 21
34 17 26 2005-06  27
     
20096
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Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20096
 India 2009 79  100 70 100 
 Indonesia 2007 60   100 58 
 Iran, 
 Islamic Republic of 2008 55 63 52 59  
 Jamaica 2008 65 52 90 65 52 
 Japan 2008   77   
 Kazakhstan 2008 72 64 83 84 65 
 Kenya 2008 37 32 69 67 20 
 Kyrgyzstan 2009 81 62 87 77  
 Lebanon 2004      
 Lesotho 2009   60 60  
 Liberia 2006 23 12 29 28 21 
 Lithuania 2008 65 60    
 Madagascar 2008   3 5 3 
 Malawi 2004 20 16 31 36 14 
 Mali 2006 39 17 31 40 43 
 Malta 2009 80 72 85 85 76 
 Marshall Islands 2007 20 10 21 25 14 
 Mauritania       
 Mauritius 2008 37 15 47 26  
 Mexico       
 Micronesia, 
 Federated States of 2006      
 Moldova 2009 52 38 81 59 40 
 Mongolia       
 Morocco 2007 61 75    
 Mozambique 2009 22 23 41 35 15 
 Myanmar 2006 45 0 67 71 40 
 Namibia 2006 74 66 84 81  
 Nepal       
 Nicaragua 2007  19    
 Niger 2006 7 8   4 
 Nigeria 2007 66 39 94 81 49 
 Palau 2008 0 23 0 0 0 
 Panama 2009 25 9 47 32 18 
 Papua New Guinea 2008 40 0 38 43 39 
 Paraguay 2008  5    
 Peru 2008 72 25 73 80 65 
 Philippines       
 Portugal 2007 55 46 74 71 47 
 Russian Federation 2008 52 45 62 64 43 
 Rwanda 2005 25 19   25 
 Saint Kitts and Nevis 2005      
 Saint Lucia 2007 48 39    
 Saint Vincent and 
 the Grenadines 2008   62 62  
 Samoa 2008      
 Sao Tome and 
 Principe 2008 60 48 65 63  
 Senegal 2005 62 37    
 Serbia 2006 71 61 83 77 64 
 Sierra Leone 2008 15 7 14 34  
 Singapore       
 South Africa 2008 77 68    
 Spain 2008      
PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 WHO 
HAD MORE THAN ONE 
SEXUAL PARTNER IN THE PAST 
12 MONTHS REPORTING THE 
USE OF A CONDOM DURING 
THEIR LAST SEXUAL 
INTERCOURSE
327
A2
Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
Survey 
year
Males Females
MOST RECENT DHS (OR MICS)7
Females
15-19 20-24 25-49 15-49 15-49
   2005-06 23 12
     
60 67    
45 64 48   
76     
71 70 59   
 36  2003 33 12
100 56    
     
39 48  2004 41 19
11 22 9 2007 22 14
     
4 2 8 2003-04 9 2
16 23 9 2004 20 16
14 21 17 2006 12 8
80 50 75   
9 7 14   
     
17 14    
     
     
60 14 50 2005 45 22
     
     
31 32 15 2009 22 24
 0 0   
77 46  2006 74 66
   2006 30 
12 30 16 2001  19
  8 2006 7 8
69 37 28 2008 33 23
0 0 60   
17 14 7   
  0   
5 8 4   
82 32 8 2007  31
   2008  
65 55 39   
56 50 41   
   2005 8 14
     
     
55 50    
  59   
53 54  2008-09 33 28
   2005 32 21
67 71 53   
11 14 4 2008 15 7
     
     
     
20096
328 Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
Males Females MalesSurvey 
Year
15-49 15-49 15-19 20-24 25-49
20096
 Suriname 2006  80    
 Swaziland 2006 56 55 74 64 50 
 Sweden 2009 36 27 33 38  
 Switzerland 2007 99 87    
 Tajikistan 2008 60 19 74 61 55 
 Thailand 2006 53 14    
 Timor-Leste 2008 25     
 Togo 2007 73 69 73 77 72 
 Tonga 2008   22   
 Tunisia 2009      
 Turkey       
 Tuvalu 2007 45     
 Uganda 2010 16 9    
 Ukraine 2009 60 61 84 73 51 
 United Kingdom of 
 Great Britain and 
 Northern Ireland 2008 82 75    
 United Republic 
 of Tanzania 2008 16 7 10 27 15 
 Uruguay 2007 69 65 78 80 56 
 Viet Nam       
 Zambia 2006 27 33 50 40 23 
 Zimbabwe 2005 36 41 71 56 22 
1 Data provided by MEASURE DHS.
2 data from two cities only.
3 female is 15-24 years only.
4 No reference 4.
5 No reference 5.
6 Methodology may vary for individual countries.
7 Demographic Health Survey (or Multiple Indicator Cluster Survey).
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Survey 
year
Males Females
MOST RECENT DHS (OR MICS)7
Females
15-19 20-24 25-49 15-49 15-49
     
52 56 55 2007 56 55
26 29    
     
20 42 15   
63 49 50   
     
69 72 64 1998 33 21
19     
     
     
     
   2006 20 24
100 75 54 2007 46 48
     
10 8 6 2007-08 22 21
71 86 56   
   2005 58 
   2007 28 33
  43 2005-06 36 41
20096
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Males FemalesTime 
Period
15-24 15-24
PERCENTAGE OF YOUNG 
PEOPLE AGED 15-24 YEARS 
WHO SAY THEY USED A 
CONDOM THE LAST TIME 
THEY HAD SEX WITH A NON-
MARITAL, NON-COHABITING 
PARTNER, OF THOSE WHO 
HAVE HAD SEX WITH SUCH 
A PARTNER IN THE LAST 
12 MONTHS.
 Albania 2008-2009 55 25
 Armenia 2005 86 
 Armenia 2000 44 
 Azerbaijan 2006 31 
 Belize 2006  50
 Benin 2006 45 28
 Benin 2001 35 19
 Benin 1996  9
 Bolivia 2008 49 
 Bolivia 2003 37 20
 Bosnia and 
 Herzegovina 2006 – 71
 Botswana 2001 88 75
 Botswana 1996 85 
 Brazil 2004  
 Brazil 1996 59 32
 Bulgaria 2005 70 57
 Burkina Faso 1998–1999 56 41
 Burkina Faso 2006  64
 Burkina Faso 2003 67 54
 Burundi 2005  25
 Cambodia 2005 84 
 Cameroon 2006  62
 Cameroon 2004 57 47
 Cameroon 1998 31 16
 Cape Verde 2005 79 56
 Central African 
 Republic 2006 60 41
 Chad 2004 25 17
 Colombia 2005  36
 Colombia 2000  30
 Congo 2005 38 20
 Congo, Democratic 
 Republic of the 2007 27 17
 Côte d’Ivoire 1998–1999 56 25
 Côte d’Ivoire 2005 53 39
 Djibouti 2005 51 26
 Dominican Republic 2007 70 44
 Dominican Republic 2002 52 29
 Dominican Republic 1996 48 12
 Eritrea 1995 81 
 Ethiopia 2005 50 28
 Ethiopia 2000 31 17
 Gabon 2000 48 33
 Gambia 2006  54
 Gambia 2000  
 Ghana 2008 46 28
 Ghana 2006 56 42
 Ghana 2003 52 33
 Guinea 2005 37 26
 Guinea 1999 32 17
 Guinea-Bissau 2006  39
 Guyana 2005 68 62
 Haiti 2005–2006 43 29
 Haiti 2000 30 19
 Honduras 2005-2006  24
Supplemental data obtained by UNICEF through the 
Multiple Indicator Cluster Survey and Demographics 
Health Survey programmes. 
MDG 6a indicator
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Males MalesFemales FemalesTime 
Period
Time 
Period
15-24 15-2415-24 15-24
 India 2005–2006 37 22
 India 2001 59 51
 Kazakhstan 1999 65 32
 Kenya 2008-2009 64 40
 Kenya 2003 47 25
 Kenya 1998 43 14
 Kyrgyzstan 2006  56
 Lesotho 2004 48 50
 Liberia 2007 22 14
 Madagascar 2003-2004 12 5
 Malawi 2006 58 40
 Malawi 2004 47 35
 Malawi 2000 38 32
 Mali 1995–1996 31 
 Mali 2006 36 17
 Mali 2001 30 14
 Marshall Islands 2007 22 9
 Moldova 2008 76 60
 Moldova 2005 63 44
 Montenegro 2006  66
 Mozambique 2008  44
 Mozambique 2003 33 29
 Namibia 2006-2007 81 64
 Namibia 2000 69 48
 Nauru – 17 10
 Nepal 2006 78 
 Nepal 2001 52 
 Nicaragua 2001  17
 Niger 2006 37 18
 Niger 1998 30 7
 Nigeria 2008 49 36
 Nigeria 2007  39
 Nigeria 2003 46 24
 Peru 2004-2006  34
 Peru 2004–2005  32
 Peru 2000  19
 Philippines 2008  13
 Philippines 2003 25 11
 Rwanda 2005 40 26
 Rwanda 2000 55 23
 Sao Tome and 
 Principe 2008-2009 63 54
 Sao Tome and 
 Principe 2006  56
 Senegal 2005 52 36
 Serbia 2006  74
 Sierra Leone 2008 22 10
 Sierra Leone 2005  20
 Solomon Islands 2007 26 17
 South Africa 2003 72 52
 South Africa 1998  20
 Suriname 2006  49
 Swaziland 2006–2007 70 54
 Tanzania, United 
 Republic of 2007-2008 49 46
 Tanzania, United 
 Republic of 2004–2005 46 34
 Tanzania, United 
 Republic of 2003–2004 47 42
 Tanzania, United 
 Republic of 1999 31 21
 Tanzania, United 
 Republic of 1996 31 18
 The former 
 Yugoslav Republic 
 of Macedonia 2005  70
 Togo 2006  50
 Togo 1998 41 22
 Trinidad and 
 Tobago 2006  51
 Tuvalu 2007 44 –
 Uganda 2004–2005 55 53
 Uganda 2006 55 38
 Uganda 2001 62 44
 Uganda 1995 42 25
 Ukraine  2007 71 68
 Uzbekistan 2006  61
 Uzbekistan 2002 50 
 Viet Nam 2005 68 
 Zambia 2001–2002 42 33
 Zambia 2007 48 38
 Zambia 2005 38 26
 Zambia 2003 40 35
 Zambia 2000 41 38
 Zambia 1996 39 20
 Zimbabwe 2005–2006 68 42
 Zimbabwe 1999 69 42
 Zimbabwe 1994 61 42
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-19 20-24 25-49 15-49
2007PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 
WHO RECEIVED AN HIV 
TEST IN THE LAST 
12 MONTHS AND WHO 
KNOW THEIR RESULTS
 Afghanistan 2007      27 
 Albania        
 Algeria 2006 0 1 0 1 1 1 1 
 Angola 2006 7 4    5 
 Antigua and 
 Barbuda 2006      25 
 Argentina 2005  8 4 12   
 Armenia        
 Austria        
 Azerbaijan        
 Bahamas        
 Barbados 2006 97 1 99 1    99 1 
 Belarus 2007 26 33 26 35 31 31 
 Belgium  8 9  5 10 9 
 Belize 2006 10 20    15 
 Benin 2006 12 15 7 17 15 14 
 Bhutan        
 Bolivia 2007 87 1 87 1 86 1 88 1 87 1 87 1 
 Bosnia and 
 Herzegovina 2006  0 0 0 0  
 Botswana        
 Brazil        
 Bulgaria        
 Burkina Faso 2007 18 23 15 28 27 21 
 Burundi 2007 91 1 93 1 91 1 92 1 93 1 92 1 
 Côte d’Ivoire 2005 3 4 2 3 4 3 
 Cambodia 2006 5 3 2 6 4 4 
 Cameroon 2004 7 5 3 6 6 5 
 Canada 2006      32 
 Cape Verde 2005 10 10 3 13 13 10 
 Central African 
 Republic 2006 15 17 10 19 17 16 
 Chad 2004 2 1 0 1 1 1 
 Chile 2007 22 35 8 33 48 28 
 China 2006 2 2    2 
 Colombia 2007 11 2 27 2    19 2 
 Congo, Republic 
 of the 2005 3 3 1 4 4 3 
 Costa Rica 2007 8 1 7 1   80 1 12 1 
 Cuba 2006 28 32 17 32 32 30 
 Cyprus        
 Democratic 
 Republic of 
 the Congo 2007 4 4 2 5 5 4 
 Djibouti        
 Dominican Republic 2007 19 21 8 22 23 20 
 Ecuador 2007  11 7 13 12  
 El Salvador        
 Equatorial Guinea        
 Eritrea 2007      6 
 Estonia        
 Ethiopia 2005 2 2    2 
 Gabon 2007 50 1 64 1 33 1 54 1 62 1 59 1 
 Gambia 2005 8 12    10 
 Germany 2007 14 11    13 
 Ghana 2006       UNGASS Indicator 7
333
A2
Annex 2: Country progress indicators and data, 2004 to 2010 | 2010 GLOBAL REPORT
Males Females Survey 
Year
Males FemalesSurvey 
Year
15-49 15-49 15-49 15-19 20-24 25-49 15-19 20-24 25-49 15-49 15-49
2009 MOST RECENT DHS (OR MICS)
Both sexes Males Females
            
2008 1 0  0 1  0 0    
2009            
2009 6 12 9 2 5 10 7 15 13   
2009 35 65 80         
2008   23         
          2005  
2009   100         
          2006  
2009 1 4 2 1   4     
            
2009 16 17 16 10 15 22 11 19 23   
            
2009 30 42 37 12 32 35 15 52 46   
2009 92 98 95 85 90 94 90 86 100 2006 5% 7%
            
2008 2 2 2 1 3 2 1 3 2 2008 2% 
2009 91 62 93         
2008 38 62 41 29 36 39 71 65 61   
2008 10 16 13         
2009 8 7 8         
2007 23 18 21       2003 2% 
2008 16 16 16         
2005 3 4 3 2 2 4 2 3 5 2005 3% 4%
2005 5 3 4 1 8 6 2 5 3 2005 5% 3%
2004 14 10 11 3 11 20 5 10 12 2004 7% 5%
            
2009 19 32 26 3 23 25 13 50 38 2005 10% 10%
2006 15 17 16       2006 6% 
2004 2 0 1 1 2 2 1 1 0 2004 2% 1%
2009 19 40 30 7 26 39 17 53 66   
            
2007 22 36 30       2005  
2009 7 8 8 2 6 9 5 11 9 2009 9% 9%
            
2008 26 32 29         
2009            
2007 4 4 4 1 4 5 2 4 4 2007 4% 4%
2008    14 55  14 48    
2007 19 21 20 5 17 24 12 12 22 2007 19% 21%
            
2008  10     8 14 10   
2006   33         
            
2008 10 15 13 7 11 11 6 29 14   
2005  2  2 2 4 2 4 1 2005 2% 2%
2010 44 66 57 12 26 64 36 51 79   
            
2009 14 12 13 7 17 14 6 16 12   
2009 4 7  2 6 5 3 8 7 2008 4% 7%
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-19 20-24 25-49 15-49
2007PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 
WHO RECEIVED AN HIV 
TEST IN THE LAST 
12 MONTHS AND WHO 
KNOW THEIR RESULTS
 Greece 2007 13 11 5 9 16 12 
 Grenada 2006 6 13 3 19 10 10 
 Guatemala        
 Guinea 2005 3 1 1 2 2 2 
 Guinea-Bissau 2006  5     
 Guyana 2005 10 11 7 17 11 11 
 Haiti 2006 5 8 3 8 8 7 
 Honduras 2006 21 1 23 1    23 1 
 Hungary 2007 0 0    0 
 India 2006 1 1 0 2 2 1 
 Israel    16 14 14 15 
 Jamaica 2004 12 19   17 16 
 Japan 2006      98 1 
 Kazakhstan 2007 4 5 2 4 5 7 
 Kenya 2003 8 7 4 9 7 14 
 Lesotho 2005 5 6 2 7 8 6 
 Liberia        
 Lithuania 2007 24 1 20 1   24 1 24 1 
 Madagascar 2004 1 3 0 3     
 Malawi 2007      11 1 
 Malaysia 2007      75 1 
 Mali 2006 3 7 2 4 3 5 
 Marshall Islands 2006 56 1 67 1 67 1 50 1  60 1 
 Mauritania 2007 10 3    5 
 Mauritius 2004    3 1 2 1 2 1 
 Mexico 2006      1 1 
 Moldova 2007 6 11 3 10 10 8 
 Mongolia        
 Montenegro 2006  3 1 4 3  
 Morocco 2007 6 1 4 1 3 1 6 1  5 1 
 Mozambique 2004 2 2 3 3 2 2 
 Myanmar        
 Namibia 2007 18 29 9 26 27 23 
 Nauru        
 Nicaragua 2007  5 2 4 7 5 
 Niger 2006 4 2 2 2 3 2 
 Nigeria 2005 9 8 3 8 11 9 
 Oman        
 Palau 2006  16 1 27 1 20 1 14 1  
 Panama        
 Papua New Guinea        
 Peru        
 Philippines 2003 2      
 Poland 2007      1 1 
 Portugal        
 Russian Federation 2007 30 1 38 1 20 1 35 1 37 1 34 1 
 Rwanda 2005 11 12 4 16 13 11 
 Saint Kitts and Nevis 2006     10 1 10 1 
 Saint Lucia 2007 34 1 39 1    36 1 
 Saint Vincent and 
 the Grenadines 2006 8 12 6 12 12 10 
 Sao Tome and 
 Principe        
 Senegal 2005 2 1 1 1 1 1 
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Males Females Survey 
Year
Males FemalesSurvey 
Year
15-49 15-49 15-49 15-19 20-24 25-49 15-19 20-24 25-49 15-49 15-49
Both sexes Males Females
2009 22 11 18 8 23 23 5 14 12   
2009 96 87 88 98 27 96 85 100 88   
2008 3 4 4 2 3 4 3 6 4   
2008   4       2005 3% 1%
2008 12 11 11 9 14 14 7 14 12   
2009 22 27 25       2005 10% 11%
2005 5 8 7 2 6 10 4 10 8 2005 5% 8%
2006 21 23 23 4 19 27 10 27 27   
            
2009 3 3 3 2 3 4 1 3 5 2005-06 1% 1%
            
2008 20 35 28 8 22 27 26 49 35   
            
2008 20 24 22 12 21 22 15 29 25   
2008 23 29  13 25 26 18 39 30 2003 8% 7%
2009          2004 5% 6%
2006 2 2 2 0 3 3 2 2 1 2007 2% 2%
2009 16 20 18         
2008    16 22  18 29  2004 1% 0%
2004 8 7  4 10  5 10  2004 8% 7%
2009   98         
2006 3 3 3 1 3 3 3 4 3 2006 3% 3%
2007 22 22 22 17 23 24 18 27 21   
2007 10 3 5         
2008 6 6 6 4 8  3 9    
            
2009 10 16 13 5 9 11 8 19 18 2005 10% 12%
2008  32 32    9 42 33   
2009   1         
2007 6 4 5         
2009 9 14 12 6 12 9 13 19 13 2009 9% 15%
2006 12 11 11 5 11 13 7 12 12   
2006 18 29  6 16  13 36  2006 18% 29%
2009 100 100 100 100 100 100 100 100 100   
2007  5          
2006 4 2 2 1 2 5 2 2 2 2006 2% 1%
2007 12 11 12 5 9 16 5 13 14 2008 7% 7%
2009   100         
2008  18 18    8 47 45   
2009 10 12 12 3 11 12 9 17 12   
2008 6 4 5 0 8 7 0 8 3   
2008 5 30 22 1 6 7 10 26 36 2007  
2008  1     0 1  2008  1%
2009            
2009 18 17 18 8 21 18 8 30 15   
2009 32 34 33 32 43 30 23 31 36   
2005 11 12 11 4 14 13 5 17 13 2005 11% 12%
2005   10   17   15   
2007 34 39 36         
2008 8 12 12 4 12 9 8 12 16   
2009 100 100 100 100 100 100 100 100 100 2008-09 23% 31%
2005 2 1 1 1 1 2 1 1 1 2005 2% 1%
2009 MOST RECENT DHS (OR MICS)
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Males Females Both sexesSurvey 
Year
15-49 15-49 15-19 20-24 25-49 15-49
2007PERCENTAGE OF WOMEN 
AND MEN AGED 15-49 
WHO RECEIVED AN HIV 
TEST IN THE LAST 
12 MONTHS AND WHO 
KNOW THEIR RESULTS
 Seychelles 2006 100 1 100 1 100 1 100 1 100 1 100 1 
 Sierra Leone 2007 8 1 9 1    9 1 
 Singapore 2007 9 7 0 13 8 8 
 Slovakia        
 Solomon Islands        
 Somalia 2004 5 1 3 1    4 1 
 South Africa 2006 90 1 90 1 90 1 90 1 90 1 90 1 
 Spain 2003      25 
 Sri Lanka 2007 0 1 0 1 0 1 0 1 0 1 0 1 
 Sudan        
 Suriname 2006  30     
 Swaziland 2007 9 22 6 18 21 16 
 Sweden        
 Switzerland 2007 7 7 5 7 7 7 
 Tajikistan 2007 4 1 2 1 2 1 5 1  3 1 
 Thailand 2006 16 22 16 22 19 19 
 The former 
 Yugoslav Republic 
 of Macedonia 2006  3 2 3 3  
 Togo 2007 16 15 10 17 17 16 
 Tonga        
 Trinidad and 
 Tobago 2006      8 1 
 Tunisia        
 Turkey 2006 100 1 100 1 100 1 100 1 100 1 100 1 
 Tuvalu        
 Uganda 2006 10 12    12 
 Ukraine 2007 11 1 20 1 12 1 19 1 16 1 16 1 
 United Kingdom 
 of Great Britain and 
 Northern Ireland 2006 1 1 3 1    2 1 
 United Republic 
 of Tanzania 2007      36 
 Uruguay 2007 20 19 15 20 20 20 
 Vanuatu        
 Viet Nam 2005 3 2 1 3 3 2 
 Zambia 2007 12 19 10 19 17 15 
 Zimbabwe 2006 7 7 4 9 7 7 
1  Methodology not harmonized with UNGASS 2008 guidelines.
2 14-26 years.
3 15-24 years.
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Males Females Survey 
Year
Males FemalesSurvey 
Year
15-49 15-49 15-49 15-19 20-24 25-49 15-19 20-24 25-49 15-49 15-49
Both sexes Males Females
            
2008 3 4  0 2 5 3 6 4 2008 3% 4%
            
2009   2         
2008 3 7 5 2 5  4 5 33   
2003 5 3 4         
2008   25         
2008            
            
2009   29         
2006  30          
2006 9 22 16 2 7 15 10 28 25 2007 9% 22%
2007 12 22 18 4 20 20 9 25 31   
2009            
2008 9 5 7 2 9 11 0 6 7   
2006 16 22 19    16 22 19   
2005  3     2 3 3   
2007 16 15 16 13 16 18 9 19 17   
2008    73   2     
            
2009 3 1 2         
2009   14         
2007 13 3 6 3 15 16 3 4 3   
2010   20       2006 10% 12%
2009 12 15 13 9 12 12 9 18 15 2007 7% 12%
2008 3 6 4 2 5 2 5 11 6   
2008 19 19 19 11 21 22 15 23 20 2007-08 19% 19%
2007 19 17 18 4 27 22 9 20 18   
2008 12 11 11         
2005 3 2 2       2005 3% 2%
2006 12 19 15 7 14 13 13 22 20 2007 12% 19%
          2005-06 7% 7%
2009 MOST RECENT DHS (OR MICS)
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20071 20092005
AllAll Male Female All Male Female
SEX WORKERSPERCENTAGE OF SEX 
WORKERS, INJECTING DRUG 
USERS AND MEN WHO 
HAVE SEX WITH MEN WHO 
BOTH CORRECTLY IDENTIFY 
WAYS OF PREVENTING THE 
SEXUAL TRANSMISSION OF 
HIV AND WHO REJECT 
MAJOR MISCONCEPTIONS 
ABOUT HIV TRANSMISSION
 Afghanistan     2  2 
 Albania        
 Angola     69  69 
 Argentina 69  67 6  96   
 Armenia 49 54 4  54    
 Azerbaijan     43  43 
 Bahamas        
 Bangladesh 23 31 30 31 31 7 30 31 
 Barbados  37 3, 4  37 3    
 Belarus 24 50 4  50 67  67 
 Belize        
 Benin     60  60 
 Bolivia     48  48 
 Bosnia and 
 Herzegovina        
 Brazil       42 
 Bulgaria  35 4  35 37 38 37 
 Burundi 4 44 2, 4  44 2 52 7  52 
 Côte d’Ivoire  32 4  32 32 7  32 
 Cameroon  40 2, 4  40 2 81 7  81 
 Chad     5  5 
 Chile        
 China 24 4 41   54  54 
 Colombia       24 
 Congo, 
 Republic of the 67       
 Costa Rica        
 Croatia     40   
 Cuba  52 49 61 60 62 56 
 Czech Republic        
 Democratic 
 Republic of 
 the Congo  30 2, 4  30 2 31  31 
 Dominican 
 Republic     73  73 
 Ecuador    47 3    
 El Salvador  6      
 Eritrea     60  60 
 Estonia  83 3, 4  83 3 7   
 Ethiopia  36 4  36 36 7  36 
 Gabon  24 13 25 27 39 26 
 Georgia 1 4 4  4 8  8 
 Greece     3  3 
 Guatemala  3 4  3 3 7  3 
 Guinea  4 4  4    
 Guinea-Bissau     31  31 
 Guyana  63  , 35  35 
 Haiti  6 4  6 6 7  6 
 Honduras  21 4  21 30 7  30 
 Hungary        
 India    38 24  24 
 Indonesia 24 28 37 26 27 7 37 25 
 Iran, Islamic 
 Republic of  8 4  8 8  8 
 Jamaica 26 26 4  26    
 Kazakhstan  63 4  63 69  69 
 Kenya       59 UNGASS Indicator 14
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20071 2009200720092005 2005
All AllAll AllAll MaleMale FemaleFemale All
INJECTING DRUG USERS MEN WHO HAVE SEX WITH MEN
    29 29     
         18 
          
       56  96 7 
60 68 69 56    54 74  
    33 7 33 38   36 
        45 36 
14 20 5 20  19 7 19  14 27 28 7 
          
61 58 51 68 58 59 53 63 56 72 
          
    20 20 0 42   
         55 
 22 5 22  36 31     
    32     62 
 29 28 34 37 37 39  32 38 
          
          
          
          
         65 
36 49 48 52 57 56 63 37 55 51 
          
       3   
       49 85 88 
          
        54 59 
         71 
          
         73 
        59 3  
        25 52 
          
 75 3 75 3 74 3 7    60 3 60 7 
          
          
36 41 5 41  38 38   0 2 25 7 
        74 10 
        33 33 7 
          
          
        67 47 
        36 37 7 
        21 8 7 
         100 
    27 24 30   30 
7 58 58 68 59 7 58 69 43 42 44 7 
 24 24 15 24 24 15   7 
          
 63 63 63 77 76 80  66 68 
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20071 20092005
AllAll Male Female All Male Female
SEX WORKERSPERCENTAGE OF SEX 
WORKERS, INJECTING 
DRUG USERS AND MEN 
WHO HAVE SEX WITH MEN 
WHO BOTH CORRECTLY 
IDENTIFY WAYS OF 
PREVENTING THE SEXUAL 
TRANSMISSION OF HIV 
AND WHO REJECT MAJOR 
MISCONCEPTIONS ABOUT 
HIV TRANSMISSION
 Kyrgyzstan 1 36 4  36 89  89 
 Lao People’s 
 Democratic 
 Republic 21    45  45 
 Latvia        
 Lithuania  24 4  24 41  41 
 Madagascar  30      
 Malawi       38 
 Malaysia  78 2   38   
 Mali 90       
 Mauritania     22 7  22 
 Mauritius  2 2, 4      
 Mexico  49 54 47    
 Moldova 35 58 4  58 29  29 
 Mongolia  29 4  29 47  47 
 Montenegro        
 Morocco 72       
 Myanmar     71  71 
 Nepal 17 32 41 30  81 36 
 Niger     11  11 
 Nigeria  33 4  33 33 7  33 
 Pakistan  10 3 21 3 <1 3 13 23 1 
 Panama  91 91 92 91 7 91 92 
 Papua New 
 Guinea  35 4  35 35 7  35 
 Paraguay     20 28 17 
 Peru       5 
 Philippines  2  2 30  30 
 Romania 14 14 4  14 11  11 
 Russian Federation  36 4  36 45  45 
 Rwanda  36 4  36 36 7  36 
 Saint Lucia        
 Sao Tome and 
 Principe    72    
 Senegal  41 4  41 41 7  41 
 Serbia     14 17 13 
 Somalia       6 
 South Africa        
 Sri Lanka  10 4  10    
 Sudan     25  25 
 Suriname  78 75 79 21   
 Swaziland  46 4  46 4 32  32 
 Sweden  46 100 45 71 60 100 
 Tajikistan  41 4  41 31  31 
 Thailand  28 23 29 38 29 41 
 The former 
 Yugoslav Republic 
 of Macedonia 10 47 67 43 47 7 67 43 
 Timor-Leste       24 
 Togo  45 46 42 52 50 52 
 Tunisia     13  13 
 Turkey 22       
 Ukraine 8 48 4  48 51  51 
 Uzbekistan     36  36 
 Viet Nam 24 35 4  35 51  51 
 Zambia  41 41 42    
1 Report date 2007, but data collection can 
vary from 2005-2007.
2 Data collection started before 2005.
3 Methodology not harmonized with UNGASS 
2008 guidelines.
4 Females only.
5 Males only.
6 Transgender.
7 Data collection started before 2008.
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20071 2009200720092005 2005
All AllAll AllAll MaleMale FemaleFemale All
INJECTING DRUG USERS MEN WHO HAVE SEX WITH MEN
 64 62 69 51 49 61 7 89 
        31 3 
 45 44 50      48
        39 39
         
         
 98 2   50     
         
         
 62 2   14    48 2 
        66 
37 64 64 66 65 65 67 38 47 
        23 54
         
7         
    76 76    68
50 66 5 66  68 68  27 45 64
         
 34 34 36 34 7 34 35  44 44 7
  20  23 26    
        78 78 7
        71 71 7
    30     49
       73 40 22
 26 27 23 45 44 57  10 34
18 30 24 63 10 10 8  45 
 46 47 43 40 40 42  26 66
         
 13 3 10 3 33 3 15 15 19   
         
         
    64 61 75   65
         
         24
        20 
         
         
         
    65 63 78   
 46 45 51 55 55 59   
 49       25 26
27 34 32 47 34 7 32 47 34 41 41 7
         27
         54
    24 24 20   23
         
21 47 47 45 55 55 53 49 47 71
    46 46 50   47
34 38 3, 5 38 3  49 49   55 3 60
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20071 2009
All Male Female All Male Female
SEX WORKERSPERCENTAGE OF SEX 
WORKERS, INJECTING DRUG 
USERS, AND MEN WHO HAVE 
SEX WITH MEN REACHED 
WITH HIV PREVENTION 
PROGRAMMES1
 Afghanistan 113 9 3 11 3 1  1 
 Angola 17   23  23 
 Argentina   82 90   
 Armenia 41 4  41    
 Azerbaijan    6  6 
 Bahamas       
 Bangladesh 54 47 57 10 7 18 7 
 Belarus 86 4  86 86  86 
 Benin 60 4  60 56  56 
 Bolivia       
 Bosnia and 
 Herzegovina       
 Brazil      47 
 Bulgaria 77 4  77 59 72 57 
 Burkina Faso 37 15 59 37 7 15 59 
 Burundi 72 2, 4  72 2 77 7  77 
 Côte d’Ivoire    7   
 Cameroon 70 2, 4  70 2    
 Chad    17  17 
 Chile    7  43 
 China 46 4  46 74  74 
 Colombia      21 
 Comoros 59 4  59 74 7 0 74 
 Costa Rica       
 Cuba 60 59 65 97 96 98 
 Czech Republic       
 Democratic Republic 
 of the Congo    26 7  26 
 Djibouti    89  89 
 Dominican Republic    44   
 Ecuador   76    
 El Salvador 73     77 
 Eritrea 88 3, 4  88 3    
 Estonia       
 Gabon 29 27 29 35 48 34 
 Georgia    67  67 
 Ghana    48   
 Greece    14  14 
 Guatemala 93 4  93 93 7  93 
 Guinea 92 4  92 89  89 
 Guyana 28 4  28    
 Honduras 23 4  23 33  33 
 Hungary       
 India    31  31 
 Indonesia 40 60 34 29 7 55 24 
 Jamaica 60      
 Kazakhstan 71 3   88  88 
 Kyrgyzstan 89 3, 4  89 3 61  61 
 Lao People’s 
 Democratic Republic    70  70 
 Latvia       
 Lebanon <1 3 11 3 22 3    
 Lithuania 43 4  43 74  74 
 Malawi 69  69    
 Malaysia 86 4   12   UNGASS Indicator 9
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2007 20092009 2007
AllAllAll MaleMale FemaleFemale All
INJECTING DRUG USERS MEN WHO HAVE SEX WITH MEN
   17 17    
        
      98  
54 55 44    10  
   2 2 0  22 
      48 71 
82 82 90 2 7 2  13 8 7 
56 54 61 64 64 64 90 85 
   0 0 0   
       51 
   32 39    
   40    37 
47 45 60 52 52 52 30 38 
        
        
      100 3 100 7 
        
        
       57 
25 25 25 39 38 45 38 75 
        
        
      26 64 
      56 92 
       65 
        
        
        
      49  
      62 58 
        
      56 56 7 
        
17 5 17  11 11   66 7 
        
      19 74 
      75 75 7 
        
      17 7 
      24 31 7 
       55 
   15 9 22  18 
45 44 55 43 7 43 52 40 44 7 
        
44 3   60 60 61 48 3 68 
78 3 78 3 78 3 38 36 48 77 3  
        
47 45 53 7     
      15 3  
      40 43 
       
   7   100 3 
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20071 2009
All Male Female All Male Female
SEX WORKERS
 Mexico 36 55 28 60 61 59 
 Moldova 96  96 15  15 
 Mongolia 64   74  74 
 Montenegro    44 43 45 
 Morocco 49 4  49 49 7  49 
 Myanmar    76  76 
 Nepal 42 56 39  93 41 
 Nigeria    49 7  49 
 Norway       
 Pakistan 3 3 3 3 2 3 10 13 6 
 Panama 76 73 78 76 7 73 78 
 Papua New Guinea 31 4  31 31 7  31 
 Paraguay 18      
 Peru   80    
 Philippines 14 4  14 55  55 
 Romania    33  33 
 Russian Federation 39   22  22 
 Saint Lucia       
 Sao Tome and 
 Principe 80 3, 4  80 3    
 Senegal       
 Serbia    30 19 38 
 Sierra Leone 73 4  73    
 Singapore   100 3    
 Slovenia       
 Sudan    2  2 
 Swaziland 77 3, 4  77 3 100  100 
 Sweden 50 3 100 3 55 3 43 41 50 
 Tajikistan 60 4  60 51  51 
 Togo 76 75 81 82 63 84 
 Tunisia    38  38 
 Turkey 42 4  42    
 Ukraine 69 4  69 58   
 United Republic 
 of Tanzania      68 
 Uzbekistan    71  71 
 Viet Nam 65 3, 4  65 3 47  47 
 Zambia 63 2, 4  63 2,3    
1 Report date 2007, but data collection can vary from 2005-2007.
2 Data collection started before 2005.
3 Methodology not harmonized with UNGASS 2008 guidelines.
4 Females only.
5 Males only.
7 Data collection started before 2008.
PERCENTAGE OF SEX 
WORKERS, INJECTING DRUG 
USERS, AND MEN WHO HAVE 
SEX WITH MEN REACHED 
WITH HIV PREVENTION 
PROGRAMMES1
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2007 20092009 2007
AllAllAll MaleMale FemaleFemale All
INJECTING DRUG USERS MEN WHO HAVE SEX WITH MEN
5 5 4 20 22 13 18 38
89 89 89 7 7 8 86 
      67 77
       
       
   53 53   69
78 5 78  57 57  47 77
   59 7 60 54  60 7
       56 7
 16 3  51 51   
      89 89 7
      10 10
       
      44 
14 13 28 11 11 17 19 29
      59 
24 33 21 14 11 21 17 
       100
       
       85 7
   21 19 25  14
       
       
       85
       
       
27 26 30 8 8 12  54
25 21 41 64 63 69  
       46
       53
 22 30    19 
46 45 50 32 31 33 50 63
       
   34 32 49  42
43 3 43 3  15 15  26 24
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Males MalesFemales FemalesAll All
20057 20077PERCENTAGE OF FEMALE 
AND MALE SEX WORKERS 
REPORTING THE USE OF A 
CONDOM WITH THEIR MOST 
RECENT CLIENT 
 Afghanistan    50 3, 5  50 3 
 Angola    78 5  78 
 Argentina       
 Armenia 89 100 89 91 5  91 
 Azerbaijan       
 Bangladesh 40 44 32 63 44 67 
 Barbados    80 5  80 
 Belarus 77 100 77 76 5  76 
 Benin    83 5  83 
 Bolivia    88 4 57 4 88 4 
 Bosnia and Herzegovina       
 Brazil       
 Bulgaria    95 5  95 
 Burkina Faso 96   99 98 99 
 Burundi 74  74 74 2, 5  74 2 
 Côte d’Ivoire    96 5  96 
 Cambodia 96  96 99 5  99 
 Cameroon    74 2,4, 5  74 2, 4 
 Canada     61 4 80 4 
 Cape Verde    74 5  74 
 Chad       
 Chile       
 China   69 82 5  82 
 Colombia    89 82 97 
 Comoros    59 5  59 
 Costa Rica    92 5  92 
 Croatia    86 2   
 Cuba    61 63 56 
 Democratic Republic 
 of the Congo    61 2, 5  61 2 
 Djibouti       
 Dominican Republic    96 2   
 Ecuador      95 
 Egypt       
 El Salvador    96 89 97 
 Eritrea    76 5   
 Estonia    94 5  94 
 Ethiopia    87 5  84 
 Gabon    67 53 67 
 Georgia   95 94 5  94 
 Germany       
 Ghana    98   
 Greece       
 Guatemala    96 91 97 
 Guinea    100 5  100 
 Guinea-Bissau      60 
 Guyana    89 5  89 
 Haiti    90 5  90 
 Honduras    68 71 66 
 India      88 
 Indonesia 55 48 56 69 72 68 
 Iran, Islamic Republic of    55 5  55 
 Jamaica 84   84   
 Japan       
 Jordan       
 Kazakhstan    97 5  97 
 Kenya       UNGASS Indicator 18
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Males FemalesAll
20097
58  58 
81 5  81 
99 1, 5  99 
   
75 1, 5  75 
63 1 44 67 
   
70  70 
25 5  25 
87 5  87 
76 5  76 
  90 
93 90 94 
99 1 98 99 
82 1, 5  82 
97 97 97 
99 1, 5  99 
73 5  73 
   
   
38 5  38 1 
  73 1 
85 5  85 
  96 
59 1, 5  59 
89   
98   
56 53 63 
62 1, 5  62 
94  94 
81  81 
  97 
21 1 9 31 
  90 
45 5  45 
94 1, 5  94 
98 1, 5  98 
76 57 77 
99 5  99 
64 62 64 
   
5 5  5 
96 1 91 97 
65 5  65 
93 5  93 
61 5  61 
90   
80 87 79 
83 5  83 
68 1 79 66 
55 1, 5  55 
97 5  97 
65 1, 5  65 
51 5  51 
96 5  96 
  88 
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Males MalesFemales FemalesAll All
20057 20077PERCENTAGE OF FEMALE 
AND MALE SEX WORKERS 
REPORTING THE USE OF A 
CONDOM WITH THEIR MOST 
RECENT CLIENT 
 Kyrgyzstan 81   84 5  84 
 Lao People’s 
 Democratic Republic 83 59 89    
 Lebanon    34 4 47 4 34 4 
 Lithuania    77 5  77 
 Madagascar    79   
 Malawi    69 5  69 
 Malaysia    35 2   
 Mali    99 5  99 
 Mauritania       
 Mauritius    100 2, 5  100 2 
 Mexico    96 96 96 
 Moldova 98   93 5  93 
 Mongolia 94 50 96 92 5  92 
 Montenegro       
 Morocco 38  38 54 5  54 
 Myanmar       
 Nepal 67   81 93 77 
 Nicaragua       
 Niger    96 5  96 
 Nigeria    98 5  98 
 Pakistan 23 7 37 34 21 45 
 Panama 92 91 92 76 64 84 
 Papua New Guinea    94 5  94 
 Paraguay    76 71 78 
 Peru     42 96 
 Philippines    65 50 65 
 Poland      46 2 
 Romania   85 85 5  85 
 Russian Federation 77   92 5  92 
 Rwanda    87 5  87 
 Sao Tome and Principe      60 
 Senegal 86  87 99 5  99 
 Serbia       
 Sierra Leone    68 5  68 
 Singapore      99 
 Somalia       
 Sri Lanka   65 89 5  89 
 Sudan       
 Suriname    70 79 68 
 Swaziland    98 5  98 
 Sweden    22 100 20 
 Switzerland     72  
 Tajikistan    75 5  75 
 Thailand    96 4, 5   
 The former Yugoslav 
 Republic of Macedonia 86 88 84 78 93 75 
 Timor-Leste       
 Togo    78 76 84 
 Tunisia       
 Turkey    33 5  33 
 Ukraine 80  80 86 5  86 
 Uruguay       
 Uzbekistan    65 5  65 
 Vanuatu       
 Viet Nam 90  90 97 4, 5  97 4 
 Zambia    81 72 82 
 Zimbabwe    4 4, 6 4 4  
1 Data collection started before 2008.
2 Data collection started before 2005.
3 Data collection period not defi ned.
4 Methodology not harmonized with UNGASS 
2008 guidelines.
5 Females only.
6 Males only.
7 Methodology may vary for individual countries.
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Males FemalesAll
20097
94 5  94 
94 5  94 
   
92 5  92 
   
  92 
61   
99 1, 5  99 
88 1, 5  88 
   
62 45 66 
91 5  91 
90 5  90 
72 1 64 73 
54 1, 5  54 
96 5  96 
 38 75 
74   
85 5  85 
98 1, 5  98 
38 33 43 
76 1 64 84 
50 42 53 
   
   
65 5  65 
   
98 5  98 
71 5  71 
87 1, 5  87 
   
97 1, 5  97 
91 93 89 
  68 1 
99   
  25 
89 1, 5  89 
45 5  45 
87   
87 5  87 
19 20 14 
 72 1, 6  
84 5  84 
92 5  92 
78 1 93 75 
  65 
88 67 89 
52 5  52 
  42 
88 5  88 
76 6 76  
81 5  81 
67 1, 5  67 
78 5  78 
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20055 20075 20095PERCENTAGE OF MEN 
REPORTING THE USE OF A 
CONDOM THE LAST TIME 
THEY HAD ANAL SEX WITH 
A MALE PARTNER
 Argentina  91  
 Armenia 30 84  
 Australia  58 3, 4 47 
 Azerbaijan   57 
 Bahamas  69 69 
 Bangladesh 49 24 31 1 
 Barbados    
 Belarus 62 67 61 
 Bolivia   69 
 Bosnia and 
 Herzegovina   56 
 Brazil   48 
 Bulgaria  46 70 
 Burkina Faso   52 
 Côte d’Ivoire  47 42 
 Cambodia  86 86 
 Cameroon   43 
 Canada   62 1 
 Chile  29 56 
 China 41 64 73 
 Costa Rica  71 65 
 Cuba  55 52 
 Czech Republic   30 
 Denmark   73 
 Dominican Republic  79 2 66 
 Egypt   13 1 
 El Salvador  83 55 
 Estonia  47 47 
 Fiji 20   
 Georgia 54  62 
 Germany  58 59 
 Ghana  48  
 Greece  89 11 
 Guatemala  78 78 
 Guyana  81 84 
 Haiti  73 73 1 
 Honduras  47 47 1 
 Hungary   25 
 India   58 
 Indonesia 48 39 57 
 Iran, Islamic Republic of   38 1 
 Jamaica   73 
 Japan  55 65 
 Kazakhstan  66 76 
 Kenya  75  
 Kyrgyzstan 68 81  
 Lao People’s 
 Democratic Republic  24 4  
 Latvia   50 
 Lebanon  39 4  
 Lithuania  58 47 
 Malaysia   21 
 Mali  54 54 
 Mauritius  52 2  
 Mexico  79 64 
 Moldova 63 48  
UNGASS Indicator 19
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20055 20075 20095
 Mongolia 13 67 78
 Myanmar   82
 Nepal  74 75
 Nicaragua   36
 Nigeria  53 53
 Norway   53
 Pakistan 8 24 
 Panama 84 86 86
 Papua New Guinea  88 4 51
 Paraguay   63
 Peru 46 47 
 Philippines  32 32
 Poland  32 2, 4 
 Portugal   43
 Romania  73 43
 Russian Federation 39 60 56
 Rwanda   50
 Saint Lucia  74 63
 Senegal 45 55 2 76
 Serbia   67
 Singapore   17
 Slovenia  75 4 43
 South Africa   35
 Spain   66
 Sri Lanka  61 61
 Suriname  89 89 1
 Sweden  42 4 51
 Switzerland  80 4 80
 Thailand  88 
 The former Yugoslav 
 Republic of Macedonia 29 56 56
 Timor-Leste   38
 Togo  60 72
 Trinidad and Tobago  47 2 
 Tunisia   40
 Turkey  37 
 Tuvalu  63 
 Ukraine 72 39 64
 United Kingdom of 
 Great Britain and 
 Northern Ireland   63 1
 Uruguay   47
 Uzbekistan  61 87
 Vanuatu   63
 Viet Nam  61 66
1 Data collection started before 2008.
2 Data collection started before 2005.
3 Data collection period not defi ned.
4 Methodology not harmonized with UNGASS 2008 guidelines.
5 Methodology may vary for individual countries.
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Males MalesFemales FemalesAll All
20071,6 20096PERCENTAGE OF INJECTING 
DRUG USERS REPORTING 
THE USE A CONDOM THE 
LAST TIME THEY HAD 
SEXUAL INTERCOURSE
 Afghanistan    35 35 
 Argentina 64 63 65 5  
 Armenia 56 56 55   
 Australia 20 3 20 3 20 3 27 27 25
 Azerbaijan 18 2   15 16 8
 Bangladesh 44 44 55 43 5 43 
 Belarus 59 57 65 59 56 68
 Benin    30 29 33
 Bosnia and Herzegovina 23 4 23  30  
 Brazil    70  
 Bulgaria 19 18 28 38 37 43
 Canada 43   39 5 42 35
 China 34 3 32 3 43 3 36 35 42
 Croatia    50  
 Egypt     5 5 
 Estonia 68 66 74 66 66 113
 Georgia 48 4 48  78 78 
 Greece 48     
 India    16 16 
 Indonesia 34 34 30 36 36 35
 Iran, Islamic Republic of 33 33 30 33 33 30
 Japan 65 4 65    
 Jordan      
 Kazakhstan 37 37 36 46 46 47
 Kyrgyzstan 11 11 9 53 55 48
 Latvia 38 40 34   
 Lebanon 15 3 15 3  43  
 Luxembourg    49  
 Malaysia 5 2   28  
 Mauritius 13 2 15 2 0 2 31  
 Mexico 29 27 38 28 29 25
 Moldova 68 73 52 36 41 12
 Montenegro      
 Morocco 13 12 21 13 12 21
 Myanmar    78 78 
 Nepal 38 4 38  51 51 
 Nigeria 66 66 68 66 66 68
 Pakistan  21  31 31 
 Paraguay 33 33 36 22  
 Philippines    22 23 0
 Portugal    38 39 31
 Romania    17 18 12
 Russian Federation 37 39 31 45 46 40
 Serbia    29 29 29
 Spain    55  
 Sweden 25 28 19 7 8 0
 Switzerland 50 3 53 3 42 3 50 5 53 42
 Tajikistan 36 33 47 28 26 40
 Thailand 35   42 45 29
 The former Yugoslav 
 Republic of Macedonia 51 51 51 51 51 51
 Tunisia    35  
 Turkey 10 9 13   
 Ukraine 55 55 56 48 50 45
 United Kingdom of 
 Great Britain and 
 Northern Ireland    44 43 46
 Uzbekistan 39 37 50 26 25 32
 Viet Nam 36 3, 4 36 3  52 52 
1 Report date 2007, but data collection can 
vary from 2005 to 2007.
2 Data Collection period started before 2005.
3 Methodology not harmonized with 
UNGASS 2008 guidelines.
4 Males only.
5 Data collection period started before 2008.
6 Methodology may vary for individual 
countries.
UNGASS Indicator 20
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Males MalesFemales FemalesAll All
20076 20096PERCENTAGE OF INJECTING 
DRUG USERS REPORTING 
THE USE OF STERILE 
INJECTING EQUIPMENT THE 
LAST TIME THEY INJECTED
 Afghanistan 46   94 94 
 Albania    82  
 Argentina 65 64 67 91  
 Armenia 95 95 93   
 Australia 71 4   80  
 Azerbaijan 77   62 62 65
 Bangladesh 34 34 74 32 1 32 
 Belarus 71 71 70 87 87 88
 Belgium    53  
 Benin    31 31 33
 Bosnia and Herzegovina 25 5 25  87 90 
 Brazil    54  
 Bulgaria 25 26 23 86 87 84
 Canada 68 3, 4     
 China 41 42 32 72 72 68
 Egypt     401 
 Georgia 93 5 93  48 48 
 Greece 67     
 Hungary    74  
 India    87 83 90
 Indonesia 82 2 82 2 89 2 88 1 88 94
 Iran, Islamic Republic of 75 75 62 74 75 62
 Japan 47 5 47    
 Kazakhstan 59 59 58 63 65 55
 Kyrgyzstan 77 76 81   
 Latvia 90 87 96 82 85 80
 Lebanon 60 4 63 4 0 4   
 Lithuania    98 98 97
 Luxembourg    71  
 Malaysia 28 2   83  
 Maldives    72 74 29
 Mauritius 32 2 32 2 33 2 72  
 Mexico 14 15 9 40 39 43
 Moldova 96 96 95 99 99 100
 Montenegro    24  
 Morocco 7 7 12 7 1 7 12
 Myanmar    81 81 
 Nepal 96 5 96  99 99 
 Nigeria 89 89 86 89 89 86
 Pakistan  28  77 77 
 Paraguay 80 80 79 71  
 Philippines 48 47 63 85 84 94
 Portugal    69 71 59
 Romania 28 2 30 2 17 2 85 86 83
 Russian Federation 82 83 81 83 85 76
 Serbia    80 81 73
 Spain    81  
 Sweden 38 38 35 58 58 58
 Switzerland 94 4 95 4 92 4 94 1 95 92
 Tajikistan 32 35 21 63 61 84
 Thailand    63 63 64
 The former Yugoslav 
 Republic of Macedonia 73 73 69 73 73 69
 Timor-Leste     3 11
 Tunisia    78  
 Turkey 10 9 13   
 Ukraine 84 85 81 87 89 84
 United Kingdom of Great 
 Britain and Northern Ireland    81 82 77
 Uzbekistan 23 23 25 82 81 81
 Viet Nam 89 5 89  95 95 
1 Data collection period started before 2008.
2 Data Collection period started before 2005.
3 Data collection period undefi ned.
4 Methodology not harmonized with UNGASS 
guidelines.
5 Males only.
6 Methodology may vary for individual 
countries.
UNGASS Indicator 21
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AllAll Male Female All Male Female
PERCENTAGE OF SEX 
WORKERS, INJECTING DRUG 
USERS, AND MEN WHO 
HAVE SEX WITH MEN THAT 
HAVE RECEIVED AN HIV 
TEST IN THE LAST 
12 MONTHS AND WHO 
KNOW THEIR RESULTS
 Afghanistan  11 5  11 4  4 
 Albania        
 Algeria        
 Angola  42 5  42 35  35 
 Argentina 36  38 65 62   
 Armenia 33 18 5  18    
 Australia  63 5  63 82  44 
 Azerbaijan     6 7  6 
 Bahamas        
 Bangladesh 2 5 6 8 5 4 7 4 4 
 Barbados  73 4, 5  73 4 73 7  73 
 Belarus 49 63 5  63 85  85 
 Belgium        
 Benin  30 5  30 87  87 
 Bolivia  78 4 85 4 78 4 45  45 
 Bosnia and 
 Herzegovina  96 2, 4   14  14 
 Brazil       18 
 Bulgaria  53 5  53 58 60 58 
 Burkina Faso  94 4, 5  94 4 100  100 
 Burundi 38 38 2, 5  38 2 65 7  65 
 Côte d’Ivoire  51 5  51 51 7  51 
 Cambodia  68 5  68 68 7  68 
 Cameroon  32 2, 5  32 2    
 Canada        
 Chad     38  38 
 Chile     7  85 
 China  29 5  29 37  37 
 Colombia  82 71 85   42 
 Comoros     100 7 0 100 
 Congo, Republic 
 of the 3       
 Costa Rica     49   
 Cuba  36 38 32 35 35 35 
 Czech Republic        
 Democratic Republic 
 of the Congo  37 2, 5  37 2 36 7  36 
 Denmark        
 Djibouti     85  85 
 Dominican Republic  64 2, 5  64 2 67  67 
 Ecuador    87 4    
 El Salvador  96 5  96   89 
 Eritrea  78   93  93 
 Estonia  52 5  56 52 7  52 
 Ethiopia  97 5  97 97 7   
 Finland        
 Gabon  54 33 55 64 52 65 
 Georgia 24 33 5  33 28  28 
 Germany        
 Ghana  39      
 Greece     66  66 
 Guatemala  93 5  93 93 7  93 
 Guinea  58 5  58    
 Guinea-Bissau     43  43 
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 Guyana  64  64 88  88 
 Haiti  71   71 7   
 Honduras  71 5  71 76  76 
 Hungary        
 India    34 32  32 
 Indonesia 15 31 52 25 33 7 57 28 
 Iran, Islamic 
 Republic of  20 5  20 20 7  20 
 Jamaica 43 43 5  43 73  73 
 Japan        
 Kazakhstan  70 5  70 81  81 
 Kenya  12 2     92 
 Kyrgyzstan  53 5  53 42  42 
 Lao People’s 
 Democratic Republic 9    14  14 
 Latvia        
 Lebanon  24 4 11 4 25 4 7  69 
 Lithuania  50 5  50 53  53 
 Luxembourg        
 Madagascar  49 5  49    
 Malawi  69 5  69    
 Malaysia  100 3, 4   20   
 Maldives     14  14 
 Mali  7   91 7  91 
 Mauritania  100 4, 5  100 4 69 7  69 
 Mauritius  30 2      
 Mexico  72 63 76    
 Moldova  31 5  31 23  23 
 Mongolia 67 53 5  53 52  52 
 Montenegro  73 4, 5  73 4 83 7   
 Morocco  51 5  51 51 7  51 
 Myanmar     71  71 
 Nepal  40 52 37  65 32 
 Nicaragua     91   
 Niger  38 5  38 45  45 
 Nigeria  38 5  38 38 7  38 
 Norway        
 Pakistan  4 4 5 14 13 15 
 Panama 77 55 59 52 55 7 59 52 
 Papua New Guinea  47 5  47 56 47 60 
 Paraguay  100 5 100 100 100  100 
 Peru    54 4 20 6 55 
 Philippines  12 5  12 19  19 
 Poland        
 Portugal        
 Romania 36 35 5  35 29  29 
 Russian Federation  61 5  61 39  39 
 Rwanda  65 5  65 7  65 
 Saint Lucia        
 Sao Tome and 
 Principe  72 4, 5  72 4 31 7  31 
 Senegal  70 5  70 70  70 
 Serbia     45 35 52 
 Sierra Leone  79 75  48 7  48 
 Singapore    100 100  100 
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         53 7 
        38 32 
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        40  
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        5 14 
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 4 4 2 4 50 4     14 4 30 
 64 60 81 73 7 73 72  28 41 
    65 7      
          
          
 100 4   33    100  
    17 15 67   10 
          
        15 4  
 20 2 24 2 0 2 75    16 2  
 31 2 28 2 48 2 32 29 49  54 50 
 34 33 38 48 49 41  38  
       23 60 78 
        81 4  
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    27 27    48 
 21 6 21  22 22   30 42 
          
          
 23 23 33 23 7 23 32  30 30 7
         56 7 
  4 4  12 12     
       45 76 76 7 
        42 67 
 100 100 100     100 100 
        21 6 
 4 4 15 1 2 0  16 7 
 <1       <1  
    36 7 35 41   27 7 
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       11  34 7 
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1  Report date 2007, but data collection can vary from 2005-2007.
2 Data collection started before 2005.
3 Data collection period not defi ned.
4 Methodology not harmonized with UNGASS 2008 guidelines.
5 Females only.
6 Males only.
7 Data collection started before 2008.
 Slovenia        
 Somalia       5 
 South Africa        
 Spain  67 2, 4, 5   67 7   
 Sri Lanka  43 5  43 43 7  43 
 Sudan     7  7 
 Suriname  62 75 59 64   
 Swaziland  94 4, 5  94 4    
 Sweden  34 4 100 4 33 4 78 70 100 
 Switzerland   38  7 38  
 Tajikistan  29 5  29 42  42 
 Thailand  53 54 52 36 35 36 
 The former 
 Yugoslav Republic 
 of Macedonia 67 47 87 39 47 7 87 39 
 Timor-Leste       53 
 Togo  40 22 89 58 43 59 
 Tonga        
 Tunisia    100 4 14  14 
 Turkey 26 97 100 97    
 Ukraine 32 46 5  46 59   
 United Kingdom 
 of Great Britain and 
 Northern Ireland        
 Uruguay     26 26  
 Uzbekistan  19 5  19 35  35 
 Vanuatu     12 7  12 
 Viet Nam  15 5  15 35  35 
 Zambia  17 14 23    
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